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Synopsis 
Background 
Allogeneic blood and marrow transplant (BMT) is widely used for the treatment of life threatening 
malignant and non-malignant diseases in both adults and children.  While it provides many patients 
with their best (and sometimes only) opportunity for long-term survival it is associated with significant 
mortality and morbidity.  Over the past two decades significant improvements in outcomes post-BMT 
and advances in supportive care, immunobiology, chemoradiotherapy and donor selection have led 
to significant changes in BMT practice worldwide.  These include an increase in frequency of BMT 
(relative to the population) for almost all indications, increased use of unrelated donors (versus 
related donors), and an increase in the age of patients eligible for BMT (largely a result of the 
introduction of reduced intensity conditioning for BMT).  In Australia in 2016, 635 patients underwent 
allogenic BMT.  Of these 42% were over 60 years of age and just over 70% were alive at one-year post-
transplant.  While this represents significant improvement over historical outcomes of BMT, long-term 
survivors experience significant long-term and late-effects of transplant including ongoing acute and 
chronic graft versus host disease (GVHD), increased risks of infections, chronic illnesses and secondary 
malignancies.   Long-term BMT survivors also report twice as many medical problems compared to 
case matched controls, are 3.5 times more likely to develop a severe/life-threatening condition than 
siblings (this increases up to 4.7 times in those with GVHD) and have higher rates of hospitalisations 
and late mortality.  
Despite increased recognition of the physiological and psychosocial adverse effects that confront 
survivors of BMT, and the publication of international recommendations for screening and 
preventative care post-BMT, little is known about the challenges faced by Australian BMT survivors.  
The aim of this study was to obtain comprehensive data regarding the late sequelae of BMT in an 
Australian setting, and to use that data to identify gaps in service provision provided to this vulnerable 
and high-risk group.    
Methods 
This study employed a cross-sectional descriptive survey design using both quantitative and 
qualitative methods to examine the physiological and psychosocial impacts of BMT and the quality of 
life (QoL) of allogeneic BMT survivors.  The survey consisted of seven instruments; six validated 
instruments including the Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-
BMT Version 4) survey, the Chronic Graft Versus Host Disease (GVHD) Activity Assessment – Patient 
Self Report (Form B), the Lee Chronic GVHD Symptom Scale, the Post Traumatic Growth Inventory, 
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the Fear of Recurrence Scale and the DASS 21, and one instrument, the Sydney Post-BMT Survey, 
purpose designed for the study. In total, participants were asked 518 questions which required a 
combination of tick box, free text and Likert scale responses and took approximately one hour to 
complete.  
Eligible study participants were all allogeneic BMT survivors (age>18 years) who had undergone an 
allogenic transplant at one of the four adult allogeneic BMT sites in New South Wales (NSW) between 
January 2000 to December 2012, were at least 12 months post-BMT, could read and write English and 
had no objection to participating in the study.  Participants who agreed were sent study packs in the 
mail and given the option to self-complete or complete the survey via a phone interview. 
Main findings 
Of the 669 BMT recipients alive at study sampling, 583 were contactable and agreed to receiving a 
study pack.  Surveys were completed and returned by 441 (66% of total eligible, 76% of those 
contacted), while 17 (3%) explicitly declined after receiving the survey and 125 (21%) did not return 
the survey nor respond to a second round of phone calls.   
Respondents consisted of 250 (56.7%) males and 191 (43.3%) females with a median age of 49 years.  
A total of 86.8% identified as being of Australian/European ethnicity and 72.2% lived in a major city. 
Most respondents (46.3%) were between 2-6 years post-transplant and (53.4%) has an underlying 
diagnosis of acute leukaemia.  Many (66.9%) reported being in CR1/CR2 at the time of transplant, over 
half (56.9%) had a sibling donor, 86.4% received peripheral blood stem cells and almost half (48.7%) 
received myeloablative conditioning for their BMT, with 28.6% receiving T-cell depletion of some 
form.  
Overall, the BMT survivors who responded to this study described extensive long-term adverse health 
related effects of BMT. In order of frequency, the BMT survivors reported chronic medical conditions 
including chronic GVHD (69.3%), iron overload (34.5%), osteoporosis/osteopenia (29.1%), cataracts 
(28.9%), hypertension (28.9%), hypercholesterolaemia (23.9%), recurrent upper respiratory tract 
infections (22.9%), diabetes mellitus (14.3%), any spinal/hip fracture (4.3%), hypothyroidism (4.1%), 
avascular necrosis (3.6%) and hyperthyroidism (1.3%). Second malignancies were experienced by 
more than a quarter of survivors, with skin cancer reported by 23%, oral cancer by 6% and ‘other 
malignancies’ by 4.9%.  The most frequently reported infections were influenza-like-illness (38.4%) 
and herpes zoster (27.9%).  Vaccination and health screening uptake were incomplete; only 31.8% of 
survivors had completed the re-vaccination schedule following BMT, 66.1% regularly saw a dentist or 
had an oral health check, 52.3% had a skin check, 63.4% had a pap smear, 53.3% had a mammogram, 
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32.4% had a bowel cancer check, and 36.2% had a prostate check.  Almost half were 
overweight/obese, a third were inactive and over 50% of those >5 years post-transplant reported 
gastrointestinal symptoms which affected nutritional status. 
BMT survivors also reported a range of adverse psychosocial impacts of transplant.  Full-time 
employment fell from 65% pre-transplant to 32.5% post-transplant, the proportion of those in the 
lowest household income strata increased from 21% to 36% and almost 30% experienced anxiety and 
depression. Sexual dysfunction was reported by 66% of females and 51% of males. Complementary 
and alternative medicine (CAM) therapy was used by 54.1% and the median number of specialists 
involved in survivor’s care was three, with the most common being dermatologists (60.3%), 
ophthalmologists (43.6%) and respiratory physicians (28.2%).   
When asked about preferences for long-term care and follow-up, approximately 75% wished to have 
their follow-up in their transplant centre or in an expert facility linked to their transplant centre.   
Conclusions 
While significant progress has been made in BMT much of this has been in relation to patient selection, 
donor identification, conditioning chemo-radiotherapy, GVHD prophylaxis and treatment and 
supportive care for the prevention and management of acute complications of BMT, far less progress 
has been made in the prevention and management of long-term and late effects of allogeneic BMT.  
And despite publication of international and Australian guidelines for post-BMT care, long-term 
follow-up (LTFU) is often not standardised or readily accessible and as a consequence, many BMT 
survivors, their carers and families, do not receive the comprehensive care they need. The results of 
this research – which provides the most comprehensive account of allogeneic BMT survivorship in a 
contemporary Australian cohort – reveal the high incidence and broad range of physiological and 
psychosocial complications that adversely affect the health and functional status of BMT survivors.   
While many of these results are similar to the extant international literature on the experience of 
survival following BMT and/or cancer therapy, some findings provide important and unique insights 
into the experience of BMT survival.  Financial insecurity and occupational vulnerability is a clear and 
very real issue for long-term survivors of BMT, a significant number do not return to work due to ill-
health (Paper 6, Chapter 10), there is unlikely to be a ‘one size fits all’ model of care (MOC) which suits 
all BMT survivors and BMT centres (Paper 2, Chapter 6), and currently available ‘standard’ measures 
of post-BMT QoL may not adequately ask the questions we need to ask in order to gain a rich picture 
of the challenges of survivorship (Paper 10, Chapter 14).  
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The results of the study reported in this thesis are critically important, both because they provide a 
comprehensive account of the experience of survival post-BMT and because they inform the 
development of policy, strategies for patient education and preventive practice, and the design and 
delivery of health care for long-term BMT survivors.  In this regard it is critical that these results are 
translated into policy and practice as to not do so would further disadvantage this highly vulnerable 
group.  
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Notes on key terms and nomenclature 
Blood and marrow transplant (BMT) is a complex medical procedure in which haematopoietic stem 
cells are used to repopulate the haematopoietic system in patients after conditioning chemotherapy 
and/or radiotherapy has been administered(1).   It can be autologous (the recipient is transplanted 
with their own cells) or allogeneic (the recipient is transplanted with cells from another person).  This 
thesis presents research on allogeneic BMT survivors only.    
The procedure was originally termed bone marrow transplant as haematopoietic stem cells had not 
been clearly described or characterised in either bone marrow or peripheral blood.  It was presumed 
that haematopoietic transplant required cells from bone marrow, and harvesting bone marrow from 
the iliac crest was the only available method to retrieve haemopoietic progenitor cells (HPC) at the 
time (circa 1960s).  As advances in cellular biology and pharmacology made clear that stem cells 
existed in many forms in different tissues, that haematopoietic progenitors were present not only in 
bone marrow but also in umbilical cord blood, and that haematopoietic stem cells could be mobilised 
into peripheral blood following administration of chemotherapy and growth factors, new terms were 
formulated; blood and marrow transplant (BMT), haematopoietic stem cell transplant (HSCT), 
haematopoietic progenitor cell transplant (HPCT), haematopoietic cell transplant (HCT), allo-graft.   
These terms are synonymous and can be used interchangeably. For continuity, throughout this thesis 
the term BMT (blood and marrow transplant) has been used.  In the manuscripts arising from this 
research the term most commonly used by the target journal has been utilised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Bosi A, Bartolozzi B, Guidi S. Allogeneic stem cell transplantation. Transplant Proc. 
2005;37(6):2667-9. 
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Thesis overview and structure 
 
The research described in this thesis used a cross sectional survey design to examine the long term 
and late effects of survival following adult allogenic BMT in New South Wales (NSW).  The study was 
conducted with the goal of describing the experience of survival following BMT and to improve the 
care provided to long-term survivors.  The study had the following aims: 
1. to describe the incidence and range of late complications of BMT and their association with 
the health and functional status of survivors; 
2. to address limitations in BMT survivorship literature – particularly with regards to the 
financial, occupational and psychosocial impact of BMT; 
3. to identify gaps in service provision provided to this vulnerable and high-risk patient group; 
4. to provide better information to patients contemplating BMT, and to their families and 
guardians, regarding the possible long-term sequelae of BMT; and 
5. to support clinical and health policy decision-making around BMT through the provision of 
more comprehensive data regarding late sequelae of BMT in an Australian setting  
The research was conducted across four adult allogenic BMT centres across the state.  At the time this 
represented all adult allogeneic sites in NSW who cared for long-term survivors of BMT.  (There are 
now five centres).  This research was completed by publication and is presented as a combination of 
chapters and stand-alone manuscripts.  Accordingly, there is a degree of repetition throughout the 
results chapters in the background, methods and limitations sections of each manuscript (Chapters 5-
15). Also, in addition to the discussion contained within each manuscript, a synopsis follows each 
paper which expands on the discussion points, provides an update in evidence (where relevant), and 
relates the findings to the implications that the data has on the education and care provided to long-
term BMT survivors. The references forming part of each manuscript appear within the published 
article, while any additional references used in the synopsis are listed at the conclusion of the synopsis.  
Together, the manuscripts address the overall aims of the research outlined above and provide a 
comprehensive account of the experience of survival following BMT in NSW.  
Chapter 1 provides a brief overview of BMT.  It includes an overview of the history of BMT, a 
description of the developments in clinical application of BMT, conditioning regimens, therapeutic 
protocols and supportive care, and subsequent improvements in survival rates of BMT.    
Chapter 2 provides an overview of the issues associated with survival following BMT by presenting a 
review of the national and international literature on the long-term and late effects of BMT by body 
system. 
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Chapter 3 provides an overview of the recommendations for BMT long-term follow up (LTFU) and a 
description of health care service provision for survivors of BMT in NSW.  This chapter also outlines 
the aims of this thesis.  
Chapter 4 presents the research methods used in this thesis including a description of the research 
sample, setting, instruments and data analysis.   
Chapters 5 presents a published manuscript titled, ‘The Experience of Survival following allogeneic 
Haematopoietic Stem Cell Transplantation (allo-HSCT) in New South Wales, Australia’.  This 
manuscript provides an overall summary of the late effects of long-term survival following BMT in 
NSW. 
Chapters 6 presents a published manuscript titled, ‘What They Want: Inclusion of Blood and Marrow 
Transplantation Survivor Preference in the Development of Models of Care for Long-Term Health in 
Sydney, Australia’.  This manuscript reports on BMT survivors preferred model of care (MOC) for the 
delivery of long term follow up (LTFU). 
Chapter 7 presents a published manuscript titled, ‘A survey of fertility and sexual health following 
allogeneic haematopoietic stem cell transplantation in New South Wales, Australia’.  This manuscript 
reports on the reproductive and sexual health of our long-term BMT survivors. 
Chapter 8 presents a published manuscript titled, ‘Adherence to cancer screening guidelines in 
Australian survivors of allogeneic blood and marrow transplantation (BMT)’.  This manuscript reports 
on the incidence of secondary cancers in long-term survivors of BMT and their subsequent adherence 
with Australian cancer screening guidelines. 
Chapter 9 presents a published manuscript titled, ‘Prevalence of high-risk health behaviours in long-
term survivors of allogeneic blood and marrow transplantation in Sydney, Australia’.  This manuscript 
reports on BMT survivor’s engagement in high-risk health behaviours known to contribute to chronic 
non-communicable conditions. 
Chapter 10 presents a published manuscript titled, ‘Changes to work status and household income of 
long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia’.  This 
manuscript reports on the long-term impact of allogeneic BMT on survivors’ work status and 
household income. 
Chapter 11 presents a published manuscript titled, ‘Oral health and dental morbidity in long-term 
allogeneic blood and marrow transplant survivors in Australia’.  This manuscript reports on the 
incidence and range of oral and dental disease occurring in long-term survivors of BMT. 
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Chapter 12 presents an in press manuscript titled, ‘A survey of infectious diseases and vaccination 
uptake in long-term haematopoietic stem cell transplant survivors in Australia’.  This manuscript 
reports on the incidence of infectious diseases and the rate of re-vaccination adherence post-BMT. 
Chapter 13 presents a published manuscript titled, ‘Epidemiology of complementary and alternative 
medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in 
Australia’.  This manuscript reports on the use of complementary and alternative medicine (CAM) 
therapies in long-term survivors of BMT.  
Chapter 14 presents a published manuscript titled, ‘Haematopoietic stem cell transplantation 
survivorship and quality of life: is it a small world after all?’.  This manuscript provides a qualitative 
account of the lived experience of BMT survivorship.   
Chapter 15 presents a published manuscript titled, ‘Nutritional issues and body weight in long-term 
survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia’.  This manuscript reports 
on issues relating to nutrition, body weight and body image in long-term survivors of BMT, and their 
impact on survivors’ quality of life (QoL). 
Chapter 16 synthesises the main findings of the results chapters and discusses their implications for 
how LTFU care and education provided to BMT survivors might be improved.   It presents the thesis 
conclusions and identifies key areas for future research, education, policy and healthcare reform. 
Table 1 details the thesis results chapters and their publication status. 
Table 1 The publication status and journal of results chapters included in this thesis 
Chapter Title 
Publication 
status 
Journal 
5 The Experience of Survival following allogeneic 
Haematopoietic Stem Cell Transplantation (allo-
HSCT) in New South Wales, Australia 
Published 
Bone marrow 
transplantation 
6 What They Want: Inclusion of Blood and Marrow 
Transplantation Survivor Preference in the 
Development of Models of Care for Long-Term 
Health in Sydney, Australia 
Published 
Biology of blood 
marrow 
transplantation 
7 A survey of fertility and sexual health following 
allogeneic haematopoietic stem cell transplantation 
in New South Wales, Australia 
 
Published 
British journal of 
haematology 
8 Adherence to cancer screening guidelines in 
Australian survivors of allogeneic blood and marrow 
transplantation (BMT) 
Published Cancer medicine 
xx 
9 Prevalence of high-risk health behaviours in long-
term survivors of allogeneic blood and marrow 
transplantation in Sydney, Australia 
Published 
Australian 
journal of cancer 
nursing 
10 Changes to work status and household income of 
long-term allogeneic blood and marrow transplant 
survivors in New South Wales, Australia 
Published 
Bone marrow 
transplantation 
11 Oral health and dental morbidity in long-term 
allogeneic blood and marrow transplant survivors in 
Australia 
Published 
Australian dental 
journal 
12 A survey of infectious diseases and vaccination 
uptake in long-term haematopoietic stem cell 
transplant survivors in Australia 
In press 
Transplant 
infectious disease 
13 Epidemiology of complementary and alternative 
medicine therapy use in allogeneic hematopoietic 
stem cell transplant survivorship patients in 
Australia 
Published Cancer medicine 
14 Haematopoietic stem cell transplantation 
survivorship and quality of life: is it a small world 
after all? 
Published 
Supportive care 
in cancer 
15 Nutritional issues and body weight in long-term 
survivors of allogeneic blood and marrow transplant 
(BMT) in NSW Australia 
Published 
Supportive care 
in cancer 
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Chapter 1: History and Progress in Allogeneic Blood and Marrow Transplant 
1.1. Chapter overview  
This chapter provides an overview of allogeneic BMT.  It includes a brief outline of the history of 
allogeneic BMT including a description of the developments in its application, conditioning regimens 
and supportive care, and subsequent improvements in survival rates following BMT.     
1.2. Introduction 
Allogeneic BMT is now established as a standard of care for a number of malignant and non-malignant 
diseases in adult and children.  The notion that BMT could be used to replace a damaged or defective 
bone marrow is almost 80 years old, having been considered as a possible strategy to ‘rescue’ those 
exposed to ionising radiation during World War II(1).  The history of the clinical development of BMT 
however, goes back 50 years, and has resulted from progress in immunobiology, pharmacology, 
pathology, and virology and, somewhat ironically, by a series of parallel socio-political events including 
the development of the pharmaceutical and nuclear weapons industries(2).  
The emergence of allogeneic BMT 
In 1975 Professor Donnall Thomas et al published an article in the New England Journal of Medicine 
describing renewed enthusiasm in the potential development of a new therapy; allogeneic bone 
marrow transplant (BMT)(3).  This therapy, which involved infusing donor bone marrow into a 
recipient to colonise their failing bone marrow, was primarily developed for the treatment of 
immunological deficiencies, leukemias and victims of radiation accidents. Proof of concept was initially 
reported by George Mathé almost two decades previously when 5 (of 6) physicists accidently exposed 
to lethal doses of total body irradiation (TBI) at the Vinca Nuclear Centre in Belgrade, Yugoslavia in 
1958 received human adult bone marrow which rescued them from ‘radiation sickness’(4).  Following 
successes in preventing the  death of laboratory animals exposed to radiation(5), and Mathés’ 
experience, clinical BMT appeared feasible and between 1959 and 1962, 154 transplants were 
performed worldwide(6).  But while these cases established the safety of intravenous infusions of 
bone marrow and the possibility of successful engraftment of donor marrow, survival beyond 4-5 
weeks post-transplant proved impossible(7). Consequently, enthusiasm for BMT as a potential 
treatment option for patients with bone marrow failure, immunodeficiency or cancer waned during 
the 1960s(6). It wasn’t until Thomas’ ground-breaking work in the late 1960s, particularly in identifying 
the importance of human leukocyte antigen (HLA) typing in recipient-donor matching, that genuine 
progress in allogenic transplantation was made.  Over the next thirty years rapid progress was made 
in BMT(8, 9) and in 2012 the one millionth BMT was celebrated(10).  Improvements in immunobiology, 
3 
 
chemoradiotherapy, supportive care and donor selection continue to improve the outcomes of BMT, 
with more and more patients becoming candidates for transplantation and surviving long term.  
A brief of history of allogeneic BMT  
1970s 
Following translation into the clinic in the early 1970s BMT was a myeloablative (MA) procedure of 
‘last resort’ for the treatment of acute leukaemia and aplastic anaemia, which used 
cyclophosphamide(11) and/or TBI(12) as conditioning and was performed only in patients who were 
young (less than 45 years of age) medically fit, and had a HLA-identical sibling.   While this extended 
the lives of some recipients by months or even years, very few survived –a 1977 report documented 
that only thirteen of 100 patients with acute myeloid leukaemia (AML) survived more than one year,  
with most recipients dying of infection and acute GVHD(12).  It was also in this decade, in 1975, that 
the first BMT was performed in Australia, in New South Wales (NSW)(13).  
1980s 
During the late 1970s and early 1980s an enormous amount of work was done internationally to better 
understand the causes of graft failure and GVHD, and to develop safe strategies for the prevention 
and treatment of GVHD.  In the early 1980s randomised studies  provided clear evidence for GVHD 
prophylaxis(14) – until that time a major cause of treatment failure and death – and methotrexate and 
cyclosporin became the agents of choice to prevent GVHD. At the about the same time, interest in T-
cell depletion of the graft to prevent GVHD increased(15), leading to exploration of different 
conditioning protocols including busulfan plus cyclophosphamide(16) and TBI plus etoposide(17).  
Following progress in the development of immunosuppressive therapies and HLA typing, the 
application of BMT was further extended from those with HLA identical sibling donors to unrelated or 
mismatched donors including haplo-identical and HLA-matched unrelated donor transplants(18).  (The 
first HLA-matched unrelated donor BMT for leukaemia was performed on ten year old Laura Graves 
on the 4th September 1979(19).  She survived for two years before dying as a result of leukemic relapse.  
The first unrelated BMT for aplastic anaemia was less ‘successful’, it was performed in an eighteen 
year old male in 1972.  Unfortunately he died of graft failure  two months post-BMT(20)). 
1990s 
During the 1990s numerous advances were made in BMT, particularly in relation to the use of 
alternative stem cell sources, transplant conditioning and antimicrobial prophylaxis and treatment.   
Notable advances included the application of ganciclovir to prevent and treat cytomegalovirus (CMV) 
infection(21) – until that time a major cause of death post-BMT – and the development of 
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haematopoietic growth factors (particularly granulocyte colony stimulating factor (GCSF)), which 
enabled dose intensification of chemotherapy, facilitated haematopoietic reconstitution and enabled 
peripheral blood stem cell harvesting for use in allogeneic and/or autologous BMT(22).  During this 
time cord blood stem cells were also identified as an alternative source of haematopoietic progenitors 
for BMT(23) – thereby increasing the number of patients, particularly among ethnic minorities, who 
could be candidates for BMT.  Although initial outcomes following cord blood transplantation were 
compromised by high rates of graft failure, infection, relapse and chronic GVHD (cGVHD)(24), 
outcomes rapidly improved with broader application.  Finally, recognition of the degree to which 
transplant outcomes were determined by T-cell immunocompetence, rather than by transplant 
conditioning intensity  stimulated the introduction of reduced intensity conditioning (RIC) and non-
myeloablative (NMA) conditioning for transplantation, the use of post-BMT donor lymphocyte 
infusions (DLI) to induce graft versus malignancy effects and the incorporation of donor chimerism 
assessment in post-BMT care(25, 26).  The impact of these developments was profound as they 
allowed the age criteria for BMT to be raised to over 60 years, enabled transplantation in those with 
significant co-morbidity and enabled the development of programs for outpatient allogenic BMT(27).  
2000s 
While scientific and clinical innovation continued to improve outcomes following BMT and broaden 
its application, the expansion of BMT internationally and progress in its safety and efficacy also 
resulted from the development of systematic processes and structures to support it.  The expansion, 
standardisation and integration of bone marrow/stem cell donor registries worldwide, and the 
expansion and standardisation of tissue typing, have substantially improved donor-recipient matching 
and BMT outcomes(28).   At the same time, the adoption of quality standards as determined by the 
Foundation for the Accreditation of Cellular Therapies (FACT) in the US (founded in 1996) and the Joint 
Accreditation Committee of the International Society for Cellular Therapy Europe (JACIE) in Europe 
(founded in 1997) improved the collection, processing and administration of haemopoietic stem cell 
therapies(29). 
Contemporary application of allogeneic BMT 
Improvements in immunobiology, chemoradiotherapy, supportive care, donor selection and quality 
management have resulted in a significant change in BMT practices and survival worldwide.  The 
American Society of Blood and Marrow Transplant (ASBMT) report that there are now ninety 
indications for which BMT is considered standard of care, or standard of care with clinical evidence 
available (but no large scale clinical trials), and standard of care for rare conditions (in which clinical 
trials are not feasible), and eighteen indications for which evidence for BMT is developing(30) (Table 
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1.1). BMT is now routinely offered for patients with lymphoid malignancies, myeloma, haemoglobin 
disorders, solid tumours, storage disorders and inborn errors of metabolism(31).   Older patients who 
were previously ineligible for BMT now regularly undergo the procedure - of the 635 allogenic BMTs 
performed in Australia in 2016, 42% were over age 60(32).  Increasing numbers of BMTs use stem cells 
from unrelated donors (rather than related donors) or haplo-identical donors. 
As the indications for BMT have expanded, so too has the number of people who undergo the 
procedure.  By 2012, over 400,000 allogenic BMTs had been performed worldwide(10). The 
Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) records that 10,482 allogeneic 
BMTs were performed in Australia (since the registry began in 1992)(33).  This increase in frequency 
is understandable as survival outcomes have improved considerably.  From an initial zero percent 
survival beyond 4-5 weeks(3), the ABMTRR now report that one-year transplant related mortality 
(TRM) has decreased from 24.3% to 18.9% for unrelated BMTs, and from 12.1% to 11.6% for HLA-
identical sibling transplants.  They also report figures for one-year survival rates just over 70% (for all 
allogeneic BMTs (Figure 1)) and ten-year survival rates of up to 77% (depending on the primary disease 
and donor type)(33). 
1.3. Summary 
Allogeneic BMT is now clearly established as optimal care for adults and children with a range of 
malignant and non-malignant disorders.  With improvements in donor selection, supportive care, 
chemoradiotherapy, immunobiology and quality management(34, 35)  more and more people are 
undergoing this life saving procedure, and more and more recipients are living long term.  While this 
represents remarkable progress, it does not come without consequence, as survival following BMT is 
associated with significant morbidity and mortality(36, 37).  The long term and late effects of BMT are 
discussed in the next chapter, followed by a description of the international long-term follow up (LTFU) 
screening and preventive care guidelines and a discussion regarding current health care service 
provision provided to BMT survivors in NSW in Chapter 3.  
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Table 1.1: Indications and disease status for BMT(30)  
Indication and Disease 
Status 
Allogeneic 
BMT 
Autologous 
BMT 
 Indication and Disease 
Status 
Allogeneic 
BMT 
Autologous 
BMT 
Acute myeloid leukemia  Hodgkin lymphoma 
CR1, low risk N C  CR1 (PET negative) N N 
CR1, intermediate risk S C  CR1 (PET positive) N C 
CR1, high risk S C  Primary refractory, 
sensitive 
C S 
CR2 S C  Primary refractory, 
resistant 
C N 
CR3+ C C  First relapse, sensitive S S 
Not in remission C N  First relapse, resistant C N 
Acute promyelocyte leukemia  Second or greater 
relapse 
C S 
CR1 N N  Relapse after autologous 
transplant 
C N 
CR2, molecular 
remission 
C S  Diffuse large B-cell lymphoma 
CR2, not in molecular 
remission 
S N  CR1 (PET negative) N N 
CR3+ C N  CR1 (PET positive) N C 
Not in remission C N  Primary refractory, 
sensitive 
C S 
Relapse after 
autologous transplant 
C N  Primary refractory, 
resistant 
C N 
Acute lymphoblastic leukemia  First relapse, sensitive C S 
CR1, standard risk S C  First relapse, resistant C N 
CR1, high risk S N  Second or greater 
relapse 
C S 
CR2 S C  Relapse after autologous 
transplant 
C N 
CR3+ C N  Follicular lymphoma 
Not in remission C N  CR1 N C 
Chronic myeloid leukemia  Primary refractory, 
sensitive 
S S 
Chronic phase 1, TKI 
intolerant 
C N  Primary refractory, 
resistant 
S N 
Chronic phase 1, TKI 
refractory 
C N  First relapse, sensitive S S 
Chronic phase 2+ S N  First relapse, resistant S N 
Accelerated phase S N  Second or greater 
relapse 
S S 
Blast phase S N  Transformation to high 
grade lymphoma 
C S 
Myelodysplastic 
syndromes 
     Relapse after autologous 
transplant 
C N 
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Low/intermeditate-1 
risk 
C N  Mantle cell lymphoma 
Intermediate-2/high 
risk 
S N  CR1/PR1 C S 
Therapy related AML/MDS  Primary refractory, 
sensitive 
S S 
CR1 S N  Primary refractory, 
resistant 
C N 
Myelofibrosis & myeloproliferative diseases  First relapse, sensitive S S 
Primary, low risk C N  First relapse, resistant C N 
Primary, 
intermediate/high risk 
C N  Second or greater 
relapse 
C S 
Secondary C N  Relapse after autologous 
transplant 
C N 
Hypereosinophilic 
syndromes, refractory 
R N  
   
Plasma cell disorders  Solid tumours 
Myeloma, initial 
response 
D S  Germ cell tumour, 
relapse 
N C 
Myeloma, sensitive 
relapse 
C S  Germ cell tumour, 
refractory 
N C 
Myeloma, refractory C C  Ewing's sarcoma, high 
risk 
N C 
Plasma cell leukaemia C C  Breast cancer, adjuvant 
high risk 
N D 
Primary amyloidosis N C  Breast cancer, 
metastatic 
D D 
POEMS syndrome N R  Renal cancer, metastatic D N 
Relapse after 
autologous transplant 
C C  Non-malignant diseases 
T-cell lymphoma  Severe aplastic anaemia, 
new diagnosis 
S N 
CR1 C C  Severe aplastic anaemia, 
relapse/refractory 
S N 
Primary refractory, 
sensitive 
C S  Fanconi's anaemia R N 
Primary refractory, 
resistant 
C N  Dyskeratosis congenita R N 
First relapse, sensitive C S  Sickle cell disease C N 
First relapse, resistant C N  Thalassemia D N 
Second or greater 
relapse 
C C  Hemophagocytic 
syndromes, refractory 
R N 
Relapse after 
autologous transplant 
C N  Mast cell diseases R N 
Lymphoplasmacytic lymphoma  Common variable 
immunodeficiency 
R N 
CR1 N N  Wiskott-Aldrich 
syndrome 
R N 
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Primary refractory, 
sensitive 
N C  Chronic granulomatous 
disease 
R N 
Primary refractory, 
resistant 
R N  Multiple sclerosis N D 
First or greater relapse, 
sensitive 
R C  Systemic sclerosis N D 
First or greater relapse, 
resistant 
R N  Rheumatoid arthritis N D 
Relapse after 
autologous transplant 
C N  Systemic lupus 
erythematosus 
N D 
Burkitt's lymphoma  Crohn's disease N D 
First remission C C  Polymyositis-
dermatomyositis 
N D 
First or greater relapse, 
sensitive 
C C  Chronic lymphocytic leukemia 
First or greater relapse, 
resistant 
C N  High risk, first or greater 
remission 
C N 
Relapse after 
autologous transplant 
C N  T-cell prolymphocytic 
leukemia 
R R 
Cutaneous T-cell lymphoma  B-cell, prolymphocytic 
leukemia 
R R 
Relapse C C  Transformation to high 
grade lymphoma 
C C 
Relapse after 
autologous transplant 
C N  
 
Plasmablastic lymphoma  
CR1 R R  
Relapse R R  
   
N, not generally recommended; C, standard of care, clinical evidence available; S, standard of care; R, standard of care, rare 
indication; D, developmental. 
 
Figure 1: One-year survival for all Australian and New Zealand allogeneic BMTs performed in recipients aged 16+(33) 
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Chapter 2: Long-term and Late Effects of BMT 
2.1. Chapter overview  
Chapter 2 provides an overview of the long-term and late effects of allogeneic BMT including their 
incidence, and risk factors by body system.  
2.2. Long term and late effects of allogeneic BMT 
Over the past two decades increasing attention has been devoted to the long term and late effects of 
cancer therapy, with increasing recognition of the substantial morbidity and mortality experienced by 
survivors of cancer therapy.  A wealth of quantitative and qualitative literature has documented the 
experience of survival following cancer, described the unmet needs of cancer survivors and supported 
the development of survivorship programs(1-5).  
Following research done in patients with solid cancer and leukaemia, and extensive evidence in 
childhood cancer survivors, over the last decade there has been a burgeoning literature on the long-
term and late physical and psychosocial effects of BMT and their impact upon BMT survivors. The 
literature demonstrates that survivors experience twice as many medical problems compared to case 
matched controls, are 3.5 times more likely to develop a severe/life-threatening condition than 
siblings (this increases up to 4.7 times in those with GVHD)(6, 7), and have higher rates of 
hospitalisations and late mortality(8). In numerical terms, the fifteen-year cumulative incidence of a 
BMT survivor experiencing any chronic health condition is 71% and of a severe/life-threatening 
condition or death due to these chronic conditions is 41%(9).  The collective impact is profound with 
BMT survivors experiencing a 30% lower life expectancy than a matched population cohort(10, 11). 
While many survivors rate their QoL highly at two years post-transplant, many BMT recipients 
experience considerable difficulty coping with the short, medium and long term physical and 
psychological sequelae of BMT and with the uncertainties of their prognosis.  
Late complications are generally defined as any complication occurring from three months post-
transplant and are often separated into ‘delayed’ (3mths to 2 years), ‘late’ (2-10 years) and ‘very late’ 
(>10 years)(12). These complications, which occur as a consequence of exposure to chemo-
radiotherapy and the impact of chronic GVHD (cGVHD) (and its treatment) affects every body system.  
Major complications of BMT include: cardiac impairment(13), endocrine dysfunction(14), 
compromised fertility(15), compromised lung and respiratory function(16), renal impairment(17), 
liver dysfunction(18, 19), skeletal disorders(20, 21), cGVHD(22, 23), immunodeficiency and 
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infection(24, 25), secondary malignancies(26, 27), ocular side effects(28), neurocognitive effects(29), 
compromised functional status(30, 31), unemployment or underemployment(30), and compromised 
QoL(32).  Each of these complications are further detailed below.  
2.3. Cardiac and circulatory disease 
All forms of vascular disease, including cardiovascular, cerebrovascular and peripheral vascular 
disease, occur with greater frequency in BMT survivors(33). Cardiac dysfunction also frequently occurs 
in survivors of BMT including cardiomyopathy, congestive heart failure (CHF), valvular dysfunction, 
ischaemic heart disease (acute myocardial infarction (AMI) or angina), arrhythmia and 
pericarditis(34).  
In a large study of late mortality post BMT it was found that 3% of treatment related deaths were 
related to cardiac toxicity.  This was found to represent a more than two-fold greater risk of premature 
death than the general population(11).  Cardiovascular death, in a separate cohort study of two-year 
post BMT survivors, had an adjusted incidence rate difference of 3.6 per 1000 person-years.  Survivors 
were also found to have an increased cumulative incidence of ischemic heart disease, cardiomyopathy 
or heart failure, stroke, vascular diseases, and rhythm disorders and an increased incidence of related 
conditions that predispose toward more serious cardiovascular disease (CVD) (hypertension (HTN), 
renal disease, dyslipidaemia, and diabetes mellitus (DM))(35). 
The leading transplant related risk factors for cardiac toxicity following BMT are cumulative exposure 
to anthracyclines, TBI or chest irradiation as part of the treatment of the primary malignancy or 
conditioning regimen, cGVHD, age at BMT and cardiac co-morbidity. Gender, non-cardiac co-
morbidities and standard cardiovascular risks are also contributing factors(36). A clear relationship 
between post-transplant cardiovascular risk factors and late coronary and CVD in long-term survivors 
has been demonstrated(13, 37).  These late cardiac events may appear years and even decades after 
BMT, with the cumulative incidence being reported as high as 22% twenty-five years after BMT. 
Established risk factors for CVD, such as HTN, dyslipidaemia, DM, smoking and physical inactivity are 
associated with a higher risk of complications post-transplant due to the high prevalence of metabolic 
syndrome reported among BMT survivors(33, 38). Allogeneic BMT recipients have showed a 2.2–fold 
increased risk of metabolic syndrome, compared to age and gender matched controls(39, 40), 
increasing their risk of CVD. Prevalence of dyslipidaemia ranges from 8.9% to 56%, depending on the 
presence of comorbid conditions or other risk factors(41, 42).  It has also been found that BMT 
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survivors were 3.65 times and 2.06 times more likely to report DM and HTN respectively, when 
compared to siblings(43).  
Importantly, two or more cardiovascular risk factors (obesity, dyslipidaemia, HTN, and DM) after BMT 
is associated with a 5.2-fold increased risk of late CVD, pre-HCT chest radiation exposure is associated 
with a 9.5-fold greater risk of coronary artery disease and the presence of multiple post-BMT 
cardiovascular risk factors is associated with a 19.5-fold risk of late cerebrovascular disease(44, 45).  
2.4. Endocrine dysfunction 
Endocrine dysfunction occurs commonly post-BMT as a result of conditioning chemoradiotherapy 
prior to BMT, cumulative chemo/radiation exposure – including from treatment prior to BMT, cGVHD 
and prolonged corticosteroid exposure(46, 47). Endocrine dysfunction can be either primary, as a 
consequence of endocrine organ failure, or secondary to hypothalamic-pituitary axis dysfunction.  
Endocrine complications of BMT, which are often more profound in patients transplanted in 
childhood or adolescence, include short stature(19%)(46), hypogonadism (25%), hypothyroidism, 
hyperthyroidism, hypoadrenalism, osteoporosis, infertility, weight  problems (both over- and 
underweight) and other metabolic risks including dyslipidaemia and DM(47, 48). Thirty-four to thirty-
nine percent have one or more indicators of metabolic syndrome(39, 49).  
Hypothalamic-pituitary dysfunction 
Hypothalamic-pituitary dysfunction commonly occurs following BMT as a complication of cranial 
irradiation or TBI, and results in gonadal dysfunction, hypothyroidism, adrenal failure and growth 
hormone (GH) deficiency. Survivors who are irradiated with doses greater than 18 Gray (Gy) are at 
greatest risk, but hypothalamic-pituitary dysfunction can occur at lower doses(48).  
Adrenal insufficiency is particularly important because unrecognised ACTH deficiency resulting in 
secondary adrenal insufficiency can be life-threatening and may be easily misdiagnosed or 
underdiagnosed because it often presents in a ‘non-specific’ fashion (for example, fatigue).  
While GH deficiency is of little clinical significance in adults, children and adolescents who undergo 
BMT frequently have compromised growth and growth velocity – depending upon their pre-
transplantation therapy and whether their transplant conditioning includes TBI(46, 48).   
Gonadal dysfunction 
14 
 
Gonadal dysfunction is highly prevalent in BMT survivors occurring in up to 92% of males and 99% of 
females(46).   Conditioning chemotherapy (particularly alkylating agents), TBI and cGVHD contribute 
to the risk of gonadal dysfunction post BMT(47, 48). While the clinical manifestations of gonadal 
dysfunction are highly dependent on the BMT recipient’s age and gender, potential effects include 
pubertal failure, infertility, sexual dysfunction, osteoporosis, fragility fractures and a range of 
troublesome symptoms including menopausal symptoms (in women), hot flushes, night sweats, mood 
disorders, insomnia, lack of concentration, arthralgia, impaired sexual function and cognitive 
impairment(50).  
Thyroid disease 
Thyroid disease occurs commonly after BMT including clinical hypothyroidism, 
subclinical/compensated hypothyroidism, hyperthyroidism, autoimmune thyroid disease, benign 
thyroid nodules and thyroid cancer. 
Clinical hypothyroidism occurs with a two-fold greater incidence in BMT survivors when compared to 
sibling controls(51), and has been reported in up to 50% of patients whose conditioning includes TBI 
and up to 11% in those who receive MA conditioning with busulfan and cyclophosphamide(33).  
Subclinical/compensated hypothyroidism generally occurs 4-7 years post-BMT but may be present in 
7% - 15% of patients in the first year after transplantation(46).  Hyperthyroidism is less common in 
long term survivors of BMT, generally occurring earlier post-BMT with 15% of survivors at 12-18 
months post BMT being affected(47, 48). Autoimmune thyroid disease also commonly occurs post-
BMT as a consequence of passive transfer from the donor and immune dysregulation associated with 
cGVHD(52, 53).   
The incidence of both thyroid nodules and thyroid cancer is substantially increased in BMT survivors, 
particularly in those who have had head and neck irradiation prior to BMT and TBI conditioning. The 
risk of malignancy is higher in those patients exposed to radiation at a younger age(54).  
Metabolic disease 
Obesity, DM and dyslipidaemia all occur with greater frequency in BMT survivors.  DM, in particular, 
occurs in up to 20% of survivors, with studies demonstrating that BMT survivors have an odds ratio 
(OR) of 3.65 of developing DM compared to their siblings when controlled for age, sex, race and body 
mass index (BMI)(47, 48, 55). TBI containing transplant conditioning, cGVHD, prolonged corticosteroid 
exposure and/or weight gain (corticosteroids, mobility), and non-Caucasian ethnicity all contribute to 
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these metabolic risks(43). Abdominal irradiation performed pre-transplant also increases the 
likelihood of pancreatic, endocrine and exocrine insufficiency post-BMT(56). 
2.5. Genital disease and sexual function 
Genital disorders, sexual dysfunction and infertility are some of the most common and confronting 
challenges facing long-term survivors of BMT. These complications occur as a result of a range of 
interrelated factors including genital cGVHD, immunosuppression, human papillomavirus (HPV) 
infection, premature ovarian and testicular failure, interruption to the sexual response cycle, 
disruption of identity, relationship breakdown, social isolation and psychological morbidity including 
anxiety and depression post BMT. The impact of these complications is profound – dramatically 
compromising the QoL, social functioning and relationships of many of those affected(50). 
Genital cGVHD 
Genital cGVHD is commonly reported post-BMT, with international studies suggesting that up to 50% 
of women surviving BMT experiencing some degree of vaginal cGVHD and 13% of men experiencing 
cGVHD of the penis(57-59).  In women, genital cGVHD can affect the vulva and vagina and may present 
with lichen planus-like changes including erosions, leukokeratosis and vaginal scarring/stenosis. 
Vulvovaginal cGVHD may be asymptomatic (thus delaying diagnosis and treatment) or cause a range 
of symptoms including vaginal dryness, burning, itching, difficulty with urination, dyspareunia, cyclic 
pain and amenorrhea (due to haematocolpos/haematometra)(60). In men, penile cGVHD may cause 
balanoposthitis, phimosis, lichen sclerosis-like changes, Peyronie’s disease and erectile 
dysfunction(59).  
Primary ovarian failure 
Primary ovarian failure (POF) is almost ubiquitous following BMT – occurring in up to 90% of women 
who undergo BMT during their reproductive years – principally as a consequence of conditioning 
chemotherapy, TBI and cGVHD(60, 61). Post-transplant ovarian failure results in infertility in most-
BMT survivors of reproductive age, increases the likelihood of osteoporosis and fragility fractures and 
causes a range of bothersome symptoms, including hot flushes, night sweats, mood disorders, 
insomnia, lack of concentration, arthralgia, impaired sexual function and cognitive impairment(50).   
Male gonadal failure and impaired spermatogenesis 
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The vast majority of men (approximately 90%) will develop azoospermia, oligospermia and sperm 
motility problems as a consequence of high-dose conditioning chemotherapy, TBI and cGVHD(62).  
While some men (up to 25%) will show some evidence of recovery (particularly those who are aged 
<30 years at the time of transplant)(63)  many will remain hypogonadal and infertile.  
Genital secondary cancers and HPV infection 
As with other viral infections, HPV occurs with a greater frequency in BMT survivors than in the 
general population. In those infected, HPV can cause genital warts, cervical, vaginal, vulvar and anal 
intraepithelial neoplasia and anogenital squamous cell cancer (SCC). The risk of cervical SCC in female 
BMT survivors is reported to be thirteen times greater than that of the general population(64).  Genital 
malignancy also occurs with much greater frequency in male BMT survivors, with premalignant or 
malignant conditions reported in 8.4% of men with genital lichen sclerosis(65). 
Sexual dysfunction 
Up to 80% of long-term BMT survivors will experience some form of sexual dysfunction(50, 66). Sexual 
symptoms include decreased interest, erectile dysfunction, anejaculation, retrograde ejaculation and 
anorgasmia.  A range of physical and psychosocial factors contribute to the likelihood and severity of 
sexual dysfunction post BMT, including: gonadal insufficiency, genital disease, altered body image, 
illness and debility, relationship dysfunction, and anxiety and depression – all of which can impact 
upon sexual desire, libido, arousal and orgasm(59, 67). 
Fertility and reproduction 
Almost all patients will become infertile following BMT, with up to 90% of patients who undergo BMT 
during their reproductive years developing primary ovarian or testicular failure as a consequence of 
high-dose conditioning chemotherapy, TBI, high dose steroids, severe infection, cGVHD, older age, 
long-term immunosuppression and pre-BMT therapy (particularly alkylating agents and pelvic 
irradiation)(60). Hypothalamic-pituitary dysfunction and secondary hypogonadism, thyroid 
dysfunction and effects on other reproductive organs (for example, the uterus) may also contribute 
to subfertility and infertility. 
While some patients – particularly those aged less than 30 years at the time of BMT and those who 
did not receive TBI as part of their conditioning therapy – will regain some gonadal function, the vast 
majority of women will enter premature menopause and the vast majority of men will have persistent 
azoospermia, oligospermia and sperm motility problems(60, 63).  
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A small number of women (0.6%) will successfully achieve a pregnancy and have a child following 
BMT(68, 69). While children born to survivors of BMT do not have higher than expected rates of cancer 
or genetic disorders, female survivors experience a range of adverse pregnancy outcomes including 
increased rates of intrauterine growth restriction (IUGR), low birth rate, preterm delivery, 
spontaneous abortion (due to decreased uterine volume), placental abruption, uterine rupture and 
caesarean section deliveries compared with the general population(70-72).  
2.6. Lung and respiratory dysfunction 
Late onset post-BMT pulmonary  complications  occur in up to 60% of BMT recipients(73) – principally 
as a consequence of cGVHD.  Pulmonary disease is a major cause of increased morbidity and mortality 
including bronchiolitis obliterans syndrome (BOS), cryptogenic organising pneumonia (COP), 
idiopathic pneumonia  syndrome  and  sinopulmonary  infections(74, 75).  Asthma  has  also  been 
reported  post-BMT  from  atopic  asthmatic  donors(76). 
BOS is reported to occur in 14%  of  long-term  survivors  of  BMT  who  develop  cGVHD(77) and 
prognosis is poor (a 13% five-year survival rate has been reported)(78).  COP has been reported in up 
to 10.3% of unrelated donor transplants(79) but has a much better prognosis than BOS, up to 80% will 
be cured(80).  
In addition to cGVHD, other risk factors for lung disease post-BMT include  pre-existing  lung  disease, 
a history of pneumonitis,  infection,  smoking  history,  MA conditioning chemotherapy,  radiation 
exposure  –  including  TBI and  pre-transplant  thoracic  radiotherapy –  advanced disease at BMT, 
hypogammaglobulinaemia, and prolonged immune compromise(33, 46). 
2.7. Renal impairment 
Chronic kidney disease (CKD) has been reported in 5-65% of survivors of allogeneic BMT(81, 82). It 
typically presents as one of three distinct clinical entities: thrombotic microangiopathy (TMA), 
nephrotic syndrome (NS), and idiopathic or GVHD-related CKD(83).  Radiation nephritis may also occur 
following TBI. One retrospective study of 266 patients demonstrated that the cumulative incidence 
increases between five and ten years after BMT(84), and in another report, a case matched control 
study, it was shown that BMT survivors who develop CKD are at increased risk of mortality compared 
to non-BMT survivors,  with mortality approaching 90% for those who progress to end stage renal 
disease (ESRD) requiring dialysis(85).  For these reasons kidney transplantation is sometimes 
performed for ESRD after BMT(86). 
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Risk factors for the development of CKD in BMT survivors include pre-BMT renal disease, primary 
diagnosis (e.g. myeloma), older age at BMT, transplant-related renal toxicity resulting from sinusoidal 
obstruction syndrome (SOS), haemorrhagic cystitis, endothelial damage from acute and/or chronic 
GVHD and infection, treatment related renal toxicity resulting from chemotherapy exposure, TBI, 
calcineurin inhibitors and antimicrobial drugs, polyoma BMT virus nephropathy, and increased rates 
of chronic illness post-BMT including HTN and DM(56, 83, 87).   
2.8. Liver dysfunction 
Late liver complications have been reported in up to 72% of BMT survivors(88), most commonly as a 
consequence of cGVHD, reactivation of viral hepatitis (HBV and HCV), prior SOS, iron overload from 
transfusions and/or ineffective erythropoiesis and/or hepatotoxic medications(46, 88, 89). Hepatic 
cGVHD occurs in 90% of patient with cGVHD(88) and may manifest with asymptomatic elevation of 
serum alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma-glutamyl transferase 
(GGT), slowly progressive cholestatic jaundice or acute hepatocellular injury(90).  
Infection with HCV is also associated with greater morbidity and mortality in BMT survivors.  Cirrhosis 
and end-stage liver disease related to chronic HCV infection has been reported to occur in 
approximately 35% of long-term survivors.  A faster rate of progression to end stage disease has also 
been reported in BMT recipients when compared to case matched controls(90); the 20-year 
cumulative incidence for death due to liver complications is 6.1%, and for severe liver complications 
(death from liver failure, cirrhosis and liver transplantation) it is 11.7%(91). 
Long-term survivors also appear to have an increased incidence of gallstones and gallstone 
complication.  This is likely related to myeloablative conditioning causing calcium bilirubinate microlith 
formation. Chronic cyclosporine or tacrolimus use can also lead to biliary symptoms and acute 
pancreatitis(90). 
2.9. Skeletal disorders 
BMT survivors have an increased risk of bone disease post-transplant, with osteopenia and 
osteoporosis incidence ranging between 3–70%(92, 93) and fractures reported in 8%(94).  When 
compared to age and sex matched general population controls, female BMT survivors have an eight-
fold increased risk of fracture and males have a seven- to nine-fold increased risk of fractures in those 
aged 45-65 years(94).   
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Multiple risk factors contribute to bone loss following BMT, including conditioning chemo-
radiotherapy, GVHD, the use of glucocorticoids and calcineurin inhibitors (especially cyclosporine), 
gonadal failure, malabsorption, chronic renal dysfunction, malnutrition, vitamin D deficiency, weight 
loss and immobility. Glucocorticoid therapy, in particular, is associated with a markedly increased risk 
of bone loss, particularly in the first few months of use. Glucocorticoids also increase fracture risk, 
with fractures occurring at a higher bone mineral densitometry (BMD) than occurs in postmenopausal 
osteoporosis(92). In each of these cases, impaired bone mineralisation occurs through a range of 
different physiological processes including disturbances of calcium and vitamin D homeostasis, 
osteoblast and osteoclast dysfunction, and growth and gonadal hormone secretion(95). Collectively 
these contribute to rapid bone loss post-BMT, which is maximal in the first 3–6 months following 
transplant(96).   
Osteonecrosis or avascular necrosis of bone (AVN) (most commonly affecting the hip, knees, ankles 
and shoulders) also occurs with increased frequency after BMT.  Although the literature on AVN in 
adult survivors of BMT is limited, AVN is reported to occur in 4–19% of survivors with a cumulative 
incidence of 3–10% at five years post-BMT(95).  
A number of risk factors for AVN have been identified, including the use of glucocorticoids, a history 
of acute lymphoblastic leukaemia (ALL), TBI, excessive alcohol intake, cGVHD, and being female. In 
BMT patients the risk of osteonecrosis is dependent upon the duration and cumulative dose of 
glucocorticoids as well as the presence of cGVHD(97). The risk is low (<3%) in patients treated with 
doses of prednisone less than 15–20mg/day(98). 
2.10. Oral and dental disease 
Late complications involving the oral cavity are common post BMT. Survivors often report oral pain, 
dryness, odynophagia, dysphagia and sensitivity (irritation from normally tolerated spices, foods, 
liquids or flavours) that may limit oral intake and they may have restricted mouth movement.  Many 
of these issues are related to cGVHD, of which the oral cavity is the most commonly affected organ(99, 
100). The presence of lichen planus, hyperkeratotic plaques, mucosal erythema, atrophy, mucoceles 
(due to inflammation and obstruction of the salivary gland ducts), pseudomembranes, ulcers, and 
restrictions due to peri-oral fasciitis or skin sclerosis are also common, and in some cases are 
diagnostic of oral cGVHD. Other causes of oral and dental complications post BMT include the late 
effects of the conditioning regimen, long-term immunosuppression, and medications which can 
contribute to xerostomia (e.g. antidepressants, anti-histamines, diuretics, muscle relaxants and some 
analgesics). 
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The most important risk factors for oral and dental complications include oral cGVHD, irradiation to 
the head and neck region, long-term immunosuppressive therapy (IST), DM, sicca syndrome, presence 
of chronic and latent infections, patient age at BMT and adequacy of post-BMT dental care(46, 101). 
Oral function is essential for many aspects of normal daily activities and any compromise can 
profoundly impact QoL, overall health and psychosocial wellbeing(102, 103). cGVHD, in particular, 
may cause a range of mucosal abnormalities including a marked risk of development of SCC of the oral 
mucosa and xerostomia(104, 105).  These issues further increase risks to oral and dental health by 
causing significant pain affecting alimentation, and nutritional status and by increasing the risk of 
dental caries, periodontal disease and oral infections(99, 101, 103). 
BMT survivors are also at risk for osteonecrosis of the jaw (ONJ).  This occurs following invasive dental 
procedures such as dental extractions and is associated with the long-term use of anti-resorptive 
therapies used for the prevention of osteoporosis, whether this is age related or iatrogenic from long-
term and/or high dose glucocorticoid use or direct use of anti-absorptive agents in diseases such as 
multiple myeloma for the management and prevention of hypercalcaemia or lytic bone lesions(106). 
Long-term bisphosphonate use is associated with ONJ, particularly zoledronic acid and 
denosumab(107).   
2.11. Immunodeficiency and infection 
Infectious complications are exceedingly common following allogeneic BMT and are an important 
cause of life-threatening emergencies and death.  In the first year post BMT, infection contributes to 
death in up to 61% of recipients(108) and in those who survive 15 years post-BMT, infection is the 
cause of death in 11% of those without cGVHD(11).  The major risk factor for late infection causing 
death post BMT, is however, cGVHD(109).  
Immunodeficiency and infection following BMT occur as a consequence of neutropenia, immune 
ablation and immunosuppression related to disease processes, splenectomy, conditioning chemo-
radiotherapy and treatments for cGVHD. Specifically, BMT recipients experience decreased thymic 
function, restricted T-cell repertoires, decreased CD4 T-cell numbers, decreased regulatory T-cells, 
decreased B-cells, or increased immature B-cells, decreased splenic size and functional 
hypersplenism(110-112).  Bacterial, fungal and viral infections all occur post BMT and further 
transplant and patient related risk factors include cord blood, HLA-mismatched or T cell-depleted 
graft, disease status at BMT, cGVHD with prolonged immunosuppression, older age, and a history of 
oncogenic viruses(46, 113). 
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International and national guidelines for prevention and management of post-BMT infection include 
recommendations for bacterial, viral, fungal, regionally limited/rare infections, infection prevention 
and control, safe living after BMT, and vaccination post-transplant(114).  A large number of pathogens 
are associated with infection post-BMT including: Streptococcus pneumoniae, Viridans Streptococci, 
Haemophilus influenzae type b, Bordetella pertussis, Cytomegalovirus (CMV), Epstein-Barr virus EBV), 
Herpes simplex virus (HSV), Varicella Zoster virus (VZV), community-acquired respiratory viral (CRV) 
infections including Influenza, Respiratory Syncytial virus, Human Metapneumovirus, Parainfluenza 
virus,  Adenoviruses, Polyomavirus BK and JC, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus 
(HCV), Herpesvirus 6, 7 and 8, Human Immunodeficiency virus (HIV), Fungal, yeast infections, mould 
infections, Mycobacterium tuberculosis (TB), Pneumocystis jiroveci Pneumonia (PCP), Toxoplasma 
gondii, Nocardia infection, Strongyloides stercoralis, Trypanosoma cruzi, Leishmania, Malaria, 
Legionnella, Methicillin-Resistant S. aureus, VRE, multi-drug resistant gram-negative Bacilli (MDR-
GNB), Clostridium difficile, Rotavirus, Norovirus, and Astrovirus.    
While immune reconstitution occurs post BMT, full T-cell immunity may take up to two years to be re-
established or longer if cGVHD persists.  Immunocompetence is defined as the ability to receive live 
vaccines (re-vaccination) which is an important infection prevention strategy post-transplant(114).   
2.12. Second malignancies 
One of the most tragic late effects of BMT is the development of a second malignancy.  Typically, there 
are three types of secondary malignancies post BMT; secondary leukaemia and lymphomas, post-
transplant lymphoproliferative disorders (PTLD) and secondary solid tumours(115).  Most PTLDs occur 
within the first months after BMT, while solid tumours and leukaemia mostly occur years to decades 
after transplant and increase in prevalence with time post-BMT(116).  
Almost all cancers have been reported post BMT including breast, skin, oropharynx, thyroid, 
oesophagus, lung, soft tissue, brain, melanoma, liver, anogenital, bone and connective tissue(64, 65, 
117-119).  B-cell neoplasms and Hodgkin’s disease have also been described but are rare(116).
Incidence rates for PTLD are up to 8.1%(120), breast cancer has a cumulative incidence of 17% at 
twenty five years in those who have received TBI(119), and secondary leukaemia or myelodysplasia is 
reported to be 4% at 7 years post BMT(121) and to be of donor-derived origin in many instances(122). 
When compared to the general population, survivors of BMT develop new solid cancers at twice the 
expected rate, with this risk increasing over time, being three-fold at fifteen years post BMT(123) with 
no plateau(118). 
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Risk factors for secondary malignancies include younger age at BMT, gender (depending on the 
malignancy), underlying diagnosis (Fanconi’s anaemia), pre-BMT exposure to EBV and HPV, prolonged 
prior chemotherapy, particularly alkylating agents,  TBI, prior irradiation, T-cell depletion of the graft, 
unrelated or mis-matched donor transplant, prolonged IST post-BMT, exposure to azathioprine post-
BMT (particularly for skin cancers), cGVHD, a second BMT and increasing time from BMT(120, 121, 
123, 124).  
2.13. Ocular side effects 
There are three main ocular late effects of allogeneic BMT(33); ocular cGVHD and keratoconjunctivitis 
sicca syndrome (KCS)/dry eye disease(46, 125, 126); cataract formation; and ischaemic microvascular 
retinopathy(46). Ocular GVHD, dry eyes and cataracts are the most common ocular complications, 
occurring in 40-60%, over 50% and 85% of long-term BMT survivors respectively(127-129).    
Ocular cGVHD profoundly impacts on BMT survivor’s QoL – decreasing their visual acuity and reducing 
their ability carry out activities of daily living(130).  Manifestations include reduced tear flow, KCS, 
sterile conjunctivitis, corneal epithelial defects and corneal ulceration and can cause a range of 
symptoms, including dryness, burning, irritation, grittiness, pain, foreign body sensation, blurred 
vision, photophobia and excessive tearing(33, 125, 126).  Other ocular complications of the posterior 
chamber include haemorrhage, optic disk oedema and infectious retinitis, uveitis, choroiditis and 
blepharitis(131).   
Risk factors for ocular complications include TBI (dose and schedule dependent), cGVHD in other 
organs, having more than one BMT, older age, DM, prolonged corticosteroid and cyclosporine 
exposure(33, 128). 
2.14. Neurocognitive effects 
Neurological complications 
Up to 16% of BMT survivors experience neurological complications affecting both the central and 
peripheral nervous system(CNS and PNS)(132).  These include immune-mediated neuropathies, 
myasthenia gravis, myositis, thrombotic microangiopathy, cyclosporin neurotoxicity, infection 
including viral meningo encephalopathy and progressive multifocal leukoencephalopathy (PML), 
metabolic encephalopathies cerebrovascular complications, demyelination, and immune-mediated 
encephalitis(133, 134).  Malignant gliomas, neuroectodermal tumours and meningiomas have also 
been reported post BMT, as have late infections of the CNS, cerebral vascular lesions and cerebral 
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angitis(134, 135).  Some of these late effects have been reported up to eighteen years post BMT(136). 
Neurological complications of BMT appear to have a profound impact on survival, with one study 
reporting a four-year probability of survival of only 12% in those who experience neurological events 
post BMT(132). 
A number of factors contribute to the risk of neurological disease post BMT including TBI, cranial 
irradiation, intrathecal chemotherapy, younger age at BMT(137), unrelated or mis-matched donor 
transplant, IST, cGVHD, and exposure to rituximab post BMT (particularly PML)(134, 138) . 
Neurocognitive complications 
Up to 40% of those who survive five years post-BMT report some form of neurocognitive deficit 
including reduced short term memory, verbal recall and motor dexterity(139).   
Risk factors for neurocognitive decline post BMT include immunosuppression with cyclosporin, TBI, 
prior cranial irradiation, intrathecal chemotherapy, younger and older age at transplant, and cGVHD. 
Prolonged hospital admission has also been associated with greater cognitive deficit after BMT(140). 
2.15. Chronic graft versus host disease 
cGVHD is one of the most common and deleterious effects of BMT, occurring in 30-75% of BMT 
survivors and profoundly impacting upon survival and QoL post-BMT, with a five year mortality rate 
of 30-50%(141).  cGvHD is a highly complex immune pathology involving donor T and B, and other 
cells, which causes donor cells to respond to alloantigen presented on host antigen presenting cells 
(APC), resulting in fibroproliferative changes.  It can be mild, presenting with a single organ symptom 
(such as lichenoid features in the mouth only), or it can be diffuse, severe and prolonged, manifesting 
as multisystemic immunological disease including systemic lupus erythematosus, Sjogren’s syndrome, 
scleroderma, rheumatoid arthritis, primary biliary cirrhosis, BOS, immune cytopenias, and chronic 
immunodeficiency(142).  In order of frequency, cGVHD affects the skin, mouth, eyes, gut, liver, joints, 
muscles, vagina, oesophagus, nails, lungs and serosa(142, 143) and can lead to a multitude of long-
term and late effects as outlined in this chapter.  
Risk factors for more severe or prolonged cGVHD include the use of older BMT recipients and donors, 
mis-matched and unrelated donor transplant, the use of peripheral blood stem cells, acute GVHD, and 
the use of DLIs(144, 145). 
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Importantly, as the treatment of cGVHD involves prolonged and often intense IST, this increases the 
risk of infection and malignancy. And while 50% of those who develop cGVHD will experience 
resolution of symptoms within seven years of commencing treatment, approximately 40% will have 
recurrent malignancy or die within seven years, and the remaining 10% will require continued 
treatment for an indefinite period of time(143, 146).  Unsurprisingly, given the extensive and pervasive 
physical impact that cGVHD can have, it is the major determinant of QoL and functional status in those 
who survive more than two years post-BMT(147). 
2.16. Compromised quality of life 
Although difficult to define QoL comprises broad concepts that affect global life satisfaction, social 
and personal functioning, achievement of life goals and inter-relationships(148).  It is a subjective, 
multidimensional concept which encompasses psychological, social, physical and contextual or 
environmental aspects of health and illness.  BMT survivors are known to experience significant 
declines in QoL in the lead up to and in the years following BMT due to the toxicity of chemo-
radiotherapy, the complications of BMT, particularly cGVHD, the medications used to prevent and 
treat these complications, including steroids and immunosuppressive therapies, and the intractable 
nature of survival with chronic illness(148).   Symptoms and issues impacting on BMT survivor QoL 
include pain, fatigue, insomnia, sexual dysfunction, declines in physical functioning, emotional 
distress, depression, post-traumatic stress, psychological and neurocognitive functioning declines, 
issues with schooling, work or returning to work, issues with marital and family roles and social 
support, caregiver burden and financial toxicity(149, 150).  
Risk factors for poorer QoL in the years post BMT include worse pre-BMT physical health, younger and 
old age at BMT, prior chemo-radiotherapy, depression, being female, low education levels, low social 
support, greater physical symptoms, unrelated donor transplants, cGVHD and exposure to 
corticosteroids(151-153).  
In studies comparing QoL of BMT survivors to sibling controls, BMT survivors are less likely to be 
married, more likely to have health related issues preventing them from holding a job, more likely to 
report difficulty maintaining health insurance and acquiring life insurance and require additional 
support with school and tertiary studies(33, 36, 154).  Over 50% experience depression or subclinical 
depression and there is some data that depression may negatively impact on survival in the first-year 
post BMT (155). Over 70% of survivors report moderate to severe symptoms of fatigue for at least five 
years post-transplant(6) and for those under 40 years, over 30% experience concerns about 
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fertility(149).  The majority of survivors report sexual dysfunction at some point post BMT(150). BMT 
survivors also have increased rates of suicide compared to the general population(156).  
Although many BMT survivors return to work post-BMT (particularly as time increases post-transplant) 
this is highly dependent on their age at transplant, their pre-BMT employment status, and the 
development and severity of cGVHD(151, 154).  Physical recovery occurs earlier than psychological 
and ‘work recovery’, and full physical and psychosocial recovery from BMT may take up to five years 
(substantially longer than the time estimated by BMT healthcare professionals(157)). 
While many survivors have ongoing psychosocial and financial concerns post BMT and many continue 
to fear the risk of relapse or recurrence of disease post-BMT(6), many survivors also report positive 
impacts of BMT including a personal strength and appreciation for life, closer interpersonal 
relationships, reprioritizing “what really matters,” renewed faith, and a sense of gratitude(150, 158).  
2.17. Summary 
Allogeneic BMT survival is associated with a multitude of adverse long term and late effects which 
affect every body system.  Many of these significantly impact the morbidity and mortality of survivors 
post-BMT and their QoL.   While methodological differences (retrospective, prospective, self-report, 
patient medical record/result review) between studies of long-term survivors, and the heterogeneity 
of cohorts studied (transplant type (autologous, allogeneic), donor type, conditioning intensity, 
primary disease and disease status at BMT) make it difficult to elucidate a clear and comprehensive 
picture of BMT survivorship, it is clear that all survivors require some degree of life long follow-
up(159).  The publication of international guidelines for BMT long-term follow up (LTFU) illustrate the 
increasing recognition of the complex health care needs of BMT survivors and the responsibility for 
transplant services to provide comprehensive preventive care(160, 161).  
The next chapter provides an overview of the guidelines for BMT LTFU and details the provision of 
services available to BMT survivors in New South Wales (NSW).   
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Chapter 3: BMT Long-Term Follow-up Service Provision in NSW 
3.1. Chapter overview  
This chapter provides an overview of the recommendations for long-term follow-up (LTFU) of BMT 
survivors and the health care services currently available for BMT recipients in NSW, including the 
provision of LTFU.  The final section of this chapter presents the research aims of this thesis.  
3.2. International guidelines for LTFU of BMT survivors 
Increasing recognition of the long-term and late effects of BMT (as detailed in Chapter 2) has led a 
number of national and international BMT organisations to develop and disseminate consensus 
guidelines for screening and prevention of late complications of BMT(1, 2).  These guidelines outline 
the surveillance tests, clinical assessments and preventive care that BMT survivors require at regular 
intervals, for life.  These tests, assessments and preventive care aim to monitor for recurrent and 
secondary malignancies, cGVHD, infections, respiratory, cardiovascular, renal, musculoskeletal, 
ocular, oral, gastrointestinal, dermatological and endocrine dysfunction, and psychosocial issues, 
among others.  
The burden of testing and treatment that follows adherence to these guidelines however, both for 
BMT survivors, their carers and health care teams is immense.  Survivors receiving follow-up care 
according to these guidelines require contact with at least six clinical specialties and need up to thirty-
four assessments annually, including health history, clinical examinations, laboratory analysis, 
diagnostic imaging, psychosocial assessments, health counselling and education (Table 3.1). 
Table 3.1: Abbreviated summary recommendations for screening and prevention of late 
complications in long-term BMT survivors by time after transplant(1)  
Recommended screening/prevention 6mo 1yr Annually 
Immunity 
Encapsulated organism prophylaxis 2 2 2 
PCP prophylaxis 2 2   
CMV testing 2 2 2 
Immunisations 1 1 1 
Ocular 
Ocular clinical symptom evaluation 1 1 1 
Ocular fundus exam * 1 * 
Oral complications 
Clinical assessment 1 1 1 
Dental assessment * 1 1 
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Respiratory 
Clinical pulmonary assessment 1 1 1 
Smoking tobacco avoidance 1 1 1 
Pulmonary function testing * * * 
Chest radiography * * * 
Cardiac and vascular 
Cardiovascular risk-factor assessment * 1 1 
Liver 
Liver function testing 1 1 * 
Serum ferritin testing   1 * 
Kidney 
Blood pressure screening 1 1 1 
Urine protein screening 1 1 1 
BUN/creatinine testing 1 1 1 
Muscle and connective tissue 
Evaluation for muscle weakness 2 2 2 
Physical activity counselling 1 1 1 
Skeletal 
Bone density testing (adult women, all allogeneic transplant recipients 
and patients at high risk for bone loss)   1 * 
Nervous system 
Neurologic clinical evaluation * 1 1 
Evaluate for cognitive development   1 1 
Endocrine 
Thyroid function testing   1 1 
Growth velocity in children   1 1 
Gonadal function assessment (prepubertal men and women) 1 1 1 
Gonadal function assessment (post pubertal women)   1 * 
Gonadal function assessment (post pubertal men)   * * 
Muco-cutaneous 
Skin self-exam and sun exposure counselling 1 1 1 
Gynaecologic exam in women * 1 1 
Second cancers 
Second cancer vigilance counselling   1 1 
Screening for second cancers   1 1 
Psychosocial 
Psychosocial/QOL clinical assessment 1 1 1 
Sexual function assessment 1 1 1 
1 = recommended for all transplant recipients 
2 = recommended for any patient with ongoing chronic GVHD or 
immunosuppression       
* = reassessment recommended for abnormal testing in a previous time period or for new 
signs/symptoms 
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While published guidelines are clearly beneficial in that they optimise, standardise and harmonise the 
post-transplant care of BMT survivors(3) many questions remain about their translation into clinical 
practice and the evidence for their utility.  While historically BMT units have been responsible for 
providing pre-, peri- and post-transplant care for BMT recipients, this is changing as more transplants 
are performed, more patients survive, and more patients become long-term survivors of BMT. While 
BMT centres are most familiar with long-term and late effects of BMT, and have access to a range of 
specialist services, new models of care (MOC) are required for BMT LTFU(4, 5).   
3.3. Health care and the provision of post-BMT care in NSW 
NSW is Australia’s most populous state with a population of 7,995,100 (as at 31 March 2018)(6).  It is 
the third largest state/territory covering an area of 800,628 square kilometres which represents 10.4% 
of Australia’s land mass(7). Health care in NSW, as across all Australia, is complex, and consists of 
public and private providers who deliver multifaceted primary health care, community services, 
emergency and hospital-based treatments, rehabilitation and palliative care.  While public sector 
health services operate within a complex funding structure administered by both federal and state 
and territory governments, private hospitals, medical and allied health practices and pharmacies are 
owned and operated by the private sector (but regulated by government)(8).   
NSW’s public health care system consists of fifteen local health districts (LHD) (health administration 
boards which operate public hospitals, institutions, health services and health support services), three 
speciality networks  (Sydney Children’s Hospital Network, Justice and Forensic Mental Health Network 
and St Vincents Health Network) and nine primary health networks (a regional network of general 
practitioner-led councils and Community Advisory Committees to ensure primary, community and 
specialist sector services work together across the region)(9).   
In total, there are 431 hospitals in NSW.  This comprises 226 public hospitals and 205 private hospitals 
and facilities(10).  Of these, only five public hospitals perform adult allogeneic BMT - Westmead 
Hospital (WH), St Vincents Hospital (SVH), Royal North Shore Hospital (RNSH), Royal Prince Alfred 
Hospital (RPA) and Liverpool Hospital (LH).  All five are located in metropolitan Sydney.  This means 
that BMT recipients who live in regional and rural NSW (2,729,742 people are reported to live outside 
the Greater Sydney area as at June 2017 (11)) must relocate to Sydney to undergo transplant and for 
the early post-transplant period (Figure 3.1).  
3.4. Early Post-BMT care for survivors in NSW 
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The care of BMT recipients during transplantation and in the first three months post-BMT is well 
established.  The focus during this period is on monitoring disease status, and surveillance and 
prevention of early post-transplant complications including acute GVHD and infection.  Following this 
period, provided there is no ongoing necessity for intensive treatment for acute GVHD, infections or 
other acute issues, the frequency of BMT Specialist follow-up is gradually decreased and the patient 
is able to return to their home.  After a patient has survived 3-12 months post-BMT, the focus of their 
care changes to monitoring for relapse, and screening for and management of cGVHD and 
maintenance of good health.  During this period many patients are transitioned to long-term and late 
effects clinics, although this care may also be delivered within standard BMT clinics.  Post-BMT care is 
generally co-ordinated by the BMT specialist and/or more commonly, by BMT advanced practice 
nurses (APN) (e.g. BMT Co-ordinators, Nurse Practitioners (NP), Clinical Nurse Consultants (CNC), 
Clinical Nurse Specialist (CNSp)) and is subsidised by Medicare and the Pharmaceutical Benefits 
Scheme (PBS). 
 
Figure 3.1: Place of residence of BMT recipients in NSW 
3.5. Models of care for BMT LTFU  
It is increasingly recognised that there is a need for flexible, heterogeneous and sustainable MOCs for 
BMT LTFU.  Rather than describe a single model for delivery of post-BMT care, survivorship guidelines 
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recognise that delivery of healthcare needs to be personalised and have therefore focussed more on 
the components of care that need to be addressed in healthcare design and delivery. In this regard it 
is notable that the Institute of Medicine (IOM) 2005 report titled ‘From cancer patient to cancer 
survivor: Lost in transition’ specified that comprehensive survivorship care should be characterised by 
safety, effectiveness, patient-centeredness, timeliness, efficiency and equity(12).  Developing and 
implementing robust LTFU MOCs to satisfy these essential components is critical, both for BMT 
centres who are perfoming more and more BMTs and for the health care system that will need to 
support more and more survivors.   
Both nationally and internationally there is no consensus regarding the optimal LTFU MOC(13, 14).  In 
the US, Canada and the UK various MOCs exist and services have typically been based on historical 
and opportunistic practices, and on cancer survivorship models(15-19).  In general terms BMT LTFU 
care is provided in four different ways:  
• LTFU care provided during routine follow-up in the BMT Clinic: 
BMT specialist/BMT APN continues to see the survivor in the BMT clinic. 
 
• LTFU care undertaken as a ‘stand-alone’ assessment/clinic visit either within the BMT clinic or 
in a dedicated BMT LTFU clinic:   
The survivor is transitioned to a dedicated LTFU clinic/team. This is distinct from the early 
post-BMT clinic, is often held in an alternate space or on a different day, (but may be run 
alongside the early post-BMT clinic), and may be staffed by a multidisiplinary team (MDT).  
 
• Collaborative LTFU care shared between the BMT centre and other providers (e.g. sub-
specialists, local haematologist, General Practitioner (GP)): 
The survivor is seen infrequently in the BMT centre (often for purposes of LTFU review and 
data collection) with the majority of follow-up test, assessments and health care delivered by 
the surivors local haematologist/GP and by community health care providers. 
 
• LTFU care with local haematologist/GP: 
The survivor is transitioned or discharged from the BMT service to the care of their local 
haematologist or GP with a care plan and recommendations for follow-up.  
3.6. BMT LTFU in NSW  
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At the time of study commencement (2012) there were no national or state guidelines for BMT LTFU, 
no standarisation or harmonisation in BMT LTFU care, no agreed processes for transitioning adult 
survivors of childhood BMT to adult health care services, few nurses employed to provide post-BMT 
care and no nurse practitioners employed in NSW in LTFU.  BMT recipients were followed up in a range 
of different settings, dependent in part upon instiutional culture, on avaiable (human and space) 
resources and existing MOCs.  Some recipients continued to receive co-ordinated care through their 
BMT centers, some were referred back to their local haematologist and many had no ongoing care 
and were lost to follow-up 2-5 years post-BMT.  The ABMTRR reported at the time there were 
estimated to be over 1,500 long-term BMT survivors(20) however hospital BMT database estimates 
were less than 900(personal communication).  With the exception of WH there was very limited 
multidisciplinary care, limited nursing involvement in post-BMT care and limited co-ordination of long-
term care.  Rural and regional BMT survivors were either required to return to the BMT centre for 
LTFU (if available) or their care was left to their local haematologist or GP (often without direction 
from the BMT centre)(Table 3.2). 
Informal discussions with BMT survivors and their carers, and with health care providers involved in 
the follow-up of BMT recipients at the time found that many BMT survivors experienced difficulties 
accessing and paying for specialist health care services, dealing with fragmentation of care and poor 
communication between health providers, and navigating between different healthcare providers, 
between the public and private sector and between the hospital and community health care systems 
(LHDs and PHNs).  Many also experienced significant difficulties as a consequence of loss or reduction 
of employment and costs related to care being inadequately subsidised by Medicare and/or the PBS. 
3.7. Research aims 
This research arose directly out of concerns regarding this suboptimal experience of BMT survivors in 
NSW, a recognition that post-BMT care was inconsistent and fragmented, and often did not satisify 
recommendations of international BMT LTFU guidelines(1), was not organised in accordance with the 
principles described by the IOM for cancer survivorship(12) and was not based on a comprehensive, 
evidence-based understanding of post-BMT survivorship in Australia. (At the time of study 
commencement the ABMTRR only collected data on date last seen, cGVHD, relapse and/or death). 
The aims of the research described in this thesis, therefore, were:  
1. to describe the incidence and range of late complications of BMT and their association with 
the health and functional status of survivors in NSW; 
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2. to address limitations in BMT survivorship literature – particularly with regard to the 
financial, occupational and psychosocial impact of BMT; 
3. to identify gaps in service provision provided to this vulnerable and high-risk patient group; 
4. to provide better information to patients contemplating BMT, and to their families and 
guardians, regarding the possible long-term sequelae of BMT, and 
5. to support clinical and health policy decision-making around BMT through the provision of 
more comprehensive data regarding the late sequelae of BMT in an Australian setting.  
The next chapter presents the research methods used to address these aims.  It includes a description 
of the research sample, setting, and instruments used, and of the data analysis performed.  
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Table 3.2:  BMT LTFU Models of Care employed across NSW at study commencement (2012)  
Centre 
# 
Allos/ 
year 
2011 
BMT Nursing 
involvement 
(FTE) 
Clinic type available 
for post-BMT 
patients  
Delivery mode 
(Led by and 
frequency) 
Located within Provider involvement 
Referral timepoint to BMT LTFU (if 
available) 
WH 62 
Yes 
(0.5 CNS2) 
2 x Post-BMT Clinics 
1 early post-BMT  
1 LTFU clinic 
Routine post-BMT 
care 
 
(BMT LTFU CNS -
weekly) 
BMT Clinic 
BMT LTFU CNS 
BMT physicians 
Dermatology 
Gynaecology 
Endocrinology 
Concurrent Respiratory medicine 
clinic runs in private rooms 
3 mo post-BMT  
Yes 
(0.3 CNC) 
Post-BMT Clinic – 
Satellite Clinic 
(Newcastle) 
Routine post-BM 
care 
(Newcastle BMT-
Co-ordinator -
monthly) 
WH pt specific 
Post-BMT Clinic 
 
BMT-Coordinator 
BMT Physician from Westmead 
(rotating physicians on a monthly 
basis) 
3 mo post-BMT 
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SVH 38 
Yes 
0.5 CNC2 
(funded by 
the NSW 
BMT 
Network) 
Post-BMT Clinic 
Specialised LTFU 
Clinic  
(BMT CNC - 
monthly) 
Specialised 
LTFU Clinic 
 
BMT LTFU CNC 
BMT Fellow 
Social worker 
(Referral to this clinical was at BMT 
physician discretion – some preferred 
to follow-up their patients 
themselves) 
2 years post-BMT 
No  
(for those 
BMT 
physicians 
who 
preferred to 
follow-up 
BMT 
patients 
themselves) 
Post-BMT Clinic 
Routine post-BMT 
care 
 
(BMT Physician) 
Haematology 
Clinic 
BMT Physician 
Referrals made within and outside 
SVH as required/per physician 
discretion 
 
RNSH 18 
Yes 
0.5 CNC2 
(funded by 
the NSW 
BMT 
Network) 
BMT LTFU Clinic 
Specialised LTFU 
care 
 
Specialised 
LTFU Clinic 
BMT CNC 
BMT Physician 
Clinical Psychologist 
Social worker 
2 years post-BMT 
44 
 
(BMT CNC – 
monthly) 
 
RPA 21 No Post-BMT Clinic 
Routine post-BMT 
care 
 
(BMT Physician) 
Haematology 
Clinic 
BMT Physician 
Referrals made within and outside 
RPA as required/per physician 
discretion 
 
LH N/A      
Liverpool did not become an 
allogeneic BMT centre until 2012 so 
they did not have any long-term 
survivors at study commencement 
CNS, Clinical Nurse Specialist; CNC, Clinical Nurse Consultant; NP, Nurse Practitioner; pt, patient; mo, months 
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Chapter 4: Methods 
4.1. Chapter overview 
This chapter outlines the methods that were employed for the research described in this thesis.  Due 
to journal word count restrictions, each manuscript contains a concise methods section (relevant to 
that manuscript), therefore some additional detail regarding study design and execution is provided 
here.   
4.2. Methods 
This study used a cross-sectional survey design that combined quantitative and qualitative methods 
to examine the long-term and late effects of allogeneic BMT performed on adults and was conducted 
in NSW.   The study included an examination of the sequelae of BMT and their association with a range 
of sociodemographic, transplant factors and the impact that these had on survivors’ experience and 
QoL. The project also aimed to identify the gaps in service provision provided to this vulnerable and 
high-risk group.  
Design 
A cross sectional survey design was employed to collect data to address the aims of this study.  This 
method was chosen because it provides an established method for determining the frequency of an 
attribute of interest/patterns of morbidity and potential risk factors, in a particular population, at a 
defined time point, in a timely and inexpensive manner(1, 2). Cross-sectional studies have been used 
extensively to determine the prevalence of risk factors and to measure the current health status, 
health practices, knowledge, and attitudes of various populations.  The data provided by cross-
sectional studies can be used for priority setting for disease control and health service planning, and 
enable hypothesis generation for future research.  In particular, observations made during the cross-
sectional surveying can be used to develop hypotheses for testing temporal relationships between risk 
factors and disease(3). In practical terms, cross-sectional studies also are efficient, affordable and can 
be conducted across multiple sites and in different settings.  For all these reasons a cross-sectional 
survey was regarded as the most appropriate means for documenting the physical and psychosocial 
health of BMT survivors in NSW.  
Research Setting 
This study was conducted in NSW, Australia.  Australia has a population of approximately 24.9 million 
people distributed throughout six states and two territories.  NSW is the most populous state with 
49 
 
approximately 7.9 million inhabitants as at March 2018(4).  In 2012 (when the study began) 554 BMTs 
were perform throughout Australia with NSW contributing 216 to this total(5).   
At the time of study inception there were five allogeneic BMT centres located in the state (however 
one centre (LH) only commenced their allogeneic BMT program in 2012 so had no eligible survivors 
for the study – accordingly only four centres were involved) - all are located in metropolitan Sydney. 
Therefore, as discussed in Chapter 3, regardless of residential location in NSW, patients who need an 
allogeneic BMT are required to relocate to the state’s capital to receive their treatment at WH, SVH, 
RNSH, RPA or LH. 
All four of the participating hospital BMT centres are National Association of Testing Authorities, 
Australia (NATA) accredited, operate as referral centres for patients domestically and internationally 
and all report their BMT outcome data to the Australasian Bone Marrow Transplant Recipient Registry 
(ABMTRR), the Centre for International Blood and Marrow Transplant Research (CIBMTR) and the 
Worldwide Network for Blood and Marrow Transplantation (WBMT).  Each unit has vast experience 
in the delivery of BMT (BMT was first performed in Australia in 1975(6)) with hospital physicians, 
nurses and scientists nationally recognised for their work in BMT through significant research output.  
Research Sample 
Eligible study participants were all BMT survivors (age >18 years) who had undergone an allogeneic 
transplant at WH, SVH, RNSH, or RPA between January 2010 – December 2012, could read and write 
English and consented to participate in the study.    
This sample time frame was chosen for several reasons: BMT techniques and supportive care have 
improved vastly over the past four decades (as detailed in Chapter 1) such that the most relevant 
issues and outcomes, for both future patients and health services, are likely to be identified in those 
who have undergone BMT in the past decade, and clinical records and contact details were reliably 
available for this cohort of patients.   
Research Procedures 
Potential participants were identified from each hospital’s BMT database and were phoned by the 
researchers or advised of the study when attending their BMT Clinic.  In each case the study was 
verbally explained to the patient and the patient was given the option of receiving a study pack in 
clinic or via the post.  Study packs consisted of an invitation letter, Patient Information Sheet (PIS) and 
Informed Consent Form (ICF) (Appendix C), and the survey instrument (Appendix D).  The invitation 
letter and PIS outlined that the purpose of the study was to examine the physical and psychosocial 
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impact of BMT and the QoL of allogeneic BMT patients, to identify gaps in services provided to 
survivors of BMT and to provide better information to patients and health care professionals on the 
possible late effects of BMT.  Participants were also advised that study participation was voluntary, 
confidential and, due to the nature of the study, unlikely to be of direct benefit to the individual 
completing the survey.  All participants were given the option of completing the survey instruments 
themselves at home or during their transplant clinic appointment, or completing the survey with the 
assistance of a member of the research team via a telephone interview. They were also given the 
opportunity to contact the investigators to address any questions they had and to receive additional 
help to answer the questionnaires if required. Participants were also given a stamp self-addressed 
envelope to post the ICF and completed survey back to the research team at the co-ordinating hospital 
(RNSH).  
A total of 669 BMT survivors were eligible for study participation.  Following phone contact, study 
packs were sent and given out in clinic to a total of 583 people (87.1% of eligible).  A follow up phone 
call was made to those survivors who did not return the survey within one month of it being 
distributed to them.  Failure to send the surveys back after this was considered non-response and no 
further contact was made. In total, the response rate was 75.6% (n=441) of the total number of 
surveys sent, and 65.9% of total population eligible for participation (Figure 4.1).   
 
Figure 4.11: Sydney Post-BMT Study Flowchart 
4.3. Study Instruments  
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The survey instrument used in this study consisted of six validated questionnaires and a survey 
designed by the research team to address areas not explored in other validated survey instruments.  
This latter survey, the Sydney Post-BMT Survey, was developed following a review of the international 
BMT literature and following input from relevant health professional and BMT survivors. The validated 
questionnaires utilised in this study were the Functional Assessment of Cancer Therapy – Bone 
Marrow Transplant (FACT-BMT Version 4), the Chronic GVHD Activity Assessment – Patient Self Report 
(Form B), the Lee Chronic GVHD Symptom Scale, DASS21, The Post Traumatic Growth Inventory, and 
the Fear of Recurrence Scale.  (Full descriptions of these survey instruments are given below).  All 
these instruments were combined into one twenty-page document for ease of completion by study 
participants (Appendix D).  This twenty-page document was then converted into a scannable 
document which simply required that study participants enter an ‘x’ in the ‘yes’, ‘no’, ‘don’t know’ or 
appropriate Likert scale box or write free text as indicated by the question.  A study specific BMT 
Clinical Data Form was also developed and used to collate clinical and transplant variables (Appendix 
E). This form was completed by the researchers, required tick-box responses and was also scannable.  
The scannable technology was utilised to aid efficiency in the data entry phase of the study.  
The Sydney Post-BMT Survey 
The Sydney Post-BMT Survey was devised by the research team in collaboration with health 
professionals involved in the care of BMT patients, including haematologists, infectious disease 
physicians, BMT nurses, BMT psychologists, and dieticians, in and discussions with transplant survivors 
attending BMT clinics.  It is a 402-question survey covering twenty areas including: 
• Demographics (6 questions) 
• Medical complications (36 questions) 
• Referrals, tests and assessment and time (35 questions) 
• Medications and treatments (27 questions) 
• Oral and dental health (15 questions) 
• Infections (17 questions) 
• Vaccinations (30 questions) 
• Complementary therapies (17 questions) 
• Cancer screening (37 questions) 
• Travel history (36 questions) 
• Close personal contacts (6 questions) 
• Lifestyle (10 questions) 
• Diet/Nutrition (19 questions) 
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• Occupation – Infection risk (11 questions) 
• Occupation – works status and functioning (35 questions) 
• Fertility and sexual function (41 questions) 
• Relationships (3 questions) 
• Preference for long term follow up care (8 questions) 
• Social, occupational attitudes, physical and psychological concerns (12 questions) 
• The three things that have impacted you most (1 question) 
The demographics section consists of six questions eliciting date of birth, BMT date, postcode, 
ethnicity, gender and education.  The medical complications section included 36 questions eliciting 
responses to known medical conditions.   The section covering referrals, tests and assessment included 
35 questions covering the types of specialist services patients had accessed, and the burden that they 
experienced as a consequence of seeking medical care.  Twenty-seven questions explored use of 
medications and other therapies.  The oral and dental health section asked fifteen questions about 
oral and dental problems that have developed since BMT.  Two sections comprising forty-seven 
questions explored infection and immunisation status pre and post-BMT.  
Complementary and alternative medicine (CAM) therapy use was elicited in seventeen questions 
while thirty-seven questions explored preventive health behaviour. Travel history, including insurance 
issues and infection health risk behaviours were explored in thirty-six questions.  Six questions asked 
about BMT survivors living arrangements and close contacts.  Lifestyle choices were elicited in ten 
questions.  While nineteen questions asked about diet and nutrition.  Post-BMT participation in high-
risk occupation was explored in eleven questions and the impact that BMT had on work status and 
functioning was explored in more detail in thirty-five questions.  Fertility and sexual function post-
BMT were investigated in forty-one questions and relationship status in three questions. Survey 
respondents where then asked what type of long term follow up care they would prefer post-BMT in 
eight questions.  Most survey questions asked for binary (yes/no) responses, although some sections 
allowed for open/free text responses eg. “if yes, how?”. 
The final two sections on the survey addressed psychosocial consequences of BMT.  The social, 
occupational attitudes, physical and psychological concerns section consisted of twelve questions – 
each of which required a five-point ordinal Likert scale response from ‘Not at all’ to ‘Very much’.  The 
final section of the survey asked a single question,” What would you say are the three things that have 
had the most impact on your QoL since your transplant (or that cause you the most distress)?” and 
provided room for participants to write a free text response. This was the only question in the survey 
that elicited purely qualitative data. 
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The Sydney Post-BMT survey was checked for face and content validity for respondent comprehension 
via piloting with six patients at two of the hospitals under study (RNSH and RPA).  Patients were 
approached at their BMT clinic visit and asked if they would be willing to complete and review the 
survey and provide any feedback they thought necessary.  All six patients approached agreed.  Five 
patients chose to self-complete the survey and send it back to the research team.  The sixth patient 
chose to review the survey by completing it in a one-on-one interview with a member of the research 
team.  All the patients understood that the surveys completed for this pilot would be destroyed once 
reviewed for validity by the research team, and the data would not be used for publication.   
No amendments were made to the survey as a result of this pilot testing.  All six patients provided 
positive feedback in relation to the aims of the survey and none had any objections to the types of 
questions asked.  The PIS however, was amended following this review.  Patients were asked to 
provide an indication of the time taken to complete the survey, which was found to be significantly 
more than the research team had estimated (originally the PIS indicated the entire survey would take 
approximately thirty minutes to complete.  This was updated to one hour). Data from this pilot testing 
was not included in the results. 
Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT Version 4) 
 
The FACT-BMT is a validated questionnaire for measuring QoL in BMT recipients(7). It takes three to 
five minutes to complete and combines two instruments, the FACT-G and a BMT subscale. The FACT-
G is a twenty eight-item self-report instrument that measures QoL (QoL) in cancer patients(8). It 
consists of five subscales measuring physical, functional, social and emotional well-being and 
satisfaction with the doctor/patient relationship. The BMT subscale includes twelve items designed to 
test QoL in BMT patients. The FACT-BMT plus the BMT subscale provides an overall QoL score. Patients 
rate themselves over the past seven days using five-step Likert scales with responses used to calculate 
overall QoL and subscale wellbeing scores.  
 
The Chronic GVHD Activity Assessment – Patient Self Report (Form B) 
 
The Chronic GVHD Activity Assessment – Patient Self Report Form B was developed by the NIH 
Consensus Development Project(9).  It is a ten-item questionnaire which asks patients to report on 
the severity and intensity (out of 10) of skin, oral, ocular and vulvovaginal symptoms as well as 
perceived global ratings of GVHD.  It takes about one minute to complete. 
 
The Lee Chronic GVHD Symptom Scale 
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The Lee Chronic GVHD Symptom Scale is a thirty-item validated questionnaire for measuring 
symptoms of cGVHD(10). It consists of seven subscales measuring adverse effects of cGVHD on skin, 
eyes, mouth, lungs, nutritional status, muscles and joints, vitality and psychological functioning.  
Patients rate themselves over the past month using five-step Likert scales.  It takes about two minutes 
to complete.  
 
The Post Traumatic Growth Inventory 
The Post Traumatic Growth Inventory is a twenty one-item questionnaire which measures post 
traumatic growth experiences in trauma survivors’ lives(11).  Tedeschi and Calhoun (1996) identified 
five major domains of growth which include 1) greater appreciation of life and changed sense of 
priorities; 2) warmer, more intimate relationships with others; 3) a greater sense of personal strength; 
4) recognition of new possibilities or paths for one’s life; and 5) spiritual development. It is widely used 
to assess positive life changes following traumatic events such as cancer, HIV, rape and disasters and 
other crises(12).  Statements including ‘I developed new interests’, ‘I know that I can handle difficult 
situations’ and ‘I learned a great deal about how wonderful people are’ expressed and the reader is 
asked to respond using a six-point Likert scale with responses ranging from, ‘I did not experience this 
change’ to ‘I experienced this change to a very great degree as a result of my crisis’.   
 
Fear of Recurrence Scale 
The Fear of Recurrence scale was developed in the early 1990s by the authors of a study looking at 
QoL in Leukemia patients.  It consists of five questions which measure individual’s thoughts 
surrounding recurrence of their disease and includes question such as ‘Because cancer is 
unpredictable, I feel I cannot plan for the future’, ‘I am afraid of my cancer coming back’ and ‘I will 
probably have a relapse in the next five years’.  Responses are asked for in the format of a 5-point 
Likert scale from ‘strongly agree’ to ‘strongly disagree’.   In total the five questions are scored out of 
twenty, and higher scores represent greater fear of recurrence than lower scores(13, 14) . 
The DASS 21 
The Depression, anxiety and stress scale (DASS 21) is a twenty one-item self-report questionnaire 
designed to measure the severity of a range of symptoms common to both depression and 
anxiety(15).   It is widely used and has been shown to be valid and reliable in both non-clinical and 
clinical cohorts(16, 17) Patients are asked to indicate how much a particular statement has applied to 
them over the past week.  It uses a four-point Likert scale which ranges from ‘did not apply to me’ to 
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‘applied to me very much, or most of the time’ for statements such as, ‘I found it hard to wind down’, 
‘I felt I had nothing to look forward to’ and ‘I felt life was meaningless’.  Each question is scored out of 
three for an overall total score out of sixty three.  A higher score indicates greater severity of 
symptoms of anxiety or depression.   
  
Sydney Post-BMT Clinical Data Form 
A one-page BMT Clinical Data Form was developed by the research team to collect information 
regarding date of transplant, date of diagnosis and stage at transplant, transplant conditioning, GvHD 
prophylaxis, stem cell source and donor type of BMT survivors.  It contained ten questions and was 
completed by the research team.  This information was retrieved from the transplant databases of 
each of the four participating transplant centres once patient consent forms had been received. This 
information enabled a comparison between clinical variables and late effects of BMT. 
Statistical Analysis  
Quantitative data  
Categorical responses were summarised using frequencies and percentages. Parametric continuous 
variables were summarised using means and standard deviations, and nonparametric variables using 
medians, interquartile ranges (IQR) or ranges. ORs and 95% confidence limits, Pearson 2 test or 
Fisher’s exact tests were used for comparative analysis of dichotomous categorical variables. Two 
sample comparisons of parametric and nonparametric data were determined using the independent 
t-test, and Wilcoxon Rank Sum tests, respectively. Comparisons of greater than two samples were 
determined using one-way analysis of variance and Kruskal–Wallis tests, respectively. Multivariable 
logistic regression and multiple regression analyses were used to adjust for confounders and to 
ascertain independent associations of explanatory variables with outcomes of interest. 
A two-tailed p value <0.05 was used as the level of statistical significance. Statistical analysis was 
performed using Stata software (Version12.1). 
Qualitative data  
De-identified responses to the QoL question, ‘What would you say are the three things that have had 
the most impact on your QoL since your transplant (or that cause you the most distress)?’ were copied 
verbatim into a word document.  The analytical framework used for coding was initially guided by the 
model of QoL conceived by Ferrell et al(18). The coding organization was performed on NVivo 
software. The thematic scheme was further refined following multiple readings and line-by-line coding 
of the text to examine, conceptualize, and categorize physical, psychological, social or spiritual 
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themes. Thematic analysis was performed independently by two members of the research team with 
final agreement on categories made after the five core members of the research team (GD, LB, NG, 
and IK) had independently read and provided commentary on both the codes and the characteristics 
of each category. 
Ethical approval and considerations 
Ethics approval was provided by the Northern Sydney Local Health District Human Research Ethics 
Committee (NSLHD HREC Reference: 1207-217M) to conduct the study at the four relevant hospitals 
across NSW; WH, SVH, RNSH and RPA.  Site Specific Governance approval was provided by each 
hospitals Research Governance Office prior to study commencement.  (See the ‘Ethical approval’ 
section of this thesis for reference details and Appendix B).  
As the majority of the target population for this study (adult survivors of allogeneic BMT) were 
continuing to receive care in BMT centres including by members of the research team and could, in 
theory, experience psychological distress as a consequence of completing this survey, the following 
strategies where employed to reduce the likelihood of harm: 
• The research team was readily available (email addresses and phone numbers were provided), 
to answer any questions or concerns that participants may have had.   
• Participants were advised that LB (a clinical psychologist with experience in working with BMT 
patients) was available should they wish to discuss concerns arising from participation in this 
study.  
• To prevent (perceived or real) coercion potential participants were not approached by their 
BMT doctor about this study – only by the research team – and all were advised that their care 
would be not impacted if they did not wish to be involved in the study.  
• Prior to completing the survey, potential participants were given a PIS and ICF, which provided 
information about the study in lay-terms.  Potential participants were given a month to 
consider if they wanted to be involved in the study.  If happy to voluntarily proceed, they were 
asked to return the signed ICF.  
• Confidentiality was assured by giving each survey a dedicated study ID and only entering de-
identified survey responses into the database for analysis. In addition, only aggregated data 
was presented so that individual responses could not be identified.   
• Data protection was assured by storing the surveys, study documents and electronic files in a 
secure locked cupboard and computer file in the haematology department at RNSH.  Only the 
researchers had access to this cupboard and password protected computer files. These 
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documents will be destroyed by shredding and confidentially erasing the files seven years 
from study closure (1st February 2021).  
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Chapter 5: The experience of survival following allogeneic haematopoietic 
stem cell transplantation (allo-HSCT) in New South Wales, Australia 
5.1. Chapter overview 
This chapter provides an overall summary of the late effects of long-term BMT survival, presenting all 
the results of this research.  It consists of a published manuscript entitled, ‘The Experience of Survival 
following allogeneic Haematopoietic Stem Cell Transplantation (allo-HSCT) in New South Wales, 
Australia’.  The manuscript reports on all domains investigated; demographics, transplant factors, 
cGVHD, chronic co-morbidities, secondary malignancies, infections and vaccination uptake, health 
screening, sexual dysfunction, polypharmacy, health professional referrals, preferences for LTFU 
service delivery, household income and employment, QoL, fear of recurrence and personal growth.  
The findings have implications for the rest of the work reported in this thesis as they reveal the extent 
of long term and late effects occurring in our study sample, and provide a point of reference for further 
in-depth analysis of the study data.  
5.2. Publication details 
Gifford G, Gilroy N, Dyer G, Brice L, Kabir M, Greenwood M, Larsen S, Moore J, Hertzberg M, Kwan J, 
Huang G, Tan, Brown L, Hogg M, Ward C, Kerridge I. “The Experience of Survival following allogeneic 
Haematopoietic Stem Cell Transplantation (allo-HSCT) in New South Wales, Australia”. Blood and 
Marrow Transplantation 2016;51(10):1361-8. 
5.3. Authors’ contributions 
GD co-designed the study, recruited study participants, collected data, interpreted the results and 
drafted the manuscript.  A signed Statement of Contribution from all authors is in Appendix A. 
5.4. Manuscript 
The published version of the manuscript follows. 
 
ORIGINAL ARTICLE
The experience of survival following allogeneic haematopoietic
stem cell transplantation in New South Wales, Australia
G Gifford1,2,3, N Gilroy4, G Dyer2,4, L Brice3, M Kabir5, M Greenwood1,2,3, S Larsen6, J Moore7, D Gottlieb8, M Hertzberg9, J Kwan8,
G Huang8, J Tan7, L Brown10, M Hogg8, C Ward1,2,3 and I Kerridge1,2,3
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) entails long-term morbidities that impair survivors’ quality of life
through broad physical and psychosocial sequelae. Current data and survival measurements may be inadequate for contemporary
Australian allo-HSCT recipients. This study sought to comprehensively describe survivorship in an up-to-date, local setting through
validated measurements and a novel questionnaire designed to complement and address limitations of current instruments. All
adults who received an allo-HSCT between 2000 and 2012 in New South Wales were eligible and included, if alive, those literate and
consenting to the study, which encompassed seven survey instruments. Four hundred and forty-three survivors participated, which
is 76% of contactable (n= 583) and 66% of eligible survivors (n = 669). Chronic GVHD (cGVHD) and co-morbidity rates were similar
to published data. Noteworthy results include prevalent sexual dysfunction (66% females, 52% males), loss of income
(low income increased from 21 to 36%, Po0.001) and employment (full-time employment fell from 64 to 33%, Po0.001),
suboptimal vaccination (31% complete), and health screening (≈50%). Risk factors for poor vaccination and health screening were
cGVHD, younger age, less education, rural/regional residence and transplantation o2 years. This study suggests that improvement
in survivorship may necessitate structural changes in the current delivery of health services.
Bone Marrow Transplantation advance online publication, 23 May 2016; doi:10.1038/bmt.2016.135
INTRODUCTION
Over the past two decades, advances in allogeneic haematopoie-
tic stem cell transplantation (allo-HSCT) have led to concomitant
increases in the number of people undergoing this procedure and
improvement in survivorship. Between 2001 and 2011, 90 000 allo-
HSCTs were performed globally,1 with 4369 of them performed in
Australia.2 With improvements in donor selection, conditioning
therapies and supportive care, more recipients are living longer,3
and up to 85% are expected to be alive at 10 years.4,5
Although allo-HSCT provides a clear beneﬁt, it is associated with
signiﬁcant morbidity and mortality.6 A range of complications may
occur anytime post transplant, including ‘early’ (o3 months),
‘delayed’ (3 months to 2 years), ‘late’ (2–10 years) and ‘very late’
(410 years).7 Although contemporary allo-HSCT recipients are
living longer than historical cohorts, published data suggest
that allo-HSCT survivors experience a 30% lower life expectancy
than a matched population6 and may experience a compromised
quality of life (QoL) owing to the ongoing physical and
psychological sequelae of cumulative therapies,8,9 failure to
reintegrate socially10,11 and uncertainty of prognosis.12
International and local bodies have recognised that research
into the health, psychological and functional status of survivors is
necessary to identify and address unmet needs of survivors
and their families, enable better education and decision-
making around BMT and inform the design and delivery of
multidisciplinary health services essential to the care of long-term
survivors.13–15 This provides the rationale both for international
and national registry studies of survivorship and ‘local’ studies of
the speciﬁc experience of allo-HSCT survivors.
This study sought to comprehensively describe contemporary
allo-HSCT survivorship in an Australian population with the
intention of providing up-to-date information to candidates for
allo-HSCT, their families and/or guardians regarding the long-term
sequelae of allo-HSCT, supporting local clinical and health policy
decision-making around allo-HSCT and optimising the care of
survivors. Speciﬁcally, the aims of this study were to document the
incidence and range of late complications and their association
with the health and functional status of allo-HSCT survivors,
address limitations in the current literature around survivorship,
particularly with regards to the ﬁnancial, occupational and
psychosocial impact of allo-HSCT, and identify gaps in the existing
care of survivors in New South Wales (NSW), Australia.
PATIENTS AND METHODS
Patients and procedures
Participants were eligible if they had undergone an allo-HSCT between 1
January 2000 and 31 December 2012 in NSW, Australia’s most populous
state (population 7.5 million),16 were 418 years of age at time of
transplant, literate in English and were alive at the time of sampling.
Potential participants’ identity and phone number were retrieved from the
four NSW adult allogeneic transplant centres’ databases. Patients were
informed about the study in a clinic visit or via a telephone call from one of
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the researchers. Patients who agreed received a study pack at the clinic or
through the post, which consisted of an invitation letter, patient
information sheet, consent form, the questionnaire and a stamped self-
addressed envelope for return of the study instrument. All participants
were given the option to complete the questionnaire themselves or via
a phone interview with a researcher. To increase recruitment, a second
phone call was made to participants who had not returned the survey
within a month. This study was approved by the Northern Sydney Local
Health District Research Ethics Committee (NSLHD Reference: 1207–217M).
Instruments
Researchers collated information from transplant databases on diagnosis,
disease status and date of transplantation, conditioning regimen, GVHD
prophylaxis, stem cell source, and donor type for each consenting
participant. All other information was obtained from patient’s self-
reported responses to the questionnaire. Participants completed a 20-
page document that amalgamated seven survey instruments: The Sydney
Post BMT Study survey (SPBS)—a questionnaire uniquely developed by the
research team—and six other instruments previously validated in allo-
HSCT populations including the Functional Assessment of Cancer Therapy–
Bone Marrow Transplant (FACT–BMT Version 4),17,18 the Chronic GVHD
Activity Assessment–Patient Self Report (Form B),19 the Lee Chronic GVHD
Symptom Scale,20 the Depression Anxiety and Stress Scale (DASS21),21 the
Post Traumatic Growth Inventory (PTGI)22 and the Fear of Recurrence
Scale.23
The Sydney Post BMT Study survey (SPBS) was uniquely designed by the
research team to address limitations in existing post-transplant assess-
ments to provide a more comprehensive account of survival. Item
construction was informed by a review of the literature, interdisciplinary
collaboration among health professionals involved in long-term care of
allo-HSCT survivors and consultation with transplant recipients and their
carers. There were 402 questions covering 20 domains, including
demographics, medical complications, referrals/investigations, pharma-
and non-pharmacotherapy, oral/dental health, infections, vaccinations,
complementary therapy, cancer screening, travel history, close personal
contacts, lifestyle, nutrition, infection risk, work status, fertility and sexual
function, relationships, long-term follow-up care, psychosocial concerns
and a qualitative question ‘What are the three things that have impacted
you most?’. The questionnaire used tick box response, short answer
questions and 5-step Likert Scale measuring attitudes and other factors.
The questionnaire was piloted in clinic and phone interviews to assess face
and content validity and to check for comprehension of the survey
questions.
Statistical analysis
Exploratory analyses of all demographic data, baseline transplant
characteristics, and post-transplant exposures and lifestyle factors were
summarised using descriptive statistics. Categorical responses were
summarised using frequencies and percentages. Parametric continuous
variables were summarised using means and SDs, and non-parametric
variables using medians and interquartile ranges. The Pearson Chi-square
or Fisher's0 Exact tests were used for dichotomous categorical variables
and Pearson’s correlation coefﬁcient to assess the relationships between
continuous variables. The McNemar test was used to assess for signiﬁcant
differences in the distribution of pre-transplant and post transplant
dichotomous variables. Comparisons of means and medians were
determined by the independent t-test and Wilcoxon Rank Sum tests for
two samples; one-way analysis of variance and Kruskal Wallis tests were
used when there were 42 samples. Multivariable logistic regression was
used to assess for signiﬁcant associations between explanatory and
outcome variables after adjusting for potential confounders. A two-tailed P
value o0.05 was considered as the level of statistical signiﬁcance.
Statistical analysis was performed using STATA 12.1 statistical package
(StataCorp, College Station, TX, USA).
RESULTS
There were 1475 allo-HSCT performed during the study period.
There were 669 recipients alive at study sampling. Of the survivors,
583 were contactable and were sent study packs. Surveys were
completed and returned by 443 (66%); while 17 (3%) declined
consent and 125 (21%) did not return the survey.
Demographics and transplant characteristics are summarised in
Table 1.
Post-allo-HSCT morbidities are detailed for cGVHD (Table 2),
chronic morbidities including secondary malignancies (Table 3),
and infectious disease (Supplementary Table 1). Summarily,
cGVHD was common (69.3%) and self-reported symptoms were
moderate-severe in 32.4%. Skin, eye, vagina and mouth were the
most symptomatic. The most reported chronic morbidities
following allo-HSCT were iron overload (32.5%), osteoporosis/
osteopenia (29.1%), hypertension (28.9%) and cataracts (28.9%).
Depression and anxiety were reported by 23.3% and 20.6%,
respectively. The most frequently reported infections were
inﬂuenza (38.4%) and herpes zoster (27.9%). A diagnosis of one
or more malignancies following allo-HSCT was reported by
24%. The odds for having chronic co-morbidities were compared
between those who have cGVHD (n = 301) and those without
cGVHD (n = 133) (Supplementary Table 2). cGVHD increased the
odds of co-morbidities, most signiﬁcantly for osteoporosis/
osteopenia (odds ratio (OR) 1.85, P= 0.01), cataracts (OR 2.26,
P= 0.001), recurrent upper respiratory tract infections (OR 1.86,
P= 0.02), diabetes mellitus (OR 2.10, P= 0.03) and anxiety
(OR 1.86, P= 0.03).
Vaccination and health screening uptake are described in
Table 4. Assessed screening were the Australian Government’s
Department of Health national screening for breast carcinoma
(women 50–74 years), cervical (sexually active women between 18
and 70 years) and bowel carcinoma (450 years). Brieﬂy, 52.3%
had skin checks, 63.4% and 53.3% of females had papanicolaou
(PAP) smear and mammography, respectively, and 66% had
regular dental reviews. Only 31.8% had completed transplant
vaccinations recommended in the ﬁrst 12 months post transplant.
Allo-HSCT of42 years was the only variable signiﬁcantly different
between survivors who were not at all vaccinated compared with
those who received all inactivated vaccines; survivors 42 years
post allo-HSCT were much more likely to be vaccinated than early
survivors (adjusted OR 12.2, 95% conﬁdence interval 3.1–49.0,
P= 0.001). Age (P= 0.93), gender (P= 0.11), income (P= 0.9), rural
residence (P= 0.71), marital status (P= 0.26), education (P= 0.31)
and cGVHD (P = 0.21) had no effect on vaccination. Polypharmacy
was common, 10% were on ﬁve and 21% were on six or more
medications; Supplementary Table 3 details medication use.
Sexual dysfunction in allo-HSCT survivors was common.
Although similar percentages of males and females resumed
sexual activity post transplant (males 69.2%, females 68.5%), both
genders reported high incidences of sexual difﬁculties. Two-thirds
of females (66.4%) and half of males (51.5%) reported any sexual
dysfunction. Being female increased the risk of post-transplant
sexual dysfunction (OR 1.8, P= 0.01), particularly for decreased
pleasure (OR 4.3, Po0.0001), libido (OR 1.4, P= 0.002) and
dyspareunia (OR 26.1, Po0.0001). Erectile dysfunction was
reported by 76.6% of males with sexual difﬁculties.
Specialist medical referrals were common (89%), and the
median number of specialty services referred was three. The
commonest were dermatology (60.3%), ophthalmology (43.6%),
respiratory (28.2%) and endocrinology (23%). Allied healthcare
referrals were fewer, with 41% reporting follow-up with at least
one allied health specialty; most commonly physiotherapy (24%),
dietetics (23%) and clinical psychology (18%). Three-quarters
(74.4%) of survivors expressed a preference for long-term follow-
up through their transplant centres or a facility linked with their
transplant centre including a satellite clinic or telemedicine facility,
while a quarter preferred their primary/local haematologist or
general practitioner.
Four hundred and twenty-one respondents reported household
income before and following allo-HSCT. The proportion of those in
the lowest household income strata increased from 21% pre-
transplant to 36% post transplant (McNemar χ2= 46.3, Po0.001)
(Figure 1a). Pre-transplant and post-transplant employment status
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was reported by 404 patients. Two hundred and sixty-one (65%)
were in full-time employment pre-transplant, which fell to 130
(32.5%) following allo-HSCT (McNemar χ2= 106.6, Po0.001).
Importantly, ill-health as a cause for being unable to work
increased from 3.4% prior to allo-HSCT to 13.8% after (McNemar
χ2= 33.0, Po0.001) (Figure 1b). Differences in pre-transplant
and post-transplant occupational and income status remained
signiﬁcant when stratiﬁed by survival cohort (o2 years, 2 to o6
years, 6 to o10 years, 4= 10 years).
QoL measured by the FACT-BMT (Version 4) demonstrated high
internal consistency, with Cronbach's alpha for the test scale of
0.83 (Table 5). The correlation between subscale and summary
FACT-BMT test scores was highest for functional well-being
(correlation coefﬁcient = 0.89) and lowest for social well-being
(correlation coefﬁcient = 0.63). Across FACT-BMT domains, social
well-being further demonstrated the lowest reliability, with
Table 1. Survivor demographics and transplant characteristics
Characteristic (number of respondents) Number (percent)
Gender (n= 441) n (%)
Male 250 (56.7%)
Female 191 (43.3%)
Age (n= 441)
Median 49
19–29 30 (6.8%)
30–39 49 (11.1%)
40–49 83 (18.8%)
50–59 130 (29.5%)
60–69 127 (28.8%)
470 22 (5.0%)
Ethnicity (n= 372)
Australian/European 323 (86.8%)
Indigenous Australian 2 (0.5%)
Asian 30 (8.1%)
Middle Eastern 7 (1.9%)
Other 10 (2.7%)
Residential location (n= 431)
Major City 311 (72.2%)
Inner Regional 85 (19.7%)
Outer Regional 31 (7.2%)
Remote 4 (0.9%)
Years since transplant (n= 441)
Median 5
o 2 years 58 (13.2%)
2 to o6 years 204 (46.3%)
6 to o10 years 117 (26.5%)
4= 10 o15 years 62 (14.1%)
Numbers by transplant year (N= 441)
2000–2005 136 (30.8%)
2006–2012 305 (69.1%)
Transplant recipients by centre (N=441)
Centre A (Westmead) 193 (43.8%)
Centre B (St Vincent's) 124 (28.1%)
Centre C (Royal North Shore) 72 (16.3%)
Centre D (Royal Prince Alfred) 52 (11.8%)
Underlying diagnosis (N= 423)
AML/ALL 169/57= 226 (53.4%)
CML 21 (5.0%)
CLL 19 (4.5%)
SAA 16 (3.8%)
NHL 79 (18.7%)
HL 5 (1.2%)
MM 14 (3.3%)
MDS/myeloproliferative disorder 39 (9.2%)
Other (unspeciﬁed) 4 (0.9%)
Remission status (N= 405)
CR1/CR2 271 (66.9%)
4CR2 22 (5.4%)
Chronic phase 18 (4.4%)
Accelerated phase and blast crisis 3 (0.7 %)
Refractory 22 (5.4%)
PR 23 (5.7%)
Other 46 (11.4%)
Donor type (N=441)
Sibling 250 (56.9%)
Haploidentical 10 (2.3%)
Matched unrelated 158 (36%)
Mismatched unrelated 21 (4.8%)
Table 1. (Continued )
Characteristic (number of respondents) Number (percent)
Stem cell source (N=441)
Bone marrow 48 (10.9%)
PBSCT 381 (86.4%)
Cord 12 (2.7%)
Conditioning (N=439)
Myeloablative 214 (48.7%)
TBI containing 101 (47.2%)
Bu/Cy 79 (36.9%)
Cy/TBI 99 (46.3%)
Bu/Flu 28 (13.1%)
Cy/ATGAM 5 (2.3%)
Cy/Flu/ATGAM 1 (0.5%)
Bu/Flu/Thymoglobulin/TBI 1 (0.5%)
Etop/TBI 1 (0.5%)
Reduced intensity 225 (51.3%)
TBI containing 26 (11.6%)
Flu/Cy 24 (10.7%)
Flu/Cy/TBI 14 (6.2%)
Flu/Mel 98 (43.6%)
FLAMSA 1 (0.4%)
Flu/BCNU/Mel/ATG 42 (18.7%)
Flu/TBI 12 (5.3%)
Other (unspeciﬁed) 34 (15.1%)
GVHD prophylaxis (N= 440)
CSA+MTX 157 (35.7%)
CSA+MTX+pred 166 (37.7%)
CSA+MMF+pred 4 (0.9%)
MTX+pred 10 (2.3%)
Tacro+MTX 0 (0.2%)
CSA+Tacro+MMF 9 (2.0%)
MMF+MTX 0
Other (unspeciﬁed) 94 (21.4%)
T-cell depletion (N=426)
Yes 122 (28.6%)
ATGAM/ATG (Fresnius/Thymoglobulin) 113 (92.6%)
Alemtuzumab (Campath) 4 (3.2%)
No 304 (71.4%)
Not reported 5 (4.1%)
Abbreviations: ATGAM= anti-thymocyte globulin; equine; Bu=busulfan;
cGVHD= chronic GVHD; CSA= cyclosporine; Cy= cyclophosphamide;
Etop= etoposide; FLAMSA= ﬂudarabine, cytarabine, amsacrine; Flu= ﬂu-
darabine; HL=Hodgkin's Lymphoma; MDS=myelodysplastic syndrome;
MM=multiple myeloma; MMF=mycophenolate mofotil; Mel=melphalan;
MTX=methotrexate; NHL=non-Hodgkin's lymphoma; PBSCT=peripheral
blood stem cell transplantation; Pred=prednisolone; SAA= severe aplastic
anaemia; tacro= tacrolimus. This table summarizes characteristics of study
participants.
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removal of this item increasing test scale reliability (from 0.83 to
0.85). Mean QoL scores showed no signiﬁcant differences when
stratiﬁed by years from transplant (P= 0.12). Lee cGVHD score
showed a negative correlation with QoL measures (Pearson’s
correlation coefﬁcient =− 0.63 ).
In total, 364 (86%) of 441 patients had an underlying cancer
diagnosis at transplantation. Median fear of cancer recurrence
score in those within 2 years of transplant was 15 (IQR 12, 19;
range 5–24) as compared with 13 (IQR 10, 16; range: 5–25) for
those who were late transplant survivors (Po0.001).
Table 2. Chronic GVHD
cGVHD characteristic
(number of respondents)
Number (percent)
cGVHD (n= 434) 301 (69.3%)
Male (n= 246) 177 (72%)
Female (n= 188) 124 (66.0%)
cGVHD by age group (N=434)
19–29 (n= 30) 19 (63.3%)
30–39 (n= 49) 31 (63.3%)
40–49 (n= 81) 58 (71.6%)
50–59 (n= 129) 89 (69%)
60–69 (n= 123) 85 (69.1%)
4= 70 (n= 22) 19 (86.4%)
cGVHD organ involvement (n= 434)
Skin 203 (46.7%)
Eyes 153 (35.2%)
Lungs 79 (18.2%)
Mouth 155 (35.7%)
Liver 99 (22.8%)
Stomach and intestines 61 (14.1%)
Nails 53 (12.2%)
Vagina (females) 41/188 (21.8%)
Penis (males) 13/246 (5.3%)
Muscle/joints 64 (14.5%)
Other organ (not speciﬁed) 18 (4.1%)
Not sure 10 (2.3%)
Lee GVHD scores (median, IQR, range)
Skin score 10 (IQR: 0, 25; Range 0–100)
Eye score 33 (IQR: 8, 75; Range 0–100)
Mouth score 0 (IQR: 0, 25: Range 0–100)
Nutrition score 0 (IQR: 0, 5: Range 0–100)
Lung score 5 (IQR: 0, 15: Range 0–70)
Psych score 17 (IQR: 0, 33: Range 0–100)
Energy score 32 (IQR: 17, 50: Range 0–100)
Global score 19 (IQR 9, 30: Range 0–77)
Vulvovaginal symptoms (females) 45 (46.8%)
GVHD patient global ratings of symptoms (N=111)
None 18 (16.2%)
Mild 57 (51.4%)
Moderate 31 (27.9%)
Severe 5 (4.5%)
Symptom severity at study compared with 1 month ago
Very much better 40 (15.2%)
Moderately better 21 (7.9%)
A little better 34 (12.9%)
About the same 149 (56.5%)
A little worse 13 (4.9%)
Moderately worse 4 (1.5%)
Very much worse 13 (0.8%)
Abbreviations: cGVHD= chronic GVHD; IQR= interquartile range. This table
summarizes the incidence, extent and severity of cGVHD in study
participants. For the Lee cGVHD score, median and interquartile range
are provided.
Table 3. Chronic co-morbidities and secondary malignancies
Co-morbidity (number of respondents) Number affected
(percentage)
Chronic medical morbidities
Hypothyroidism (n= 391) 16 (4.1%)
Hyperthyroidism (n = 390) 5 (1.3%)
Diabetes mellitus (n= 398) 57 (14.3%)
Any of the above (n = 395) 75 (19.0%)
Osteoporosis/osteopaenia (n = 399) 116 (29.1%)
Avascular necrosis (n = 389) 14 (3.6%)
Any spinal/hip fracture (n= 392) 17 (4.3%)
Hypertension (n = 409) 118 (28.9%)
Hypercholesterolaemia (n = 402) 96 (23.9%)
Cataracts (n= 409) 118 (28.9%)
Iron overload (n = 403) 131 (32.5%)
Recurrent upper respiratory tract infections
(n= 402)
92 (22.9%)
Malignancies
Skin cancer (n = 404) 93 (23%)
BCC 41 (44%)
SCC 14 (15%)
Melanoma 5 (6%)
Combined mixed 17 (18%)
BCC+SCC 14 (15%)
BCC+melanoma 2 (2%)
SCC+melanoma 1 (1%)
Unspeciﬁed/unknown 16 (17%)
Oral cancers (n = 392) 6 (1.5%)
Other malignancies (n = 370) 18 (4.9%)
Urological (prostate and/or bladder) 5 (27%)a
Breast 2 (11%)
Bowel 1 (6%)
Ovarian 1 (6%)
Head (unspeciﬁed) 1 (6%)
Myeloid sarcoma 1 (6%)
Haematological–relapsed disease§§ 2 (11%)
Haematological–secondary malignancy§ 5 (27%)
Depression and anxiety, self reported
Self-reported depression (N= 407) 95 (23.3%)
Self-reported anxiety or depression (N= 403) 83 (20.6%)
Self-reported anxiety and/or depression
(N= 409)
118 (28.8%)
Depression anxiety and stress scores (DASS21) Median (IQR; range)
n= 438
Depression score 4 (2, 14; 0-40)
Normal (0–9) 287 (65.2%)
Mild (10–13) 41 (9.4%)
Moderate (14–20) 65 (14.8%)
Severe (21–27) 23 (5.2%)
Extremely severe (28+) 22 (5%)
Anxiety score median (IQR, range) n = 438 4 (2,10; 0-42)
Normal (0–7) 280 (63.7%)
Mild (8–9) 31 (7.1%)
Moderate (10–14) 58 (13.2%)
Severe (15–19) 23 (5.2%)
Very severe (20+) 46 (10.5%)
Stress score (median, IQR, range) n = 437 8 (2,16; 0-42)
Normal (0–14) 315 (72.1%)
Mild (15–18) 35 (8.0%)
Moderate (19–25) 40 (9.1%)
Severe (26–33) 34 (7.8%)
Very severe (34+) 13 (3.0%)
Total DASS21 score median (IQR, range) n = 437 20 (8, 40; 0-118)
Abbreviations: BCC=basal cell carcinoma; DASS= The Depression Anxiety
Stress Scales, see reference 37; IQR= interquartile range; SCC= squamous
cell carcinoma. §Two non-Hodgkin lymphomas (primary=AML, severe
aplastic anaemia); two Hodgkin lymphomas (primary=NHL); one post
transplant lymphoproliferative disease. §§One relapsed AML; one relapsed
mantle cell lymphoma. This table summarizes the physiological (including
malignant) and psychological chronic co-morbidities experienced by
study participants, reported as a percentage of respondents. a3 prostate,
1 bladder, 1 bladder + prostate.
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There were some differences between genders in personal
growth following allo-HSCT measured by PTGI; females exhibited
greater growth than males in relationship with others (Po0.001),
personal strength (Po0.001) and spiritual growth (Po0.001).
DISCUSSION
This study is the largest and most comprehensive assessment of
allo-HSCT survivorship in a contemporary Australian cohort. The
results reveal a high incidence and broad range of physiological
and psychosocial complications that adversely affect the health
and functional status of survivors.
The incidence of cGVHD was 69% for the studied group, which
is within reported ranges in the literature despite an older cohort
(median age 54), utilisation of unrelated and mismatched donors
(43.1%) and PBSC (86.4%).1,24,25
Chronic physiological effects were common with 57% of the
study group reporting two or more active medical co-morbidities.
Importantly, cGVHD increased the odds of chronic medical and
psychological sequelae, particularly osteoporosis/osteopenia, diabetes
mellitus, cataracts, recurrent respiratory tract infections and anxiety.
After cGvHD, sexual dysfunction was the most adversely
affected domain following allo-HSCT reported by allo-HSCT
survivors in this study. Over 95% of study participants provided
insight into resumption of sexual activity following allo-HSCT,
which was similar between males and females (69%). Approxi-
mately 60% of respondents reported sexual difﬁculties post
transplant (66.4% females, 51.5% males). As sexual dysfunction
likely results from multiple chronic physical and psychological co-
morbidities, our results suggest the need for a comprehensive
multidisciplinary approach to prevention and management that
includes education of allo-HSCT candidates and partners prior to
transplantation, ongoing assessment and counselling post
Table 4. Health checks, cancer screening and vaccination
Health screen/promotion (number of respondents) Uptake (percentage)
Skin checks (n = 436) 228 (52.3%)
Colorectal carcinomal screening (n = 432) 140 (32.4%)
Cervical carcinoma screening (n = 186) 118 (63.4%)
Breast carcinoma screening (n = 184) 98 (53.3%)
Prostate checks (n = 246) 89 (36.2%)
Regular dental and oral reviews (n = 436) 288 (66.1%)
Vaccination uptake statusa (n= 428)
Complete 31.80%
Partial 57.90%
No vaccine 7.20%
Uncertain 3%
Vaccination
Diphtheria, tetanus, pertussis (n = 419) 303 (72.3%)
1 to o2 years from allo-HSCT 36/56 (64.3%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 75/107 (70.1%)
⩾ 10 years from allo-HSCT 40/57 (70.2%)
Polio (n = 416) 280 (67.3%)
1 to o2 years from allo-HSCT 36/58 (62.1%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 65/106 (61.3%)
⩾ 10 years from allo-HSCT 32/55 (58.2%)
Haemophilus inﬂuenza (n= 405) 229 (56.5%)
1 to o2 years from allo-HSCT 30/53 (56.6%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 53/104 (51.0%)
⩾ 10 years from allo-HSCT 17/52 (32.7%)
Hepatitis B (n= 414) 270 (65.2%)
1 to o2 years from allo-HSCT 35/56 (62.5%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 62/105 (59.1%)
⩾ 10 years from allo-HSCT 29/54 (53.7%)
Pneumococcal vaccine for Streptococcus
pneumoniae (n = 402)
226 (56.2%)
1 to o2 years from allo-HSCT 29/53 (54.7%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 51/106 (48.1%)
⩾ 10 years from allo-HSCT 28/53 (52.8%)
Inﬂuenza (n = 426) 349 (81.9%)
1 to o2 years from allo-HSCT 40/56 (71.4%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 95/113 (84.1%)
⩾ 10 years from allo-HSCT 48/58 (82.8%)
Meningococcal vaccine for Neisseria
meningitidis (n = 407)
201 (49.3%)
1 to o2 years from allo-HSCT 31/54 (57.4%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 47/103 (45.6%)
⩾ 10 years from allo-HSCT 16/55 (29.1%)
Measles, mumps, rubella (n = 409) 226 (55.3%)
1 to o2 years from allo-HSCT 16/52 (30.8%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 66/106 (62.2%)
⩾ 10 years from allo-HSCT 31/57 (54.4%)
Varicella (n = 399) 106 (26.6%)
1 to o2 years from allo-HSCT 11/53 (20.7%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 28/100 (28%)
⩾ 10 years from allo-HSCT 8/53 (15.1%)
Human papillomavirus (females, n = 174) 26 (14.9%)
1 to o2 years from allo-HSCT 1/20 (5%)
2 to o6 years from allo-HSCT 15/82 (18.3%)
6 to o10 years from allo-HSCT 9/48 (18.7%)
⩾ 10 years from allo-HSCT 1/24 (4.2%)
The number of patients who take up health checks, screening and
vaccination, and as a percentage of respondents are provided. ainﬂuenza,
diphtheria, tetanus pertussis (dTpa), poliovirus, hepatitis B, haemophilus
inﬂuenza type b (Hib), pneumococcus and meningococcus.
% Change in income status
from pre to post transplant
% Change in work status
from pre to post transplant
Non-responders
Non responders
Retired
Unable to work
Unemployed
Casual
Homemaker
Part time
Full-time
High income
Middle income
Low income
-15.0% -10.0% -5.0% 0.0% 5.0% 10.0% 15.0% 20.0%
-40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0%
a
b
Figure 1. (a, b) Social changes following allo-HSCT; (a) income (b)
work status. Change in income as a percentage following allo-HSCT
is shown in a. Change in employment status as a percentage
following allo-HSCT is shown in b. A full color version of this ﬁgure is
available at the Bone Marrow Transplantation journal online.
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transplant and early specialist referral to prevent delayed
diagnosis and treatment.
The psychosocial impact of allo-HSCT was profound, affected by
loss of employment and reduced income. Social re-integration
was modest, with signiﬁcant underemployment, unemployment
and non-return to work (most often as a consequence of chronic
ill-health), and increase in the number of survivors in the lowest
income bracket. Although strategies aimed at the prevention and
treatment of chronic physical and psychological complications of
allo-HSCT may improve social re-integration and minimise
ﬁnancial disenfranchisement, these are unlikely to completely
ameliorate the psychosocial impacts of allo-HSCT. These results
suggest potential transplant recipients should receive pre-
transplant and post transplant counselling and be directed to
seek appropriate assistance to reorganise their ﬁnances and
assets. This study shows that ‘ﬁnancial toxicity’ is an adverse effect
of allo-HSCT that should be considered on par with other long-
term effects. In addition, ﬁnancial stress may contribute to non-
adherence and lifestyle modiﬁcations that are detrimental to a
survivor’s QoL.26 A graded, objective measure of ﬁnancial toxicity
is needed.27,28
Improvements in vaccination and uptake of screening following
allo-HSCT are urgently needed. Less than a third of respondents
had completed the recommended post-transplant vaccination
schedule, and this is reﬂected by a high incidence of vaccine-
preventable diseases (42%). These alarming statistics suggests that
current systems are resulting in an unacceptably high ‘miss’ rate
and arguably mandate a change in vaccination promotion and
delivery. Furthermore, national immunisation guidelines for allo-
HSCT and other transplant recipients have been available and
published within the most recent editions of the national
Australian Immunisation handbook that is easily accessible to
the public and healthcare workers. In this regard, it is noteworthy
that in multivariate analysis, demographic differences and the
presence of cGVHD had no effect on vaccination uptake, whereas
those who had an allo-HSCT for over 2 years were 12 times more
likely to be vaccinated. The results suggest that there are barriers
to vaccination during the ﬁrst 2 years post transplant and that
these are unrelated to the presence or severity of cGvHD or to
baseline demographics. Of those who had received vaccinations
(31% complete, 51% partial), three-quarters were administered by
general practitioners—an important reminder both of the
importance of primary/local healthcare providers in the long-
term care of allo-HSCT recipients and of the need for ongoing
communication with, and education of, health practitioners
involved in the care of survivors.29,30 That said, the fact that most
allo-HSCT survivors receive post-transplant care through their
transplant centre and express a preference for centrally coordi-
nated care suggests that long-term follow-up clinics may need to
provide post transplant vaccination service, at the very least for
survivors who do not have a general practitioner.
Other health screenings assessed in the study were also
suboptimal. Only 52% of respondents had routine skin checks, a
disappointing response given the high incidence of skin
malignancies following allo-HSCT and the high background
incidence of both melanoma and non-melanoma cancers in
Australia.31,32 Likewise, only 63% and 53%, respectively, of female
survivors of allo-HSCT had had recommended PAP smear cervical
carcinoma screening and 53% screening mammography. Just two-
thirds of survivors have regular dental/oral reviews; older age,
higher income and residing in a metropolitan area were predictors
of regular dental review. Non-attendance was reported to be due
to ﬁnances by a third and due to thinking that dental reviews were
unnecessary by another third. There is an urgent need for
education about the long-term effects of oral health following
allo-HSCT. These results may also evidence systemic failings as it is
well recognised that there are a number of ﬁnancial and structural
barriers that prevent Australians accessing affordable dental care;
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with a 2010 Australian Institute of Health and Research survey
reporting that 30% of adults avoided dentists owing to costs
(http://www.aihw.gov.au/dental/cost/). Although there are public
dental services in New South Wales, and some transplant centres
have access to hospital-based dental clinics, the waiting times are
long and the location inconvenient for many survivors.
Summarily, these results suggest that survivors with cGVHD
should receive additional psychological intervention, dedicated
screening and aggressive prevention and treatment of osteo-
porosis/ostepenia and diabetes mellitus. Other groups identiﬁed
in need of additional focus to reinforce and improve health
screening are younger transplant recipients, those with less
education, those in the ‘early’ post-transplant period and survivors
residing in rural/regional Australia.
Although the large number of participating survivors, high
response rate, multi-centre cohort and comprehensive assessment
makes it likely that these results represent an accurate account of
the experience of contemporary survivors of allo-HSCT in Australia,
there are a number of factors that may limit the generalisability of
these results to allo-HSCT survivors in other countries and settings.
First, despite the high response rate (76%), participation was
incomplete resulting in possible participation bias. Second, the
study was a cross-sectional study that included only those alive at
study recruitment, thereby excluding those who may have died
because of post-transplant complications, which may have been
more rapidly progressive or highly lethal. Third, the use of a
questionnaire as the research methodology has well-recognised
inherent limitations, including recall and misclassiﬁcation biases
that, despite piloting, the use of validated instruments and simple
English, could potentially limit self-reported response internal
validity. Misclassiﬁcation biases may go in either directions,
thereby over-estimating or under-estimating effects. Fourth, the
veracity of participants’ responses was not compared with medical
records, which may compromise factorial validity. Fifth, the
questionnaire could not distinguish between the effects of cGVHD
from complications of its treatment—a limitation that may be of
no consequence to the study of chronic health, as most survivors
with cGVHD require prolonged immunosuppression. Sixth, the
respondents to this study were disproportionately white/Cauca-
sians (86.9%), thus limiting the ability to generalise to other ethnic
groups.
This study provides the largest and most comprehensive
account of the incidence and range of late complications
following allo-HSCT in a contemporary population of Australian
survivors. For the most part, the incidence of cGVHD and chronic
post transplant co-morbidities were similar to that reported in
available literature.6,24,25 Our results also reveal the extent to
which allo-HSCT transforms the lives of survivors—causing
psychological, social and sexual dysfunction, ﬁnancial insecurity
and occupational vulnerability in many survivors. Perhaps most
worryingly, this study also suggests that the care of allo-HSCT
recipients is deﬁcient in many ways, with suboptimal health
screening, dental care and vaccination uptake as areas of unmet
need in Australian allo-HSCT survivors. Addressing these deﬁ-
ciencies will clearly require a multidisciplinary approach and may
necessitate changes in the delivery of healthcare to Australian
patients. Extrapolating from paediatric experiences33–35 and
overseas models (such as the Fred Hutchison Cancer Research
Centre/Seattle Cancer Care Alliance or MD Anderson Cancer
Centre in the United States),30 centralized co-ordination through a
long-term follow-up survivor’s clinic may best address inadequa-
cies of the current system. Such structures may avoid fragmenta-
tion of services and provides continuity of care, both of which are
essential to address complex problems such as sexual dysfunction
and adherence/compliance with health promotion. But the
success of such a service cannot be assumed and would need
to be the focus of ongoing research. Irrespective of what model of
care proves to be most effective, the results of this study make
clear that as allo-HSCT recipients live longer, the focus of care and
resources must proportionately shift to improving their QoL and
optimising their experience of survivorship.
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5.5. Synopsis 
This paper presents the most comprehensive account of the experience of survival in an Australian 
cohort of allogeneic BMT recipients.   It provides detailed data on late effects of BMT which enable 
comparison with registry and single centre data from international transplant centres.  In addition, 
these data provide the first account of a number of hitherto unknown aspects of BMT survivorship 
e.g. the financial and occupational impact of BMT, and so enables identification of areas of unmet 
need.  
Other areas of unmet need revealed by these data include adherence with general population cancer 
screening guidelines, dental care, vaccination uptake and prevalent sexual dysfunction.  The insights 
described here are important because each of them significantly adds to the burden of illness 
experienced by BMT survivors and may increase their morbidity and mortality.  These issues are 
explored further in subsequent chapters of this thesis: 
• Cancer screening in Chapter 8 
• Dental care in Chapter 11 
• Vaccination uptake in Chapter 12 (in press manuscript) 
• Sexual dysfunction in Chapter 7 
• Income and occupational changes in Chapter 10 
Importantly, these data add significantly to what is known about BMT survival in Australia.  While the 
ABMTRR follow BMT recipients for life, it only collects information on; date last seen, relapse, 
secondary cancers, cGVHD and death.  The lack of comprehensive regular and uniform data collection 
on all aspects of BMT survivorship makes it difficult to determine the extent of the impact of long-
term BMT survival, how morbidity may change over time and how long-term morbidity and mortality 
varies or compares to national and international outcomes. These data are critical for any subsequent 
efforts to improve long-term survivorship.  
In this regard it is noteworthy that since publication of this manuscript the ABMTRR commenced a 
pilot project (ASTRO BMT LTFU Module) to include data fields addressed in this study including 
screening and preventative care tests and assessments. It is anticipated that potential future 
implementation of this LTFU Module nation-wide would greatly increase Australia and NZ’s ability to 
improve LTFU outcomes and survivorship, to monitor progress and inform heath care delivery, patient 
and clinician education and informed consent requirements in real-time.  Indeed, without collection 
of data on long-term outcomes, the types of long-term issues identified in this study will continue to 
compromise BMT survival and QoL.  
71 
The results of this study have important implications for BMT patients, BMT units, haematologists, 
GPs, APNs and others who are involved in the care of BMT survivors.   These results are also relevant 
to state government policymakers, who have committed to keep people healthy and out of 
hospital(1).   
While these results provide important metrics about BMT outcomes, they also raise important 
questions for future research and for those concerned with the design and delivery of health care 
services for BMT survivors.  The challenge for policymakers and health care providers is two-fold: 
firstly to prove that screening and preventive care, and comprehensive LTFU can reduce the late 
effects of BMT and improve the experience of BMT survival, and secondly, to articulate the ways in 
which the unmet needs of BMT survivors can be addressed and the care that they are provided with 
be improved.   
Chapter references 
1. NSW Ministry of Health, 2014.  NSW State Health Plan: Towards 2021 (accessed 30.11.18 
https://www.health.nsw.gov.au/statehealthplan/Publications/NSW-state-health-plan-towards-
2021.pdf).
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Chapter 6: What they want: inclusion of blood and marrow transplantation 
survivor preference in the development of models of care for long-term 
health in Sydney, Australia 
6.1. Chapter overview 
This chapter reports on BMT survivors preferred MOC for the delivery of LTFU.  It consists of a 
published manuscript entitled, ‘What They Want: Inclusion of Blood and Marrow Transplantation 
Survivor Preference in the Development of Models of Care for Long-Term Health in Sydney, Australia’.  
The manuscript reports on the demographic, socioeconomic, transplant factors, and complication of 
BMT associated with different preferences for follow-up.  Specifically, BMT survivors were asked about 
preferred location (transplant centre and/or local health care setting including satellite clinic and 
telemedicine options), provider (transplantation team and/or local/referring haematologist and/or 
general practitioner) and model (specialised LTFU care provided at one site only, or shared care). 
Overwhelmingly, the results showed that BMT survivors want their transplant team involved (in some 
form) in their long-term care.  This is particularly true for BMT survivors who experience cGVHD.  This 
has major resource implications for BMT centres as they need to ensure provision of equitable and 
high quality long-term care, accommodate the care preferences of BMT survivors and ensure the 
sustainability of inpatient and outpatient care in the context of finite health resources.  Just as 
importantly however, our results emphasise the importance of other health care providers in the long-
term care of BMT survivors including subspecialist, referring haematologists, local medical 
practitioners advanced practice nurses and other allied health care staff.  This suggests that further 
work will be required to ensure optimal communication and collaboration within the health sector, 
particularly as BMT survivors move between different health providers and different health care 
contexts during the course of their illness and recovery.  
6.2. Publication details 
Dyer G, Gilroy N, Brown L, Hogg M, Brice L, Kabir M, Greenwood M, Larsen SR, Moore J, Hertzberg M, 
Kwan J, Huang G, Tan J, Ward C & Kerridge I. "What They Want: Inclusion of Blood and Marrow 
Transplantation Survivor Preference in the Development of Models of Care for Long-Term Health in 
Sydney, Australia." Biol Blood Marrow Transplant 2016;22(4):731-743. 
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Four hundred forty-one adult allogeneic blood and marrow transplantation (BMT) survivors participated in a
cross-sectional survey to assess long-term follow-up (LTFU) model of care preference. Survey instruments
included the Sydney Post BMT Survey, Functional Assessment of Cancer Therapy-BMT, Depression Anxiety
Stress Scales 21, the Chronic GVHD Activity AssessmentdPatient Self Report (Form B), the Lee Chronic GVHD
Symptom Scale and the Post-Traumatic Growth Inventory. We found most BMT survivors (74%) would prefer
LTFU with their transplantation physicians alone or in combination with transplantation centerelinked ser-
vices (satellite clinics or telemedicine) Over one-quarter indicated a preference for receiving comprehensive
post-transplantation care in a “satellite” clinic staffed by their BMT team situated closer to their place of
residence, with higher income, higher educational level, and sexual morbidity being signiﬁcant social factors
inﬂuencing this preference. Regular exercise was reported less often in those who preferred telemedicine,
which may reﬂect reduced mobility. The factor most strongly associated with a preference for transplantation
center follow-up was the severity of chronic graft-versus-host disease. Full- and part-time work were
negatively associated with transplantation center follow-up, possibly implying decreased dependency on the
center and some return to normalcy. This study is the ﬁrst to explore the preferences of BMT survivors for
long-term post-transplantation care. These data provides the basis for LTFU model of care development and
health service reform consistent with the preferences of BMT survivors.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION who are alive at 2 years can expect to live long term [1,2].
Advances in transplantation technologies, better patient
and donor selection, and improved supportive care over the
past 2 decades have signiﬁcantly improved outcomes of bone
marrow transplantation (BMT) such that 70% to 80% of thosedgments on page 736.
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ty for Blood and Marrow Transplantation.Unfortunately, many of these survivors experience signiﬁ-
cant late morbidity and mortality. A collective effect of
underlying disease and comorbidities, prior treatment,
toxicity of conditioning therapies and immunosuppression,
and effects of graft-versus-host disease (GVHD) [3-5] results
in a 59% cumulative incidence of developing a chronic health
condition by 10 years after transplantation [6], a 3.5-fold
increased risk of developing a severe or life-threatening
condition compared with siblings [7], and a 30% lower life
expectancy in adult BMT survivors [8]. Each of these
G. Dyer et al. / Biol Blood Marrow Transplant 22 (2016) 731e743732long-term and late effects are even more profound in adult
survivors of childhood BMT [9-11]. Life-long follow-up is,
therefore, essential to optimize the beneﬁt and minimize the
prevalence and impact of the adverse late effects of BMT [12].
Consensus guidelines for screening and preventative
practices for long-term survivors of BMT have been avail-
able for almost a decade [13,14]. These guidelines, agreed to
by 7 international BMT organizations, outline the surveil-
lance tests, clinical assessments, and preventative care that
BMT survivors require at regular intervalsdfor lifedto
monitor for recurrent and secondary malignancies; chronic
GVHD; infections; respiratory, cardiovascular, renal,
musculoskeletal, ocular, oral, gastrointestinal, dermatolog-
ical, and endocrine dysfunction; and psychosocial issues,
among others. Given the range of morbidities experienced
by BMT survivors, it is unsurprising that a BMT survivor
receiving follow-up care according to these guidelines
would require up to 34 assessments annually; including
health history, clinical examinations, laboratory analysis,
diagnostic imaging, psychosocial assessments, health
counseling and education; and involve at least 6 clinical
specialties [14]. This demand is likely to increase in coming
years as the indications for BMT expand, more recipients of
BMT survive [15], knowledge of late effects increases, and
the BMT physician workforce plateaus [16,17]. Although
there is broad agreement about the necessity for compre-
hensive follow-up of BMT survivors, the demand for long-
term follow-up (LTFU) is placing an overwhelming
demand on the capacity of transplantation centers (TC) that
have historically been responsible for such care. Given the
diverse needs of transplantation survivors and the variable
capacity of TCs to provide LTFU [18], different models for
delivery of long-term health care for BMT survivors have
been developed. Drawing on experience in both cancer
survivorship and chronic care, these models of care include
variations of specialized LTFU clinics at BMT centers, referral
back to local hematologists and/or primary care providers,
shared care models, telemedicine, and videoconferencing
[12,19-25].
Patterns of BMT activity, BMT survival, and issues with
BMT LTFU in Australia mimic international trends [26]. BMTs
are only performed in selected major urban tertiary centers
that have the necessary expertise, training, resources, and
accreditation. BMT recipients who live in rural and regional
areas must relocate to metropolitan areas for the pre, peri-,
and acute post-transplantation period. Returning to their
homes, many BMT survivors experience difﬁculties with
access to and cost of specialist services, fragmentation of
care, and poor communication in a complex health care
system, which includes public and private services, and are
easily lost to follow-up, particularly as time from trans-
plantation increases. This has meant large variations in care
and long-term outcomes, particularly for BMT units that
perform fewer than 50 allogeneic transplantations per year.
Establishing an effective model of long-term care is essential
to reduce late effects and prevent premature mortality [12].
We report the results of a cross-sectional study of long-term
survivors of BMT in New South Wales (NSW), Australia to
identify their preferences for long-term care; to examine the
demographic, socioeconomic, and transplantation factors
and sequelae associated with different preferences for
follow-up; to identify gaps in service provision provided to
this vulnerable and high-risk patient group; and to support
clinical and health policy decision-making around long-
term care.METHODS
Background to NSW BMT Service
NSW is Australia’s most populous state, with a population of w 7.5
million, and covers an area of 800,628 km [2]. Over one third of the residents
live outside the greater Sydney area [27]. At the time of study commence-
ment, there were 4 adult allogeneic centers in NSW, all based in Sydney and
collectively performing approximately 175 BMTs annually [26]. A survey of
BMT survivors was undertaken to explore survivors’ health status,
demographics, service utilization, and follow-up preferences.Patients and Procedures
Potential participants were identiﬁed from allogeneic transplantation
databases from all adult allogeneic TCs in NSW. Participants were eligible if
they were 18 years of age (at the time of survey) and had undergone an
allogeneic BMT at an adult BMT center between January 1, 2000 and
December 31, 2012, were 17 years at the time of transplantation, could
read and write English, and could provide consent. Names and phone
numbers were provided to the research team. Consenting participants were
given the option to self-complete the questionnaire or complete it via a
phone interviewwith 1 of the researchers. A second round of telephone calls
was made to 178 participants who had not returned the survey within
1 month. All authors had access to primary clinical trial data. The study
protocol was approved by the Northern Sydney Local Health District Human
Research Ethics Committee (NSLHD Reference: 1207-217M).Instruments
The Sydney Post-BMT Study Survey was developed by the research team
from a review of the literature and discussion with patients attending BMT
LTFU clinics. The survey comprised 402 questions grouped into 20 domains
and included questions relating to specialist referrals and LTFU preferences
with respect to location and provider. Other relevant domains included
demographics, medical complications, tests and assessments, medications
and therapies, infections, vaccinations, complementary therapy use, cancer
screening, relationship status income, and lifestyle factors after allogeneic
BMT. The questionnaire used tick-box responses, short-answer questions,
and 5-step Likert scales measuring attitudes and other factors and took
approximately 1 hour to complete. The questionnaire was piloted with 6
BMT survivors in clinic and phone interviews to assess face and content
validity and to check for comprehension. For each consenting participant,
data were collected on dates of diagnosis and transplantation, stage/
remission status at transplantation, transplantation conditioning, GVHD
prophylaxis, stem cell source, and donor type.
Preference for LTFU for specialist care and health service utilizationwere
analyzed according to a range of demographic, transplantation, psychoso-
cial, and lifestyle variables assessed using the Functional Assessment of
Cancer TherapyeBone Marrow Transplant (FACT-BMT Version 4) [28,29],
anxiety stress and depression (the DASS 21) [30-32], chronic GVHD (Chronic
GVHD Activity AssessmentePatient Self Report [Form B] [33] and the Lee
Chronic GVHD Symptom Scale) [34], and the Post-Traumatic Growth
Inventory score [35,36]. For ease of completion, all instruments were com-
bined into 1 booklet.Statistical Analysis
Categorical responses were summarized using frequencies and per-
centages. Parametric continuous variables were summarized using means
and standard deviations, and nonparametric variables using medians,
interquartile ranges, or ranges. Odds ratios (OR) and 95% conﬁdence limits
(CI), Pearson chi-square test, or Fishers exact tests were used for compara-
tive analysis of dichotomous categorical variables. Adjusted OR (AOR) to
account for potential confounding effects were determined using multi-
variable logistic regression analysis. Two sample comparisons of parametric
and nonparametric data were determined using the independent t-test, and
Wilcoxon rank-sum tests, respectively; greater than 2 sample comparisons
were determined using 1-way analysis of variance and Kruskal Wallis tests.
A 2-tailed P value < .05 was used as the level of statistical signiﬁcance.
Statistical analysis was performed using STATA version 12.1 statistical
package (StataCorp, College Station, TX).RESULTS
A total of 1475 allogeneic BMT were performed in the
study period. Of the 667 recipients known to be alive at study
sampling, 581 (87%) were contactable and were sent study
packs. Four hundred forty-one (66% of total eligible, 76% of
those contacted) returned the completed survey. Three
percent declined participation.
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191 (43%) were female. The median age of survey
respondents was 54 years (range, 19 to 79). The median age
at time of transplantation procedure was 49 years (range, 17
to 71). (Table 1)LTFU Provider Preferences
One or more preferences for medical follow-up were
indicated by those surveyed (Figure 1). Overall, 275 (62.3%)
preferred a single provider for their primary transplantation
follow-up (ie, general practitioner [GP] alone, localTable 1
Demographic, Social, and Clinical Characteristics of Transplantation Survi-
vors Responding to Survey (n ¼ 441)
Characteristic Distribution
Sociodemographic
Gender (male) n/total (%) 250 of 441 (57)
Age, median (range), yr 54 (19-79)
Postcode location
City/inner regional n/total (%) 396 of 431 (92)
Income status (AUD) n/total responses (%)
Low income $20,000-$39,999 155 of 423 (37)
Middle income $40,000-$79,999 123 of 423 (29)
High income  $80,000 145 of 423 (34)
Educational status n/total responses (%)
Some high school 53 of 333 (16)
Completed high school 79 of 333 (24)
Trade qualiﬁcations/diploma 47 of 333 (14)
Some university 24 of 333 (7)
Completed university 130 of 333 (39%)
Transplantation factors
Time since transplantation, median (range), yr 5 (1-14)
Underlying diagnosis n/total responses (%)
Acute leukemia 226 of 423 (53)
Other* 197 of 423 (47)
Donor type n/total responses (%)
Sibling related 250 of 439 (57)
Matched unrelated 158 of 439 (36)
Haploidentical/mismatched 31 of 439 (7)
Conditioning n/total responses (%)
Myeloablative 214 of 439 (49)
Reduced intensity 225 of 439 (51)
Post-transplantation morbidity and quality of life
cGVHD
Total reported cGVHD since transplantation
n/total responses (%)
301 of 434 (69)
Total LEE GVHD score, median (range) 19 (0-77)
Chronic diseases/psychological morbidity
n/total responses (%)
Bone disease (osteopenia, spinal fractures, or
avascular necrosis)
126 of 400 (32)
Cardiovascular risk factors (diabetes,
hypertension, or elevated cholesterol)
180 of 414 (43)
Cancer (mouth, skin, or other) 108 of 389 (28)
Anxiety 83 of 403 (21)
Depression 95 of 407 (23)
DASS21, median score (range) 20 (0-118)
Lifestyle n/total responses (%)
Smoke 33 of 438 (7)
Drink alcohol 282 of 441 (64)
Exercise/play sport 300 of 436 (69)
Always use sun protection (sunscreen, hat,
clothing sunglasses)
333 of 431 (77)
BMI, median (range) for males 25 (17-63)
BMI, median (range) for females 24 (16-53)
Total FACT BMT, median (range) 110 (32-144)
AUD indicates Australian dollars; DASS, depression anxiety stress scales;
BMI, body mass index; FACT, functional assessment of cancer therapy.
* Other includes chronic myeloid leukemia, chronic lymphocytic leuke-
mia, severe aplastic anemia, non-Hodgkin lymphoma, Hodgkin lymphoma,
multiple myeloma, myelodysplastic disorder/myeloproliferative disease,
and other (unspeciﬁed).hematologist [LH] alone, or transplantation physician [TP]
alone). An additional 149 (33.8%) preferred a combination of
providers and 17 (3.8%) indicated no preference.
The majority (44.9%) of those surveyed indicated a pref-
erence for their TP alone to be primarily responsible for their
LTFU care. The second preferred option included a combi-
nation of TP and LH (14.2%), followed by LH alone (13.1%), GP
and LH and TP (7.7%), GP and TP (7.7%), GP alone (4.3%), or GP
and LH (4.1%) (Figure 1).
Of the 441 patients surveyed, 329 (74.6%) indicated a
follow-up preference that included a TP, 173 (39.2%) included
a LH, and 105 (23.8%) included a GP.Setting or Location for LTFU Care
Of the locations for delivery of LTFU care, 234 (53%) sur-
vey respondents indicated a single site as their preferred
option, and 185 (42%) indicated a preference for a combi-
nation of locations. Overall, 22 (5%) indicated no preference
for LTFU location. Figure 2TC
Overall, 328 of 441 (74%) BMT survivors reported a pref-
erence for follow-up at TC alone or in combinationwith other
provider locations, such as satellite clinics linked with a TC or
telemedicine services administered by the primary TC. Of the
entire cohort, TC alone was the preferred option by
121 (27.4%) and LH practice alone was preferred by 57
(12.9%). Twenty-one (5%) indicated a preference for follow-
up with GP practice alone, 18 (4.1%) for telemedicine alone,
and 17 (3.8%) for satellite clinic alone (Figure 2). Four of 7
patients with post-transplantation hematological malig-
nancies (2 relapse, 5 unspeciﬁed) nominated a LTFU prefer-
ence with LH alone. Appendix 1
On univariate analysis, variables associated with an
increased preference for TC or TC-linked follow-up included
being in a married/de facto relationship (OR, 1.67; P ¼ .04)
and sexual dysfunction (OR, 2.15; P¼ .006). Those in full-time
or part-time employment indicated a decreased though
nonsigniﬁcant preference for follow-up with TC or TC-linked
services (OR, .67; P ¼ .08). On multivariable analysis, no
variables showed a signiﬁcant association with a preference
for TC or TC-linked follow-up. Those reporting increased
severity of GVHD symptoms showed a trend towards
increased preference for TC or TC-linked follow-up (AOR,
1.16; 95% CI, .99 to 1.36; P ¼ .06) and those in full- or part-
time employment showed a trend towards decreased pref-
erence for TC or TC-linked follow-up (AOR, .44; 95% CI, .19 to
1.03; P ¼ .06).
No signiﬁcant differences in nontransplantation-related
chronic disease, cancer, or psychological morbidity were
observed in those who preferred LTFU in a TC or TC-linked
service.
No signiﬁcant difference in cancer screening was
observed between survivors preferring LTFU with TC or
TC-linked service, with the exception of Pap smear uptake in
females. Females preferring follow-up through TC or
TC-linked services were less likely to report having had a
post-transplantation Pap smear (OR, .50; 95% CI, .22 to 1.06:
P ¼ .05). After adjusting for potential confounders including
age, educational status, residential location, marital status,
GVHD severity, and sexual dysfunction, no signiﬁcant dif-
ference was observed (AOR, .19; 95% CI, .03 to 1.25; P ¼ .08).
Figure 1. Distribution of preferred medical providers nominated by HCST survivors for their LTFU care.
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Overall, 119 of 441 (27.0%) BMT survivors indicated a
preference for LTFU that included a satellite clinic attended
by a TP from the center where they had received their allo-
graft. Of these, 17 (14.3%) indicated a preference for satellite
clinic follow-up alone, with the remainder indicating a
preference for satellite clinic in combinationwith other LTFU
options. Appendix 2
Those preferring LTFU in satellite clinic settings were
more likely to be from amiddle/high income group (OR,1.98;
95% CI, 1.20 to 3.33; P ¼ .005) and to have a higher educa-
tional status (OR, 2.07; 95% CI, 1.23 to 3.49; P¼ .003), deﬁned
as partial or complete attainment of a university
qualiﬁcation.Figure 2. Location prefThe rates of chronic GVHD (cGVHD) did not differ signif-
icantly between groups expressing a positive or negative
preference for satellite clinic follow-up. However, the self-
reported cGVHD symptoms described as moderate/severe
were signiﬁcantly lower in those preferring follow-up in a
satellite clinic setting (OR, .55; 95% CI, .29 to 1.0; P¼ .04), and
median self-reported current GVHD severity scores were
signiﬁcantly lower (P ¼ .05).
Sexual dysfunction was signiﬁcantly higher in those
expressing a preference for satellite clinic follow-up (OR,
2.61; 95% CI, 1.46 to 4.74; P < .001).
After adjusting for potential confounders, those factors
that retained a signiﬁcant association with a preference for
satellite clinic care included higher income status (AOR, 4.67;erence for LTFU.
G. Dyer et al. / Biol Blood Marrow Transplant 22 (2016) 731e743 73595% CI, 1.22 to 17.8; P ¼ .02), educational status (AOR, 3.26;
95% CI, 1.28 to 8.30; P ¼ .01), and sexual dysfunction (AOR,
3.27; 95% CI, 1.21 to 8.78; P ¼ .02).
Telemedicine Location for LTFU
Overall, 92 of 441 (20.9%) BMT survivors reported a
preference for follow-up that included a telehealth facility. Of
these, few (18, 19.6%) indicated a preference for LTFU using
telehealth alone, with the majority indicating a preference
for telehealth in combination with LH practice, TC, satellite
clinic, or GP practice.
Patients preferring the use of telehealth in LTFU
compared with those who did not tended to be younger
(median, 52 versus 55 years; P ¼ .07), to have signiﬁcantly
higher educational status (P ¼ .004), and to have been
conditioned using a myeloablative regimen (P ¼ .06).
Appendix 3
Higher psychological morbidity in those preferring tele-
medicine was reﬂected in higher median DASS21 scores (22
versus 18; P ¼ .03) and a trend towards higher self-reported
anxiety and/depression (P ¼ .06). Sexual dysfunction was
more commonly reported in those expressing a preference
for telemedicine (OR, 3.96; 95% CI, 1.20 to 16.8; P¼ .06). After
adjustment for potential confounders using multivariable
logistic regression, those factors that retained signiﬁcance
included educational status (AOR, 5.10; 95% CI, 1.72 to 15.1;
P ¼ .003) and sexual dysfunction (AOR, 3.25; 95% CI, 1.02 to
10.3; P ¼ .05).
A reduced odds of regular exercise (OR, .6; 95% CI, .4 to
1.0; P ¼ .04) was reported in those patients reporting a
preference for telemedicine. After adjusting for age, gender,
chronic diseases, and GVHD severity, exercise remained
independently and signiﬁcantly associated with reduced
telemedicine preference (AOR, .46; 95% CI, .24 to .87; P¼ .02).
No signiﬁcant differences were reported for cGVHD, self-
reported severity of GVHD symptoms, and Lee GVHD scores
in those preferring telehealth compared with those prefer-
ring nonetelehealth-based locations for LTFU.Figure 3. Referral patterns. Additional referrals: oncologist-breast cancer (1), catara
(1), dietitian (1), drug trial (1), endocrine clinic (1), gastrointestinal endoscopist (1
(1), maxillofacial surgeon (1), oral clinic (1), osteopath (1), palliative medicine (
specialist (1), upper gastrointestinal surgeon (1), hormone replacement review (tes
unspeciﬁed (1).Specialist and Allied Health Referrals
The median number of specialist medical referrals was 3
(interquartile range, 1 to 4; range, 0 to 11) with the most
common referral being to ophthalmologists (60.1%), derma-
tologists (43.7%), and, in women, gynecologists (51.6%).
Forty-eight percent had been referred to 1 or more allied
health professionals (range, 0 to 6), including physiothera-
pists (24.3%), dietitians (23.8%), and psychologists (19.0%)
(Figure 3).
One third (19 of 57, 33.3%) of those who were within
2 years of transplantation were attending a hospital or
medical/practice facility at least once per month, and of
these, 9 of 19 (47%) were being seen at least weekly. Of those
who were 2 or more years since transplantation, medical
practice or hospital attendances were reported at least
monthly in 98 of 376 (26%) and of these, 76 of 98 (77%) were
attending a medical facility at least weekly. A requirement to
stay overnight and close to the hospital/medical facility was
reported by 52 of 439 (11.8%) of survey respondents. The
variety of accommodation arrangements for those who are
required to stay overnight included hospital accommodation
(16 of 52, 30.8%) other subsidized accommodation (from
charitable organizations/foundations (10 of 52, 19.2%), lod-
ging with friends or family (23 of 52, 44.2%), and paid
accommodations (20 of 52, 38.5%)).DISCUSSION
There is now broad agreement that LTFU is necessary to
reduce the mortality and morbidity associated with BMT
[12,14]. How this care should be delivered, however, remains
uncertain and contested [20,21]. This study is the ﬁrst to
explore the preference of BMT survivors for long-term post-
transplantation care.
The results of this study conﬁrm what is known about
post-BMT survival that health care utilization by long-term
BMT survivors is high [37], that cGVHD is a major determi-
nant of quality of life [38], and that medical issues, fatigue,ct surgeon (1), chiropractor (3), counselor (2), dentist (6), diabetes educator
), hematology (2), head/neck surgeon (1), lung transplant team (1), multiple
1), pelvic physiotherapy (1), podiatrist (2), rheumatologist (7), skin cancer
tosterone) (1), trichologist (1), urogynecologist (1), vascular surgeon (1), and
G. Dyer et al. / Biol Blood Marrow Transplant 22 (2016) 731e743736depression, and emotional distress are high compared with
those of other cancer survivor populations [3,4,39-41]. A
model of care for LTFUmust, therefore, address the increased
health care needs of this population in ways that are sus-
tainable, cost-effective, and consistent with the preferences
of BMT survivors.
This study demonstrated that the majority of BMT survi-
vors would prefer LTFU with their TP and that 74% preferred
follow-up at a TC or through a satellite clinic or telemedicine
service linked with or administered by that TC. One-quarter
indicated a preference for receiving comprehensive post-
transplantation care in a satellite clinic staffed by their
BMT team situated closer to their place of residence. A
number of social factors, including higher income, educa-
tional status, and sexual morbidity, were signiﬁcantly asso-
ciated with a preference for satellite care. Fewer patients
expressed interest in telemedicine/web-based care, with
those interested in these options having higher educational
status and sexual morbidity. The observation that exercise
was reported less often in those who preferred telemedicine
may reﬂect reduced mobility. The factor that showed the
greatest trend towards preference for transplantation center
follow-up was the severity of cGVHD symptoms. In contrast,
those in full-time or part-time work showed a trend towards
decreased preference for TC or TC-linked follow-up, which
may reﬂect a declining dependency on TC-based care as
patients’ lives return to normal.
These are important ﬁndings, particularly for countries
like Australia where TCs are concentrated in major urban
centers, as they provide support for the development of
models of care that are responsive to different medical and
sociodemographic needs of BMT survivors. But devolved
models of post-transplantation care that integrate facilities,
specialties, and models of care beyond the TC are only likely
to work where they are sufﬁciently organized and resourced
[42]. In this regard, it is noteworthy that recent studies
suggest that the survival of BMT patients from rural/regional
areas is not inferior if LTFU is carefully and rigorously
structured and if there is good communication between
referring specialists and GPs [43-45]. Likewise, it is reassur-
ing that recent data in a range of patient populations,
including solid organ transplant recipients and patients with
cancer, suggest that satellite clinics staffed by personnel from
tertiary hospitals have shown similar patient outcomes,
subjective health status, and clinical efﬁciency when
compared with outcomes from tertiary clinics [46-48] and
that telemedicine can be successfully used to deliver pre-
ventive health care, including for sexual and relationship
counseling, weight management, advice regarding nutrition
and exercise, and mental health care [49-53].
Although the sample size and high response rate (76%)
make it likely that these results represent an accurate
account of BMT survivor’s preferences for long-term care,
there are a number of limitations to our study that may limit
the generalizability of these results to BMT survivors in other
countries and other settings. These limitations are princi-
pally a function of our study population and include Aus-
tralia’s geographical size, predominantly urban population,
concentration, climate, and health system, which includes
both universal publicly funded and private health care.
Additionally, we did not speciﬁcally ask participants if they
had private health insurance or relied upon public health
care (in large measure as these are not generally regarded as
inﬂuencing the standard post-BMT care in Australia) and so
are not sure of the impact this has on preferences forfollow-up. Also, we did not ask about preferences for nurse-
led services, which are commonly used in international BMT
centers and cancer care but less a feature of BMT care in
Australia [54,55]. It is also possible that the account of patient
preferences for post-BMT care is compromised by the use of
quantitative instruments incorporate dichotomous vari-
ables; however, each of the instruments used in the study
have been validated in the target population and so provide
the basis for further qualitative study.
This study has provided important insights into BMT
survivor preferences for long-term care in an Australian
cohort. Given the number of survivors who prefer LTFU at
and/or coordinated by their TC, it is clear that TC need to
standardize their follow-up, clearly deﬁne referral pathways
for ancillary and specialist medical services, and ensure LTFU
guidelines are disseminated to all relevant health providers
and communicated effectively with the range of primary and
tertiary care providers involved in post-BMT care [56].
Should other models of care be integrated into the long-term
care of BMT survivors, including satellite clinics and tele-
health, attention should be paid to the likely adopters of
these services and their needs, particularly if these modes of
care are chosen for delivery of psychosexual health care and
health education. As the success of any model of care is likely
to reﬂect the speciﬁc context of its application, further work
will be required to establish if this care does indeed decrease
morbidity and mortality of long-term BMT survivors.ACKNOWLEDGMENTS
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Appendix 1
Sociodemographic Factors, Transplantation Factors, and Post-Transplantation Complications associatedwith a Preference for LTFUWhenThere is TC Involvement
(TC, Satellite Clinic, or Telemedicine)
Factors LTFU with TC, Satellite
Clinic, or Telemedicine
(n ¼ 328)
LTFU that Excludes TC
or TC-Linked
Care (LH, GP, or No Follow-Up
Preference) (n ¼ 113)
OR (95% CI) P Value AOR (95% CI)
P Value
Gender
Male 188 (57.3%) 62 (54.9%) 1.1 (.70-1.74) .65 1.36 (.60-3.05)
P ¼ .46Female 140 (42.7%) 51 (45.1%)
Age, median (IQR, range), yr 54 (45-62, 19-79) 53 (43-62, 21-74) 1.00 (.99-1.02) .52 1.00 (.97-1.03)
P ¼ .92
Postcode
RA1/2 (major city/inner regional) 298 (93.1%) 98 (88.3%) 1.79 (.80-3.89) .12 1.62 (.51-7.22)
P ¼ .41RA3/4 (outer regional/remote) 22 (6.9%) 13 (11.7%)
Relationship status
Married/de facto 265 (81.5%) 79 (72.5%) 1.67 (.97-2.85) .04 1.15 (.39-3.39)
P ¼ .78Single, divorced, separated 60 (18.5%) 30 (27.5%)
Income status (AUD)
Middle/high income (>$40,000) 205 (64.9%) 63 (58.9%) 1.29 (.80-2.07) .27
Low income ($20,000-$39,999) 111 (35.1%) 44 (41.1%)
Education status
Some/completed university 117 (48.0%) 37 (41.6%) 1.29 (.77-2.18) .30
Other (diploma, trade, secondary) 127 (52.0%) 52 (58.4%)
Occupational status
Full-time/part-time 149 (48.2%) 60 (58.2%) .67 (.41-1.07) .08 .44 (.19-1.03)
P ¼ .06Other (home duties, casual, retired
unable to work, retired)
160 (51.8%) 43 (41.8%)
Age at transplantation, yr
Median (IQR; range) 49 (39-57; 17-71) 46 (36-55; 17-70) .35
Time since transplantation, yr
Median (IQR; range) 5 (3-8; 1-14) 5 (3-9; 1-14) .44
Underlying disease
Acute leukemia 172 (54.3%) 54 (50.9%) 1.14 (.72-1.82) .55
Other*,z 145 (45.7%) 52 (49.1%)
Stage of disease at transplantation
CR 1/2 200 (61.0%) 71 (62.8%) .92 (.58-1.47) .73
Othery 128 (39.0%) 42 (37.2%)
Conditioning
Myeloablative 158 (48.5%) 56 (49.6%) .96 (.61-1.50) .84
RIC 168 (51.5%) 57 (50.4%)
Donor type
Matched (sibling, unrelated) 304 (93.2%) 104 (92.0%) 1.19 (.47-2.81) .67
Haploidentical/mismatched 22 (6.8%) 9 (8.0%)
cGVHD
Yes 227 (70.7%) 74 (65.5%) 1.27 (.78-2.05) .30
No 94 (29.3%) 39 (34.5%)
Patient global ratings GVHD
Moderate/severe 74 (37.2%) 22 (32.3%) 1.24 (.67-2.34) .47
None/mild 125 (62.8%) 46 (67.7%)
Severity score, median (IQR), 0-10 3 (1-6) 3 (1-5) 1.06 (.96-1.17) .24 1.16 (.99-1.36)
P ¼ .06
Reporting GVHD worse than 1 month ago 17 (8.5%) 2 (3.2%) 2.83 (.64-25.9) .26
183 (91.5%) 61 (96.8%)
LEE cGVHD symptom score, median (IQR)
Skin 10 (0-25) 7 (0-25) .14
Eye 33 (8-75) 25 (0-67) .12
Mouth 0 (0-25) 0 (0-38) .12
Lung 5 (0-19) 3 (0-15) .39
Nutrition 0 (0-5) 0 (0-5) .46
Muscle/joint 2 (0,6) 2 (0-6) .41
Energy 32 (17-50) 32 (18-46) .70
Mental emotional 17 (0-42) 8 (0-25) .01
Total 20 (9-31) 17 (10-26) .40
Chronic diseases
Any chronic diseasez 231 of 317 (72.9.5%) 76 of 105 (72.4%) .92
Any cancerx 80 of 287 (27.9%) 27 of 101 (26.7%) .82
Psychological and sexual morbidity
Anxiety 65 of 300 (21.7%) 18 of 103 (17.5%) 1.30 (.71-2.48) .36
Depression 72 of 303 (23.8%) 23 of 104 (22.1%) 1.10 (.63-1.96) .73
Anxiety and/or depression 92 of 304 (30.3%) 26 of 105 (24.8%) 1.32 (.78-2.28) .28
Total DASS21 score, median (IQR) 20 (10-40) 18 (6-38) .27
Sexual dysfunction 138 of 222 (62.2%) 29 of 67 (43.3%) 2.15 (1.19-3.90) .006 1.61 (.73-3.55)
P ¼ .24
(Continued on next page)
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Appendix 1
(continued)
Factors LTFU with TC, Satellite
Clinic, or Telemedicine
(n ¼ 328)
LTFU that Excludes TC
or TC-Linked
Care (LH, GP, or No Follow-Up
Preference) (n ¼ 113)
OR (95% CI) P Value AOR (95% CI)
P Value
Cancer screening
Skin check 172 of 324 (53.1%) 56 of 112 (50%) 1.13 (.72-1.78) .57
Bowel check 106 of 321 (33.0%) 34 of 111 (30.6%) 1.11 (.68-1.84) .64
Pap smear (F)k 80 of 135 (59.3%) 38 of 51 (74.5%) .50 (.22-1.06) .05 .19 (.03-1.25)
P ¼ .08
Mammogram (F) 73 of 133 (54.9%) 25 of 51 (49.0%) 1.26 (.63-2.54) .47
Prostate (M) 64 of 184 (34.8%) 25 of 62 (40.3%) .79 (.42-1.50) .43
Lifestyle
Smoking 21 of 326 (6.4%) 12 of 112 (10.7%)
Alcohol 205 of 328 (62.5%) 77 of 113 (68.1%)
Exercise/sport 220 of 326 (67.5%) 80 of 110 (72.7%)
Sun protection 252 of 319 (67.3%) 81 of 112 (72.3%)
BMI, median (IQR) 25 (22-28) 25 (22-28) .79
Total FACT BMT 110 (94-121) 109 (92-127) .47
Post-transplantation growth inventory score 58 (43-72) 59 (33-68) .20
IQR indicates interquartile range; CR, complete remission; RIC, reduced-intensity conditioning; F, female; M, male.
Adjusted odds derived from multivariable logistic regression ﬁtting the following potential confounders: age, gender, occupational status, marital status, res-
idential location (metro/inner regional), GVHD severity, sexual dysfunction.
* Other includes chronic myeloid leukemia, chronic lymphocytic leukemia, severe aplastic anemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple
myeloma, myelodysplastic disorder/myeloproliferative disease, and other (unspeciﬁed).
y Includes > 2 complete remissions, refractory, chronic phase, accelerated phase, blast crisis, partial remission, other (unspeciﬁed).
z Any chronic disease includes hypertension, hypercholesterolemia, diabetes, bone disease (osteoporosis, osteopenia, spinal/hip fractures, or avascular ne-
crosis), iron overload, thyroid disease.
x Any cancer includes skin, mouth or other speciﬁed.
k Adjusted odds derived from multivariable logistic regression ﬁtting the following potential confounders: age, educational status, marital status, residential
location, sexual dysfunction, and GVHD severity.
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Appendix 2
Sociodemographic, Transplantation Factors, and Post-transplantation Complications associated with a Preference for LTFU that Includes a Satellite Clinic
Factor LTFU with Satellite
Clinic  Other Option
(n ¼ 119)
Options that Exclude
Satellite Clinic (n ¼ 322)
OR (95% CI) P Value AOR (95% CI)
P Value
Gender
Male 70 (58.8%) 180 (55.9%) 1.13 (.72,1.77) .58 1.20 (.49-3.00)
P ¼ .68Female 49 (41.2%) 142 (44.1%)
Age, median (IQR; range), yr 54 (45-61; 22-75) 54 (44-62; 19-79) 1.0 (.98-1.02) .77 1.03 (.99-1.08)
P ¼ .09
Postcode
RA1/2 (Major city/inner regional) 106 (91.3%) 290 (92.0%) .91 (.41-2.21) .82 .70 (.12-4.08)
P ¼ .70RA3/4 (Outer regional/remote) 10 (8.7%) 25 (7.8%)
Relationship status
Married/de facto 96 (81.4%) 248 (78.5%) 1.20 (.68-2.15) .51
Single, divorced, separated 22 (18.6%) 68 (21.5%)
Income status (AUD)
Middle/high income (>$40,000) 84 (74.3%) 184 (59.3%) 1.98 (1.20,3.33) .004 4.67 (1.22-17.8)
P ¼ .02Low income ($20,000-$39,999) 29 (25.7%) 126 (40.7%)
Education status
Some/completed university 54 (59.3%) 100 (41.3%) 2.07 (1.23-3.49) .003 3.26 (1.28-8.30)
P ¼ .01Other (diploma, trade, secondary) 37 (40.7%) 142 (58.7%)
Occupational status
Full-time/part-time 55 (49.5%) 154 (51.2%) .94 (.59-1.48) .77 .71 (.25-2.03)
P ¼ .53Other (home duties, casual, retired unable to work) 56 (50.4%) 147 (48.8%)
Age at transplantation, yr
Median (IQR; range) 49 (39-55) 49 (37-56) .95
Time since transplantation, yr
Median (IQR; range) 5 (3-8) 5 (3-8) .49
Underlying disease
Acute leukemia 60 (53.6%) 166 (53.4%) 1.01 (.64-1.59) .97
Other* 52 (46.4%) 145 (46.6%)
Stage of disease at transplantation
CR 1/2 73 (61.3%) 198 (61.5%) 1.00 (.64-1.59) .98
Othery 46 (38.7%) 124 (38.5%)
Conditioning
Myeloablative 59 (49.6%) 155 (48.4%) 1.05 (.67-1.63) .83
RIC 60 (50.4%) 165 (51.6%)
Donor type
Matched (sibling, unrelated) 113 (95.8%) 295 (91.9%) 1.99 (.73-6.80) .21
Haploidentical/mismatched 5 (4.2%) 26 (8.1%)
cGVHD
Yes 86 (74.1%) 215 (67.6%) 1.37 (.83-2.30) .19
No 30 (25.9%) 103 (32.4%)
Patient global ratings GVHD
Moderate/severe 21 (26.6%) 75 (39.9%) .55 (.29-1.00) .04
None/mild 58 (73.4%) 113 (60.1%)
Severity score, median (IQR), 0-10 2 (1-4) 3 (1-6) .05 .99 (.83-1.18)
P ¼ .94
Reporting GVHD worse than 1 month ago 2 (2.6%) 17 (9.1%)
75 (97.4%) 169 (90.9%) .26 (.03-1.17) .07
LEE cGVHD symptom score, median (IQR)
Skin 15 (5-30) 10 (0-25) .03
Eye 25 (17-67) 33 (8-75) .94
Mouth 0 (0-12) 0 (0-37) .006
Lung 5 (0-10) 5 (0-20) .16
Nutrition 0 (0-5) 0 (0-5) .17
Muscle/joint 2 (0-5) 2 (0-6) .56
Energy 29 (17-43) 32 (17-50) .42
Mental emotional 17 (0-33) 17 (0-33) .90
Total 17 (8-28) 20 (10-32) .23
Chronic diseases
Any chronic diseasez 84 of 114 (73.7%) 223 of 308 (72.4%) 1.07 (.64-1.80) .79
Any cancerx 30 of 109 (27.5%) 77 of 279 (27.6%) .99 (.58-1.67) .99
Psychological and sexual morbidity
Anxiety 20 of 114 (17.5%) 63 of 289 (21.8%) .76 (.41-1.36) .34
Depression 26 of 116 (22.4%) 69 of 291 (23.7%) .93 (.53-1.59) .78
Anxiety and/or depression 33 of 116 (28.4%) 85 of 293 (29.0%) .97 (.58-1.60) .91
Total DASS21 score, median (IQR) 18 (10-34) 20 (8-40) .65
Sexual dysfunction 63 of 86 (73.3%) 104 of 203 (51.2%) 2.61 (1.46-4.74) <.001 3.27 (1.21-8.78)
P ¼ .02
Cancer screening
Skin check 68 of 118 (57.6%) 160 of 318 (50.3%) .17
Bowel check 38 of 116 (32.3%) 102 of 316 (32.3%) .92
Pap smear (F)k 27 of 46 (58.7%) 91 of 140 (65%) .44
Mammogram (F) 30 of 46 (65.2%) 68 of 138 (49.3%) .06
Prostate (M) 26 of 69 (37.7%) 63 of 177 (35.6%) .76
(Continued on next page)
G. Dyer et al. / Biol Blood Marrow Transplant 22 (2016) 731e743740
Appendix 2
(continued)
Factor LTFU with Satellite
Clinic  Other Option
(n ¼ 119)
Options that Exclude
Satellite Clinic (n ¼ 322)
OR (95% CI) P Value AOR (95% CI)
P Value
Lifestyle
Smoking 8 of 118 (6.8%) 25 of 320 (7.8%) .72
Alcohol 83 of 119 (69.7%) 199 of 322 (61.8%) .12
Exercise/sport 76 of 118 (64.4%) 224 of 318 (70.4%) 0.22
Sun protection 92 of 118 (78.0%) 241 of 313 (77.0%) .83
BMI, median (IQR) 25 (22-28) 25 (22-28) .50
Total FACT BMT 110 (94-120) 109 (93-125) .70
Post-transplantation growth inventory score 57 (44-71) 59 (38-70) .77
Adjusted odds derived from multivariable logistic regression ﬁtting the following potential confounders: age, gender, occupational status, income, educational
status, residential location (metro/inner regional compared to outer regional/remote), GVHD severity, sexual dysfunction.
* Other includes chronic myeloid leukemia, chronic lymphocytic leukemia, severe aplastic anemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple
myeloma, myelodysplastic disorder/myeloproliferative disease, and other (unspeciﬁed).
y Includes > 2 complete remissions, refractory, chronic phase, accelerated phase, blast crisis, partial remission, other (unspeciﬁed).
z Any chronic disease includes hypertension, hypercholesterolemia, diabetes, bone disease (osteoporosis, osteopenia, spinal/hip fractures, or avascular ne-
crosis), iron overload, thyroid disease.
x Any cancer includes skin, mouth or other speciﬁed.
k Adjusted odds derived from multivariable logistic regression ﬁtting the following potential confounders: age, educational status, marital status, residential
location, sexual dysfunction, and GVHD severity.
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Appendix 3
Sociodemographic Factors, Transplantation Factors, and Post-transplantation Complications associated with a Preference for LTFU that Includes Telemedicine
Factor LTFU with
Telemedicine  Other
Option (n ¼ 92)
LTFU Options that Exclude
Telemedicine (n ¼ 349)
OR (95% CI) P
Value
AOR (95% CI)
P Value
Gender
Male 55 (59.8%) 195 (55.9%) 1.17 (.72-1.93) .51 1.02 (.38-2.74)
P ¼ .97Female 37 (40.2%) 154 (44.1%)
Age, median (IQR; range), yr 52 (43,58; 24-70) 55 (44,63; 19-79) .99 (.97-1.01) .07 1.02 (.98-1.07)
P ¼ .33
Postcode
RA1/2 (Major city/inner regional) 81 (91%) 315 (92%) .87 (.36-2.29) .74 .46 (.08-2.60)
P ¼ .38RA3/4 (Outer regional/remote) 8 (9%) 27 (8%)
Relationship status
Married/de facto 74 (82.2%) 270 (78.5%) 1.26 (.68-2.47) .43
Single, divorced, separated 16 (17.8%) 74 (21.5%)
Income status (AUD)
Middle/high income (>$40,000) 56 (62.9%) 212 (63.5%) 1.02 (.61-1.70) .92
Low income ($20,000-$39,999) 33 (37.1%) 122 (36.5%)
Education status
Some/completed university 42 (61.8%) 112 (42.3%) 2.20 (1.23-3.98) .004 5.10 (1.72-15.1)
P ¼ .003Other (diploma, trade, secondary) 26 (38.2%) 153 (57.7%)
Occupational status
Full-time/part-time 35 (42.2%) 174 (52.9%) .65 (.39-1.08) .08 .77 (.26-2.28)
P ¼ .64Other (home duties, casual, retired unable to work) 48 (57.8%) 155 (47.1%)
Age at transplantation, median (IQR; range), yr 47 (37-52) 50 (38-57) .06
Time since transplantation, median (IQR; range), yr 5 (3-8) 5 (3-8) .56
Underlying disease
Acute leukemia 48 (53.3%) 178 (53.4%) 1.00 (.61-1.63) .98
Other* 42 (46.7%) 155 (46.5%)
Stage of disease at transplantation
CR 1/2 58 (63.0%) 213 (61.0%) 1.09 (.66-1.81) .72
Othery 34 (37.0%) 136 (39.0%)
Conditioning
Myeloablative 53 (57.6%) 161 (46.4%) 1.57 (.96-2.57) .06 1.80 (.62-5.22)
P ¼ .28RIC 39 (42.4%) 186 (53.3%)
Donor type
Matched (sibling, unrelated) 88 (96.7%) 320 (91.9%) 2.57 (.76-13.47) .16
Haploidentical/mismatched 3 (3.3%) 28 (8.1%)
cGVHD
Yes 64 (70.3%) 237 (69.1%) 1.06 (.62-1.83) .82
No 27 (29.8%) 106 (30.9%)
Patient global ratings GVHD
Moderate/severe 21 (37.5%) 136 (64.4%) 1.08 (.56-2.08) .79
None/mild 35 (62.5%) 75 (35.6%)
Severity score, median (IQR), 0-10 3 (1-5) 3 (1-6) .79 .95 (.79-1.16)
P ¼ .63
Reporting GVHD worse than 1 month ago 6 (10.9%) 13 (6.3%) 1.84 (.54-5.49) .24
49 (89.1%) 195 (93.7%)
LEE cGVHD symptom score, median (IQR)
Skin 10 (0-31) 10 (0-25) .38
Eye 33 (17-75) 33 (8,75) .52
Mouth 0 (0-25) 0 (0-25) .49
Lung 5 (0-20) 5 (0-15) .69
Nutrition 0 (0-5) 0 (0-5) .78
Muscle/joint 3 (0-7) 2 (0-6) .20
Energy 36 (21-54) 32 (14-50) .10
Mental emotional 21 (8-42) 17 (0-33) .18
Total 19 (9-36) 18 (9-29) .44
Chronic diseases
Any chronic diseasez 66 of 89 (74.2%) 239 of 331 (72.2%) 1.10 (.63-1.97) .71
Any cancerx 19 of 94 (22.6%) 87 of 303 (28.7%)
Psychological and sexual morbidity
Anxiety 21 of 84 (25.0%) 62 of 319 (19.4%) 1.38 (.74-2.50) .26
Depression 27 of 87 (31.0%) 68 of 320 (21.2%) 1.67 (.94-2.90) .06
Anxiety and/or depression 32 of 87 (36.8%) 86 of 322 (26.7%) 1.60 (.93-2.70) .06 1.34 (.44-4.02)
P ¼ .60
Total DASS21 score, median (IQR) 22 (10-46) 18 (8-38) .03
Sexual dysfunction 48 of 62 (77.4%) 119 of 227 (52.4%) 3.96 (1.20-16.8) <.001 3.25 (1.02-10.35)
P ¼ .05
Cancer screening
Skin check 43 of 91 (47.2%) 185 of 345 (53.6%) .77 (.47,1.26) .28
Bowel check 26 of 91 (28.6%) 113 of 340 (33.2%) .8 (.46-1.37) .40
Pap smear (F) 20 of 35 (57.1%) 98 of 151 (64.9%) .7 (.3,1.6) .39
Mammogram (F) 23 of 36 (63.9%) 75 of 148 (50.7%) 1.7 (.8-4.0) .15
Prostate (M) 15 of 54 (27.8%) 74 of 192 (38.5%) .61 (.29,1.23) .14
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(continued)
Factor LTFU with
Telemedicine  Other
Option (n ¼ 92)
LTFU Options that Exclude
Telemedicine (n ¼ 349)
OR (95% CI) P
Value
AOR (95% CI)
P Value
Lifestyle
Smoking 5 of 92 (5.4%) 28 of 346 (8.0%) .39
Alcohol 63 of 92 (68.5%) 219 of 349 (62.7%) .30
Exercise/sportk 55 of 92 (59.8%) 245 of 346 (70.8%) .04 .46 (.24-.87)
P ¼ .02
Sun protection 73 of 91 (80.2%) 260 of 340 (76.5%) .45
BMI, median (IQR) 25 (22, 28) 25 (22, 28) .86
Total FACT BMT 108 (94-119) 110 (93-125) .30
Post-transplantation growth inventory score 53 (41-71) 59 (40-71) .66
Adjusted odds derived from multivariable logistic regression ﬁtting the following potential confounders: age, gender, occupational status, educational status,
residential location (metro/inner regional compared to outer regional/remote), anxiety/depression, GVHD severity, conditioning at transplantation, and sexual
dysfunction.
* Other includes chronic myeloid leukemia, chronic lymphocytic leukemia, severe aplastic anemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple
myeloma, myelodysplastic disorder/myeloproliferative disease, and other (unspeciﬁed).
y Includes > 2 complete remissions, refractory, chronic phase, accelerated phase, blast crisis, partial remission, other (unspeciﬁed).
z Any chronic disease includes hypertension, hypercholesterolemia, diabetes, bone disease (osteoporosis, osteopenia, spinal/hip fractures, or avascular ne-
crosis), iron overload, thyroid disease.
x Any cancer includes skin, mouth or other speciﬁed.
k Adjusted odds for exercise derived from multivariable logistic regression ﬁtting the following potential confounders: age, gender, GVHD severity, any
chronic disease.
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6.5. Synopsis 
This manuscript provides the only national or international data on BMT survivors preference for long 
term care including the association of care preferences with demographics, co-morbidities and QoL.  
For the first time, therefore, we have empirical data to support the development of MOCs tailored to 
the specific needs of BMT survivors, including those with severe cGVHD, those who have returned to 
work, those living in rural areas, those transitioning from hospital-based to community care and those 
who are less mobile. 
These insights are important because hitherto limited attention has been paid to outpatient and 
community care of BMT survivors and BMT LTFU is a relatively new area of practice and not universally 
well established. For the most part, acute and early post-BMT care is provided exclusively by the 
transplant team in the BMT centre.  It is well co-ordinated and managed - generally by a small team 
of BMT specialist doctors and APNs.  LTFU in contrast, is less well established and more complex, more 
open-ended and involves multiple subspecialists and allied health professionals, is provided in tertiary 
and primary care settings and in the public and private sector, and often relies upon the survivor 
navigating this fragmented care themselves. (As the manuscript shows, even at two years post BMT, 
when the highest risk of relapse has passed, over a quarter of survivors are continuing to attend for 
medical care at least monthly and the range of non-BMT specialists involved in survivor care is 0-11).    
In this regard it is noteworthy that since study commencement the NSW Agency for Clinical Innovation 
(ACI), BMT Network has been working on the development of a state-wide BMT LTFU MOC.  This work 
has been prompted by publication of the results of an informal review of BMT LTFU services at each 
of the allogenic centres in NSW which showed that there was no consistent, robust LTFU process in 
place to accommodate the care needs of BMT survivors (detailed in Chapter 3; Table 3.1).  Just as 
worryingly, every BMT centre reported a proportion of survivors who were lost to follow-up and no 
centre was able to show full compliance with clinical guidelines for BMT LTFU(1).  It is anticipated that 
development (and implementation of) a MOC to inform the required care and pathway of both adult 
and adult survivors of childhood BMT will greatly increase NSW’s ability to improve LTFU outcomes 
and survivorship.  While only in the early stages of development however, it appears that no single 
MOC suits all types of BMT survivors, a finding supported by the results of this manuscript and by 
recent international literature(2-5). (This is explored further in the discussion section (Chapter 16) of 
this thesis).   
It is increasingly clear that BMT centres need to establish a MOC for LTFU processes specific to their 
needs (centre, patient, clinician) in order to harmonise data collection, optimise data reporting, and 
88 
reduce variation in care in order to improve long-term outcomes.  Establishing and adopting a MOC 
which aligns centre BMT LTFU goals, service capacity and configuration, and survivor and clinician 
preference will ensure that BMT survivors are able to access services, expertise and resources that are 
consistent with their needs and values.  
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Chapter 7: A survey of fertility and sexual health following allogeneic 
haematopoietic stem cell transplantation in New South Wales, Australia. 
7.1. Chapter overview 
This chapter reports on the reproductive and sexual health of our long-term BMT survivors.  It consists 
of a published manuscript entitled, ‘A survey of fertility and sexual health following allogeneic 
haematopoietic stem cell transplantation in New South Wales, Australia’.  The manuscript reports on 
sexual function and fertility issues analysed according to demographics, transplant factors, co-
morbidities and QoL scores.  
The results of the manuscript demonstrate that while most BMT survivors resume sexual activity post 
BMT, sexual dysfunction is prevalent in both sexes, but it occurs significantly more often in women 
(66% vs 51%).  It was also found that genital cGVHD occurs disproportionately more often in women 
than in men (22.1% vs 5%).  And while a small proportion of our survivors had successful live births in 
the years following BMT, it is noteworthy that women of childbearing age were more likely not to be 
offered fertility preservation treatments prior to BMT. The findings have implications for sexual health 
and fertility education and support both pre and post-BMT and highlight the importance of quality 
gynaecological care and review in the longer-term post-transplant.  
7.2. Publication details 
Dyer G, Gilroy N, Bradford J, Brice L, Kabir M, Greenwood M, Larsen SR, Moore J, Hertzberg M, Kwan 
J, Brown L, Hogg M, Huang G, Tan J, Ward C & Kerridge I. "A survey of fertility and sexual health 
following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia." Br J 
Haematol 2016;172(4):592-601. 
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7.4. Manuscript 
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Summary
Four hundred and twenty-one adult allogeneic haematopoietic stem cell
transplant (HSCT) survivors participated in a cross-sectional study to assess
sexual dysfunction and infertility post-transplant. Survey instruments
included the Sydney Post-Blood and Marrow Transplant (BMT) Survey,
Functional Assessment of Cancer Treatment (FACT) – BMT, the Depres-
sion, Anxiety, Stress Scales (DASS 21), the Chronic Graft-versus-Host Dis-
ease (cGVHD) Activity Assessment- Patient Self Report (Form B), the Lee
cGVHD Symptom Scale and The Post-Traumatic Growth Inventory. Most
HSCT survivors reported sexual difficulties (51% of males; 66% of
females). Men reported erectile dysfunction (79%) and decreased libido
(616%) and women reported loss of libido (83%), painful intercourse
(73%) and less enjoyment of sex (68%). Women also commonly reported
vaginal dryness (73%), vaginal narrowing (34%) and vaginal irritation
(26%). Woman had much higher rates of genital cGvHD than men (22%
vs. 5%). Age and cGVHD were significantly associated with sexual dysfunc-
tion. Few survivors had children following transplant (33%). However, for
those of reproductive age at HSCT, 22% reported trying to conceive, with
103% reporting success. This study is the largest to date exploring sexual
function in survivors of allo-HSCT. This data provides the basis for health
service reform to better meet the needs of HSCT survivors, including evi-
dence to support counselling and education both pre- and post-transplant.
Keywords: allogeneic HSCT, sexual dysfunction, infertility, survivors, sur-
vey, Australia.
Allogeneic haematopoietic stem cell transplantation (HSCT)
is an established treatment for malignant and non-malignant
diseases affecting both adults and children. Advances in
patient and donor selection, management of acute toxicities
and supportive care have significantly improved outcomes
following transplant with 1-year survival rates now 80% or
more for some conditions (Mohty & Mohty, 2011; Pasquini
& Zhu, 2014). Unfortunately, many HSCT survivors experi-
ence significant morbidity following HSCT with late effects
reducing the quality and duration of their life (Savani et al,
2011). Sexual dysfunction and infertility are among the most
prevalent long-term sequelae (Mosher et al, 2009).
Sexual dysfunction and infertility occurs primarily because
of the adverse effect of high dose chemo-radiotherapy, result-
ing in interruption of the sexual response cycle, decreased
libido, erectile and ejaculatory dysfunction, vaginal alter-
ations (dryness, narrowing, fibrosis), dyspareunia and infer-
tility or sub-fertility due to primary ovarian failure and
impaired spermatogenesis (Carter et al, 2006; Humphreys
et al, 2007). In general, women tend to experience more
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sexual dysfunction than men (78% at 1 year compared to
50%), are more likely to experience long-term sexual dys-
function and are more likely to be infertile following HSCT
(Marks et al, 1997; Humphreys et al, 2007; Thygesen et al,
2012). While successful pregnancies have occurred in sur-
vivors of HSCT, they are rare, 06% in the largest report on
over 37 000 HSCT survivors (both allogeneic and autolo-
gous) (Salooja et al, 2001). With the exception of a limited
number of registry studies, there is limited data on sexual
dysfunction and infertility post-HSCT with most studies
reporting small populations from single centres. There is no
data describing the late effects in an Australian cohort of
HSCT survivors. The aims of this cross-sectional study were
to present data on the range and frequency of sexual dys-
function and infertility in survivors of HSCT, to address gaps
in service provision and to provide better information to
those undergoing HSCT, their families/carers and health care
professionals.
Methods
Patients and procedures
Potential participants were identified from allogeneic trans-
plant databases of all adult allogeneic transplant centres in
New South Wales [NSW; Australia’s most populous state –
~75 million in 2013 (Australian Bureau of Statistics, 2014)].
Participants were eligible if they were ≥18 years of age and
had undergone an allogeneic HSCT between 1 January 2000
and 31 December 2012, could read and write English and
could provide consent. Names and phone numbers were pro-
vided to the research team. Consenting participants were
given the option to self-complete the questionnaire or com-
plete it via a phone interview with one of the researchers. A
second round of telephone calls were made to participants
who had not returned the survey within a month. All
authors had access to primary clinical trial data. The study
protocol was approved by the Northern Sydney Local Health
District Human Research Ethics Committee (NSLHD Refer-
ence: 1207-217M).
Instruments
The Sydney Post-BMT Study Survey (SPBS) (Appendix S1)
was developed by the research team. Item construction was
informed by a review of the literature and discussions with
patients attending HSCT long-term follow-up clinics. It con-
sisted of 402 questions grouped into 20 domains, including
questions relating to fertility and sexual function. Other rele-
vant domains included demographics, medical complications,
specialist referrals, tests and assessments, medications and
therapies, infections, vaccinations, complementary therapy
use, cancer screening, close personal contacts, lifestyle, diet
nutrition, occupational and relationship status following stem
cell transplantation. The questionnaire used tick box
responses, short answer questions and 5-step Likert scales
measuring attitudes and other factors and took approxi-
mately 1 h to complete. The questionnaire was piloted in
clinic and phone interviews to assess face and content valid-
ity and comprehension.
Associations between sexual function and fertility were
explored against demographics, medical complications, post-
transplant medical therapies, treatments and complementary
therapies, relationship status and social determinants, includ-
ing income and occupational status. The relationships
between sexual function and fertility were further explored
against a range of validated survey instruments that mea-
sured quality of life [Functional Assessment of Cancer Ther-
apy – Bone Marrow Transplant (FACT-BMT Version 4;
Cella et al, 1993; McQuellon et al, 1997)], anxiety stress and
depression [The DASS (Depression Anxiety Stress Scales) 21]
(Lovibond & Lovibond, 1996; Crawford & Henry, 2003;
Dahm et al, 2013), chronic graft-versus-host disease (GVHD)
[The Chronic GVHD Activity Assessment – Patient Self
Report (Form B) (Pavletic et al, 2006) and The Lee Chronic
GVHD Symptom Scale (Lee et al, 2002b)] and an assessment
of life changes in response to traumatic events (The Post-
Traumatic Growth Inventory score) (Tedeschi & Calhoun,
1996; Morris et al, 2013). For ease of completion all instru-
ments were combined into one booklet.
For each participant, data was collected on dates of diag-
nosis and transplant, stage/remission status at transplant,
conditioning, GVHD prophylaxis, stem cell source and donor
type, which was completed by the research team. This infor-
mation was used to compare HSCT clinical variables and the
impact on sexual function and fertility in survivors.
Statistical analysis
Categorical responses were summarized using frequencies
and percentages. Parametric continuous variables were sum-
marized using means and standard deviations, and non-para-
metric variables using medians and interquartile ranges. The
Pearson v2 test or Fishers Exact tests were used for compara-
tive analysis of dichotomous categorical variables. Two sam-
ple comparisons of means and medians were determined
using the independent t-test and Wilcoxon Rank Sum tests
respectively; greater than two sample comparisons of means
and medians were determined using one way analysis of
variance (ANOVA) and Kruskal–Wallis tests, respectively. A
two-tailed P < 005 was used as the level of statistical
significance.
Statistical analysis was performed using the STATA ver-
sion 12.1 statistical package (StataCorp, College Station, TX,
USA).
Results
A total of 1475 allogeneic HSCT were performed in the study
period. Of the 669 survivors known to be alive at study sam-
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pling, 583 were contactable and were sent study packs. Four
hundred and forty-one (66% of total eligible, 76% of those
contacted) returned the completed survey. Three per cent
declined participation (Fig 1).
Patient characteristics
Of those who completed the survey, 250 (57%) were male and
191 (43%) female. The median age of survey respondents was
54 years (range: 19–79). The median age at time of transplant
was 49 years (range: 17–71). Forty per cent of survey respon-
dents were 6 or more years post-transplant. The majority of
patients resided in a major city (72%), were of middle/high
income status (53%) and were in a married or defacto rela-
tionship (79%). The main indication for transplantation was
acute leukaemia (62%). Matched siblings accounted for 57%
of donors and a myeloablative conditioning regimen was used
in 49% of transplant procedures (Table I).
Resumption of sexual activity post-HSCT
A total of 421 respondents provided information about sexu-
ality, fertility and sexual activity post-HSCT; 241 (964%) of
250 males and 178 (932%) of 191 females.
One hundred and sixty-seven (692%) males and 122
(685%) females reported resumption of sexual activity post-
transplant; 30 (124%) of males and 21 (118%) of females
had not yet resumed sexual activity post-HSCT. The remain-
ing 44 (183%) of males and 35 (197%) females reported
being sexually inactive pre and post-transplant.
Males who had resumed sexual activity had a median age
of 52 years, compared to 58 years for those who had not yet
resumed sexual activity post-transplant (P = 004). The med-
ian years since transplantation in males who had returned to
sexual activity was 5 years, and was not significant from
males who had not yet returned to sexual activity. Males
who had resumed sexual activity showed no significant dif-
ferences in relationship status, donor type, diagnosis, condi-
tioning, remission status or distribution of comorbidities
when compared to males who had not resumed sexual activ-
ity. Morbidity from cGVHD was significantly higher in males
who had not resumed sexual activity post-transplant. These
males reported significantly higher rates of moderate and
severe cGVHD symptoms (P = 003), significantly higher Lee
Chronic GVHD scores (P = 001) and had significantly
higher rates of immunosuppression (P = 001) and anti-
infective drug use (P = 0007). Males who had not returned
to sexual activity post-transplant had significantly lower
scores on physical (P = 001), functional (P = 0009) and
HSCT FACT subscales (P = 0003), and had significantly
lower scores on composite FACT scores (P = 001). No sig-
nificant difference was observed in the Post-Traumatic
Growth Inventory scores for males who had resumed sexual
activity (Tables II and III).
n = 1475
Allogeneic HSCT
2000-2012
n = 669
Allogeneic BMT survivors
806 (55%)
Deceased/status uncertain
n = 583 survivors (82.7%)
contacted, sent survey
n = 441 survivors (66%)
Returned Completed questionnaire
86 Unable to be contacted
17 (3%) declined consent
125 surveys not returned
Fig 1. Post-haematopoietic stem cell transplan-
tation (HSCT) survey study flowchart.
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Females who had resumed sexual activity had a median age
of 49 years compared to 57 years for those who had not
resumed sexual activity (P = 006) and were more likely to be
further out from their date of transplant than those who had
not resumed sexual activity with a median duration of 6 years
since transplantation, compared to 3 years (P = 00009).
Females returning to sexual activity were more likely to be in a
married/defacto relationship, though this was not statistically
significant (P = 009). In contrast to male survivors of HSCT,
the self-reported severity of GVHD symptoms and Lee GVHD
scores were not significantly different in women who had, or
had not resumed sexual activity. Females who had returned to
sexual activity had significantly higher FACT BMT subscale
scores, but did not have any significant differences across other
FACT domains or in the post-transplant Growth Inventory
scores. Females who had resumed sexual activity reported sig-
nificantly higher rates of anxiety and/or depression (P = 005).
The use of psychotropic medications (antidepressants, anxi-
olytics and/or sedatives) was not significantly different between
the two groups. The underlying haematological diagnosis, con-
ditioning regimen, donor type, medical comorbidity profile
and medication use was not significantly different in females
who had resumed sexual activity (Tables II and III).
Sexual dysfunction
Fifty-one per cent of males who had resumed sexual activity
since their HSCT reported difficulties with sexual function
since transplant (Table IV). The majority (77%) of sexual dif-
ficulties in males related to erectile dysfunction, and decreased
libido was the second most common reported problem
(62%). Pain with intercourse accounted for 9% of sexual dif-
ficulties. Of the 122 females who had resumed sexual activity
since their HSCT, 81 (66%) reported having difficulties with
sexual function since transplant (Table IV). Specific issues in
those who had resumed sexual activity post-transplant were
compared across genders. Females had significantly less enjoy-
ment of sex [odds ratio (OR) 43 95% confidence interval
(CI) 22, 88 P < 00001], less sexual desire (OR 30 95% CI
14, 66 P = 0002) and more pain with intercourse (OR 26
95% CI 102, 713 P < 00001) when compared to their male
counterparts. Sexual problems arising from partner issues
were similar between the two genders.
Genital pathology
The only genital pathology reported in men was penile
cGVHD, which occurred in 13 (5%) of 250 respondents.
Genital problems reported by sexually active females
included vaginal dryness (73%), vaginal narrowing (34.%),
vaginal irritation and soreness (26.%), thrush (8.%), cystitis
(17%) and lower back pain (27%). Vaginal dryness was the
only symptom that was statistically significantly different
between women who were sexually active and those who
were not (OR 52 95% CI 25, 11; P < 00001).
Table I. Participant characteristics.
Socio-demographic
Gender (n = 441)
Male 250 (567)
Female 191 (433)
Age (years) at survey (n = 441)
Median (IQR; range) 54 (44, 62; 19–79)
Age (years) at transplant (n = 441)
Median (IQR; range) 49 (37, 56; 17–71)
Ethnicity (n = 372)
Caucasian, European 323 (868)
Other* 49 (132)
Educational status (n = 335)
University (some/completed) 154 (462)
Other 179 (538)
Post transplant income status (n = 423)
Low income $20 000–$39 999 155 (366)
Middle income $40 000–$79 999 123 (291)
High income ≥$80 000 145 (343)
Residence (n = 431)
Major city 311 (722)
Other (inner regional, outer regional, remote) 120 (278)
Relationship status (n = 436)
Married/defacto 344 (793)
Other (separated, single, divorced) 90 (207)
Transplant-related
Years since transplant (n = 443)
<2 58 (131)
2 to <6 204 (463)
6 to <10 117 (265)
≥10 62 (141)
Underlying diagnosis (n = 425)
Acute leukaemia (AML/ALL) 226 (534)
Other† 197 (466)
Remission status (n = 405)
First/second complete remission 271 (669)
Other‡ 134 (331)
Donor type (n = 439)
Sibling 250 (569)
Matched unrelated 158 (360)
Haploidentical 10 (23)
Mismatched unrelated 21 (48)
Stem cell source (n = 441)
Bone marrow 48 (109)
Peripheral blood 381 (864)
Cord blood 12 (27)
Conditioning chemotherapy (n = 439)
Myeloablative 214 (487)
Reduced intensity 225 (512)
Values are expressed as n (%) unless otherwise stated. IQR,
interquartile range.
*Other education-secondary school (some or complete); trade or
diploma.
†Other diagnoses: chronic myeloid leukaemia; chronic lymphocytic
leukaemia (non-Hodgkin lymphoma; Hodgkin lymphoma; multiple
myeloma; myelodysplastic syndrome/myeloproliferative disorder;
Other (unspecified)
‡Other remission status; more than second complete remission;
Refractory; chronic Phase; Accelerated Phase; Blast crisis; Partial
Remission; other (unspecified).
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Menstrual irregularities
Seventy-nine (44%) of 178 females reported having men-
strual cycles prior to HSCT. Fourteen (18%) reported a
return of menstrual function post-transplant, of which seven
experienced a temporary cessation of up to 2 years following
the transplant procedure.
Fertility post-HSCT
Three hundred and ninety-three participants provided a
response to questions regarding post-transplant conception.
Thirty-five of 395 respondents indicated that they had tried
to conceive post-HSCT: 21 (10%) males and 14 (8%)
females. Of these 35 participants, 15 (43%) were successful
Table II. Demographic, social and clinical variables and their association with resumption of sexual activity post-transplant, by gender.
Males Females
Resumed sexual
activity
post-HSCT
(n = 167)
Not resumed
sexual activity
post-HSCT
(n = 30) P value
Resumed sexual
activity
post-HSCT
(n = 122)
Not resumed
sexual activity
post-HSCT
(n = 21) P value
Socio-demographic factors
Age (years) at survey, median (range) 52 (21–79) 58 (21–73) 004 49 (21–75) 57 (34–69) 006
Years since transplant, median (range) 5 (1–14) 5 (1–14) 032 6 (1–14) 3 (1–8) 00009
Relationship status
Married/defacto 137/166 (825%) 22/30 (733%) 031 106/119 (89%) 15/20 (75%) 009
Single, divorced, separated 29/168 (175%) 8/30 (267%) 13/119 (11%) 5/20 (25%)
Transplant factors
Diagnosis
Acute leukaemia 75/140 (536%) 14/25 (560%) 082 76/102 (655%) 14/18 (737%) 060
Other diagnoses 65/140 (536%) 11/25 (440%) 40/102 (355%) 4/18 (263%)
Donor type
Sibling 89/166 (536%) 16 (533%) 055 74 (607%) 12 (571%) 093
Haploidentical 4/166 (24%) 1 (33%) 3 (25%) 1 (48%)
Unrelated (matched) 63/166 (380%) 13 (433%) 38 (315%) 7 (333%)
Unrelated (mismatched) 10/166 (60%) 0 7 (57%) 1 (48%)
Conditioning
Myeloablative 84 (509%) 11 (367%) 015 77 (631%) 10 (476%) 018
Reduced Intensity 81 (491%) 19 (633%) 45 (369%) 11 (524%)
Remission status
CR1/CR2 95 (569%) 14 (467%) 030 87 (713%) 17 (810%) 036
Other 72 (431%) 16 (533%) 35 (287%) 4 (190%)
Post-transplant factors
Comorbidity
Cardiovascular risk factors 69 (437%) 16 (533%) 013 45 (369%) 6 (286%) 062
Bone disease 39 (243%) 11 (367%) 015 41 (336%) 5 (238%) 045
Anxiety/depression 48 (287%) 8 (267%) 082 32 (262%) 1 (48%) 005
Thyroid disease 5 (34%) 2 (71%) 031 7 (57%) 2 (95%) 062
Iron overload 53 (356%) 6 (231%) 026 34 (279%) 6 (286%) 10
Medical therapy
Immunosuppression 65 (389%) 19 (633%) 001 26 (213%) 5 (238%) 078
Anti-infective 67 (401%) 20 (667%) 0007 39 (320%) 10 (476%) 016
Psychotropic medication 37 (222%) 5 (167%) 063 22 (180%) 3 (143%) 100
Hormone replacement 12 (72%) 0 022 41 (336%) 5 (238%) 045
Chronic GVHD
Self-reported severity
None 20/105 (191%) 1/19 (53%) 003 15/77 (195%) 1/12 (83%) 066
Mild 55/105 (524%) 6/19 (316%) 41/77 (532%) 6/12 (500%)
Moderate 18/105 (171%) 7/19 (368%) 18/77 (234%) 4/12 (333%)
Severe 12/105 (114%) 5/19 (263%) 3/77 (39%) 1/12 (83%)
Lee chronic GVHD score
Median (range) 16 (0–77) 30 (5–54) 001 15 (0–61) 20 (6–47) 040
HSCT, haematopoietic stem cell transplantation; CR1/CR2, first/second complete remission; GVHD, graft-versus-host disease.
Numbers in bold indicate statistically significant.
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(11 males; 4 females). Females who successfully conceived
were all aged less than 30 years and males less than 41 years
at the time of transplantation (P = 008).
Of the 15 successful pregnancies, 6 (40%) were the result
of natural conception (two females; four males) and two
were the result of natural conception that followed prior
attempts at in vitro fertilization (IVF), including IVF in one
male and his partner and IVF followed by implantation of a
donor egg in one female. A total of seven successful pregnan-
cies were the result of IVF; six (all males) with IVF alone
and one IVF and donor egg (female). No association was
found between the use of reproductive technologies by HSCT
survivors with residential location (major city versus inner or
outer regional) and household income.
Fertility preservation pre HSCT
Forty-seven (20%) of 233 males reported banking sperm
pre-HSCT with a median age (at transplant) of 31 years
[inter-quartile range (IQR) 24–40; range 18–51]. There were
no statistically significant socio-demographic differences (in-
come, residence) between males who did and did not bank
sperm Donor type did have a significant effect on banking
sperm with those who had a haplo/MUD or mismatched
transplant being 26 times more likely to bank than those
who had a matched sibling transplant (95% CI 128, 544;
P = 0004). Males who had a myeloablative HSCT had a
threefold higher rate of banking sperm than those who had
reduced intensity conditioning (95% CI 167, 658; P =
Table III. Quality of life measures (FACT-BMT), post-traumatic growth inventory measures and resumption of sexual activity post-transplant, by
gender.
Males Females
Resumed sexual
activity post-HSCT
Not resumed sexual
activity post-HSCT P value
Resumed sexual
activity post-HSCT
Not resumed sexual
activity post-HSCT P value
FACT scores, median (range)
FACT-physical 24 (0–28) 19 (5–28) 001 25 (0–28) 24 (12–28) 034
FACT-social 21 (4–28) 22 (1–27) 092 22 (7–28) 21 (14–28) 070
FACT-emotional 17 (1–24) 17 (7–20) 066 16 (0–20) 17 (0–20) 077
FACT-functional 21 (4–28) 16 (0–28) 0009 21 (5–28) 19 (8–28) 021
FACT-HSCT subscale 30 (9–40) 26 (7–38) 0003 29 (11–40) 26 (18–32) 002
FACT-G 82 (22–104) 70 (40–95) 003 83 (36–104) 81 (61–103) 058
FACT BMT Total 113 (32–144) 94 (52–129) 001 111 (49–141) 109 (80–134) 023
Post-Traumatic Growth
Inventory, median (range)
54 (0–96) 54 (16–79) 074 63 (12–103) 53 (18–93) 035
HSCT, haematopoietic stem cell transplantation; FACT, Functional Assessment of Cancer Treatment; BMT, Bone Marrow Transplantation.
Numbers in bold indicate statistically significant.
Table IV. Sexual dysfunction reported by males and females who had resumed sexual activity post-transplant.
Type of sexual dysfunction
Sexual dysfunction following
resumption sexual activity (females)
(n = 81)
Sexual dysfunction following
resumption sexual activity (males)
(n = 86)
Odds ratio (95%
confidence interval) P value
Decreased enjoyment of sex 55/81 (679%) 28/86 (326%) 43 (22, 88) <00001
Pain with intercourse 59/81 (728%) 8/86 (93%) 261 (102, 713) <00001
Decreased sexual desire 67/81 (827%) 53/86 (616%) 30 (14, 66) 0002
Difficulties with arousal 47/81 (58%) N/A Not comparable to males –
Difficulties with erection N/A 66/86 (767%) Not comparable to females –
Difficulties with partner
regarding issue of sex
27/81 (333%) 28/86 (326%) 103 (05, 21) 091
Other Other difficulties described by
females included vaginal bleeding/
dryness/graft-versus-host disease
(11) mobility/flexibility issues (1)
post-gynaecological surgery
problems (1) body confidence (1)
low libido (1) partner issues (1)
Other difficulties described by males
included recurrent hospitalizations
(1), neurological damage to penis
following episode of shingles (1),
reduced muscular strength & joint
pains and breathing difficulties (3)
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00004) though this was not significant when adjusting for
the effect of younger age for those receiving myeloablative
conditioning [adjusted odds ratio (AOR) 082; 95% CI
032, 208; P = 067).
Three hundred and sixty-one participants responded to
the question of embryo banking after a cycle of IVF. A total
of 6 (2%) reported using this technology (two males and
four females). Three hundred and twenty-nine participants
reported whether or not they had donated ovarian tissue and
frozen eggs for storage. Overall, 7 (2%) had used this proce-
dure (six females and one male HSCT recipient with his
female partner).
The most common reasons for young women (aged 18–
29) to have not pursued fertility preservation pre-HSCT were
they had already completed a family or were too sick to have
done so. For females in the 30–39 years age group, 40%
declined the procedure but in a significant proportion (23%)
the reproductive intervention was not offered. In females
aged 40–49, the majority declined the procedure, though
15% reported that it had not been offered. Of male HSCT
survivors who did not store sperm this was generally because
they declined to do so (79%) or were too unwell to undergo
the procedure (8%). Only 8 (5%) men, 2 of whom were
under 40 years of age, were not offered sperm storage
(Tables V and VI).
Discussion
While sexual dysfunction has previously been documented in
HSCT survivors, most reports are from single centres and/or
comprise small sample sizes. This study is the largest to date
exploring sexual activity in survivors of allogeneic HSCT and
the largest and most comprehensive study of fertility and
sexuality in an Australian context. While the high response
rate (76%) and use of validated instruments makes it likely
that these results represent an accurate account of the experi-
ence of survivors of HSCT, the heterogeneity and restricted
ethnic diversity in our population may limit the generaliz-
ability of these results to HSCT survivors in other countries
and settings. The results from this research are also limited
by the fact that it relied upon self-report and because no data
is available about non-responders. Further, the instruments
used in this study were ones that are widely used in HSCT
settings to assess quality of life, physical and psychosocial
function in HSCT survivors and were not specifically tar-
geted at sexual function.
This study demonstrates that the majority of HSCT sur-
vivors experience a wide range of sexual difficulties in the
years following transplantation. Although most had resumed
sexual activity, a significant proportion reported sexual diffi-
culties (51% of males; 66% of females). Common to both
genders were loss of libido and less enjoyment of sexual
activity while 72% of women experienced pain with inter-
course. These results are broadly consistent with other
reports of sexual dysfunction after HSCT (Marks et al, 1997;
Lee et al, 2002a; Tierney et al, 2007). As with other studies,
age and cGVHD were significantly associated with sexual
dysfunction post-HSCT (Heinonen et al, 2001; Lara et al,
2010; Mueller et al, 2013; Wong et al, 2013).
While most patients generally resumed sexual activity post-
HSCT, consistent with other research, we found that this
occurs most frequently and earlier in men than in women,
and in younger HSCT survivors (Watson et al, 1999; Shanis
et al, 2012). The association between cGVHD and the lack of
return to sexual activity appeared to be more evident in males
than females, with males who had not resumed sexual activity
following transplant reporting higher rates of immunosup-
pression, higher anti-infective drug use and higher self-
reported cGVHD symptoms which is in keeping with previ-
ous studies (Lee et al, 2002a; Humphreys et al, 2007; Lara
et al, 2010). Quality of life measures, especially those reflect-
ing physical and functional well-being, were lower in males
Table V. Reasons given by females who did not use medically assisted reproductive methods pre-transplant by age.
Age range (years) 18–29 (n = 19) 30–39 (n = 30) 40–49 (n = 26) 50–59 (n = 47) 60–69 (n = 21) ≥70 (n = 1) All (N = 144)
Not offered (n = 19) 1 (53%) 7 (23%) 4 (154%) 2 (43%) 0 0 14/144 (97%)
Declined 1 (53%) 12 (40%) 18 (692%) 44 (936%) 20 0 95/144 (66%)
Too sick or other
health problems
5 (263%) 2 (67%) 3 (115%) 1 (21%) 0 0 11/144 (76%)
Completed family 12 (631%) 9 (30%) 1 (38%) 0 1 1 24/144 (16%)
Table VI. Reasons given by males who did not use medically assisted reproductive methods pre-transplant by age.
Age range (years) 18–29 (n = 7) 30–39 (n = 16) 40–49 (n = 43) 50–59 (n = 63) 60–69 (n = 28) ≥70 (n = 1) All (N = 156)
Not offered (n = 19) 1 1 2 3 1 0 8/156 (51%)
Declined 0 8 34 54 27 1 124/156 (795%)
Too sick or other
health problems
1 4 5 2 0 0 12/156 (77%)
Completed family 3 3 2 4 0 0 12/156 (77%)
G. Dyer et al
598 ª 2015 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 172, 592–601
who had not returned to normal sexual activity and Lee
cGVHD scores were significantly higher in these survivors.
Female HSCT survivors commonly report a range of geni-
tourinary symptoms with significant vulvo-vaginal cGVHD
occurring in 221% of women who develop cGVHD post-
transplant. Genitourinary symptoms are more often reported
in women who have resumed sexual activity however it is
unclear if sexual activity exacerbated the problem, or if sex-
ual activity allowed women to identify these problems (Spi-
nelli et al, 2003; Zantomio et al, 2006; Stratton et al, 2007).
As has been reported elsewhere, HSCT is invariably associ-
ated with premature ovarian failure and azoospermia; how-
ever, small numbers of survivors, particularly those aged
under 30 years at the time of HSCT, may recover ovarian
function/spermatogenesis and fertility (Sanders et al, 1988;
Wang et al, 1998; Grigg et al, 2000; Salooja et al, 2001; Rovo
et al, 2006; Jadoul et al, 2011; Wu et al, 2012). The majority
of HSCT survivors are rendered infertile, however because
the mean age at HSCT is 49 years this may not constitute a
significant concern for many HSCT survivors. While few
HSCT survivors attempt to conceive post-transplant, many
will be successful (43%), often with assisted reproductive
technologies (Lipton et al, 1997; Demeestere et al, 2006;
Donnez et al, 2011). Unfortunately such technologies are
expensive and are located primarily in metropolitan areas –
raising questions about equity of access. The challenges
involved in conception post-HSCT underlie the importance
of utilizing pre-HSCT fertility preservation measures, includ-
ing sperm storage, ovarian tissue and/or oocyte or embryo
storage (Lee et al, 2006; Wallace, 2011; Joshi et al, 2014). In
this regard it was noteworthy that, in our population, a sig-
nificant number of women rather than men (23% vs. 5%
respectively) were not offered reproductive interventions.
While this probably reflects practical difficulties associated
with fertility preservation methods in women, it also high-
lights continuing uncertainty regarding the availability and
efficacy of techniques for females.
This study provides important insights into sexual
dysfunction and infertility in an Australian cohort of HSCT
survivors. Given the high prevalence of continued sexual dys-
function in the post-HSCT period (>66% for females, >50%
for males), it is clear that pre-HSCT counselling and post-
HSCT care needs to include full disclosure and assessment of
the effects of transplant on sexual health and fertility, both
for men and women, with greater attention paid to vaginal
cGVHD than currently occurs. Consensus guidelines have
recently been released with recommendations for regular,
integrated gynaecological review both pre- and post-HSCT
(Frey Tirri et al, 2015; Stratton, 2015). While such practice
change seems undeniable, further work is required to estab-
lish whether other pre- and post-HSCT interventions, includ-
ing education, counselling and early treatment, improves
sexual function and quality of life outcomes for survivors.
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7.5. Synopsis 
This manuscript provides the largest and most comprehensive account of sexual function and fertility 
post allogeneic BMT in Australia.  The results indicate that sexual dysfunction is common post-BMT, 
that sexual dysfunction is complex and multifactorial, and the data clearly showed that women are 
disproportionately affected by symptoms of sexual dysfunction and are often not given the option to 
preserve fertility prior to transplantation.   
The results presented in this paper have implications for pre and post-BMT discussions and education 
regarding these ‘hidden’ and often under-reported adverse effects of BMT, as these have a profound 
impact on survivors’ QoL. Educating and consenting BMT recipients and their partners about the likely 
impact that BMT may have on their relationship, sexuality and fertility, and establishing systems and 
practices that enable the early recognition of sexual dysfunction, may facilitate clinical and 
psychological care and improve both sexual function and QoL outcomes for both men and women.    
In this regard it is noteworthy that there appears to be general lack of training for physicians and allied 
health professionals to adequately address such issues with patients and their partners(1-3).Thus, 
education and training of health care professionals involved in the care of long term survivors in how 
to initiate these conversations is also pivotal.   
While fertility preservation is often not possible for BMT recipients, either because the kinetics or 
phenotype of their disease make it impossible, or because treatment prior to BMT has already 
rendered patients infertile, it seems increasingly likely that considerations regarding fertility may need 
to be more explicitly included in the care of BMT recipients.  Ovarian cryopreservation in particular is 
becoming a more established option for women of reproductive age who are likely to become infertile 
because of their treatment.  While fertility is not a concern for most adult BMT recipients, progress in 
reproductive sciences and the increase in maternal age at first pregnancy, suggest that BMT services 
will need to be more prepared to explicitly address these issues pre and post-transplant.   
Likewise, while BMT services have been focussed simply on ensuring survival, improvements in BMT 
outcomes and survivorship demand that more attention is focused on QoL.  This is particularly the 
case for those domains of QoL that have been ignored within hospitals and health services and that 
have not been a part of routine history taking and care, such as sexuality.  Attending to the sexual 
health of BMT recipients will require cultural, educational and systemic reform of BMT services and is 
an area where the involvement of APNs may have a profound impact.  This is also an area where 
research is desperately needed in order to more clearly identify the barriers to addressing issues of 
fertility, sexuality and identity pre-BMT and to improving the medical and behavioural interventions 
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that definitively improve both sexual function and fertility preservation and treatment in this 
vulnerable and high-risk group.  
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Chapter 8: Adherence to cancer screening guidelines in Australian survivors 
of allogeneic blood and marrow transplantation (BMT) 
8.1. Chapter overview 
This chapter reports on the incidence of secondary cancers in long-term survivors of BMT and their 
subsequent adherence with Australian cancer screening guidelines.  It consists of a published 
manuscript entitled, ‘Adherence to cancer screening guidelines in Australian survivors of allogeneic 
blood and marrow transplantation (BMT)’.  The manuscript reports on demographics, socioeconomics, 
transplant factors, co-morbidities and QoL scores associated with compliance with cancer screening.  
Specifically, survivors were asked about compliance with recommended general population screening 
for bowel, cervical and breast cancer and also skin cancer screening due to the high incidence of skin 
cancer in Australian populations(1) and because allogenic BMT survivors, particularly  those with skin 
cGVHD who receive prolonged IST and azole antifungal agents are at significantly increased risk of skin 
cancer(2).  
The results of this study demonstrate that secondary cancers post BMT are common (24%) and that 
despite an increased risk of cancer, our BMT survivors were not fully compliant with either general 
population cancer screening guidelines, or cancer screening and preventative care guidelines specific 
for BMT survivors(3).  Disturbingly, many survivors noted that they did not adhere to cancer screening 
guidelines because they did not believe it was necessary or because they had not been advised to do 
so by their treating team. The findings have profound implications for education and counselling of 
both BMT recipients and health care professionals involved in their long-term care.  At the same time, 
however, our results place onus upon researchers to demonstrate proof of efficacy for cancer 
screening in this population. 
8.2. Publication details 
Dyer G, Larsen SR, Gilroy N, Brice L, Greenwood M, Hertzberg M, Kabir M, Brown L, Hogg M, Huang G, 
Moore J, Gottlieb D, Kwan J, Tan J, Ward & Kerridge I. "Adherence to cancer screening guidelines in 
Australian survivors of allogeneic blood and marrow transplantation (BMT)." Cancer Med 
2016;5(7):1702-16. 
8.3. Authors’ contributions 
GD co-designed the study, recruited study participants, collected data, interpreted the results and 
drafted the manuscript.  A signed Statement of Contribution from all authors is in Appendix A. 
8.4. Manuscript 
The published version of the manuscript follows. 
 
 
1Introduction
Survivors of allogeneic Blood and Marrow Transplant 
(BMT) are at a significant risk of developing many long- 
term and adverse late effects in the years following 
transplantation [1]. Of these late effects, secondary malig-
nancies are a particular concern. Cumulative incidence 
rates of up to 12% at 15 years post- BMT have been 
reported, and no plateau has been identified [2, 3]. All 
cancers have been found to occur in survivors of BMT 
ORIGINAL RESEARCH
Adherence to cancer screening guidelines in Australian 
survivors of allogeneic blood and marrow transplantation 
(BMT)
Gemma Dyer1,2, Stephen R. Larsen3, Nicole Gilroy2, Lisa Brice4, Matt Greenwood1,4,5, Mark 
Hertzberg6, Masura Kabir7, Louisa Brown8, Megan Hogg9, Gillian Huang9, John Moore10, David 
Gottlieb9, John Kwan9, Jeff Tan10, Christopher Ward1,4,5 & Ian Kerridge1,4,5
1Northern Clinical School, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia
2Blood and Marrow Transplant Network, New South Wales Agency for Clinical Innovation, Sydney, NSW, Australia
3Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
4Department of Haematology, Royal North Shore Hospital, St. Leonards, NSW, Australia
5Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, NSW, Australia
6Department of Haematology, Prince of Wales Hospital, Camperdown, NSW, Australia
7Westmead Breast Cancer Institute, Westmead, NSW, Australia
8Department of Haematology, Calvary Mater Newcastle, Newcastle, NSW, Australia
9Department of Haematoloy, Westmead Hospital, Sydney, NSW, Australia
10Department of Haematology, St Vincents Hospital, Sydney, NSW, Australia
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Australia, blood and marrow transplant 
(BMT), cancer screening, late effects, 
secondary cancers, survivors
Correspondence
Gemma Dyer, Cancer Institute NSW, P.O. Box 
41, Alexandria NSW Australia 1435.  
Tel: +61 403776117; Fax: 02 8374 3600; 
E-mail: gem.dyer@gmail.com
Funding Information
This research was funded by the New South 
Wales Agency for Clinical Innovation, Blood 
and Marrow Transplant Network and 
supported by the Northern Blood Research 
Centre. These sponsors are public health 
organizations that support medical science 
and health-care reform
Received: 10 February 2016; Revised: 14 
March 2016; Accepted: 15 March 2016
doi: 10.1002/cam4.729
Abstract
Allogeneic Blood and Marrow Transplant (BMT) survivors are at high risk of 
secondary cancers. Although current guidelines endorse survivors following 
Country- specific general population screening recommendations to mitigate this 
risk, little is known about cancer screening adherence in Australian BMT sur-
vivors. We conducted a cross- sectional survey of 441 BMT survivors who were 
>1 year post transplant, to explore rates of screening for secondary cancers and 
to identify barriers to cancer screening recommendations. Survey instruments 
included the Sydney Post- BMT Survey, FACT- BMT, DASS 21, The Chronic 
Graft versus Host Disease (GVHD) Activity Assessment–Patient Self- Report (Form 
B), the Lee Chronic GVHD Symptom Scale, Fear of Cancer Recurrence Scale, 
and The Post Traumatic Growth Inventory. Fifty- seven percent of respondents 
were male, median age 54 years, and 40% were >6 years post- BMT. Rates of 
cancer screening adherence were as follows: cervical 63.4%, breast 53.3%, skin 
52.4%, and bowel 32.3%. Older BMT survivors and those >2 years post trans-
plant were more likely to undergo cancer screening. Improved quality of life 
was associated with screening for skin, breast, and cervical cancer. Fear of cancer 
recurrence negatively impacted on cervical screening. For those who had not 
undergone screening, the majority reported not being advised to do so by their 
treatment team. This study is the largest and most comprehensive to date ex-
ploring cancer screening adherence in BMT survivors in Australia. These data 
provide the basis for health service reform to better meet the needs of BMT 
survivors and provide evidence to support counseling and education of both 
patients and professionals.
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with skin, thyroid, oral cavity, esophagus, breast, liver, 
brain/nervous system, bone, and connective tissue cancers, 
all more frequently diagnosed in BMT survivors than the 
general population [4–6]. Risk factors for higher rates of 
secondary cancers include younger age at BMT, total body 
irradiation (TBI), prolonged immunosuppression, chronic 
graft- versus- host disease (cGVHD), and smoking prior to 
allogeneic BMT [5–8].
For almost a decade international consensus guidelines 
for the care of long- term survivors of BMT have been 
available [9, 10]. These guidelines include recommenda-
tions for cancer screening, preventive health care and 
health promotion, noting that survivors follow general 
population screening recommendations in their country 
for breast, cervical, skin, genital, and bowel cancer, and 
avoid high- risk behaviors (smoking, excess drinking, over-
weight and obesity, inactivity, and unprotected skin UV 
exposure). These guidelines also make clear that in patients 
with chronic GVHD, additional attention needs to be paid 
to surveillance for oral, pharyngeal, and early skin cancer. 
While some controversy exists regarding the commence-
ment, frequency, and modality for breast cancer screening, 
it is generally suggested that for woman who received 
TBI and/or chest irradiation, mammography screening 
should be commenced at age 25 or 8 years after radiation 
exposure, whichever occurs later, but no later than age 
40 years [8, 10, 11].
In Australia, the Commonwealth Government funds 
three national screening programs to reduce the burden 
of cancer nationwide; Breast Screen Australia, the National 
Cervical Screening Program, and the National Bowel Cancer 
Screening Program. These programs offer free screening 
to the Australian public at specific age and interval time 
points (Table 1) [12, 13]. Cancer Australia (the lead 
national cancer control agency) also advocates known 
healthy lifestyle behaviors such as quitting smoking, being 
‘sun smart’, being active, maintaining a healthy diet, and 
limiting alcohol intake for the entire population. 
Participation in these programs and health promotion 
behaviors in Australian BMT survivors is largely unknown.
Despite the availability of long- term follow- up guidelines 
[9, 10], and the excess burden of secondary cancers post 
allogeneic BMT [14], international studies have shown 
that cancer screening uptake and health behaviors in BMT 
survivors are similar, if not worse than people who have 
had cancer but not had an allogeneic BMT, and people 
who have never had cancer [15, 16]. In this study we 
aimed to explore rates of screening for secondary malig-
nancies in an Australian cohort of allogeneic BMT survivors 
and identify barriers to adherence with cancer screening 
recommendations.
Methods
A cross- sectional survey of BMT survivors was undertaken 
to explore late effects of BMT and the quality of survival 
post transplant. This survey of BMT survivors in New 
South Wales (NSW) Australia included questions regard-
ing rates of secondary cancers, adherence to cancer 
screening, and modifiable healthy lifestyle behavior, 
together with demographic and social characteristic asso-
ciated with barriers to uptake of cancer screening 
recommendations.
NSW is Australia’s most populous state with a popula-
tion of ~7.5 million and covers an area of 800,628 km2. 
Over a third of residents live outside the greater Sydney 
area [17]. At the time of study commencement there 
were four adult allogeneic transplant centers in NSW, all 
Table 1. Australia’s National Cancer Screening Programs with recommendations for the general population [13].
Cancer Screening Program [13] Recommendations [13]
BreastScreen Australia BreastScreen Australia invites women aged 50–74 to have free 2 yearly mammogram. Women 
aged 40–49 and 75 and over are eligible to receive free mammograms, but do not receive an 
invitation to attend.
National Bowel Cancer Screening Program 
(NBCSP)
The NBCSP invites men and women turning 50, 55, 60, 64, 65, 70, 72, and 74 to screen for 
bowel cancer.
Participants are sent a free, easy to use screening kit that can be completed at home. 
Between 2015 and 2020, more age groups will be added to the screening program:
• 2017—68, 58, and 54 year olds.
• 2018—62 and 66 year olds.
• 2019 and 2020—52 and 56 year olds.
National Cervical Screening Program (NCSP) The NCSP invites all women aged between 18 and 70 who have ever been sexually active to have 
2 yearly Pap tests.
Cervical screening is provided through general practice, community or women’s health centers, 
family planning clinics, sexual health clinics, or Aboriginal Medical Services.
From 1 May 2017, the NCSP will be changed to inviting women aged 25–74 years (both HPV 
vaccinated and unvaccinated) to undertake an HPV test every 5 years.
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based in Sydney and collectively performing approximately 
175 BMTs annually [18].
Potential participants were identified from allogeneic 
transplant databases from all adult allogeneic transplant 
centers in NSW. Participants were eligible if they were 
>18 years of age and had undergone an allogeneic BMT 
between 1 January 2000 and 31 December 2012, could 
read and write English, and could provide consent. Names 
and phone numbers were provided to the research team. 
Consenting participants were given the option to self- 
complete the questionnaire or complete it via a phone 
interview with one of the researchers. A second round 
of telephone calls was made to 187 participants who had 
not returned the survey within a month. All authors had 
access to primary clinical trial data. The study protocol 
was approved by the Northern Sydney Local Health District 
Human Research Ethics Committee (NSLHD Reference: 
1207- 217M).
Instruments
Participants were asked to complete seven instruments.
The Sydney Post BMT Study Survey (SPBS) was devel-
oped by the research team from a review of the literature 
and discussion with patients attending BMT long- term 
follow- up clinics. The survey comprised 402 questions 
grouped into 20 domains and included questions relating 
to secondary cancer diagnosis, cancer screening adherence, 
and lifestyle behavior choices. Other relevant domains 
included demographics, medical complications, tests and 
assessments, medications and therapies, infections, vac-
cinations, complementary therapy use, relationship status, 
income (Australian Dollars, AUD), and lifestyle factors, 
following allogeneic BMT. The questionnaire used tick 
box responses, short answer questions, and five- step Likert 
scales measuring attitudes and other factors and took 
approximately 1 h to complete. The questionnaire was 
piloted with six BMT survivors in clinic and phone inter-
views to assess face and content validity and to check 
for comprehension. For each consenting participant, data 
were collected on dates of diagnosis and transplant, stage/
remission status at transplant, transplant conditioning, 
GVHD prophylaxis, stem cell source, and donor type.
Cancer screening adherence and health behavior choices 
were analyzed according to a range of demographic, trans-
plant, psychosocial, and lifestyle variables assessed using 
the Functional Assessment of Cancer Therapy – Bone Marrow 
Transplant (FACT-BMT Version 4) [19, 20], anxiety stress 
and depression (The DASS 21) [21–23], chronic GVHD 
(The Chronic GVHD Activity Assessment – Patient Self 
Report (Form B) [24], The Lee Chronic GVHD Symptom 
Scale) [25], the Fear of Cancer Recurrence (FoCR) Scale 
[26], and The Post Traumatic Growth Inventory (PTGI) 
score [27, 28]. For ease of completion all instruments 
were combined into one booklet.
Statistical analysis
Categorical responses were summarized using frequencies 
and percentages. Parametric continuous variables were 
summarized using means and standard deviations, and 
nonparametric variables using medians, interquartile ranges 
(IQR), or ranges. Odds ratios and 95% confidence limits, 
Pearson χ2 test, or Fishers Exact tests were used for com-
parative analysis of dichotomous categorical variables and 
multivariable logistic regression to adjust for relevant 
confounders. Two sample comparisons of parametric and 
nonparametric data were determined using the independ-
ent t- test, and Wilcoxon rank sum tests, respectively; 
greater than two- sample comparisons were determined 
using one- way Analysis of Variance (ANOVA) and Kruskal–
Wallis tests, respectively. A two- tailed P- value <0.05 was 
used as the level of statistical significance.
Statistical analysis was performed using STATA version 
12.1 statistical package (StataCorp, College Station, TX).
Results
A total of 1475 Allogeneic BMT were performed in the 
study period. Of the 669 recipients known to be alive at 
study sampling, 583 were contactable and were sent study 
packs. Four hundred and forty one (66% of total eligible, 
76% of those contacted) returned the completed survey. 
Three percent (17) declined participation.
Of those completing the survey, 250 (57%) were male 
and 191 (43%) female. The median age of survey respond-
ents was 54 years (Range: 19–79). The median age at 
time of transplant was 49 years (Range: 17–71) (Table 2).
Secondary cancer diagnosis
One hundred and six (24.0%) reported a diagnosis of at 
least one cancer following BMT of which 104 were non-
relapse malignancies. Skin cancers accounted for the largest 
number of secondary cancers (Table 3).
Cancer screening
Skin cancer screening
A total of 436 (98.9%) participants provided a response 
to whether or not they had had undergone skin cancer 
screening since transplant. Two hundred and twenty eight 
(52.3%) reported having had a skin check and 208 (47.7%) 
reported never having had a skin check since BMT. Of 
those who reported having had a skin check, 75% had 
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done so in the preceding 18 months (range 1 month to 
9 years). One hundred and sixty six of the 228 (72.8%) 
reported attending for skin checks at least once a year.
Demographic, social, transplant- related, treatment- 
related, and behavioral factors were assessed for their 
association with having skin checks as part of cancer 
screening post transplant. Of note, skin checks were not 
significantly associated with skin GVHD, receipt of azole 
antifungals, or outdoor occupations (gardening, construc-
tion, or agriculture). Univariate analysis demonstrated a 
significantly increased odds of skin checks with older age, 
higher education status, being in a married or defacto 
relationship, and a high compliance with “sun smart” 
behaviors including the routine use of sunscreen, hats, 
sun protective attire, sunglasses, and sun avoidance during 
the daily periods for peak exposure. Factors associated 
with a reduced odds of skin checks on univariate analysis 
included an acute leukemia diagnosis, receipt of a myeloa-
blative conditioning regimen, and being within 2 years 
of transplant. After adjusting for potential confounders, 
those factors that demonstrated an independent and sig-
nificant association with having skin checks post transplant 
included older age (Adjusted 1.03 95% CI: 1.0, 1.05; 
P = 0.03), higher educational status (Adjusted Odds Ratio 
Table 2. Participant characteristics.
Sociodemographic
Gender (n = 441)
Male n (%) 250 (56.7%)
Female n (%) 191 (43.3%)
Age (years) at survey (n = 441)
Median (IQR; range) 54 (44,62; 19–79)
Age (years) at transplant (n = 441)
Median (IQR; range) 49 (38, 56; 17–71)
Ethnicity (n = 372)
Caucasian, European n (%) 323 (86.8%)
Other n (%) 49 (13.2%
Educational status (n = 333)
University (some/completed) n (%) 154 (46.2%)
Other1 n (%) 179 (53.8%)
Post transplant income status (AUD4) (n = 423)
Low income $20,000–$39,999 n (%) 155 (36.6%)
Middle income $40,000–$79,999 n (%) 123(29.1%)
High income ≥ $80,000 n (%) 145 (34.3%)
Residence (n = 431)
Major city n (%) 311 (72.2%)
Other (inner regional, outer regional, remote) n 
(%)
120 (27.8%)
Relationship status (n = 434)
Married–Defacto n (%) 344 (79.3%)
Other (separated, single, divorced) n (%) 90 (21.8%)
Transplant –related
Years since transplant (n = 441)
<2 years n (%) 58 (13.1%)
=2 to <6 years n (%) 204 (46.3%)
=6 to <10 years n (%) 117 (26.5%)
≥10 years n (%) 62(14.1%)
Underlying diagnosis (n = 423)
Acute leukemia (AML/ALL) n (%) 226 (53.4%)
Other2 n (%) 197 (46.6%)
Remission status (n = 405)
First/second complete remission 271 (66.9%)
Other3 134 (33.1%)
Donor type (n = 441)
Sibling n (%) 250 (59.9%)
Matched unrelated n (%) 158 (36.0%)
Haploidentical n (%) 10 (2.3%)
Mismatched unrelated n (%) 21 (4.8%)
Stem cell source(n = 441)
Bone marrow n (%) 48 (10.9%)
Peripheral blood n (%) 381 (86.4%)
Cord blood n (%) 12 (2.7%)
Conditioning chemotherapy (n = 439)
Myeloablative 214 (48.7%)
Reduced intensity 225 (51.3%)
1Other Education—secondary school (some or complete); trade or 
diploma.
2Other diagnoses: CML, Chronic Myeloid Leukemia; CLL, Chronic 
Lymphocytic Leukemia; NHL, Non- Hodgkin Lymphoma; HL, Hodgkin 
Lymphoma; MM, Multiple Myeloma; Myelodysplastic Syndrome/
Myeloproliferative disorder; Other (unspecified).
3Other remission status; more than second complete remission; 
Refractory; Chronic Phase; Accelerated Phase; Blast Crisis; Partial 
Remission; other (unspecified).
4AUD—Australian Dollars; IRQ, interquartile ranges.
Table 3. Secondary cancer diagnosis post blood and marrow transplant 
(BMT).
Cancer types (N = Number of 
Responses)
n (% reporting cancer 
type of total responses)
Skin cancer (n = 404) 93(23.0%)
Skin cancer type % of all skin cancers
Basal cell carcinoma (BCC) 41 (44%)
Squamous cell carcinoma (SCC) 14 (15%)
Melanoma 5 (6%)
Mixed 17 (18%)
BCC + SCC 14(15%)
BCC + Melanoma 2 (2%)
SCC + Melanoma 1(1%)
Unspecified/don’t know 16(17%)
Mouth cancers (n = 392) 6 (1.5%)
Other (n = 370) 18 (4.9%) 
n (% of all other cancers)
Urological (prostate and/or bladder) 5/18 (27%)1
Breast 2(11%)
Bowel 1(6%)
Ovarian 1(6%)
Myeloid sarcoma 1(6%)
Head (unspecified) 1(6%)
Hematological (nonrelapse) 5 (27%)2
Hematological (relapse) 2(11%)3
13 prostate, 1 bladder, 1 bladder + prostate.
21 NHL (primary = AML); 1 NHL (Primary = SAA); 2 Hodgkin Lymphoma 
(Primary = NHL); 1 post transplant lymphoproliferative disease.
31 Relapse AML; 1 relapse Mantle Cell Lymphoma; AUD, Australian 
Dollars
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[AOR]: 1.87 95% CI: 1.11, 3.15; P = 0.02), and “Sun 
smart” behavior (AOR: 1.89 95% CI: 1.06, 3.37; P = 0.03).
Compliance with skin cancer screening was further 
assessed against measures including quality of life (FACT- 
BMT and subscales) and psychological morbidity (DASS21 
and subscales), Lee GVHD scores, self- reported GVHD 
symptom severity, and Fear of Cancer recurrence and 
Post Transplant Growth Inventory scores. Survivors who 
had skin checks had significantly higher scores on FACT 
emotional subscale (P = 0.03), BMT subscale (P = 0.007), 
and overall FACT- BMT scores (P = 0.03), and significantly 
lower scores on depression subscales (P = 0.02), with no 
significant difference observed on other subscale or com-
posite DASS21 measures (Appendix A1).
Reasons cited for not undergoing skin cancer screening 
in 208 patients included lack of time in 13 (6.2%), cost 
in five (2.5%), and belief that screening was not necessary 
in 54 (26.0%). One hundred and forty nine patients 
(71.6%) indicated that they had not been advised by their 
treating team to undergo skin cancer screening. Twenty 
nine (13.9%) of those who had never undertaken skin 
cancer screening were receiving azole antifungal 
therapy.
Bowel cancer screening
A total of 432 participants provided a response to whether 
or not they had undergone bowel cancer screening (either 
colonoscopy or stool hemoccult testing) since transplant. 
One hundred and forty (32.4%) reported having had a 
bowel cancer check and 292 (67.6%) reported not having 
had a bowel cancer check since BMT. Of those who 
reported having had a bowel cancer check, 75% had done 
so in the preceding 2 years (range <1 month to 11 years). 
Forty- seven of 140 (33.8%) reported having bowel checks 
at least every 2 years.
On univariate analysis, older BMT survivors and those 
in a married or defacto relationship showed a significantly 
increased odds of undergoing bowel cancer screening. 
Transplant- related factors including an underlying diag-
nosis of acute leukemia and receiving myeloablative con-
ditioning were associated with significantly decreased odds 
of bowel cancer screening. On multivariable analysis, the 
only variable with an independent and significant increased 
association with bowel cancer screening was older age 
(AOR: 1.06; 95% CI: 1.03, 1.08; P < 0.0001).
No significant differences were evident in DASS21 and 
FACT- BMT scores and subscales, Lee GVHD or other 
psychosocial metrics in those who reported bowel screen-
ing and those who did not (Appendix A2).
Of the 292 patients who did not have bowel screening, 
8 (2.7%) cited time, 2 (0.7%) cost, and 75 (25.7%) feel-
ing that screening was not necessary as the main reasons 
for not attending to a bowel check since transplant. Two 
hundred and twenty five patients (77% of those not hav-
ing a bowel cancer check) reported that they had not 
been advised to undergo bowel cancer screening by their 
treating team.
Cervical cancer screening
A total of 186 of female participants provided a response 
to whether or not they had had a Paapaniolou (pap) 
smear since transplant. One hundred and eighteen (63.4%) 
females reported having had a pap smear and sixty eight 
(36.6%) reported not having had a pap smear since BMT. 
Of those who reported having had a pap smear, 75% 
had done so in the preceding 2 years (range: 1 month 
to 5 years).
Younger age was significantly associated with having 
had a pap smear (P = 0.04) and women who were less 
likely to have had a pap smear if within 2 years of the 
transplant procedure. Following multivariable analysis, a 
trend for a reduced odds with older age was observed 
(AOR: 0.97; 95% CI: 0.94, 1.0: P = 0.09) and a signifi-
cantly reduced odds of pap screening for women less 
than 2 years post transplant (AOR: 0.30; 95% CI: 0.11, 
0.85: P = 0.02).
Those reporting cervical cancer screening post transplant 
showed no overall differences in DASS 21 scores, although 
on a trend toward lower Anxiety scores was observed in 
females who had undergone pap screening (P = 0.06). 
Patients undergoing pap screening reported a trend toward 
higher emotional subscale scores (P = 0.054) and signifi-
cantly higher functional well- being (P = 0.008) and overall 
scores on FACT- BMT (P = 0.02). This would suggest a 
positive association between improved quality of life in 
women who had pap screening. Lower uptake of cervical 
screening was associated with a significantly increased fear 
of cancer recurrence (FoCR) score (P = 0.003). 
(Appendix A3).
Barriers to undergoing cervical cancer screening included 
lack of time in 8 (11.8%), cost in 2 (2.9%), and a belief 
that Pap screening was not necessary in 20 (29.4%). A 
total of 31 women (45.6%) reported that they had not 
been advised to have a Pap smear by their treating team.
Breast cancer screening
A total of 184 female participants provided a response 
to whether or not they had had a mammogram for breast 
cancer screening since transplant. Ninety- eight (53.3%) 
females reported having had a mammogram and 86 (46.7%) 
reported not having had a mammogram since BMT. 
Seventy- five percent reporting having a mammogram in 
the preceding 2 years (range 2.5 month to 4 years). The 
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age of first mammogram was reported by 68 women; in 
their 20s (8), 30s (12), 40s (31), 50s (16), and 60s (1). 
Older age (AOR: 1.11; 95% CI: 1.07, 1.16; P < 0.001) 
and residing in a city/inner- regional center (AOR: 5.33; 
95% CI: 1.37, 20.8; P = 0.03) were the only variables 
associated with a significantly increased odds of screening 
mammography on multivariable analysis. Total Body 
Irradiation (TBI) as part of the conditioning regimen 
showed a trend toward increased mammography uptake 
(AOR: 2.35; 95% CI: 0.99, 5.58; P = 0.052) and being 
less than 2 years post transplant a trend toward decreased 
mammography uptake (AOR: 0.31; 95% CI: 0.09, 1.05; 
P = 0.06).
For those reporting mammography screening post trans-
plant, there were no overall differences in DASS 21 scores, 
although lower depression subscales were associated with 
mammography uptake (P = 0.04). Patients undergoing 
mammography reported significantly higher emotional 
(P < 0.001) and BMT subscale scores on FACT- BMT 
(P = 0.02). This would suggest a positive association 
between improved quality of life in women who had 
mammography. Mammography screening was associated 
with significantly lower median Lee GVHD severity scores 
(P = 0.02), although no significant differences were observed 
using the alternative metric for GVHD severity (cGVHD 
activity assessment Form B) (Appendix A4).
For those not having mammography, 5 (5.8%) reported 
lack of time, 2 (2.3%) had an issue with cost, 23 (26.7%) 
felt it was not necessary, and 57 (66.3%) reported not 
being advised by their treating team to undergo breast 
cancer screening.
Discussion
The results of this study confirm that secondary cancers 
occur commonly after allogeneic transplantation [7, 29, 
30] and that cancer screening is not being performed 
according to recommended BMT long- term follow- up 
guidelines [10, 15] or with recommendations for cancer 
screening in the general Australian population [12]. Our 
cohort had lower rates of screening for bowel cancer 
(32.3%), cervical cancer (63.4%), and breast cancer (53.3%) 
than previous studies in BMT survivor populations [31]. 
These rates are, however, similar to adherence rates among 
the general Australian population who participate in Breast 
Screen Australia (55%), the National Cervical Screening 
Program (58%), and the National Bowel Cancer Screening 
Program (33%) [12]. Only half of the cohort had had a 
skin cancer check (52.4%) following transplant. This is 
significant because although there is currently insufficient 
evidence to support population- based screening for non-
melanocytic and melanoma skin cancer [32], and skin 
cancer screening not recommended by major public health 
bodies [12, 32], Australians experience a melanoma inci-
dence rate 11 times that of the average world rate [12] 
and BMT recipients are at markedly higher risk of devel-
oping all forms of skin cancer as a consequence of cuta-
neous graft- versus- host disease (GVHD), long- term use 
of immunosuppressive drugs, and azole antifungal agents 
[29].
In this study the major determinant of cancer screen-
ing, with the exception of cervical screening, was older 
age. In contrast to other studies, which have shown that 
being further out from BMT decreased adherence to pre-
ventive care practices [31], we observed a trend toward 
increased screening for skin, bowel, and breast cancers 
in late compared to early transplant survivors. A signifi-
cant association with cervical screening was observed in 
females beyond the first 2 years of their transplant pro-
cedure. It is difficult, however, to know the significance 
of this finding as there are no data regarding whether 
the age time points for general population cancer screen-
ing apply to BMT survivors, many of whom experience 
an increased risk from a younger age of secondary cancer, 
particularly breast and skin cancers. For this reason alone 
the ‘benchmarking’ of cancer screening adherence against 
general population recommendations raise real questions 
regarding best practice and the possibility of both over- 
and underdiagnosis [33]. In this regard it is noteworthy 
that rates of cancer screening in our study population 
were not only inconsistent with recommendations for 
general population screening but also with recommenda-
tions for BMT recipients and for high- risk cancer survivors. 
The finding that women exposed to TBI were no more 
likely to have mammography or to commence mammog-
raphy at an earlier age is of enormous concern given 
the recognized association between radiation exposure and 
breast cancer [34].
Interestingly, our study found a significant association 
between participation in skin, cervical, and breast cancer 
screening and higher quality of life. Although this is reas-
suring to those involved in post transplant care, it runs 
counter to recent literature that suggests that cancer screen-
ing can increase anxiety and overdiagnosis [33, 35]. There 
are at least two possible explanations for this finding—
firstly, that those who report higher quality of life may 
be more motivated to maintain good health, or conversely, 
participating in cancer prevention may confer quality of 
life and survival benefits.
We were unable to identify a significant association 
between social factors such as being in a married/defacto 
relationship with increased screening uptake, a finding 
that is otherwise well- described in other cancer screening 
studies [36–39].
Fear of cancer recurrence (FoCR) in those with an 
underlying hematological malignancy at transplantation 
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was investigated for its associations with screening uptake. 
FoCR was negatively associated with cervical screening 
uptake, but had no association with other screening pro-
cedures. Positive measures of personal growth assessed 
using the PGTI was not associated with adherence to 
cancer screening. The severity of GVHD symptoms was 
further explored for any potential association with screen-
ing uptake. We hypothesized that more symptomatic 
GVHD may result in patients being under closer medical 
surveillance and, therefore, more likely to be screened for 
cancers. Lee GVHD scores were observed to in fact be 
lower in females who did undergo post transplant breast 
screening, which may also attest to the better quality of 
life that such patients have.
Perhaps most importantly, the results of our study 
provide clues as why BMT survivors may not participate 
in cancer screening programs. Over a quarter of our 
respondents reported that they did not feel that screening 
was necessary—suggesting failures in the education and/
or counseling of transplant recipients—a finding reported 
in previous studies [14]. In addition, of those who reported 
that they had not undergone any cancer screening, the 
vast majority gave the reason that the screening test/s 
had not been recommended by their treating team. While 
we did not verify this report for individual patients, it 
is consistent with the findings of studies conducted in 
general populations [40] and may likely be true in this 
population given the inadequate resourcing of post trans-
plant care in many BMT centers. Cost was reported to 
be a barrier to uptake for very few survivors in our study; 
however, financial difficulties (low income) have been 
shown to impact cancer screening rates in other popula-
tions [38]. This may be a function of Australia’s afore-
mentioned free national cancer screening programs. The 
barrier of cost was reported for younger survivors who 
do not meet age criteria (e.g., annual mammograms for 
those age 25 years if they had TBI). These explanations 
for the low rates of adherence with cancer screening rec-
ommendations are also consistent with the literature that 
suggests that many factors may act as barriers to optimal 
preventive care including: lack of knowledge regarding 
the importance of cancer screening in both patients and 
providers, deficiencies in the organization of preventive 
health- care services [31], and skepticism regarding the 
value of screening [33, 41].
This study is important because it is one of the largest 
studies describing adherence with cancer screening guide-
lines in a BMT population and the first to explore cancer 
risk behavior and adherence to cancer screening guidelines 
in an Australian cohort of BMT survivors. Although the 
sample size and high response rate (76%) make it likely 
that these results represent an accurate account of BMT 
survivor’s health behaviors, there are a number of 
limitations to our study which may limit the generalizability 
of these results to BMT survivors in other countries and 
other settings. These limitations are principally a function 
of our study population and include Australia’s geographi-
cal size, population pattern, climate and health system 
(which includes both universal publicly funded and private 
health care), and funded national cancer screening pro-
grams. The fact that the study relied upon self- reporting 
and did not capture data on nonresponders also limits 
our findings. Another area which may have been of inter-
est is that relating to digital rectal examination (DRE) 
and/or prostate- specific antigen (PSA) for prostate cancer 
screening in BMT survivors, however, due to the con-
troversy regarding these modalities [42–45], and that 
general population prostate cancer screening is not rec-
ommended in Australia, we did not ask participants about 
this. Additionally, it should be noted that as only two of 
the respondents had a recurrence of the malignancy for 
which they were transplanted, our findings only apply to 
survivors who remain disease free following BMT. Also, 
as we did not ask respondents about adherence to cancer 
screening guidelines pre- BMT, we are not able to make 
any correlation between pre- and post- BMT practices.
What this study makes clear is that recommendations 
for cancer screening and for preventive health- care post- 
BMT are, in many situations, not being followed by 
health- care services and/or adopted by the target popula-
tion. Although the exact reasons for this require further 
qualitative study, it seems likely that this is a result of 
both systems failures and inadequate or unsuccessful patient 
education. It is also possible, but entirely speculative, that 
this may result from awareness that there is currently 
limited data to support cancer screening in BMT patients—
including those most at risk. Absence of good quality 
long- term data does not, however, create an argument 
for therapeutic nihilism or for failures to deliver com-
prehensive care post- BMT. Rather, data from studies such 
as this one should be used to drive the development and 
implementation of models of chronic care post- BMT that 
address gaps in health promotion, behavior modification, 
and cancer screening in order to prevent morbidity and 
mortality in long- term BMT survivors and increase aware-
ness in health professionals and patients alike of the 
increased risk of secondary cancers in survivors of BMT.
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Appendix A1. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), 
and their associations with having skin cancer screening.
Skin check 
N = 228
No skin check 
N = 208
OR (95% CI) Adjusted OR(95% CI)1 
P- value
Gender
Male 127/228 (55.7%) 121/208 (58.2%) 0.90 (0.61, 1.34)
Female 101/228 (44.3%) 87/208 (41.8%) 0.61
Age (median, IQR) 58 (48, 64) 51 (42, 59) 1.03 (1.02, 1.05) 1.03 (1.0, 1.05)
<0.0001 P = 0.03
Residence
City/inner regional 209/223 (93.7%) 182/203 (89.7%) 1.72 (0.81, 3.77)
Outer regional/remote 14/223 (6.3%) 21/203 (10.3%) 0.13
Education
Some/completed university 91/173 (52.6%) 60/156 (38.5%) 1.77 (1.12, 2.82) 1.87 (1.11, 3.15)
Trade/some or complete secondary school 82/173 (47.4%) 96/156 (61.5%) 0.03 P = 0.02
Household income (AUD)
Low income $20,000–$39,999 71 (32.7%) 83 (41.3%) 0.69 (0.45, 1.05) 0.73 (0.42, 1.27)
Middle/high income ≥ $40,000 146 (67.3%) 118 (58.7%) 0.07 P = 0.27
Marital status
Married/Defacto 188/225 (83.6%) 152/205 (74.1%) 1.77 (1.08, 2.92) 0.80(0.42, 1.51)
Single/divorced/separated 37/225 (17.3%) 53/205 (25.8%) 0.02 P = 0.48
Occupation
Gardener 11/210 (5.2%) 1/187 (0.5%)
Building/construction 17/211 (8.1%) 13/189 (6.9%)
Agriculture/Farm worker 9/209 (4.3%) 7/189 (3.7%) 1.44 (0.77, 2.79)
0.22
Any outdoor occupation
Yes (Gardener, Builder, Ag worker) 31/215 (14.4%) 20/192 (10.4%)
No 184/215 (85.6%) 172/192 (89.6%)
Years since transplant
<2 years 20/228 (8.8%) 37/208 (17.8%) 0.44 (0.23, 0.82) 0.69 (0.32, 1.48)
≥2 years 208/228 (91.2%) 171/208 (82.2%) 0.005 P = 0.34
Underlying diagnosis 100/215 (46.5%) 123/203 (60.6%) 0.56 (0.38, 0.85)
Acute leukemia 115/215 (53.5%) 80/123 (39.4%) 0.004 0.70 (0.42, 1.16)
Other P = 0.17
Donor type
Matched (sibling/unrelated) 213/226 (94.2%) 190/208 (91.3%) 1.55 (0.70, 3.54)
Mismatched (haploidentical, unrelated) 13/226 (5.8%) 18/208 (8.7%) 0.24
Conditioning
Myeloablative 98/226 (43.4%) 115/208 (55.3%) 0.62 (0.42, 0.92) 0.85 (0.49, 1.48)
Reduced Intensity 128/226 (56.6%) 93/208 (44.7%) 0.01 P = 0.57
Self- reported skin GVHD
Yes 113/228 (49.5%) 89/208 (42.8%) 1.31 (0.88, 1.95)
No 115/228 (50.4%) 119/208 (57.2%) 0.16
Medications
Immunosuppression
Yes 73/228 (32.0%) 82/208 (39.4%) 0.72 (0.48, 1.09)
No 155/228 (68.0%) 126/208 (60.6%) 0.11
Azole antifungals
Yes 24/228 (10.5%) 29/208 (13.9%) 0.73 (0.39, 1.34)
No 204/228 (89.5%) 179/208 (86.1%) 0.27
Routine use of sun protection
Yes 183/223 (82.1%) 147/203 (72.4%) 1.74 (1.07, 2.84) 1.89 (1.06, 3.37)
No 40/223 (17.9%) 56/203 (27.6%) 0.02 P = 0.03
DASS 21 score (median, IQR) 18 (8, 38) 20 (10,42) P = 0.2
Depression subscale 4 (0,12) 6 (2,14) P = 0.03
Anxiety subscale 4 (2,10) 4 (2,12) P = 0.53
Stress subscale 8 (2,16) 8 (4,16) P = 0.69
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Skin check 
N = 228
No skin check 
N = 208
OR (95% CI) Adjusted OR(95% CI)1 
P- value
FACT- BMT score (median, IQR) 112 (96, 125) 106 (88,119) P = 0.01
Physical well- being subscale 24 (20, 27) 24 (19,26) P = 0.09
Social well- being subscale 22 (17,25) 20 (15, 24) P = 0.11
Emotional well- being subscale 17 (15, 19) 16 (14,19) P = 0.03
Functional well- being subscale 21 (16,24) 19 (14,24) P = 0.08
BMT well- being subscale 29 (25,33) 27 (23,32) P = 0.007
LEE GVHD score (Median, IQR) 21 (9,32) 19 (10, 29) P = 0.51
Global severity GVHD symptoms (%)
None 23 (16.1%) 16 (13.3%) P = 0.64
Mild 65 (45.5%) 64 (53.3%)
Moderate 39 (27.3%) 29 (24.2%)
Severe 16 (11.2%) 11 (9.2%)
Fear of cancer recurrence (median, IQR) 13 (10,16) 14 (11, 17) P = 0.22
Post transplant growth inventory score 57 (37, 70) 60 (44,70) P = 0.42
AUD, Australian Dollars; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory.
1Variables included in multivariable logistic regression model to adjust for confounding: age, education, income and marital status, time from trans-
plant (<2 years compared to later), underlying diagnosis (acute leukemia compared to other), conditioning regimen (myeloablative compared to re-
duced intensity), and “sun smart” practices.
Bold text indicates statistically significant figures.
Appendix A1. Continued.
Appendix A2. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), 
and their associations with having bowel cancer screening.
Bowel Ca screen No Bowel Ca Screen OR (95% CI) Adjusted OR (95% CI)
N = 140 N = 292 P- value P- value1
Gender
Male 79/140 (56.4%) 168/292(57.5%) 0.95(0.62, 1.47)
Female 61/140 (43.6%) 124/292 (42.5%) 0.83
Age (Median, IQR) 59(53, 64) 50(40, 60) 1.06(1.03, 1.08) 1.06 (1.03,1.08)
<0.0001 P < 0.0001
Residence
City/inner regional 128/137(93.4%) 262/285(91.9%) 1.25(0.54, 3.15)
Outer regional/remote 9/137(6.6%) 23/285(8.1%) 0.69
Education
Some/completed University 50/105(47.6%) 101/222(45.5%) 1.09(0.66,.78)
Trade/some or complete secondary school 55/105(52.4%) 121/222(54.5%) 0.72
Household income (AUD)
Low income $20,000–$39,999 56/136(41.2%) 95/280(33.9%) 1.36(0.87, 2.12)
Middle/High income ≥ $40,000 80/136 (58.8%) 185/280(66.1%) 0.15
Marital status
Married/Defacto 116/136(85.3%) 222/289(76.8%) 1.75(0.99, 3.20) 1.14(0.63, 2.07)
Single/Divorced/separated 20/136(14.7%) 67/289(23.2%) 0.04 P = 0.65
Years since transplant
<2 years 13/140(9.3%) 44/292(15.1%) 0.58(0.27, 1.14) 0.61(0.30, 1.21)
≥2 years 127/140(90.7%) 248/292(84.9%) 0.13 P = 0.16
Underlying diagnosis
Acute Leukemia 60/135 (44.4%) 158/279(56.6%) 0.61(0.39, 0.95) 0.75(0.48, 1.19)
Other 75/135(55.6%) 121/279 (43.4%) 0.02 P = 0.23
Donor type
Matched (sibling/unrelated) 126/138(91.3%) 274/292(93.8%) 0.69(0.30, 1.62)
Mismatched (haploidentical, unrelated) 12/138 18/292(6.2%) 0.42
Conditioning
Myeloablative 57/138(41.3%) 155/292(53.1%) 0.62(0.40, 0.95) 1.20(0.72,2.00)
Reduced Intensity 81/138(58.7%) 137/292(46.9%) 0.02 P = 0.49
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Bowel Ca screen No Bowel Ca Screen OR (95% CI) Adjusted OR (95% CI)
N = 140 N = 292 P- value P- value1
GVHD
Yes 98/135(72.6%) 196/290(67.6%) 1.27(0.79, 2.06)
No 37/135(27.4%) 94/290(32.4%) 0.3
Self- reported GUT GVHD
Yes 26/140 (18.6%) 34/292 (11.6%)  1.73(0.95, 3.12) 1.66(0.90, 3.05
No 114/140(81.4%) 258/292(88.4%) 0.05 P = 0.10
Medications
Immunosuppression
Yes 49/140(35.0%) 103/292 (35.3%) 0.98(0.63, 1.54)
No 91/140(65.0%) 189/292(64.7%) 0.95
DASS 21 score (Median, IQR) 19(10,38) 20(9,40) P = 0.97
Depression subscale 4(2,14) 6(2,14) P = 0.79
Anxiety subscale 4(2,8) 6(2,10) P = 0.43
Stress subscale 10(4,18) 8(2,16) P = 0.43
FACT- BMT score(Median, IQR) 112(93, 122) 108(92,122) P = 0.39
Physical well- being subscale 24(20, 26) 24(19,26) P = 0.46
Social well- being subscale 22(17,25) 21(16, 24) P = 0.14
Emotional well- being subscale 17(14, 19) 17(14,19) P = 0.79
Functional well- being subscale 20(15,24) 20(15,25) P = 0.83
BMT subscale 29(24,33) 28(23,32) P = 0.51
LEE GVHD score (median, IQR) 16(8, 28) 21(10,32) P = 0.06
Global severity GVHD symptoms (%)
Mild 15(16.5%) 26 (15.0%) P = 0.76
Moderate 47(51.6%) 81 (46.8%)
Severe 20(22.0%) 48 (27.7%)
Very Severe 9(9.9%) 18(10.4%)
Fear of cancer recurrence (Median, IQR) 13(10, 15) 14(10,17) P = 0.3
Post transplant growth inventory Score 58(42, 70) 58(38, 71) P = 0.81
AUD, Australian Dollars; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory
1Variables included in multivariable logistic regression model to adjust for confounding: age, marital status, time from transplant (<2 years compared 
to later), underlying diagnosis (acute leukemia compared to other), conditioning regimen (myeloablative compared to reduced intensity), and gut 
GVHD.
Bold text indicates statistically significant figures.
Appendix A2. Continued.
Appendix A3. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), and 
their associations with cervical cancer screening
Cervical screen N = 118 No cervical 
screen N = 68
OR (95% CI) Adjusted OR (95% CI)1
P- value
Age (Median, IQR) 50(42, 58) 56 (42, 63)  0.04 0.97(0.94, 1.00)
P = 0.09
Residence
City/inner regional 109/117(93.2%) 58/65(89.2%) 1.64(0.48, 5.47)
Outer regional/remote 8/117(6.8%) 7/65(10.8%) 0.4
Education
Some/completed University 41/93 (44.1%) 19/54 (35.2%) 1.45(0.69, 3.09)
Trade/some or complete secondary school 52/93(55.9%) 35/54 (64.8%) 0.3
Household income (AUD)
Low income $20,000–$39,999 45/113 (39.8%) 25/66(37.9%) 1.81(0.86, 3.93) 1.13(0.58,2.19)
Middle/High income ≥ $40,000 68/113(60.2%) 41/66(62.1%) 0.09 P = 0.71
Marital status
Married/Defacto 92/113 (81.4%) 52/87 (77.6%) 1.26(0.55, 2.82)
Single/Divorced/separated 21/113 (18.6%) 15/67(22.4%) 0.54
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Cervical screen N = 118 No cervical 
screen N = 68
OR (95% CI) Adjusted OR (95% CI)1
P- value
Years since transplant
<2 years 8/118 (6.8%) 14/68 (20.6%) 0.28(0.09, 0.77) 0.30(0.11, 0.85)
≥2 years 110/118 (93.2%) 54/68(79.4%) 0.008 P = 0.02
Underlying diagnosis
Acute Leukemia 71/111(64.0%) 39/66(59.1%) 1.22(0.62, 2.40)
Other 40/111(36.0%) 27/66(40.9%) 0.52
Donor type
Matched (sibling/unrelated) 108/118(91.5%) 64/68(94.1%) 0.67(0.15, 2.47)
Mismatched (haploidentical, unrelated) 10/118(8.5%) 4/68(5.9%) 0.58
Conditioning
Myeloablative 70/118(59.3%) 33/68(48.5%) 1.55(0.81, 2.95) 0.98(0.47, 2.03)
Reduced Intensity 48/118(40.7%) 35/68(51.5%) 0.15 P = 0.97
GVHD
Yes 78/117(66.7%) 44/66(66.7%) 1.0(0.50, 1.98)
No 39/117(33.3%) 22/66(33.3%) 1
Self- reported vaginal GVHD
Yes 25/118(21.2%) 16/68(25.5%) 0.87(0.40, 1.92)
No 93/118(78.8%) 52/68(76.5%) 0.71
Medications
Immunosuppression
Yes 25/118 (21.2%) 21/68(30.9%) 0.60(0.30, 1.26) 0.78(0.38, 1.61)
No 93/118 (78.8%) 47/68(69.1%) 0.14 P = 0.50
DASS 21 score (Median, IQR) 18(8,34) 20(10,40) P = 0.21
Depression subscale 4(1,9) 4(0,12) P = 0.28
Anxiety subscale 4(1,8) 6(2, 10) P = 0.06
Stress subscale 8(2,14) 10(4,16) P = 0.63
FACT- BMT score (Median, IQR) 111(99, 123) 104(91, 119) P = 0.02
Physical well- being subscale 25(22,27) 24(18,26) P = 0.12
Social well- being subscale 22(17,26) 21(18,26) P = 0.89
Emotional well- being subscale 17(15,19) 16(14, 18) P = 0.054
Functional well- being subscale 21(18,26) 19(16,23) P = 0.008
BMT well- being subscale 28(25,32) 27(22, 32) P = 0.07
LEE GVHD score (Median, IQR) 14 (8, 28) 19(9, 28) P = 0.25
Global severity GVHD symptoms (%)
Mild 12(16.0%) 6(17.1%)
Moderate 41(54.5%) 15(42.9%) P = 0.68
Severe 19(25.3%) 12(34.3%)
Very Severe 3(4.0%) 2(5.7%)
Fear of cancer Recurrence (Median, IQR) 12(9,15) 15(10,18) P = 0.003
Post transplant Growth Inventory Score 59(44,71) 68(49, 82) P = 0.1
PTGI, The Post Traumatic Growth Inventory.
1Potential confounders included in multivariable logistic regression: age, income status (low compared to middle/high income), early post transplant 
(within 2 years), conditioning regimen (myeloablative compared to reduced intensity), and taking immunosuppression (tacrolimus, cyclosporine, my-
cophenolate, or prednisolone). IRQ, interquartile ranges.
Bold text indicates statistically significant figures.
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Mammogram N = 98 No Mammogram N = 86 OR (95% CI) P- value Adjusted1 OR (95% 
CI) P-value
Age (median, IQR) 57(50, 63) 43(32, 54) 1.09 (1.06, 1.13) 1.12(1.08, 1.17)
<0.0001 P < 0.0001
Residence
City/inner regional 92/96 (95.8%) 73/84(86.9%) 3.46(0.97, 15.4) 4.81(1.16, 19.9)
Outer regional/remote 4/96 (4.2%) 11/84 (13.1%) 0.06 P = 0.03
Education
Some/completed University 35/83(42.2%) 23/63(36.5%) 1.27(0.61, 2.63)
Trade/some or complete secondary 
school
48/83(57.8%) 40/63(63.5%) 0.49
Household income (AUD)
Low income $20,000–$39,999 39/96 (40.6%) 30/82(36.6%) 1.18(0.62, 2.28)
Middle/High income ≥ $40,000 57/96 (59.4%) 52/82(63.4%) 0.58
Marital status
Married/Defacto 80/94(85.1%) 62/84(73.8%) 2.03(0.90, 4.64) 1.13(0.42, 3.07)
Single/divorced/separated 62/94 (73.8%) 22/84(26.2%) 0.06 P = 0.63
Years since transplant
<2 years 6/98 (6.1%) 14/86 (16.3%) 0.33(0.10, 0.99) 0.31(0.09, 1.05)
≥2 years 92/98 (93.9%) 72/86(83.7%) 0.03 P = 0.06
Underlying diagnosis
Acute Leukemia 57/96(59.4%) 53/81(65.4%) 0.77(0.40, 1.50)
Other 39/96 (40.6%) 28/81(34.6%) 0.41
Donor type
Matched (sibling/unrelated) 90/98(91.8%) 79/86 (92.9%) 0.99(0.29, 3.30)
Mismatched (haploidentical, unrelated) 8/98(8.2%) 7/86(7.1%) 1
Conditioning
Myeloablative 49/98(50%) 56/86(65.1%) 0.53(0.28, 1.01) 0.98(0.41, 2.37)
Reduced intensity 49/98(50%) 30/86(34.9%) 0.04 P = 0.98
Total body irradiation
Yes 34/98 (34.7%) 28/86(32.6%) 1.1 (0.57, 2.13) 2.35(0.99, 5.58)
No 64/98(65.3% 58/86(67.4%) 0.76 P = 0.052
GVHD
Yes 61/96(63.5%) 60/85(70.6%) 0.73(0.37, 1.42)
No 35/96(36.5%) 25/85(29.4%) 0.31
Medications
Immunosuppression
Yes 22/98 (22.5%) 24/86(27.9%) 0.75(0.36, 1.54)
No 76/98(77.5%) 62/86(72.1%) 0.39
DASS 21 score (median, IQR) 19(8,30) 20(8,40) P = 0.36
Depression subscale 4(0,8) 6(2,12) P = 0.04
Anxiety subscale 4(2,8) 4(2,10) P = 0.3
Stress subscale 10(3,14) 8(2,16) P = 0.99
FACT- BMT score (Median, IQR) 114(101, 126) 107(93, 119) P = 0.02
Physical well- being subscale 25(21,27) 24(20,27) P = 0.24
Social well- being subscale 22(17,26) 20(17,25) P = 0.18
Emotional well- being subscale 18(16,19) 16(13,18) P < 0.001
Functional well- being subscale 21(17,26) 20(16, 23) P = 0.15
BMT well- being subscale 29(25,32) 27(23,31) P = 0.049
Appendix A4. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, and 
PTGI), and their associations with breast cancer screening.
15© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Cancer Screening Adherence in Australian BMT SurvivorsG. Dyer et al.
Mammogram N = 98 No Mammogram N = 86 OR (95% CI) P- value Adjusted1 OR (95% 
CI) P-value
LEE GVHD score (Median, IQR) 12(7, 24) 19(11, 29) P = 0.02
Global severity GVHD symptoms (%)
Mild 12(16.0%) 6 (17.1%) P = 0.68
Moderate 41 (54.7%) 15 (42.9%)
Severe 19 (25.3%) 12 (34.3%)
Very Severe 3(4.0%) 2(5.7%)
Fear of cancer recurrence (Median, IQR) 13(9, 15) 14(9, 17) P = 0.48
Post transplant growth inventory score 61(51, 75) 59(42, 72) P = 0.26
AUD, Australian Dollars; BMT, Bone marrow transplantation; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory
1Potential confounders included in multivariable logistic regression: age, residential status, marital status, early post transplant (within 2 years), con-
ditioning regimen (myeloablative compared to reduced intensity), and whether total body irradiation was used (Yes, No).
Bold text indicates statistically significant figures.
Appendix A4. Continued.
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8.5. Synopsis 
This manuscript provides the largest and most comprehensive account of cancer screening adherence 
in Australian allogeneic BMT survivors.  The results indicate that secondary cancers post-BMT are 
common and that urgent attention is required to improve both knowledge of and compliance with 
cancer screening guidelines post BMT.   
While rates of cancer screening adherence in our BMT survivors were comparable to that of the 
Australian general population (bowel 32.4% vs 39%, cervical 63.4% vs 56%, breast 53.3% vs 55%), this 
is deeply problematic as rates of cancer are higher (OR for some cancers in survivors of BMT are up to 
fifteen times the general population(4)).  These data along with the fact that more than 25% of 
respondents did not feel that cancer screening was necessary and more than 75% had not been 
advised to undergo cancer screening by their treatment team - has significant implications for BMT 
survivors, health care professionals involved in their long term care and public health authorities who 
provide cancer screening services and health promotion.  While widely recognised as an issue in 
oncology care and in BMT, these results suggest that more needs to be done to educate BMT survivors 
of the prolonged and increasing risk (to date no plateau in incidence has been identified(5)) of 
secondary cancer post-BMT.  This is particularly important for survivors who experience cGVHD and 
are on prolonged IST.  This will not only improve the validity and rigor of consent but also enable early 
identification and treatment of secondary cancers. 
In this regard it is noteworthy that there is limited data about the efficacy of cancer screening in BMT 
survivors.  In particular, we do not know if general population cancer screening, or BMT specific cancer 
screening will prevent or decrease morbidity and mortality in long-term survivors.  This is a major 
lacunae as without this data it may be difficult to convince clinicians and health services to change 
their practice and add focus on health promotion in BMT survivor care.   
Interestingly, we found that survivors with a better QoL were more motivated to follow screening and 
preventative care recommendations for their long-term care.  This suggest that better, more 
comprehensive post-BMT care that engage patients more fully in their care and is cognizant of their 
lived experience and social world may both improve survivor QoL and improve cancer screening 
uptake in this vulnerable and high-risk group.   
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Chapter 9: Prevalence of high-risk health behaviours in long-term survivors of 
allogeneic blood and marrow transplantation in Sydney, Australia 
9.1. Chapter overview 
This chapter reports on BMT survivors’ engagement in high-risk health behaviours known to 
contribute to chronic non-communicable conditions. It consists of a published manuscript entitled, 
‘Prevalence of high-risk health behaviours in long-term survivors of allogeneic blood and marrow 
transplantation in Sydney, Australia’.  The manuscript correlates demographics, socioeconomics, 
transplant factors, co-morbidities and QoL scores with high-risk lifestyle and health behaviour choices 
of BMT survivors and with survivors’ adherence with preventive health measures advocated by leading 
health promotion and cancer control agencies (Cancer Australia, the Cancer Institute NSW etc.) and 
international and national BMT LTFU guidelines.  Specifically, BMT survivors were asked about 
smoking, drinking >2 standard drinks per day, weight/BMI, physical activity levels and compliance with 
‘sun smart’ behaviours (defined as always/routinely wearing sunscreen, hat, sunglasses, collared long 
sleeve shirts and avoiding sun exposure between 11-3pm).   
The results of this study demonstrate that BMT survivors may engage in high risk health behaviours 
following transplant, despite the increased risks to their long-term health.  The is significant because 
it is likely to result in an excess of many preventable chronic health conditions such as CVD and 
respiratory disease, DM, osteoporosis, anxiety and depression, and secondary cancers.  The findings 
have implications for education and support both pre and post-BMT and highlight the importance of 
both health promotion advocacy and health promotion programs in Australia.   
9.2. Publication details 
Dyer G, Larsen SR, Gilroy N, Brice L, Kabir M, Hogg M, Brown L, Hertzberg M, Greenwood M, Moore J, 
Gottlieb D, Huang G, Tan J, Ward C, Kerridge I. “Prevalence of high-risk health behaviours in long-term 
survivors of allogeneic blood and marrow transplantation in Sydney, Australia”. Australian Journal of 
Cancer Nursing 2017:18(2):16-23. 
9.3. Authors’ contributions 
GD co-designed the study, recruited study participants, collected data, interpreted the results and 
drafted the manuscript.  A signed Statement of Contribution from all authors is in Appendix A. 
9.4. Manuscript 
The published version of the manuscript follows. 
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Abstract
Allogeneic	 blood	 and	marrow	 transplantation	 (BMT)	 survivors	 are	 at	 a	 significantly	 increased	 risk	 of	many	 preventable	 conditions	
that	 cause	 long-term	morbidity	 and	mortality.	 The	 aim	 of	 this	multi-centre	 cross-sectional	 study	was	 to	 examine	 Australian	 BMT	
survivors	and	their	engagement	in	high-risk	health	behaviour	known	to	contribute	to	these	conditions.	Of	441	New	South	Wales	(NSW)	
participants,	smoking,	drinking	more	than	recommended,	being	overweight/obese,	and	 inactivity	was	reported	by	7.5%,	 12.1%,	48.1%,	
and	33%,	respectively.	Rates	of	"sun-smart"	behaviours	were	high	(77%).	Time	since	transplant,	lower	levels	of	education	and	chronic	
graft-versus-host	disease	(GVHD)	resulted	in	decreased	odds	of	good	health	behaviour.	Our	results	suggest	that	despite	well-defined	
long-term	risks,	certain	subsets	of	long-term	survivors	continue	to	engage	in	high-risk	health	behaviours.	Therefore,	targeted,	lifelong	
counselling	and	education	by	nurses	about	the	importance	of	adhering	to	preventative	health	behaviours	is	critical	to	improve	long-
term	outcomes.
Keywords: Bone	marrow	transplant	survivors,	cancer	survivors,	health	behaviours,	high-risk	health	behaviours.
Please note that the data presented in this manuscript forms part of the Sydney post-bone marrow transplant survey report produced 
for the the New South Wales Agency for Clinical Innovation (ACI)1.
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Introduction
Allogeneic	 blood	 and	 marrow	 transplantation	 (BMT)	 is	 a	
lifesaving	 medical	 procedure	 used	 for	 the	 treatment	 of	 many	
malignant	 and	 non-malignant	 diseases	 in	 adults	 and	 children.	
With	 advances	 in	 transplantation	 techniques	 and	 supportive	
care,	up	to	85%	who	are	alive	at	two	years	post-BMT	will	survive	
long-term2.	However,	survival	is	not	without	consequence.	Many	
long-term	 survivors	 experience	 chronic	 morbidity,	 decreased	
quality	 of	 life	 (QoL)	 and	 late	 non-transplant	 related	mortality.	
The	effects	of	graft-versus-host	disease	 (GVHD)	—	a	condition	
in	 which	 the	 donor	 T-cells	 recognise	 the	 patient	 as	 foreign	
—	 combined	 with	 late	 toxicities	 associated	 with	 chemo-
radiotherapy	 and	 immunosuppression,	 place	 survivors	 at	 a	
significantly	 increased	 risk	of	many	preventable	chronic	health	
conditions.	 Cardiovascular	 and	 respiratory	 disease,	 diabetes	
mellitus,	 osteoporosis,	 endocrine	 and	 gonadal	 failure,	 anxiety,	
depression	 and	 secondary	 cancers	 all	 commonly	 occur	 after	
BMT3,	and	result	in	mortality	rates	four-	to	nine-fold	higher	than	
those	 observed	 in	 an	 age-adjusted	 general	 population	 for	 at	
least	30	years	after	BMT4.
According	 to	 international	 consensus	 guidelines	 for	 the	 long-
term	 care	 of	 survivors	 of	 allogeneic	 BMT,	 primary	 preventive	
behaviours	 should	be	 espoused	 in	 an	 attempt	 to	mitigate	 this	
increased	 risk	 of	 poor	 long-term	 health5.	 Specifically,	 these	
guidelines	 state	 survivors	 of	 BMT	 should	 eat	 a	 healthy	 diet,	
not	 smoke,	 drink	 alcohol	 in	 moderation	 (<2	 drinks	 per	 day),	
maintain	 a	 healthy	 weight,	 avoid	 excessive	 sun	 exposure	 and	
wear	sunscreen,	and	follow	age-specific	guidelines	for	physical	
activity5	(Australian	physical	activity	recommendations	for	18–64	
years	are	at	least	150–300	minutes	of	moderate	intensity	exercise	
or	75–150	minutes	of	vigorous	intensity	exercise	per	week,	plus	
at	 least	 2	 days	 per	 week	 of	 muscle-strengthening	 activities6).	
Early	adoption	of	these	modifiable	behaviours,	it	is	argued,	may	
help	 attenuate	 a	 subset	 of	 the	 chronic	 health	 conditions	 that	
survivors	experience	and	improve	survivors’	QoL7.
While	 these	 guidelines	 have	 been	 available	 for	 a	 decade8	 and	
campaigns	addressing	these	behaviours	have	existed	in	Australia	
directed	at	the	general	population	for	many	years	(for	example,	
Life be in it9, Slip, Slop Slap10,	 Every cigarette is doing you 
damage11, Measure up12,	Swap it, don’t stop it13	and	Live Lighter14),	
it	 is	 recognised	 that	 behaviour	 modification	 can	 be	 difficult,	
even	 in	 the	context	of	cancer	 survivorship.	 People	are	 familiar	
with	 how	 to	 prevent	 morbidity	 (or	 prevent	 further	 morbidity	
in	 the	context	of	allogeneic	BMT	survivorship),	but	knowledge	
does	 not	 necessarily	 result	 in	 a	 desired	 behaviour15.	 Indeed,	
while	 a	 cancer	 diagnosis	 is	 thought	 to	 represent	 a	 "teachable	
moment",	many	 studies	 have	 found	 that	 despite	 the	 increased	
risks	to	health,	when	compared	to	non-cancer	controls,	cancer	
survivors	 continue	 to	 need	 education	 and	 assistance	 to	 help	
change	health	behaviour	in	the	longer	term16-22.
Although	 there	 is	 a	 growing	 body	 of	 literature	 on	 health	
behaviours	of	cancers	survivors23-27,	there	is	a	paucity	of	data	on	
survivors	of	BMT	and	no	data	 regarding	 the	health	behaviours	
of	Australian	 BMT	 survivors.	We	 report	 the	 results	 of	 a	 cross-
sectional	 survey	 of	 long-term	 survivors	 of	 allogeneic	 BMT	 in	
New	South	Wales	(NSW)	to	identify	their	participation	in	primary	
preventive	 health	 behaviours;	 to	 examine	 the	 demographic,	
socio-economic	and	transplant	factors	and	sequelae	associated	
with	 lifestyle	 and	 health	 behaviour	 choices;	 to	 identify	 gaps	
where	cancer	nurses	are	best	able	to	assist	this	vulnerable	and	
high-risk	patient	group;	and	to	use	this	data	to	support	clinical	
and	health	policy	decision-making	for	long-term	care.
Methods
Patients and procedures
Potential	participants	were	identified	from	the	databases	of	all	
adult	 allogeneic	 transplant	 centres	 in	 NSW.	 Participants	 were	
eligible	 if	 they	 were	 >18	 years	 of	 age	 (at	 the	 time	 of	 survey)	
and	had	undergone	an	allogeneic	BMT	at	an	adult	BMT	centre	
between	1	January	2000	and	31	December	2012,	were	>17	years	at	
the	time	of	transplant,	could	read	and	write	English	and	could	
provide	 consent.	 Names	 and	 phone	 numbers	 were	 provided	
to	 the	 research	 team.	 Consenting	 participants	 were	 given	 the	
option	to	self-complete	the	questionnaire	or	complete	it	via	a	
phone	 interview	with	one	of	 the	 researchers.	A	 second	 round	
of	 telephone	 calls	was	made	 to	 178	participants	who	had	not	
returned	the	survey	within	a	month.	No	participant	elected	to	
be	phone-interviewed.	All	authors	had	access	to	primary	clinical	
trial	 data.	 The	 study	 protocol	 was	 approved	 by	 the	 Northern	
Sydney	Local	Health	District	Human	Research	Ethics	Committee	
(NSLHD	Reference:	1207-217M).
Instruments
Engagement	 in	 high-risk	 health	 behaviours	 was	 analysed	
according	 to	 a	 range	of	 demographic,	 transplant,	 psychosocial	
and	lifestyle	variables	assessed	using	six	survey	instruments	(five	
validated	and	one	designed	specifically	for	the	study).	The	five	
validated	 instruments	 included	 the	 Functional Assessment of 
Cancer Therapy — Bone Marrow Transplant (FACT-BMT Version 
4)28,29,	 anxiety	 stress	 and	 depression	 (The DASS 21)30-32,	 chronic	
GVHD	 (The Chronic GVHD Activity Assessment — Patient Self 
Report — Form B)33	and	The Lee Chronic GVHD Symptom Scale34	
and	The Post-Traumatic Growth Inventory score35,36.
The	sixth	survey	instrument,	the	Sydney Post-BMT Study Survey	
was	 purpose-designed	 for	 the	 study	 by	 the	 research	 team	
following	literature	review	and	discussion	with	patients	attending	
BMT	 late	 effects	 clinics	 —	 to	 cover	 issues	 not	 addressed	 in	
existing	 surveys.	 The	 survey	 comprised	402	questions	 grouped	
into	 20	 domains	 and	 included	 questions	 relating	 to	 high-risk	
health	behaviour:	smoking,	drinking,	exercise,	diet	and	body	mass	
index	 (BMI),	 and	 being	 "sun-smart".	 ("Sun-smart"	 behaviour	was	
defined	 in	 the	 survey	 as	 "always/routinely	 wearing	 sunscreen,	
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hat,	sunglasses,	shirts	with	long	sleeves	and	a	collar,	and	avoiding	
being	 in	 the	 sun	 between	 11	 am	 and	 3	 pm".)	 Other	 relevant	
domains	 included	 demographics,	 medical	 complications,	
tests	 and	 assessments,	 medications	 and	 therapies,	 infections,	
vaccinations,	 complementary	 therapy	 use,	 cancer	 screening,	
relationship	 status,	 income,	 and	 lifestyle	 factors	 following	
allogeneic	 BMT.	 The	 questionnaire	 used	 tick-box	 responses,	
short-answer	 questions	 and	 five-step	 Likert	 scales	 measuring	
attitudes	and	other	factors	and	took	approximately	one	hour	to	
complete.	The	questionnaire	was	piloted	with	BMT	survivors	to	
assess	face	and	content	validity	and	to	check	for	comprehension.	
For	each	consenting	participant,	data	was	collected	on	dates	of	
diagnosis	 and	 transplant,	 stage/remission	 status	 at	 transplant,	
transplant	conditioning,	GVHD	prophylaxis,	stem	cell	source	and	
donor	type.
Statistical analysis
Categorical	 responses	were	 summarised	 using	 frequencies	 and	
percentages.	Parametric	continuous	variables	were	summarised	
using	 means	 and	 standard	 deviations,	 and	 non-parametric	
variables	 using	 medians,	 interquartile	 ranges	 (IQR)	 or	 ranges.	
Odds	 ratios	 and	 95%	 confidence	 limits,	 Pearson	 chiχ2	 test	
or	 Fisher's	 exact	 tests	 were	 used	 for	 comparative	 analysis	 of	
dichotomous	 categorical	 variables.	 Adjusted	 odds	 ratios	 to	
account	 for	 potential	 confounding	 effects	 were	 determined	
using	 multivariable	 logistic	 regression	 analysis.	 Two	 sample	
comparisons	 of	 parametric	 and	 nonparametric	 data	 were	
determined	 using	 the	 independent	 t-test,	 and	Wilcoxon	 Rank	
Sum	 tests,	 respectively;	 greater	 than	 two	 sample	 comparisons	
were	determined	using	one-way	Analysis	of	Variance	 (ANOVA)	
and	Kruskal	Wallis	tests.	A	two-tailed	p	value	<0.05	was	used	as	
the	level	of	statistical	significance.
Statistical	 analysis	 was	 performed	 using	 STATA	 version	 12.1	
statistical	package	(StataCorp,	College	Station,	TX,	USA).
Results
A	 total	 of	 1,475	 allogeneic	 BMT	were	 performed	 in	 the	 study	
period.	 Of	 the	 667	 recipients	 known	 to	 be	 alive	 at	 study	
sampling,	581	(87%)	were	contactable	and	were	sent	study	packs.	
Four	hundred	and	forty-one	(66%	of	total	eligible,	76%	of	those	
contacted)	 returned	 the	 completed	 survey.	 Three	 per	 cent	
declined	participation	(Figure	1).
Of	 those	 completing	 the	 survey,	 250	 (57%)	 were	 male	 and	
191	 (43%)	 female.	 The	 median	 age	 of	 survey	 respondents	 was	
54	 years	 (range:	 19–79).	 The	median	 age	 at	 time	 of	 transplant	
procedure	 was	 49	 years	 (range:	 17–71).	 The	 median	 time	 since	
BMT	was	5	years	(range:	1–14)	(Table	1)
A	 range	 of	 lifestyle	 factors	 were	 surveyed	 including	 smoking,	
alcohol	consumption,	weight/BMI,	exercise	and	diet.
Smoking
A	total	of	33/438	(7.5%)	of	BMT	survivors	were	smokers	—	21/247	
(8.5%)	males,	and	12/191	(6.3%)	females.	Twelve	(36.4%)	reported	
smoking	<5	cigarettes/day	on	average;	7	(21.2%)	reported	5	to	<10	
cigarettes;	and	13	(39.4%)	>10	cigarettes	per	day.	One	survivor	did	
not	 report	 quantity.	 On	 univariate	 analysis	 factors	 associated	
with	 significantly	 lower	 odds	 of	 smoking	 included	 having	
some	 level	 of	 university	 education,	 having	 chronic	GVHD,	 and	
if	 there	 had	 ever	 been	 a	 referral	 to	 a	 respiratory	 specialist	 or	
physiotherapist.	 There	 was	 no	 significant	 association	 between	
chronic	co-morbidities	and	smoking.	The	odds	of	being	diabetic	
and	 a	 smoker	 were	 lower,	 though	 this	 was	 not	 statistically	
significant.
On	 multivariate	 analysis,	 adjusting	 for	 potential	 confounders,	
years	 from	 date	 of	 transplant	 was	 associated	 with	 increased	
odds	of	smoking	(OR	1.25;	95%	CI	1.08,	1.45;	p=0.01)	and	any	level	
of	university	education	was	associated	with	decreased	odds	of	
smoking	(OR	0.12;	95%	CI	0.03,	0.60;	p=0.003).
No	measures	 of	 personal	 growth	 (PTGI),	 depression	 stress	 and	
anxiety	(DASS	21)	or	QoL	demonstrated	a	significant	difference	
between	smokers	and	non-smokers.
Alcohol
A	total	of	282/441	(63.9%)	of	survivors	drank	alcohol,	 including	
179/250	(71.6%)	males,	and	103/191	(53.9%)	females.	Thirty-three	
(12.1%)	of	those	who	drank	alcohol	reported	drinking	more	than	
two	standard	drinks	per	day	on	average,	(29	male,	4	female).	Six	
(2%)	males	exceeded	four	standard	drinks	per	day
On	 univariate	 analysis	 factors	 associated	 with	 significantly	
lower	 odds	 of	 alcohol	 use	 included	 lower	 income	 status	 and	
being	diabetic.	An	increased	odds	of	alcohol	use	was	observed	
in	males,	those	who	worked,	those	with	any	level	of	university	
education	and	those	with	mild	or	no	symptoms	of	GVHD.
Figure 1: Study flowchart 
*Reproduced with permission from the Agency for Clinical 
Innovation BMT Network Long-Term Follow-Up Group1
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Figure 1: Study Flowchart 
*Study flowchart reproduced with permission from the Agency for Clinical Innovation BMT Network 
Long-Term Follow-Up Group(1)  
 
  
	 Volume	18	Number	2	–	November	2017	 19
On	 multivariate	 analysis	 adjusting	 for	 potential	 confounders,	
years	from	date	of	transplant	was	associated	with	an	increased	
odds	of	alcohol	consumption	(OR	1.13;	95%	CI	1.01,	1.26;	p=0.04)	
and	male	gender	(OR	2.50;	95%	CI	1.18,	5.28;	p=0.02).
We	further	examined	associations	between	alcohol	consumption	
and	 other	 measures	 of	 personal	 growth	 (PTGI),	 depression	
stress	 and	 anxiety	 (DASS	 21)	 and	QoL.	When	 adjusting	 for	 the	
effects	of	age,	gender	and	years	 since	transplant,	we	observed	
significantly	increased	odds	of	improved	QoL	(FACT	BMT	score)	
and	 alcohol	 consumption.	 Significantly	 lower	 measures	 of	
depression,	anxiety	and	stress	were	also	seen	in	those	consuming	
alcohol.	Comparative	measures	of	personal	growth	(PTGI	scores)	
were	lower	in	those	who	consumed	alcohol.
"Sun-smart" behaviour
A	 total	 of	 333/431	 (77.3%)	 of	 survivors	 reported	 sun-smart	
behaviour,	 including	 192/243	 (79.0%)	 males,	 and	 141/188	 (75%)	
females.
On	univariate	analysis,	those	who	reported	sun-smart	behaviour	
had	 significantly	 higher	 morbidity	 from	 GVHD	 (p=0.03),	 as	
measured	 using	 the	 LEE	GVHD	 score.	Other	 factors	 positively	
associated	 with	 sun-smart	 behaviours	 included	 referral	 to	 a	
dietitian	(OR	1.84;	95%	CI	0.98,	3.63;	p=0.047)	and	a	history	of	skin	
cancer	(OR	2.39;	95%	CI	1.21,	5.07;	p=0.008).
On	 multivariate	 analysis,	 no	 significant	 associations	 were	
observed	between	socio-demographic	variables,	co-morbidities,	
GVHD	or	referral	patterns.
No	 significant	 associations	 were	 shown	 between	 sun-smart	
behaviours	and	measures	of	personal	growth	(PTGI),	depression	
stress	and	anxiety	(DASS	21)	or	QoL	(FACT	BMT),	after	adjusting	
for	the	effects	of	age,	gender	and	years	since	transplant.
Weight/BMI
A	total	of	197/405	(48.6%)	of	survivors	had	a	normal	BMI	(>18.5	to	
25),	including	103/229	(45.0%)	males,	and	94/176	(53.4%)	females.	
Thirty-six	of	those	surveyed	did	not	respond	to	the	question	on	
weight	 and/or	 height	 (from	which	 BMI	was	 derived).	 Thirteen	
Table 1: Demographic, social and clinical characteristics of post-
transplant survivors responding to survey (n=441)
Characteristic Distribution
Socio-demographic  
Gender (Male) n/total	(%) 250/441	(57%)
Median age in years	(range) 54	(19–79)
Postcode location
City/inner	regional	n/total	(%)
	
396/431	(92%)
Income status (A$) n/total responses (%)
Low	income	$20,000–$39,999
Middle	income	$40,000–$79,999
High	income	>=$80,000
	
155/423	(37%)
123/423	(29%)
145/423	(34%)
Educational status n/total responses (%)
Some	high	school
Completed	high	school
Trade	qualifications/diploma
Some	university
Completed	university
 
53/333	(16%)
79/333	(24%)
47/333	(14%)
24/333	(7%)
130/333	(39%)
Transplant factors
Years since transplant — median (range) 	5	(1–14)
Underlying diagnosis n/total responses (%)
Acute	leukaemia
Other	*
	
226/423	(53%)
197/423(47%)
Donor type n/total responses (%)
Sibling	related
Matched	unrelated
Haploidentical/mismatched
	
250/439	(57%)
158/439	(36%)
31/439	(7%)
Conditioning n/total responses (%)
Myeloablative
Reduced	intensity
	
214/439	(49%)
225/439	(51%)
Post-transplant morbidity and quality of life
cGVHD
Total	reported	cGVHD	since	transplant	n/total	
responses	(%)
Total	LEE	GVHD	score	— median	(range)
	
301/434	(69%)	
19	(0–77)
Chronic diseases/psychological morbidity 
n/total responses (%)
Bone	disease	(osteopenia,	spinal	fractures	or	
avascular	necrosis)
Cardiovascular	risk	factors	(diabetes,	
hypertension	or	elevated	cholesterol)
Cancer	(mouth,	skin,	or	other)
Anxiety
Depression
Depression,	anxiety,	stress	(DASS	21)	— median	
score	(range)
		
126/400	(32%)	
180/414	(43%)	
108/389	(28%)
83/403	(21%)
95/407	(23%)
20	(0–118)
Lifestyle n/total responses (%)
Smoke
Drink	alcohol
Exercise/play	sport
Always	use	sun-protection	(sunscreen,	hat,	
clothing	sunglasses
Median	BMI	(range)	for	males
Median	BMI	(range)	for	females
	
33/438	(7%)
282/441	(64%)
300/436	(69%)
333/431	(77%)	
25	(17–63)
24	(16–53)
Total FACT BMT — median (range) 110	(32–144)
*	CML,	CLL,	SAA,	NHL,	HL	MM,	MDS/Myeloproliferative	disease,	other	
(unspecified)
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(3.2%)	of	 survey	 respondents	were	underweight	 (BMI	 <18.5),	 128	
(31.6%)	 were	 overweight	 (BMI	 >25	 to	 <30)	 and	 67	 (16.5%)	 were	
obese	(BMI	>30).
On	univariate	analysis,	those	with	normal	BMI	had	lower	odds	of	
diabetes	and	anxiety.
On	 multivariate	 analysis,	 normal	 BMI	 was	 associated	 with	
significantly	lower	odds	of	diabetes	(OR	0.46;	95%	CI	0.23,	0.92;	
p=0.02)	and	a	trend	towards	being	more	years	out	from	the	date	
of	the	transplant	(OR	1.07;	95%	CI	1.00,	1.14;	p=0.052).
No	 significant	 associations	 were	 shown	 between	 those	 with	
normal	BMI	and	measures	of	personal	growth	(PTGI),	depression	
stress	and	anxiety	(DASS	21)	or	QoL	(FACT	BMT),	after	adjusting	
for	the	effects	of	age,	gender	and	years	since	transplant.
Diet
Sixty-five	 per	 cent	 of	 survivors	 in	 the	 early	 post-transplant	
group	 (<2	years)	 reported	 that	 their	eating	habits	had	 returned	
to	normal.	In	those	survivors	who	were	two	or	more	years	post-
transplant,	77%	(292/379)	reported	that	their	eating	habits	had	
returned	to	normal.
One	hundred	and	 thirty-one	 survivors	 reported	changing	 their	
diet	since	having	a	BMT	(29.6%).	The	four	most	common	changes	
included:	 avoiding	 particular	 food	 and	 food	 groups	 (37%,	 n=	
48/131),	 focus	 on	 healthy	 eating	 (35%,	 46/131),	 reducing	 meat	
consumption	 (16%,	 21/131)	 and	 choosing	 organic	 foods	 (11%,	
14/131).	 Twelve	 per	 cent	 (52/441)	 of	 survivors	were	 taking	 oral	
nutritional	supplements	at	the	time	of	the	survey.
Physical activity
A	total	of	300/436	(68.8%)	of	survivors	reported	regular	exercise	
post-BMT,	including	168/247	(68.0%)	males,	and	132/189	(69.8%)	
females.
Two	hundred	and	one	 (67%)	of	 those	who	exercised	did	 so	at	
least	three	times	per	week.
On	 univariate	 analysis,	 the	 odds	 of	 exercise	 uptake	 were	
significantly	lower	in	those	reporting	chronic	GVHD,	hypertension	
and	 diabetes.	 Similarly,	 referral	 to	 a	 rehabilitation	 specialist,	
dietitian	or	social	worker	was	also	associated	with	 lower	odds	
of	exercise.	An	increased	odds	of	exercise	was	observed	in	those	
with	no	or	mild	GVHD	symptoms
On	 multivariate	 analysis,	 adjusting	 for	 potential	 confounders,	
diabetes	and	social	worker	referral	showed	a	trend	towards	less	
exercise,	though	this	association	was	not	statistically	significant.
We	further	examined	associations	between	exercise	uptakes	and	
other	measures	of	personal	growth	(PTGI),	depression	stress	and	
anxiety	(DASS	21)	and	QoL.	When	adjusting	for	the	effects	of	age,	
gender	and	years	since	transplant,	we	observed	that	exercise	was	
associated	with	a	significantly	better	QoL	measures	(FACT	BMT	
score)	 and	 reduced	measures	of	 anxiety,	 depression	 and	 stress	
(DASS	21	scores).	No	significant	association	between	exercise	and	
personal	growth	was	observed.
Discussion
This	 study	 is	 the	 first	 to	 provide	 a	 comprehensive	 account	 of	
high-risk	health	behaviour	in	a	cohort	of	long-term	survivors	of	
BMT	in	Australia.	Our	results	reveal	that	some	survivors	continue	
to	engage	in	high-risk	health	behaviour,	despite	their	 increased	
risks	 to	 long-term	 survival2,5.	 Seven	 and	 a	 half	 per	 cent	 of	
survivors	 reported	smoking,	with	nearly	40%	of	those	smoking	
>10	cigarettes/day,	12.1%	reported	drinking	>two	standard	drinks	
per	day,	and	almost	half	had	a	higher	than	normal	BMI	(30%	were	
overweight	 and	 almost	 17%	 were	 obese).	 Pleasingly,	 however,	
77%	reported	being	"sun-smart",	68.8%	were	physically	active	and	
35%	reported	that	they	had	made	efforts	to	eat	a	healthy	diet	
post-transplant.
In	studies	of	English,	Swiss	and	North	American	BMT	survivors,	
it	 was	 found	 that	 when	 compared	 to	 both	 gender-matched	
siblings37	 and	 the	 general	 population38-40,	 BMT	 survivors	 tend	
to	 have	 better	 health-promoting	 habits	 across	 all	 health	
behaviours	 than	 comparators	 with	 the	 exception	 of	 "active"	
health	behaviours,	such	as	physical	activity	and	eating	a	healthy	
diet.	 When	 we	 compare	 our	 results	 to	 Australian	 Bureau	 of	
Statistics	(ABS)	data,	our	survivors	also	appear	to	engage	less	in	
high-risk	health	behaviour	than	the	general	population41	(in	2012	
the	ABS	reported	that	16%	of	adults	smoked	daily,	19.5%	of	adults	
consumed	 >two	 standard	 drinks	 per	 day,	 62.5%	 of	 Australians	
aged	18	years	and	over	were	either	overweight	(35.3%)	or	obese	
(27.5%),	 only	 a	 third	 were	 physically	 active,	 and	 5.1%	 reported	
eating	the	recommended	daily	amount	of	fruit	and	vegetables37).	
However,	 despite	 these	 positive	 findings,	 these	 behaviours	 do	
remain	concerning,	given	the	significant	and	pervasive	long-term	
co-morbidities	to	which	BMT	survivors	are	predisposed42-50.
Our	results	reveal	that	time	since	transplant	and	being	male	were	
significantly	 associated	 with	 smoking	 and	 high-risk	 drinking,	
whereas	 higher	 levels	 of	 education,	 GVHD	 and	 referral	 to	 a	
respiratory	 physician	 or	 physiotherapist	 decreased	 the	 odds	
that	 a	 survivor	 would	 be	 a	 smoker.	 This	 is	 consistent	 with	
studies	done	in	other	settings,	which	also	reported	that	younger	
age	 at	 BMT,	 lower	 education	 levels	 and	 lack	 of	 knowledge	 of	
recommendations	for	post-BMT	care	are	important	variables	for	
health	behaviours19,37,39,51,52.	There	are	several	possible	explanations	
for	 this.	 Firstly,	 as	 the	 time	 since	 BMT	 increases,	 survivors	
generally	 have	 less	 contact	 with	 their	 BMT	 centres	 and	 with	
other	health	services,	and	so	may	receive	fewer	reminders	about	
the	 necessity	 for	 adopting	 and	 maintaining	 positive	 health	
behaviours.	 Secondly,	 as	 BMT	 recipients	 survive	 beyond	 the	
highest	risk	period	(the	first	two	years	post-BMT)	 it	 is	possible	
that	they	may	begin	to	believe	that	they	are	 "in-the-clear"	and	
so	 free	 to	 resume	 (harmful)	 pre-BMT	 behaviour.	 Importantly,	
while	others	have	reported	that	psychological	distress	 is	often	
a	 trigger	 for	 smoking	 and	 drinking53,	 we	 found	 no	 association	
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between	decreased	QoL,	depression,	anxiety	and	stress	or	lower	
PTGI	 scores,	 and,	 in	 contrast,	 found	 that	 those	 who	 reported	
drinking	alcohol	to	excess	had	better	QoL	and	lower	depression,	
anxiety	and	stress.
While	 it	 is	 reassuring	 that	 a	 high	 percentage	 (77.3%)	 of	 our	
survivors	 reported	 "sun-smart"	behaviours	—	and	 that	 this	 rate	
is	 higher	 than	 reported	 in	 the	 Australian	 general	 population54	
—	 there	 are	 two	 important	 points	 to	 stress.	 The	 first	 is	 that	
skin	cancer	in	Australia	is	common;	the	incidence	of	melanoma	
is	 11	 times	 that	 of	 the	 average	world	 rate41.	 And	 the	 second	 is	
that	 allogeneic	 BMT	 further	 increases	 the	 risk	 of	 all	 types	 of	
skin	 cancer	 due	 to	 the	 long-term	 use	 of	 immunosuppressive	
drugs,	chronic	cutaneous	GVHD,	and	the	use	of	azole	antifungal	
agents55.	 Therefore,	 no	 amount	 of	 sun	 exposure	 is	 acceptable	
for	 Australian	 survivors	 of	 BMT.	 In	 our	 study,	 higher	 reported	
GVHD	 morbidity,	 a	 history	 of	 skin	 cancer,	 and	 referral	 to	 a	
dietitian	 were	 significantly	 associated	 with	 adoption	 of	 "sun-
smart"	 behaviour.	 While	 it	 is	 unsurprising	 that	 skin	 chronic	
GVHD	 and	 previous	 skin	 cancer	would	 increase	 the	 likelihood	
that	survivors	would	be	more	aware	of	the	vulnerability	of	their	
skin,	the	positive	association	with	dietitian	referral	is	less	clear,	
although	may	simply	reflect	contact	time	with	health	services,	
and,	in	particular,	with	health	professionals	whose	focus	is	much	
broader	than	curing	the	underlying	disease	and/or	treating	the	
acute	side	effects	of	BMT.
At	 two	 years	 post-BMT,	 a	 third	 of	 survivor	 reported	 dietary	
changes	post-BMT	—	avoiding	particular	food	and	food	groups,	
focusing	 on	 healthy	 eating,	 reducing	meat	 consumption	 and/
or	choosing	organic	 foods.	The	 fact	 that	many	 survivors	 (77%)	
returned	to	their	pre-BMT	diet,	and	that	only	a	third	had	made	
efforts	 to	 improve	 their	 nutritional	 intake	 is	 consistent	with	 a	
recent	 Japanese,	 population-based	 study	 that	was	 not	 able	 to	
identify	 differences	 in	 nutritional	 intake	 between	 cancer	 and	
non-cancer	survivors56.	While	this	may	reflect	the	complex	and	
intractable	nature	of	eating	behaviour,	it	may	also	be	indicative	
of	the	lack	of	data	regarding	the	impact	of	diet	on	chronic	non-
communicable	diseases	in	cancer	survivors	and,	therefore,	both	
the	difficulty	that	health	professionals,	and	in	particular	nurses,	
have	 in	 counselling	 survivors	 on	 the	most	 appropriate	 diet	 to	
decrease	their	long-term	health	risks,	and	that	survivors	have	in	
making	dietary	choices.
In	 contrast,	 regular	 exercise	has	been	clearly	 shown	 to	 impact	
QoL,	 survival	 and	 (possibly)	 cancer	 progression17	 post-BMT.	 In	
our	study,	68.8%	reported	doing	some	form	of	exercise.	Variables	
that	decreased	the	odds	of	exercising	 included	chronic	GVHD,	
hypertension,	and	referral	to	a	rehabilitation	specialist,	dietitian	
or	social	worker.	This	data	reveals	the	profound	limitations	that	
chronic	morbidity,	particularly	GVHD,	which	can	affect	any	area	
of	the	body,	has	on	survivors	of	BMT,	restricting	their	mobility	
and	increasing	their	need	for	psychosocial	support.
Our	data	reveal	that	many	survivors	of	BMT	appear	to	be	making	
an	 effort	 to	 maintain	 their	 health	 and	 wellbeing,	 compared	
to	 the	 general	Australian	 population.	Our	 results	 also	 suggest,	
however,	 that	 given	 the	 much	 greater	 health	 risks	 associated	
with	BMT,	much	more	needs	to	be	done	to	encourage	adoption	
of	positive	health	behaviours,	particularly	 in	certain	subsets	of	
survivors.	 While	 more	 research	 is	 needed	 to	 define	 the	 best	
way	to	prevent	non-communicable	disease	in	survivors	of	BMT,	
health-promoting	 education	 and	 support,	 preferably	 provided	
by	advanced	practice	nurses	who	are	uniquely	placed	to	assist	
cancer	survivors,	should	be	rigorously	pursued18.
Despite	 the	 large	 sample	 size	 and	 high	 response	 rate	 (76%)	
there	 are	 a	 number	 of	 limitations	 to	 our	 study	 that	may	 limit	
the	 generalisability	 of	 these	 results	 to	 BMT	 survivors	 in	 other	
countries.	 Because	 we	 relied	 upon	 self-reporting	 and	 did	 not	
capture	data	on	non-responders,	we	do	not	know	whether	BMT	
survivors	 who	 had	 died	 prior	 to	 study	 commencement	 had	
better	or	worse	 engagement	with	 good	health	 behaviour.	 It	 is	
also	possible,	as	with	other	health	surveys,	that	positive	health	
behaviour	 may	 have	 been	 over-reported	 and	 negative	 health	
behaviour	 under-reported.	 Another	 limitation	 is	 that	 we	 did	
not	ask	about	pre-BMT	behaviour,	therefore	we	are	not	able	to	
comment	on	 any	 change	 in	 rates	 of	 smoking,	 drinking,	 BMI	or	
exercise,	nor	diet	type	pre-	to	post-BMT	in	our	survivors.	Finally,	
because	 only	 English	 speakers	 were	 eligible	 to	 participate	 in	
this	study,	we	are	not	able	to	comment	on	other	culturally	and	
linguistically	 diverse	 (CALD)	 populations,	 who	 may	 very	 well	
have	different	health	knowledge	and	behaviour.
Conclusion
This	 study	 is	 the	 largest	 to	 explore	 health	 behaviours	 in	
survivors	 of	 BMT	 in	 Australia.	 We	 found	 that	 despite	 well-
defined	 long-term	 risks,	 certain	 subsets	of	 long-term	 survivors	
continue	to	engage	in	high-risk	behaviours	post-BMT,	including	
smoking,	 drinking	 alcohol	 to	 excess	 and	 failing	 to	 perform	
regular	 exercise.	 Our	 results	 also	 suggest	 that	 adherence	 to	
recommendations	 regarding	 preventive	 health	 behaviours	 may	
require	 ongoing	 education	 and	 counselling	 and	 that	 particular	
groups	of	patients	—	men,	those	with	lower	levels	of	education	
and	those	with	chronic	GVHD,	should	be	the	focus	of	targeted	
post-BMT	nursing	education	and	support.
While	 the	 lives	 of	 increasing	 numbers	 of	 adults	 and	 children	
are	 saved	 by	 BMT,	many	 survivors	 bear	 the	 burden	 of	 chronic	
and	 serious	 illness.	 While	 much	 more	 research	 is	 needed	 in	
BMT	 survivorship	 and	 chronic	 non-communicable	 diseases	 to	
test	whether	—	 and	which	—	 health	 behaviour	 changes	make	
a	 lasting	 difference	 to	 long-term	 BMT	 outcomes,	 there	 is	 no	
doubt	that	transplantation	clinicians	needs	to	extend	their	"gaze"	
beyond	 the	 acute	 phases	 of	 transplantation	 to	measures	 that	
may	prevent,	detect	and	treat	modifiable	illness	in	survivors.
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9.5. Synopsis 
This manuscript provides the largest and most comprehensive account of health behaviour in 
Australian allogeneic BMT survivors.  The results indicate that survivors may continue to engage in 
high-risk health behaviour despite well-defined preventive health behaviour recommendations post-
BMT.   
While rates of high-risk health behaviours in our BMT survivors were comparable to or better than 
that of the Australian general population (smoking 7.5% vs 16%, drinking > 2 standard drinks per day 
12.1% vs 19.5%, overweight 30% vs 35.3%, obese 17% vs 27.5%, physically active 68.8% vs 33.3%) they 
are still problematic as rates of chronic non-communicable conditions after BMT are almost six times 
that of sibling comparators(1), with some chronic or malignant diseases including oral and 
oesophageal cancer occurring up to fifteen times more often than the general population(2).  This has 
significant implications for BMT survivors, health care professionals involved in their long-term care 
and public health authorities who are responsible for health promotion and preventive health 
education. In this regard our results clearly suggest that more needs to be done to educate BMT 
survivors on the increased risk of serious long-term morbidity (the fifteen-year cumulative incidence 
of severe/life-threatening/fatal conditions has been reported to be 41%(1)).  This is particularly 
important for male survivors, those with lower levels of education and those with cGVHD. 
However, as with cancer screening in this population, there are also limited data about the efficacy of 
preventive health behaviour post-BMT.  In particular, we do not know if adopting health behaviours 
recommended by public health and cancer advocacy bodies for the general population will prevent 
morbidity and mortality in long term BMT survivors.  This is a major lacunae as without this data it 
may be difficult to convince BMT survivors of the necessity to quit smoking, stop drinking alcohol to 
excess, maintain a healthy weight, eat a healthy diet, meet physical activity recommendations and 
avoid excessive UV exposure.   
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Chapter 10: Changes to work status and household income of long-term 
allogeneic blood and marrow transplant survivors in New South Wales, 
Australia 
10.1. Chapter overview  
This chapter reports on the long-term impact of allogeneic BMT on survivors’ work status and 
household income.  It consists of a published manuscript entitled: ‘Changes to work status and 
household income of long-term allogeneic blood and marrow transplant survivors in New South 
Wales, Australia’. The manuscript reports on the pre and post-BMT occupational status and income of 
BMT survivors and their association with demographic, transplant characteristics and cGVHD.  
These results demonstrate that BMT has a significant impact on the work status and household income 
of long term survivors. Many are unable to remain in full-time work and retire due to ill-health, 
consequently experiencing a significant reduction in their household income. The impact of this is 
likely to be profound – exacerbating carer burden, social isolation and medication non-adherence.  
The findings have implications for the education and support provided to BMT recipients and their 
carers by health care staff and health care and government agencies including Department of Health, 
Department of Jobs and Small Business, Department of Human Services (Centrelink), Medical Services 
Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC), workers unions 
and not for profit and charitable patient and carer support services such as the Cancer Council, Arrow 
Foundation and the Leukaemia Foundation.  As this manuscript was published as a letter to the editor, 
the results are further discussed in the synopsis section of this chapter.  
10.2. Publication details 
Dyer G, Brice L, Gilroy N, Kabir M, Hertzberg M, Greenwood M, Larsen SR, Moore J, Gottlieb D, Huang 
G, Hogg M, Brown L, Tan J, Ward C, Kerridge I. “Changes to work status and household income of long-
term allogeneic blood and marrow transplant survivors in New South Wales, Australia”. Bone Marrow 
Transplant 2018;53(7):926-31. 
10.3. Authors’ contributions 
GD co-designed the study, recruited study participants, collected data, interpreted the results and 
drafted the manuscript.  A signed Statement of Contribution from all authors is in Appendix A. 
132 
 
10.4. Manuscript 
The published version of the manuscript follows. 
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As long-term survival following Blood and Marrow
Transplant (BMT) improves, it is increasingly important to
explore the long-term impact it has on survivors’ lives,
including their work status and household income.
Previous studies suggest that 50–70% of survivors return
to work within 1 year of BMT1–4 and up to 72% at 10 years
post BMT5. The accuracy of these estimates are open to
question however, as these studies are small, combine sur-
vivors of both autologous and allogeneic transplant, reﬂect
historical age-bias in selection for transplantation, and
appear inconsistent with reports that more than half of
survivors and families report a decline in income post BMT
and experience signiﬁcant ﬁnancial hardship as a result.6,7
In this multi-centre, cross-sectional study we aimed to
identify the changes in work status and household income
in a large cohort of allogeneic BMT survivors, and examine
the demographic, socioeconomic, transplant factors and
sequelae associated with those changes.
Eligible participants were allogenic BMT survivors >18
years, transplanted between January 2000 and December
2012 in New South Wales, Australia, who could read and
write English, and provide consent. Potential participants
were identiﬁed from the transplant databases of the adults
BMT centres in NSW, and were asked to complete seven
questionnaires; the Sydney Post-BMT Study Survey,
FACT-BMT Version 48,9, DASS2110–12, The Chronic
GVHD Activity Assessment – Patient Self Report
(Form B)13, The Lee Chronic GVHD Symptom Scale14, the
Fear of Cancer Recurrence (FoCR) Scale15 and The Post
Traumatic Growth Inventory (PTGI)16,17.
The Sydney Post BMT Study Survey (SPBS) was
developed by the research team and comprised 402 ques-
tions grouped into 20 domains including socio-demo-
graphics, pre and post transplant work status, functioning
and household income. The questionnaire used tick box
responses, short answer questions and 5-step Likert scales
to measure attitudes. It was piloted to assess face and
content validity and to check for comprehension. For each
consenting participant data was also collected on diagnosis
and transplant details.
Income and occupational data were stratiﬁed by survivor
demographics and baseline transplant characteristics using
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descriptive statistics. Categorical responses were sum-
marised using frequencies and percentages. Parametric
continuous variables were summarised using means and
standard deviations, and medians and interquartile ranges
for non-parametric data. Dichotomous categorical variables
were tested using the Pearson Chi-square or Fishers’ Exact
tests, and the relationship between continuous variables
were assessed using Pearson’s correlation coefﬁcient. The
McNemar test was used to assess for signiﬁcant differences
in the distribution of pre and post transplant variables such
as full time (FT) employment and low-income status.
Means and medians were compared using the independent
Student's t-test and Wilcoxon Rank Sum tests for two
samples; where there were >2 samples one-way analysis of
Variance (ANOVA) and Kruskal Wallis tests were used.
Multivariable logistic regression was used to assess for
signiﬁcant associations between explanatory and outcome
variables after adjusting for potential confounders. A two-
tailed P value <0.05 was considered as the level of statis-
tical signiﬁcance.
Statistical analysis was performed using Stata software
(Version12.1).
The study protocol was approved by the Northern Syd-
ney Local Health District Human Research Ethics Com-
mittee (NSLHD Reference: 1207–217M).
A total of 1475 allogeneic BMTs were performed in the
study period. Of the 669 recipients known to be alive at
study sampling, 583 were contactable. In total 441 (66% of
total eligible, 76% of those contacted) completed the survey
and 17 patients (3%) declined participation.
Respondents included 250 (57%) males and 191 (43%)
females. The median age of survey respondents was 54
years (Range: 19–79). The median time since transplant was
5 years (Range: 1–14) (Table 1).
Pre and post transplant employment status was provided
by 404 survivors. In total, 261 (64.6%) were in FT
employment pre transplant, and only 130 (32.2%) post-
BMT (McNemar X2 (1 df)= 106.6, P< 0.001). Three
hundred and forty (84.2%) reported being in any paid
employment (FT, part-time (PT) or casual) pre transplant
which fell to 233 (57.8%) post transplant (McNemar
X2 (1 df)= 88.8, P< 0.0001).
Table 1 Demographic, social and clinical characteristics of BMT
survivor respondents (n= 441)
Characteristic Distribution
Socio-Demographic
Gender (Male) n/total (%) 250/441 (57%)
Median Age in years (range) 54 (19–79)
Postcode location
City/inner regional n/total (%) 396/431 (92%)
Household income status (AUD) n/total responses (%)
Low income $20,000–$39,999 155/423 (37%)
Middle income $40,000–$79,999 123/423 (29%)
High income ≥$80,000 145/423 (34%)
Educational status n/total responses (%)
Some high-school 53/333 (16%)
Completed High school 79/333 (24%)
Trade qualiﬁcations/diploma 47/333 (14%)
Some university 24/333 (7%)
Completed university 130/333 (39%)
Transplant factors
Years since transplant- Median (Range) 5 (1–14)
Underlying diagnosis n/total responses (%)
Acute Leukaemia 226/423 (53%)
Other* 197/423(47%)
Donor type n/total responses (%)
Sibling related 250/439 (57%)
Matched Unrelated 158/439 (36%)
Haploidentical/Mismatched 31/439 (7%)
Conditioning n/total responses (%)
Myeloablative 214/439 (49%)
Reduced Intensity 225/439 (51%)
Post transplant Morbidity and Quality of life
cGVHD
Total reported cGVHD since transplant n/total
responses (%)
301/434(69%)
Total LEE GVHD score-Median (range) 19 (0–77)
Chronic Diseases/Psychological morbidity n/total responses (%)
Bone Disease (osteopenia, spinal fractures or
avascular necrosis)
126/400(32%)
Cardiovascular risk factors (Diabetes,
Hypertension or elevated cholesterol)
180/414 (43%)
Cancer (mouth, skin, or other) 108/389 (28%)
Anxiety 83/403 (21%)
Depression 95/407(23%)
Depression, Anxiety, Stress (DASS21) Median
score (range)
20 (0–118)
Lifestyle n/total responses (%)
Smoke 33/438(7%)
Drink alcohol 282/441(64%)
Exercise/play sport 300/436(69%)
333/431(77%)
Table 1 (continued)
Characteristic Distribution
Always Use sun-protection (sunscreen, hat,
clothing sunglasses
Median BMI (range) for males 25(17–63)
Median BMI (range) for females 24(16–53)
Total FACT BMT –Median (Range) 110(32–144)
*CML, CLL, SAA, NHL, HL MM, MDS/Myeloproliferative disease,
other (unspeciﬁed)
G. Dyer et al.
Ta
bl
e
2
C
ha
ng
es
to
em
pl
ym
en
t
an
d
in
co
m
e
st
at
us
po
st
B
M
T
by
de
m
og
ra
ph
ic
an
d
tr
an
sp
la
nt
va
ri
ab
le
s
V
ar
ia
bl
e
C
ha
ng
es
to
F
U
L
L
T
IM
E
(F
T
)
em
pl
oy
m
en
t
po
st
B
M
T
C
ha
ng
es
to
A
N
Y
P
A
ID
em
pl
oy
m
en
t
po
st
B
M
T
C
ha
ng
es
to
L
O
W
IN
C
O
M
E
st
at
us
po
st
B
M
T
n/
to
ta
l
(%
)
in
F
T
em
pl
oy
m
en
t
pr
e
tr
an
sp
la
nt
n/
to
ta
l
(%
)
in
F
T
em
pl
oy
m
en
t
po
st
tr
an
sp
la
nt
%
di
ff
er
en
t
M
cN
em
ar
X
2
(1
df
)
P
va
lu
e
n/
to
ta
l
(%
)
in
pa
id
em
pl
oy
m
en
t
pr
e
tr
an
sp
la
nt
n/
to
ta
l
(%
)
in
pa
id
em
pl
oy
m
en
t
po
st
tr
an
sp
la
nt
%
di
ff
er
en
t
M
cN
em
ar
X
2
(1
df
)
P
va
lu
e
n/
to
ta
l
(%
)
in
lo
w
in
co
m
e
st
at
us
pr
e
tr
an
sp
la
nt
n/
to
ta
l
(%
)
in
lo
w
in
co
m
e
st
at
us
po
st
-
tr
an
sp
la
nt
%
di
ff
er
en
t
M
cN
em
ar
X
2
(1
df
)
P
va
lu
e
A
ge
gr
ou
p
(y
ea
rs
(y
rs
)
at
tim
e
of
tr
an
sp
la
nt
)
<
40
yr
s
78
/1
28
(6
1.
9%
)
59
/1
26
(4
6.
8%
)
−
15
.1
0%
7.
68
0.
00
6
10
9/
12
6
(8
6.
5%
)
99
/1
26
(7
8.
6%
)
−
7.
90
%
3.
57
0.
06
31
/1
26
(2
4.
6%
)
35
/1
26
(2
7.
8%
)
3.
10
%
0.
57
0.
45
40
<
50
yr
s
72
/9
9
(7
2.
2%
)
33
/9
9
(3
3.
3%
)
−
38
.9
0%
37
.1
<
0.
00
01
87
/9
9
(8
7.
9%
)
65
/9
9
(6
5.
7%
)
−
22
.2
0%
18
.6
2
<
0.
00
01
16
/1
02
(1
5.
7%
)
33
/1
02
(3
2.
4%
)
16
.7
0%
17
<
0.
00
01
50
<
60
yr
s
83
/1
21
(6
8.
6%
)
30
/1
21
(2
4.
8%
)
−
43
.8
0%
53
<
0.
00
01
10
3/
12
1
(8
5.
1%
)
56
/1
21
(4
6.
3%
)
−
38
.9
0%
47
<
0.
00
01
27
/1
33
(2
0.
3%
)
62
/1
33
(4
6.
6%
)
26
.3
0%
33
.1
<
0.
00
01
>
60
yr
s
28
/5
8
(4
8.
3%
)
8/
58
(1
3.
8%
)
−
34
.4
0%
20
<
0.
00
01
41
/5
8
(7
0.
7%
)
13
/5
8
(2
2.
4%
)
−
48
.3
0%
28
<
0.
00
01
13
/6
0
(2
1.
7%
)
23
/6
0
(3
8.
3%
)
16
.7
0%
8.
33
0.
00
4
G
en
de
r
M
al
e
17
7/
22
8
(7
7.
6%
)
93
/2
28
(4
0.
8%
)
−
36
.8
0%
73
.5
<
0.
00
01
19
9/
22
8
(8
7.
3%
)
13
2/
22
8
(5
7.
9%
)
−
29
.4
0%
59
.8
<
0.
00
01
37
/
23
8
(1
5.
5%
)
82
/2
38
(3
4.
4%
)
18
.9
0%
33
.2
<
0.
00
01
F
em
al
e
84
/1
76
(4
7.
7%
)
37
/1
76
(2
1.
0%
)
−
26
.7
0%
34
<
0.
00
01
14
1/
17
6
(8
0.
1%
)
10
1/
17
6
(5
7.
4%
)
−
22
.7
0%
29
.6
<
0.
00
01
50
/1
83
(2
7.
3%
)
71
/1
83
(3
8.
8%
)
11
.5
0%
13
.4
0.
00
03
M
ar
ita
l
st
at
us
M
ar
ri
ed
—
de
fa
ct
o
21
0/
31
8
(6
6.
0%
)
10
5/
31
8
(3
3.
0%
)
−
33
.0
0%
85
.5
<
0.
00
01
27
1/
31
8
(8
5.
2%
)
18
7/
31
8
(5
8.
8%
)
−
26
.4
0%
69
.2
<
0.
00
01
53
/3
31
(1
6.
0%
)
99
/3
31
(2
9.
9%
)
13
.9
0%
33
.1
<
0.
00
00
1
O
th
er
48
/8
0
(6
0.
0%
)
23
/8
0
(2
8.
7%
)
−
31
.2
0%
20
.2
<
0.
00
01
64
/8
0
(8
0.
0%
)
42
/8
0
(5
2.
5%
)
−
27
.5
0%
18
.6
<
0.
00
01
32
/8
4
(3
8.
1%
)
49
/8
4
(5
8.
3%
)
20
.2
0%
10
.7
0.
00
1
In
co
m
e
st
at
us
P
re
B
M
T
L
ow
in
co
m
e
pr
e
B
M
T
25
/8
2
(3
0.
5%
)
17
/8
2
(2
0.
7%
)
−
9.
70
%
3.
6
0.
06
53
/8
2
(6
4.
6%
)
38
/8
2
(4
6.
3%
)
−
18
.3
0%
10
.7
0.
00
1
M
id
dl
e-
H
ig
h
in
co
m
e
pr
e
B
M
T
22
6/
30
5
(7
4.
1%
)
10
9/
30
5
(3
5.
7%
)
−
38
.4
0%
10
1.
4
<
0.
00
00
1
27
6/
30
5
(9
0.
5%
)
18
8/
30
5
(6
1.
6%
)
−
28
.8
0%
77
.4
<
0.
00
00
1
C
hr
on
ic
G
V
H
D
Y
es
18
0/
27
2
(6
6.
2%
)
83
/2
72
(3
0.
5%
)
−
35
.7
0%
83
.3
<
0.
00
01
23
4/
27
2
(8
6.
0%
)
15
5/
27
2
(5
7.
0%
)
−
29
.0
0%
67
.1
<
0.
00
01
57
/2
91
(1
9.
6%
)
10
4/
29
1
(3
5.
7%
)
16
.1
0%
32
<
0.
00
01
N
o
77
/1
26
(6
1.
1%
)
45
/1
26
(3
5.
7%
)
−
25
.4
0%
22
.3
<
0.
00
01
10
0/
12
6
(7
9.
4%
)
75
/1
26
(5
9.
5%
)
−
19
.9
0%
18
.9
<
0.
00
01
28
/1
23
(2
2.
8%
)
47
/1
23
(3
8.
2%
)
15
.4
0%
14
.4
0.
00
01
B
M
T
co
nd
iti
on
in
g
M
ye
lo
ab
la
tiv
e
12
6/
19
9
(6
3.
3%
)
70
/1
99
(3
5.
2%
)
−
28
.1
0%
40
.2
<
0.
00
00
1
17
3/
19
9
(8
6.
9%
)
12
9/
19
9
(6
4.
8%
)
−
22
.1
0%
33
.4
<
0.
00
00
1
44
/2
01
(2
1.
9%
)
61
/2
01
(3
0.
3%
)
8.
40
%
7.
81
0.
00
5
R
ed
uc
ed
in
te
ns
ity
13
3/
20
3
(6
5.
5%
)
58
/2
03
(2
8.
6%
)
−
35
.9
0%
65
.8
<
0.
00
00
1
16
5/
20
3
(8
1.
3%
)
10
2/
20
3
(5
0.
2%
)
−
31
.1
0%
55
.9
<
0.
00
00
1
43
/2
19
(1
9.
6%
)
92
/2
19
(4
2.
0%
)
22
.4
0%
42
.1
<
0.
00
01
D
on
or
ty
pe
S
ib
lin
g
14
9/
23
0
(6
4.
8%
)
71
/2
30
(3
0.
9%
)
−
33
.9
0%
66
.1
<
0.
00
00
1
19
0/
23
0
(8
2.
6%
)
12
9/
23
0
(5
6.
1%
)
−
26
.5
0%
53
.9
<
0.
00
00
1
52
/2
39
(2
1.
8%
)
91
/2
39
(3
8.
1%
)
16
.3
0%
31
<
0.
00
00
1
M
U
D
*/
M
is
m
at
ch
ed
/
H
ap
lo
11
0/
17
2
(6
3.
9%
)
57
/1
72
(3
3.
10
%
)
−
30
.8
0%
40
.7
<
0.
00
00
1
14
8/
17
2
(8
6.
0%
)
10
2/
17
2
(5
9.
3%
)
−
26
.7
0%
35
.3
<
0.
00
00
1
35
/1
80
(1
9.
4%
)
62
/1
80
(3
4.
4%
)
15
.0
0%
16
.2
<
0.
00
00
1
Work status and income in Australian allogenic BMT survivors
Ill-health as a cause for being unable to work increased
from 14 (3.4%) pre BMT to 55 (13%) post transplant
(McNemar X2 (1 df)= 33.0 P < 0.001). Those in retirement
increased from 5.4% to 18.8% (McNemar X2 (1 df)= 54.0
P< 0.001).In total 50 of the 76 (65.8%) in retirement post
transplant, had retired due to poor health and 89 (54.6%) of
the 163 not in retirement reported they were not employed
due to health issues.
Household income status was provided by 421 survivors.
Those in the lowest household income strata (<$39,999pa)
increased from 20.7% pre transplant to 36.3% post trans-
plant (McNemar χ2 test (1 df= 46.3) P< 0.0001). At the
same time the proportion in the high-income strata
(≥$80,000) fell from 46.1% to 34.4% (McNemar χ2 test (1
df= 27.6) P< 0.0001). There was a non-signiﬁcant change
for those in middle income strata ($40,000–$79,999)
(33.2% decreased to 29.2% (McNemar χ2 test (1 df= 2.5)
P= 0.12).
Changes to employment status (FT and any paid)
and low household income was further compared pre
and post transplant, and stratiﬁed by a range of
variables including age group at BMT, gender, relationship
status at BMT, low income status pre BMT, cGVHD,
conditioning regimen, donor type, and years since
transplant.
Signiﬁcant declines in FT work status were reported
across all income strata other than those already in the low-
income strata pre transplant(P= 0.06). For those moving
into a low-income bracket, signiﬁcant increases were
reported across all strata except for those less than 40 years
of age at BMT (p= 0.45). (Table 2).
In multivariate analysis the only variable found to have a
positive and signiﬁcant association in maintaining any paid
employment was being in paid employment pre BMT (OR
7.87, 95% CI 2.79, 22.24; P< 0.0001). For those aged ≥50
years at BMT the odds of being in any paid employment
post transplant was signiﬁcantly reduced (OR 0.20; 95% CI
0.10, 0.40; P< 0.0001) with severe GVHD demonstrating a
trend towards signiﬁcance (OR 0.54; 95% CI 0.27–1,05;
P= 0.07).Longer duration post transplant demonstrated a
positive association with being in paid employment, that
trended towards signiﬁcance (OR 1.09; 95% CI 0.99, 1.20;
P= 0.06)(Table 3).
After adjusting for pre transplant household income
status, being in Low income bracket pre transplant (OR
15.3: 95% CI 6.74, 33.8; P< 0.0001) and having severe
GVHD (OR 3.17; 95% CI 1.61, 6.22; P= 0.001) were the
only independent variables found to be positively associated
with being in a low-income bracket post-BMT. Older
patients (age> 50yrs) showed a trend towards having sig-
niﬁcantly increased odds of being in a low-income bracket
(OR 1.85, 95% CI 0.92, 3.69; P= 0.08) post-BMT.
(Table 3).Ta
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Being in a married/de-facto relationship at transplant
(OR 0.44; 95% CI 0.20, 0.92; P= 0.03). and having mye-
loablative conditioning (OR 0.41; 95% CI 0.20, 0.83; P=
0.01) were variables associated with a signiﬁcantly reduced
odds of being in a low-income bracket post transplant.
Work type (physical/non-physical) was provided by
376 survivors. There was a signiﬁcant increase in the pro-
portion of survivors doing non-physical work post BMT
(59% pre BMT versus 75.5% post (McNemar X2 (1 df)=
48.0 P< 0.0001)) and a signiﬁcant reduction in the pro-
portion doing physical work (37.5% pre BMT versus 21%
post (McNemar X2 (1 df)= 49.3 P< 0.0001)).
Changes to occupation/ﬁeld of work post-BMT was
reported by 168 (of 396) (42.4%). Reasons reported for not
returning to previous ﬁeld of work included physical lim-
itations (114, 67.9%), concerns about health risks in the
workplace (54, 32.1%), psychological/emotional limitations
(42, 25%), cognitive limitations (28, 16.8%), employer
concerns about ability to undertake required tasks (28,
16.7%), being made redundant (24, 14.3%), employer
concerns about liability (21, 12.5%), exhausting sick leave
to attend appointments (20, 11.9%), unsatisfactory rede-
ployment/change in work responsibilities (11, 6.6%) and
reallocation of hours/shifts (11, 6.6%).
In total 85 (63.9%) of the 133 who reported trying to ﬁnd
employment post-BMT, reported feeling that being a BMT
recipient hindered their employability, and 40 (10.2%)
employed respondents also described experiencing work-
place discrimination including unreasonable limitations
being placed upon responsibilities (15, 37.5%), difﬁculty
securing employment (17, 42.5%), workplace harassment
(5, 12.5%), forced redundancy (5, 12.5%), job transfer (6,
5.0%), and denial of promotion (5, 2.5%).
Only 9 of 379 (2.4%) respondents had received some
form of counselling regarding their legal rights to
employment.
This study is the largest ever study to explore the impact
of allogeneic BMT on work status and functioning, and
household income in long-term survivors. We demonstrate
that survival is associated with signiﬁcant and substantial
reductions in FT employment, any paid employment and in
household income compared with the general population.
(During the study period the Australian general population
unemployment rate was 6.3%18 and the average FT weekly
earnings were $1539.40 (equivalent to an annual income of
~$80,000)19).
While other studies have found that gender (female),
worse physical functioning and age (>25 years) are asso-
ciated with delayed return to work or unemployment4,20,21
this was not evident in our population. Our analysis showed
that being in paid employment pre BMT, and age <50 years
predicted being in employment post BMT. We also found
that being in a low-income bracket pre BMT and having
severe cGVHD was associated with being in a low-income
bracket post BMT, while being in a relationship and
receiving myeloablative transplant conditioning were asso-
ciated with a reduced odds of being in a low-income bracket
post BMT. (The effect of cGVHD on employment has been
variable, with some studies reporting a negative effect and
others ﬁnding no association4,20,22). There was further trend
towards longer survival post BMT being associated with a
return to paid employment post BMT.
Although the sample size and high response rate (76%)
make it likely that these results represent an accurate
account of the impact of BMT on NSW survivor’s work
status and household ﬁnances, there are several limitations
to our study that restrict the generalizability of these results
to BMT survivors in other settings including participation
bias, self-report, exclusion of non-English-speaking survi-
vors and the failure to capture data on non-responders and
the ﬁnancial circumstances of caregivers to household
income. Cross-sectional studies like this also have limited
Table 3 Variable and their independent association with being in any paid employment and/or in a low income bracket post transplant
Variable Being in any paid employment post BMT Being in a low income bracket post BMT
OR 95% CI P value OR 95% CI P value
Paid employment pre BMT 7.87 2.79–22.24 <0.0001
Low income bracket pre BMT 0.72 0.32–1.59 0.41 15.31 6.74, 33.8 <0.0001
Age at BMT ≥ 50 years 0.2 0.10–0.40 <0.0001 1.82 0.91, 3.66 0.09
Male Gender 0.89 0.49–1.64 0.72 0.84 0.44, 1.59 0.59
Severe GVHD* 0.54 0.27–1.05 0.07 3.17 1.61, 6.22 0.001
Married /Defacto 0.79 0.37–1.69 0.54 0.44 0.20, 0.92 0.03
Myeloablative conditioning 0.63 0.31–1.26 0.19 0.41 0.20, 0.83 0.01
Sibling Donor 0.86 0.48–1.54 0.6 1.13 0.61, 2.08 0.7
Years since BMT 1.09 0.99–1.20 0.06 0.99 0.90, 1.08 0.76
The bold ﬁgures are statistically signiﬁcant
*Severe GVHD was deﬁned as those with LEE GVHD score (>30). This represented LEE GVHD scores in >75th centile
Work status and income in Australian allogenic BMT survivors
capacity to test inferences about causal or temporal
relationships.
Our results suggest that being older (aged over 50 years),
single, and developing severe cGVHD are predictive of
experiencing an adverse ﬁnancial impact of BMT and being
unable to return to work post transplant. While these data
may provide the basis for development of an algorithm to
predict the likely impact of BMT on a recipient’s occupa-
tional and ﬁnancial status and the likelihood of return to
work post-BMT any predictive model will need further
testing in a separate validation population. It is crucial that
this is done, however, as patients need to understand the full
impact that BMT will have on their lives.
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10.5. Synopsis 
Previous studies have explored the cumulative effect of post-BMT sequelae on survivors’ QoL 
reporting high rates of anxiety and depression, social isolation, carer burden(1-3) and relationship 
dysfunction(4-6).    These effects also impact upon survivors’ capacity to effectively return to their 
‘pre-BMT’ lives(3). While a number of studies have noted the impact that employment difficulties and 
decreased income may have on QoL(7-10), at the time of publication this study provided the most 
comprehensive analysis of the occupational and economic impact of BMT.   
More specifically, this manuscript presented the largest dataset of the occupational and financial 
impact of BMT on allogenic survivors reported internationally and the first data on Australian BMT 
survivors.  The results make clear that long term survival following BMT is associated with substantial 
reductions in full-time employment, any paid employment and in household income.  Many survivors 
are required to change their occupation or field of work post-BMT, mostly due to physical limitations 
following BMT.  Despite this, few received employment counselling post-BMT, even though some 
experienced difficulties and discrimination in the workplace.  
Over 40% of survivors in our study did not return to work post-BMT, with 65% of those retiring doing 
so because of ill health.  These figures are consistent with studies in other BMT populations – as is our 
finding that up to 10% experience some form of employment discrimination, face challenges finding 
employment, are inappropriately denied promotion or have limitations placed on their workplace 
responsibilities(10, 11).   
Consistent with international literature on the experience of cancer and BMT survivors(10, 12-14)  we 
found those who were able to return to work, did not have to ‘downsize’ their career and/or 
experienced less financial impacts of BMT enjoyed a higher QoL, while age and cGvHD were the 
strongest predictors of adverse financial and occupational impact of BMT.  
These are important findings because work is central to a person’s life and identity and ‘return to 
work’ is a reliable indicator of physical and social recovery post-BMT(10).   But these data are also 
important because they provide the basis for development of an algorithm that may be used to predict 
the likely impact of BMT on a recipient’s occupational and financial status, and predict the likelihood 
that they will return to work post-BMT. While any predictive model would need further testing in a 
separate validation population, these results suggest that being older (aged over 50 years), single, 
having a RIC BMT and developing severe cGVHD are predictive of experiencing an adverse financial 
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impact of BMT and being unable to return to work post-transplant, while being in paid employment 
pre-BMT may increase the likelihood that a BMT survivor will return to work post-BMT.   
The results of this manuscript provide a cogent reminder of the necessity for, and importance of LTFU 
of BMT survivors and the need to prepare BMT recipients for the profound impact that BMT may have 
on them and on their families, including on QoL, economic and social status and even medication non-
adherence(15, 16). For these reasons alone, despite the discomfort physicians may feel about 
speaking about the financial impacts of treatment(15, 17), finances and occupational issues should 
routinely be discussed pre-transplant and should remain the focus of continuing education, 
counselling and support in the longer term to improve outcomes.  
Finally, this manuscript provides important insights into the impact that BMT may have on survivors’ 
work status and household income.  These data may benefit BMT programs in many ways – enabling 
BMT patients to make more realistic post-transplant employment plans, informing occupational 
rehabilitation programmes, occupational health services, and employers and guiding government 
policy for long-term BMT survivors.  Furthermore, if a return-to-work risk prediction tool were to be 
developed and sensitively deployed so that it does not inappropriately discourage patients at higher 
risk from seeking BMT or physicians from offering BMT to patients at higher ‘financial risk’, this may 
enable BMT physicians to give patients a more accurate picture of the likely socioeconomic and 
occupation impact of BMT, allow patients and families to realistically prepare for time off work and to 
arrange their household finances, and give patients, family members and employers the opportunity 
to prepare for life post-BMT(18).   
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Chapter 11: Oral health and dental morbidity in long-term allogeneic bone 
marrow transplant survivors in Australia 
11.1. Chapter overview 
This chapter reports on the incidence and range of oral and dental disease occurring in long-term 
survivors of BMT. It consists of a published manuscript entitled, ‘Oral health and dental morbidity in 
long-term allogeneic bone marrow transplant survivors in Australia’.  The paper discusses the 
demographic, socioeconomic, transplant factors, and co-morbidities associated with oral and dental 
disease.  It also discusses compliance with dental care, and the impact of oral and dental disease on 
QoL.  Specifically, survivors were asked about oral and dental symptoms and diagnoses of oral disease, 
including oral cGVHD and oral cancer.  Survivors were also asked how often they attended for dental 
care, the time since their last visit, and, if they did not attend a dentist regularly, the reasons for not 
doing so.  
The results of this study make clear that oral and dental morbidity post-BMT is common and that 
despite the increased risk, a third of the respondents to our survey were not compliant with either 
general population recommendations or recommended dental care for BMT survivors(1).  
Disturbingly, many survivors noted that they did not attend for dental care as they did not feel it was 
necessary or because they had not been specifically advised to do so by their treating team.  Just as 
worryingly, although perhaps not unsurprisingly, many survivors also reported not attending a dentist 
due to concerns about its cost.  These findings have clear implications for the provision of oral and 
dental care education and counselling for BMT recipients both pre and post-transplant.  But they also 
have clear implications for health care professionals involved in the long-term care of BMT survivors 
as there is no doubt that survivors do not seem to be getting the message that dental care is important.  
And most importantly of all, these findings send a message to health policy makers that public dental 
care in Australia is in urgent need of reform.  
11.2. Publication details 
Dyer G, Brice L, Schifter M, Gilroy N, Kabir M, Hertzberg M, Greenwood M, Larsen SR, Moore J, Gottlieb 
D, Huang G, Hogg M, Brown L, Tan J, Ward C and Kerridge I. Oral health and dental morbidity in long-
term allogeneic blood and marrow transplant survivors in Australia. Aust Dent J. 2018;63(3):312-9. 
11.3. Authors’ contributions 
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GD co-designed the study, recruited study participants, collected data, interpreted the results and 
drafted the manuscript.  A signed Statement of Contribution from all authors is in Appendix A. 
11.4. Manuscript 
The published version of the manuscript follows. 
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ABSTRACT
Background: Oral and dental disease is a major cause of long-term morbidity following allogeneic blood and marrow
transplantation (Allo-BMT). This study aimed to describe the extent and range of oral and dental complications in BMT
recipients and to identify gaps in service provision provided to this high-risk group.
Methods: Participants were Allo-BMT recipients, aged >18 years, and received transplants between 2000 and 2012 in
NSW. They completed seven surveys, the purpose-designed Sydney Post-BMT Study survey and six other validated
instruments.
Results: Of 441 respondents, many reported dry mouth (45.1%), dental caries (36.7%), mouth ulcers (35.3%), oral
GVHD (35.1%), gingivitis (16.2%), tooth abscess (6.1%) and oral cancer (1.5%). Regular dental visits were reported by
66.2% of survivors. Middle–high income, older age and geographic location showed a positive association with regular
dental visits. Of those who did not visit the dentist regularly, 37% stated they did not feel it necessary, 36% reported
cost and 20% stated it was not advised by the treating team.
Conclusion: Despite oral complications commonly occurring after Allo-BMT, many survivors receive inadequate dental
care. These results emphasize the need for improved oral health education, the importance of regular dental checks and
improvement in the delivery of dental health services for BMT survivors.
Keywords: Blood and marrow transplant, cancer survivors, dental complications, stem cell transplant.
Abbreviations and acronyms: ALLO-BMT = Allogeneic Blood & Marrow Transplant; BMT = Blood & Marrow Transplant.
(Accepted for publication 31 May 2018.)
INTRODUCTION
Allogeneic blood and marrow transplant (BMT) is
increasingly used for many malignant and non-malig-
nant haematological diseases with great success. The
Australasian Bone Marrow Transplant Recipient Reg-
istry (ABMTRR) reports that 10-year survival figures
for some conditions now approach 70%.1 But while
survival rates continue to improve, many survivors
experience long-term and late morbidity. The 15-year
post-BMT cumulative incidence of chronic health con-
ditions is 71%2 with BMT survivors experiencing a
decreased life expectancy compared with an age- and
gender-matched normative population.3 Importantly,
the link between chronic health conditions and poor
oral/dental health has been well established4 with oral
and dental complications of BMT reported in up to
80% of survivors.5
The post-BMT oral and dental manifestations and
complications relate specifically to chronic graft vs.
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host disease (GVHD) – an immunological condition
in which donor-derived T, B and Natural Killer
(NK) cells attack normal host tissues. When chronic
GVHD involves the mucosal lining of the oral cavity
(and oro-pharynx), which occurs in up to 83% of
patients who develop chronic GvHD,6 this may
cause characteristic mucosal features of lichen pla-
nus, with lichenoid striations, papules, plaques,
including depapillation of the dorsal tongue and
highly symptomatic oral mucosal atrophy, erosion,
excoriation and ulceration with consequent limita-
tion in mouth opening and tongue movement and
contribute to oral squamous cell carcinoma.7–11
Chronic GVHD also can involve the salivary glands
(and indeed all of the exocrine glands to a variable
degree), in keeping with the clinical presentation
seen with Sjogren’s syndrome and with the same
consequent salivary hypofunction, loss of taste,
decreased salivary protection against dental caries
and the development of multiple mucoceles.12,13 The
incidence of osteonecrosis of the jaw (ONJ) is also
increased in survivors of BMT given the use of bis-
phosphonates to address osteoporosis resulting from
premature gonadal failure and chronic corticosteroid
use, and the increased rates of chronic dental disease
(dental caries and periodontal disease) necessitating
dental extractions.9,14–16
Risk factors for post-BMT dental and oral disease
include radiotherapy to the head and neck region, age
at BMT, underlying diagnosis of Fanconi’s anaemia
and GVHD.17 As oral and dental disease can signifi-
cantly impair quality of life (QoL),18–20 it is now
widely recommended that BMT survivors receive life-
long follow-up including at least yearly oral clinical
assessments and dental review.2,17,21
The routine provision of long-term dental care post-
BMT is, however, enormously challenging.22,23 Barri-
ers to implementing oral care standards for cancer
survivors include gaps in knowledge (clinician and
patient), reliance on tradition, inconsistent or absent
oral assessments, diverse oral care regimens and prac-
tices, an insufficient and/or conflicting evidence base,
lack of accepted universal standard of care, adminis-
trative and clinical issues, and lack of interdisciplinary
collaboration.24,25 In addition, the cost of dental care
in Australia also negatively impacts upon the number
of patients who receive dental care. Indeed, the Aus-
tralian Institute of Health and Welfare (AIHW)26
found that 44.9% of those aged 25–44 years avoided
or delayed visiting a dentist due to cost. This cross-
sectional study aimed to describe the extent and range
of oral complications in allogenic BMT recipients in
NSW and identify gaps in dental service provision
provided to this high-risk group, in order to support
clinical and health policy decision making around
long-term care.
METHODS
Potential participants were identified from the trans-
plant databases of the adult transplant centres in
NSW. (At the time of study commencement, there
were four adult allogeneic transplant centres in NSW,
collectively performing approximately 175 BMTs
annually27). Participants were eligible if they were
≥18 years of age and had undergone an allogeneic
BMT between 1st January 2000 and 31st December
2012, could read and write English and could provide
consent. Consenting participants were given the
option to self-complete the questionnaire or complete
it via a phone interview with one of the researchers.
A second phone call was made to 187 participants
who had not returned the survey within a month. No
participants completed the survey via a phone inter-
view. All authors had access to primary clinical trial
data. The study protocol was approved by the North-
ern Sydney Local Health District Human Research
Ethics Committee (NSLHD Reference: 1207-217M).
Instruments
Participants were asked to complete seven
questionnaires
The Sydney Post BMT Study Survey (SPBS) was
developed by the research team from a review of the
literature and discussions with patients attending
BMT clinics. The survey comprised 402 questions
grouped into 20 domains including socio-demo-
graphics, quality of life and morbidity relating to oral
and dental health. The questionnaire used tick box
responses, short answer questions and 5-step Likert
scales measuring attitudes and other factors. The
questionnaire was piloted with six BMT survivors in
clinic and phone interviews to assess face and content
validity and to check for comprehension. For each
consenting participant, data were collected on dates
of diagnosis and transplant, stage/remission status at
transplant, transplant conditioning, GVHD prophy-
laxis, stem cell source and donor type.
Oral health and dental morbidity were analysed
according to a range of demographic, transplant, psy-
chosocial and lifestyle variables assessed using the
Functional Assessment of Cancer Therapy – Bone
Marrow Transplant (FACT-BMT Version 4),28,29
chronic GVHD (The Chronic GVHD Activity Assess-
ment – Patient Self Report (Form B)30 and The Lee
Chronic GVHD Symptom Scale).31
Statistical analysis
Oral and dental health data were stratified by survivor
demographics and baseline transplant characteristics
© 2018 Australian Dental Association 313
Oral and dental health post blood and marrow transplant
using descriptive statistics. Categorical responses were
summarized using frequencies and percentages. Distri-
bution of categorical variables was described using
percentages and continuous variables using median,
interquartile ranges and range. Odds ratios and 95%
confidence intervals, Pearson’s chi-square/Fishers’
exact tests were used for analysis of dichotomous cat-
egorical variables, Wilcoxon rank sum test for two
sample comparisons of medians and Kruskal–Wallis
test for > 2 sample comparison of medians. Multivari-
able logistic regression was used to adjust for relevant
confounders. A two-tailed P < 0.05 determined the
level of statistical significance.
Statistical analysis was performed using Stata soft-
ware (Version12.1).
RESULTS
A total of 1475 Allogeneic BMT were performed in
the study period. Of the 669 recipients known to be
alive at study sampling, 583 were contactable. Four
hundred and forty-one (66% of total eligible, 76% of
those contacted) completed the survey. Seventeen
patients (3%) declined participation, while 125 (21%)
did not return the survey (Fig. 1).
Respondents included 250 (57%) males and 191
(43%) females. The median age of survey respondents
was 54 years (range 19–79). The median time since
transplant was 5 years (range 1–14) (Table 1).
Oral health and dental morbidity
The most common dental and oral health problems
reported by BMT survivors were dry mouth (45.1%),
mouth ulcers (35.3%), tooth caries (36.7%) and oral
GVHD (35.1%). Sixteen per cent reported gum dis-
ease/gingivitis, 6% had experienced a dental abscess,
4.8% broken teeth or tooth loss, 1.8% gum reces-
sion,1.5% a diagnosis of oral cancer and 0.2%
osteonecrosis of the jaw. One per cent required root
canal therapy (1%), 3.8% had required other dental
intervention (wisdom teeth, dental extractions and fill-
ings) (3.8%) but less than two per cent (1.6%) were
edentulous.
Fig. 1 Study ﬂowchart.
Table 1. Demographic, social and clinical characteris-
tics of BMT survivor respondents (n = 441)
Characteristic Distribution
Socio-demographic
Gender (male) n/total (%) 250/441 (57%)
Median age in years (range) 54 (19–79)
Postcode location
City/inner regional n/total (%) 396/431 (92%)
Income status (AUD) n/total responses (%)
Low income $20 000–$39 999 155/423 (37%)
Middle income $40 000–$79 999 123/423 (29%)
High income ≥$80 000 145/423 (34%)
Educational status n/total responses (%)
Some high school 53/333 (16%)
Completed high school 79/333 (24%)
Trade qualifications/diploma 47/333 (14%)
Some university 24/333 (7%)
Completed university 130/333 (39%)
Transplant factors
Years since transplant, median (range) 5 (1–14)
Underlying diagnosis n/total responses (%)
Acute leukaemia 226/423 (53%)
Other* 197/423 (47%)
Donor type n/total responses (%)
Sibling related 250/439 (57%)
Matched unrelated 158/439 (36%)
Haploidentical/mismatched 31/439 (7%)
Conditioning n/total responses (%)
Myeloablative 214/439 (49%)
Reduced intensity 225/439 (51%)
Post-transplant morbidity and quality of life cGVHD
Total reported cGVHD since transplant
n/total responses (%)
301/434 (69%)
Total LEE GVHD score, median (range) 19 (0–77)
Chronic diseases/psychological morbidity n/total responses (%)
Bone disease (osteopenia, spinal fractures or
avascular necrosis)
126/400 (32%)
Cardiovascular risk factors (diabetes,
hypertension or elevated cholesterol)
180/414 (43%)
Cancer (mouth, skin or other) 108/389 (28%)
Anxiety 83/403 (21%)
Depression 95/407 (23%)
Depression, anxiety, stress (DASS21), median
score (range)
20 (0–118)
Lifestyle n/total responses (%)
Smoke 33/438 (7%)
Drink alcohol 282/441 (64%)
Exercise/play sport 300/436 (69%)
Always use sun protection (sunscreen, hat,
clothing sunglasses)
333/431 (77%)
Median BMI (range) for males 25 (17–63)
Median BMI (range) for females 24 (16–53)
Total FACT BMT, median (range) 110 (32–144)
*CML, CLL, SAA, NHL, HL MM, MDS/myeloproliferative disease,
other (unspecified).
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Of the 69.3% BMT survivors who reported a diag-
nosis of chronic GVHD, 51.5% of these had oral
GVHD (35.1% of all respondents).
Regular dental visits
Overall, 288/436 (66.2%) of patients reported visiting
a dentist on a regular basis (at least annually). The
proportion of those visiting a dentist was similar
across survival cohorts with rates of dental review in
early transplant survivors being comparable to rates
in late survivors (Table 2).
Factors associated with regular dental review
Patients having regular dental follow-ups were signifi-
cantly older (adjusted OR 1.02, 95% CI 1.008, 1.04,
P = 0.004), were more likely to live in the city/
metropolitan area (adjusted OR 1.74, 95% CI 1.10,
2.75, P = 0.02) and were more likely to be from the
middle/high-income group (adjusted OR 1.83, 95%
CI 1.18, 2.83, P = 0.007). Gender and quality of life
(FACT-BMT score) were not significantly associated
with regular dental visits (Table 3). Those who visited
a dentist regularly also had higher rates of dental
pathology (such as caries, dry mouth, oral GVHD)
though none of these associations was statistically sig-
nificant. It is unclear whether higher rates of dental
morbidity in those attending a dentist regularly
reflected improved diagnosis or the presence of symp-
toms driving patients to seek dental care.
Time from last dental visit
Two hundred and fifty-six (88.9%) of the 288
patients who visited a dentist on a regular basis
reported the time since their last dental review. The
median time reported was 10 months (IQR 7, 13,
range <1 month, 34 months). Patients who were less
than 2 years from transplant were significantly more
likely to have had a more recent dental review (me-
dian of 8 months) compared with those who were
more than 10 years post transplant (median of
13 months, P < 0.05, Kruskal–Wallis test) (Table 4).
Reasons reported for not regularly attending a dentist
Among the reasons cited by the 148 who did not
attend a dentist regularly were cost (54, 36.4%), an
assumption that it was not necessary (55, 37.2%),
lack of direction to attend for dental care given by the
treating team (30, 20.3%) or lack of time (28,
18.9%). Less commonly, survivors noted that they did
not regularly attend for dental care because they were
edentulous (13, 8.9%), had a fear of dentists (2,
1.3%), had too great a distance to travel,1 had “more
pressing” medical concerns (3, 0.7%) or had low
platelets (1, 0.7%).
DISCUSSION
This is the largest study of oral and dental morbidity
in allogeneic BMT survivors in Australia. The results
of this study demonstrate that oral complications fol-
lowing BMT are common and that one third of BMT
survivors are not receiving regular dental reviews
according to recommended BMT long-term follow-up
guidelines.17,21 In many cases, this appears to result
from ignorance of the need for dental care, inadequate
communication from BMT teams regarding the
importance of routine post-BMT dental care or the
out-of-pocket costs associated with dentistry.
BMT survivors experienced higher rates of tooth
caries than the general Australian population (36.7%
vs. 28.2% Australian men and 22.7% Australian
women).26 However, rates of dental disease and dry
mouth were similar to rates reported in patients trea-
ted for head and neck cancer ((36.7% vs. 34% report-
ing dental disease and 45% vs. 52% experiencing a
dry mouth32).
In total, 69.3% of our survivors reported a diagno-
sis of chronic GVHD, and over half of these survivors
experienced oral chronic GVHD. This is significant
for two reasons. First because our respondents report
much higher rates of cGVHD than large international
registries (e.g. Japan 41% 33 and the USA 37% 34).
And second because oral cGvHD is a risk factor for
developing oral and oesophageal cancer10 – which
occurs with a standard incidence ratio (SIR) of 15.7
in BMT recipients compared with the general popula-
tion.33 Together these findings highlight the
importance of life-long, vigilant oral and dental care
follow-up in those with any history of GVHD.
Interestingly, despite the significant effects that
chemo-radiotherapy can have on the oral cavity, in
our study dental disease and symptoms were not asso-
ciated with a reduced quality of life score. This is con-
sistent with other studies of both autologous and
allogeneic BMT survivors11 and onco-haematological
patients,35 which have described weak, non-significant
association between dental/oral disease and decreased
Table 2. Proportion in survival cohorts (years since
transplantation) and regular dental visits
Years since transplant
(N = number of responses)
Number visiting dentist on a
regular basis (%)
1–2 years (N = 58) 38 (65.5%)
2 < 6 years (N = 203) 139 (68.5%)
6 < 10 years (N = 115) 74 (64.3%)
≥10 years (N = 60) 37 (61.7%)
All (N = 436) 288 (66.1%)
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QoL when compared with healthy controls. The
explanation for this finding is uncertain but may be
because oral health becomes less of a priority and oral
symptoms have less of an impact when a patient has
been diagnosed and treated for cancer, has had to face
the possibility of dying and has been separated from
the family and friends and all that is familiar to
them.35
Somewhat reassuringly, two thirds (66.2%) of sur-
vivors reported that they attended regular dental vis-
its, including survivors <2 years and >10 years post
BMT. This rate is similar to dental attendance rates in
other cancer survivor populations including adult sur-
vivors of childhood cancer.36–38 The time from last
dental visit, however, varied across the cohorts, rang-
ing from 1 to 14 months in those 1–2 years post
BMT to 2–34 months in those >10 years post BMT.
Differences in longitudinal dental attendance rates
were also identified in a US study of 4195 cancer sur-
vivors that found that dental visits decreased (statisti-
cally and clinically significantly) during and after
cancer treatment. Taken together, these studies sug-
gest that the further survivors are from diagnosis/
treatment, the less likely they are to attend to dental
and oral health – which may reflect decreased contact
with the health system and/or education/reminders
about the importance of oral health, or the impact of
other life priorities.39
This study found that middle–high income, older
age and geographic location of survivors showed a
positive association with regular dental visits and
retained significance when adjusting for effects of con-
founders. This resonates with a 2004 study of adult
survivors of childhood cancer which compared sur-
vivors to sibling’s dental utilization practices.36 The
authors found that minority subjects, those with lower
levels of education, no health insurance and annual
incomes of less than $US20 000 were less likely to
report a recent dental visit. They also noted that
males who had cranial radiation were more likely to
have seen a dentist recently, than those who had not
had cranial radiation. Female gender has been found
to have a positive association with more recent dental
care40 and has been supported in a systematic review
of patterns and drivers of healthcare use in long-term
childhood cancer survivors41; higher income, private
health insurance, attending follow-up care, chronic
health conditions, prior radiotherapy, being female
and older age increase survivor healthcare utilization.
We did not find that gender had an impact on our
study population, however. With regard to the Aus-
tralian general population, income, health insurance
and location do play a role in oral health. Untreated
caries is reported as 23.5% in major cities and
increases up to 37.6% in remote/very remote areas,
and those with higher incomes and insurance had
lower rates of caries and periodontal (gum) disease,
and fewer missing teeth.26
Of our survivors who did not visit the dentist regu-
larly, many (36.4%) attributed this to the personal
cost of dental care. In Australia, total expenditure on
dental services (excluding hospital services) in 2012–
2013 was $8706 million, an increase of over $2761
Table 3. Socio-demographic factors and association with regular dental reviews
Factors (N = number of responses) Regular dental visit
(N = 288)
No regular dental visit
(N = 148)
OR (95% CI)
P value
Adjusted odds ratio
(AOR) P value
Age (years)
Median (IQR)
56
(IQR 45, 63; 19–79)
52
(IQR 43, 60; 22–73)
P = 0.007 1.02 (1.008, 1.04)
P = 0.004
Gender
Female
Male
131/288 (45.5%)
157/288 (54.5%)
58/148 (39.2%)
90/148 (60.8%)
1.3 (0.85, 1.98)
P = 0.21
1.37 (0.89, 2.12)
P = 0.14
Household income (AUD)
Middle/high income (≥$40 000)
Low income ($20 000–39 999)
Missing
185/274 (67.5%)
89/274 (32.5%)
14
78/144 (54.2%)
66/144 (45.8%)
4
1.76 (1.14, 2.71)
P = 0.007
1.83 (1.18 2.83)
P = 0.007
Residence
Metropolitan city
Other regional/remote
Missing
213/281 (75.8%)
68/281 (24.2%)
7
94/145 (64.8%)
51/145 (35.2%)
3
1.70 (1.07, 2.69)
P = 0.02
1.74 (1.10, 2.75)
P = 0.02
FACT-BMT score
High QoL (above 50th centile)
Low QoL (lower 50th centile
147/288 (51.0%)
141/288 (49.0%)
68/148 (46.0%)
80/148 (54.0%)
1.22 (0.81, 1.86)
P = 0.31
1.19 (0.78, 1.83)
P = 0.40
Table 4. Relationship between years from transplant
procedure and time to last dental visit
Time since transplant
(N = number of responses)
Months since last visit to
a dentist median (range)
1 < 2 years post transplant
(N = 27)
8 months (<1–14 months)
2 to <6 years post transplant
(N = 128)
10 months (1–29 months)
6 to <10 years post transplant
(N = 66)
10 months (1–27 months)
≥10 years (N = 35) 13 months (2–34 months)
All respondents (N = 256) 10 months (<1–34 months)
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million from a decade previous,26 with 58% of this
paid directly out of pocket by individuals to private
practitioners. Public dental services exist, but are
available only to select groups with very low
income.42 In NSW alone, there are over 68 000 adults
awaiting public dental treatment,43 with wait times
(varying by state) of between 1 and 2.5 years.44 These
data suggest that the public dental system is simply
unable to cope with the current demand. So while the
World Health Organisation (WHO) confirm that oral
health is integral to overall health and can assist in
constraining health costs,4 Australian policy makers
first needs to improve access to dental services and
provide comprehensive treatment and continuity of
care45 to those most disadvantaged, before any bur-
den can be eased. For even for those who have private
health insurance with dental cover, many Australian
residents (77%) still make co-payments towards den-
tal visits and 19% report a large financial burden
from doing so.26,45 Indeed, in this regard, it is little
wonder so many BMT survivors avoid dental visits
due to cost as 16.8%–40.9% of the Australian general
population also avoid or delay visiting a dentist
because of cost.26
Interestingly, lack of education on behalf of both
BMT survivors and clinicians contributed to low com-
pliance with regular dental reviews, 37.2% felt that it
was not necessary and 20.3% stated that they were
not advised to do so by their treating team. This has
the potential to cause avoidable health-related bur-
dens for survivors and is economically costly for the
State. In an analysis of Western Australian data,
65 000 hospitalizations with a total cost of $157mil-
lion occurred over a 10-year period for potentially
avoidable oral health conditions.46 Total numbers and
rates of admissions steadily increased over the period
with dental caries being the most common pre-
ventable condition (53%).46,47 This is highly relevant
given our increasing numbers of long-term survivors
and the rates of dental caries they experience. BMT
clinicians are not the only healthcare professionals not
providing adequate oral health education, however. In
a study of head and neck cancer patients, only 53%
of survivors reported explicit recommendations for
post-treatment dental examinations.48 Patient educa-
tion represents a cheap and easily implementable
strategy for improving the oral health of BMT sur-
vivors. In general, oral health education across the
healthcare sector needs to improve; oral morbidity
that is exacerbated by a lack of vigilant oral and den-
tal care clearly places unnecessary burdens on patients
and the health system.
Although this was a multi-centre study and the
sample size and high response rate (76%) make it
likely that these results represent an accurate account
of the impact of BMT on NSW survivor’s oral and
dental health, there are a number of limitations to our
study that restrict the generalizability of these results
to BMT survivors in other countries and other set-
tings. Participation bias, self-report, only surveying
those who can read and write English and not captur-
ing data on non-responders are all limitations. In
addition, we did not ask respondents if they had pri-
vate health insurance (which includes dental cover),
which may have provided insightful information
about dental visits as lack of; lack of dental insurance
has been shown to delay dental care in other studies
of cancer survivors.40 Also, as our survivors received
transplants prior to 2013, and were surveyed in late
2014, we are not able to report how many survivors
had a dental review within 1 year of BMT, as per fol-
low-up recommendations. Furthermore, previous stud-
ies have reported that recipient HLA haplotype
impacts oral health;49 unfortunately, we did not have
access to tissue typing results for our study, but it
may be worth further consideration for risk stratified
preventative oral health care in an overburdened
heath system. A final limitation to note is that cross-
sectional studies like ours restrict inferences about
causal or temporal relationships.
This study confirms the significant morbidity associ-
ated with oral complications after BMT. Socio-eco-
nomic status, location and patient education
contribute to low compliance with dental care. These
results emphasize the need for improved oral health
education for both survivors and clinicians, the impor-
tance of regular dental checks, and improvement in
the delivery of dental health services in Australia for
BMT survivors. Potential solutions to address this
issue are not necessarily expensive or difficult to
implement but will likely to be the subject of intense
professional debate. It is also likely that efforts to
improve the dental health of BMT survivors will need
to concurrently address deficiencies in funding, work-
force and therapeutics. This may include employment
of oral medicine specialists by BMT units50 and spe-
cialists in Special Needs Dentistry, increased funding
of pre-, peri- and post-BMT dental care – perhaps
according to a Medicare fee schedule similar to the
Federal Department of Veteran Affairs for Gold Card
holders or Totally & Permanently Incapacitated ex-
service personnel, and PBS approval of high-intensity,
fluoride dentifrices and pharmacological sialagogues
to assist BMT patients maintain their oral and dental
health. The need to improve dental care for BMT sur-
vivors in self-evident – what is required is action.
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11.5. Synopsis 
This paper provides the largest and most comprehensive account of oral and dental morbidity in 
Australian allogeneic BMT survivors.  The results indicate that oral and dental complications post-BMT 
are common, that many survivors do not receive dental care post-BMT and that urgent attention is 
required to improve patients and health professionals knowledge of, and compliance with, guidelines 
for dental care post-BMT.   
While it is reassuring that approximately two third of our survivors received regular dental care, given 
the increased risks to oral health experienced by BMT survivors compared to the general population, 
this represents very few patients who receive appropriate care.  It is also enormously concerning that 
many survivors are not aware that they should visit a dentist and/or have not been advised to do so 
by their treatment team. The factors that predict attendance for dental care are sadly predictable, 
with socioeconomic status (high income and older age), residential location (metropolitan), and 
patient education the factors that are most positively significantly associated with dental care 
compliance.  
In this regard it is also noteworthy that over a third (36.4%) of BMT survivors in this study do not 
attend regularly for dental care because of the costs of doing so.  This finding and the fact that cost is 
a major (negative) factor in regards to the adequacy of the general Australian population dental 
care(2), suggests that improvements in health education and counselling will not be enough to 
improve the oral health of BMT survivors and that radical policy reform is needed to make dental care 
more accessible and more affordable.  
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Chapter 12: A survey of infectious diseases and vaccination uptake in long-
term haematopoietic stem cell transplant survivors in Australia  
12.1. Chapter overview 
This chapter reports on infectious diseases and adherence with guidelines for post-BMT vaccination 
in our survivors. It consists of a manuscript entitled ‘A survey of infectious diseases and vaccination 
uptake in long-term haematopoietic stem cell transplant survivors in Australia’.  The manuscript 
reports on rates of self-reported infectious diseases experienced post-BMT and vaccination uptake 
according to the Australian Immunisation Handbook (AIH) schedule, and describes the demographic, 
transplant, psychosocial and lifestyle factors that influence rates of adherence. 
These results demonstrate that vaccine preventable disease (VPD) post-BMT are common (41.7%), 
and that despite their increased risks of infection, very few survivors (31.8%) completed the 
recommended AIH post-BMT vaccination schedule. No factors significantly and reliable predicted 
rates of vaccination post-BMT.  While income strata showed a trend towards lower vaccination rates, 
it was not significant, nor was the education level of survivors or rates of cGVHD.    
It seems likely that a number of factors contributed to rates of post-BMT vaccination.  Importantly, 
despite many survivors (69.8%) reporting that they received their post-BMT vaccinations from their 
GP, only 50% of respondents reported that their GP received any documentation or advice with regard 
to the vaccination schedule.  These findings have profound implications for the organisation of post-
BMT care, for communication between BMT centres and primary care practitioners, and for the 
education of BMT survivors and health providers. Critical improvements in communication, funding 
and support between tertiary and primary health services, and between public and private practices 
are clearly required to improve vaccination adherence.  It is likely however, that rates of adherence 
may also be increased if future research can clearly demonstrate proof of post-BMT vaccination and 
outline the clinical, social and economic benefits that accrue from routine vaccination.   
12.2. Publication details  
Dyer G, Gilroy N, Brice L, Kabir M, Gottlieb D, Huang G, Hogg M, Brown L, Greenwood M, Larsen S, 
Moore J, Hertzberg M, Tan J, Ward C, Kerridge I. “A survey of infectious diseases and vaccination 
uptake in long-term haematopoietic stem cell transplant survivors in Australia” Transplant Infectious 
Diseases, In press (accepted 10th December 2018). 
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Abstract   
Background 
This cross-sectional survey aimed to establish the prevalence of infectious diseases and vaccination 
uptake in long-term allogeneic hematopoietic stem cell transplants (HSCT) survivors in New South 
Wales, in order to reduce long-term post-HSCT morbidity and mortality and enhance long-term care.  
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Patients and methods 
HSCT survivors aged over 18 years and transplanted between 2000–2012 in New South Wales (NSW) 
were eligible to participate.  Survivors self-completed the Sydney Post BMT Study survey, FACT-BMT 
(V4), Chronic Graft versus Host Disease (cGVHD) Activity Assessment Self Report, Lee Chronic GvHD 
Symptom Scale, DASS21, Post Traumatic Growth Inventory, and the Fear of Recurrence Scale.   
Results 
Of the 583 HSCT survivors contacted, 441 (78%) completed the survey.  Respondents included 250 
(57%) males and median age was 54 years (range 19-79 years). The median age at time of transplant 
was 49 years (Range: 17-71), the median time since HSCT was 5 years (Range: 1-14) and 69% had 
cGVHD.  Collectively, 41.7% of survivors reported a vaccine preventable disease (VPD) with the most 
common being influenza-like-illness (38.4%), varicella zoster/shingles (27.9%), pap smear 
abnormalities (9.8%), pneumococcal disease (5.1%) and varicella zoster (chicken pox) (4.6%).  Only 
31.8% had received the full post-HSCT vaccination schedule, and the majority (69.8%) of these had 
received the vaccines via their General Practitioner. cGVHD was not found to be a significant factor on 
multivariate analysis for those who were vaccinated. There was a trend towards lower vaccination 
rates in patients in a lower income strata.  
Conclusions 
Vaccinating post-HSCT survivors to prevent infections and their consequences has an established role 
in post-HSCT care.  Improving rates of post-HSCT vaccination should be a major priority for BMT units.  
Keywords: Haematopoietic Stem Cell Transplant, Survivors, Vaccinations, Vaccine preventable 
diseases, infectious diseases. 
Main text 
Introduction  
As worldwide application and frequency of allogeneic hematopoietic stem cell transplantation (HSCT) 
has increased1,2, long-term survival has become more commonplace – over 80% of recipients who are 
alive at 5 years post-HSCT can expect to be alive ten years post-HSCT3,4.  Simulating these trends, 
prevalence estimates of HSCT survivors in the US (alone) by 2030 is 500,0005. Notwithstanding the 
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success of HSCT, this ever growing population of long-term survivors experiences long-term and late-
effects of transplant including ongoing acute and chronic graft versus host disease (GVHD), increased 
risks of infections, chronic illnesses and secondary malignancies6-9.   Long-term HSCT survivors report 
twice as many medical problems when compared to case matched controls, are 3.5 times more likely 
to develop a severe/life-threatening condition than siblings (this increases up to 4.7 times in those 
with GVHD),7,10 and have higher rates of hospitalisations and late mortality11.  
Despite advances in supportive care and anti-infective strategies and treatments, infectious diseases 
remain a challenge and contribute substantially to this excess morbidity and mortality.  The 
Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) report infection to be a 
contributing cause of transplant related mortality (TRM) in the first-year post HSCT in 61%, as well as  
in 46% and 55% of matched sibling, and other related and unrelated donor transplants respectively12. 
The most common infections reported include Pneumocystis jirovecii, encapsulated bacteria, fungi, 
varicella-zoster virus (VZV), cytomegalovirus, and respiratory viruses13,14. Notwithstanding some 
questionable efficacy may be reduced in the face of prolonged immune dysregulation, delayed 
immune reconstitution and GVHD15, nevertheless, revaccinating HSCT survivors against vaccine 
preventable diseases (VPD) is universally recommended16.  
Schedules for re-vaccination post-HSCT have existed for over two decades17 however these have 
varied considerably between and within countries (including time points and choice of vaccine). In 
2009 a global collaboration involving nine major HSCT, infectious diseases and public health bodies 
published guidelines for preventing infectious complications, and in so doing harmonised the 
revaccination schedule based on HSCT calendar (time post HSCT) and event status (GVHD, 
immunosuppressive therapy)16.  Since HSCT is an expensive, lifesaving, increasingly utilised complex 
medical procedure18 mitigating infection risk by vaccinating post-HSCT recipients against VPD should 
be routinely employed.  However, international data suggests that HSCT survivors are not routinely 
vaccinated and adherence to post-HSCT re-vaccination schedules is frequently poor19-22. 
Australian specific vaccination guidelines are published in the Australian Immunisation Handbook 
(AIH)23.  These are online, free and easily accessible and are based on the international 
recommendations16,24.  In this study we aimed to ascertain the prevalence of infectious diseases and 
rate of vaccination uptake (according to the AIH schedule) in a large cohort of long-term HSCT 
survivors in New South Wales (NSW), the largest state in Australia. 
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Methods 
This cross-sectional survey of HSCT survivors in NSW included questions regarding post HSCT 
infections, vaccination uptake, cGVHD and demographic and social characteristics. Potential 
participants were identified from the transplant databases of all four adult allogeneic transplant 
centres in NSW (there are now 5 allogeneic adult HSCT centres in NSW).  Participants were eligible if 
they were >18 years of age and had undergone an allogeneic HSCT between 1st January 2000 and 31st 
December 2012, could read and write English and could provide informed consent.  Names and phone 
numbers were provided to the research team and in each case the study was verbally explained to the 
patient over the phone or when attending their BMT clinic.   Consenting participants were sent study 
packs (which included a patient information sheet, an informed consent form and the survey 
instrument) in the post and were given the option to self-complete the questionnaire and return it via 
a stamped self-addressed  or complete it via a phone interview with one of the researchers.  A second 
round of telephone calls was made to 187 participants who had not returned the survey within a 
month.  No participant wished to complete the survey via a phone interview.  Phone calls and 
discussions in BMT clinics with potential participants and sending of the study packs via the post 
occurred over a 3-month period between September - December 2013.  Survey close date was March 
2014. All authors had access to primary clinical trial data.  The study protocol was approved by the 
Northern Sydney Local Health District Human Research Ethics Committee (NSLHD Reference: 1207-
217M). 
Instruments 
Participants were asked to complete seven instruments.  
The Sydney Post BMT Study Survey (SPBS) was developed by the research team from a review of the 
literature and discussion with patients attending HSCT long-term follow-up clinics.  The survey 
comprised 402 questions grouped into 20 domains and included questions relating to socio-
demographics, co-morbidities, infections, vaccine uptake, HSCT complications, quality of life, and 
household income.   The questionnaire used tick box responses, short answer questions, and 5-step 
Likert scales measuring attitudes and other factors, and took approximately 1 hour to complete.  The 
questionnaire was piloted with six HSCT survivors in clinic and phone interviews to assess face and 
content validity and to check for comprehension. For each consenting participant, data was collected 
on dates of diagnosis and transplant, stage/remission status at transplant, transplant conditioning, 
GVHD prophylaxis, stem cell source and donor type. 
159 
 
Infectious diseases and vaccine update were analysed according to a range of demographic, 
transplant, psychosocial and lifestyle variables assessed using the Functional Assessment of Cancer 
Therapy – Bone Marrow Transplant (FACT-BMT Version 4)25,26, anxiety stress and depression (The DASS 
21)27-29, chronic GVHD (The Chronic GVHD Activity Assessment – Patient Self Report (Form B)30 and The 
Lee Chronic GVHD Symptom Scale)31 and the Fear of Cancer Recurrence (FoCR) Scale32 and The Post 
Traumatic Growth Inventory (PTGI) score33,34.  For ease of completion all instruments were combined 
into one booklet. 
Statistical Analysis 
Infectious diseases and vaccine uptake were stratified by demographic data, and baseline transplant 
characteristics using descriptive statistics.  Categorical responses were summarised using frequencies 
and percentages. Parametric continuous variables were summarised using means and standard 
deviations, while medians and interquartile ranges were used for non-parametric data.  The Pearson 
Chi-square or Fishers’ Exact tests were used for dichotomous categorical variables and Pearson’s 
correlation coefficient enabled assessment of the relationships between continuous variables. 
Comparisons of means and medians were determined by the independent t-test and Wilcoxon Rank 
Sum tests for 2 samples; one way analysis of Variance (ANOVA) and Kruskal Wallis tests were used 
when there were >2 samples. Multivariable logistic regression was used to assess for significant 
associations between explanatory and outcome variables after adjusting for potential confounders.  A 
two-tailed P value <0.05 was considered as the level of statistical significance. 
 Statistical analysis was performed using Stata software (Version12.1).  
Results 
A total of 1,475 allogeneic HSCT were performed in the study period.  Of the 669 recipients known to 
be alive at study sampling, 583 were contactable and were sent study packs.   Four hundred and forty 
one (66% of total eligible, 76% of those contacted) returned the completed survey.  Three percent 
(17) declined participation.  (Figure 1) 
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Of those completing the survey, 250 (57%) were male and 191 (43%) female. The median age of survey 
respondents was 54 years (Range: 19-79). The median time since transplant was 5 years (Range: 1-14) 
cGVHD was reported by 69% (Table I).   
Table 1. Demographic, social and clinical characteristics of HSCT survivor respondents (n=441) 
Characteristic   Distribution 
Socio-Demographic   
Gender (Male) n/total (%) 250/441 (57%) 
Median Age in years (range) 54 (19-79) 
Postcode Location   
City/inner regional n/total (%) 396/431 (92%) 
Income status (AUD) n/total responses (%)   
Low income $20,000-$39,999    155/423 (37%) 
Middle income $40,000-$79,999  123/423 (29%) 
High income >=$80,000  145/423 (34%) 
Educational status n/total responses (%)   
Some high-school 53/333 (16%) 
Completed High school 79/333 (24%) 
Trade qualifications/diploma 47/333 (14%) 
Some university 24/333 (7%) 
Completed university 130/333 (39%) 
Transplant factors 
Years since transplant- Median (Range)  5 (1-14) 
Underlying diagnosis n/total responses (%)   
Acute Leukaemia 226/423 (53%) 
Other* 197/423(47%) 
Donor type n/total responses (%)   
Sibling related 250/439 (57%) 
Matched Unrelated 158/439 (36%) 
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Haploidentical/Mismatched 31/439 (7%) 
Conditioning n/total responses (%)   
Myeloablative 214/439 (49%) 
Reduced Intensity 225/439 (51%) 
Post transplant Morbidity and Quality of life 
cGVHD      
Total reported cGVHD since transplant n/total responses 
(%) 
301/434(69%) 
Total LEE GVHD score-Median (range) 19 (0-77) 
Chronic Diseases/ Psychological morbidity n/total 
responses (%) 
  
Bone Disease (osteopenia, spinal fractures or avascular 
necrosis) 
126/400(32%) 
Cardiovascular risk factors (Diabetes, Hypertension or 
elevated cholesterol) 
180/414 (43%) 
Cancer (mouth, skin, or other) 108/389 (28%) 
Anxiety 83/403 (21%) 
Depression 95/407(23%) 
Depression, Anxiety, Stress (DASS21) Median score 
(range) 
20 (0-118) 
Lifestyle n/total responses (%)   
Smoke 33/438(7%) 
Drink alcohol 282/441(64%) 
Exercise/play sport 300/436(69%) 
Always Use sun-protection (sunscreen, hat, clothing 
sunglasses 
333/431(77%) 
Median BMI (range) for males 25(17-63) 
Median BMI (range) for females 24(16-53) 
Total FACT BMT –Median (Range) 110(32-144) 
* CML, CLL, SAA, NHL, HL MM, MDS/Myeloproliferative disease, other (unspecified) 
Infectious diseases 
Frequency and distribution of post-transplant infections  
Patients were asked about what infections they had been diagnosed with since transplantation (Table 
2). The most frequently reported infections included influenza-like illness/recurrent colds (45.7%), 
herpes zoster (27.9%), fungal infection (15.2%) and pneumococcal disease (5.1%). Female patients 
were asked about Pap smear abnormalities detected since transplant; 9.8% reported a Pap smear 
abnormality. Genital warts were reported in 5% of males and 1.6% of female transplant recipients. 
HSCT survivors who reported having had pertussis or pneumococcal disease were significantly older 
than those without these diseases (Table 3). The median age of those with pertussis was 65 years 
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compared to 54 years of those without the disease (p=0.01). The median age of those with 
pneumococcal disease was 62 years compared to a median of 53 years for those without the disease 
(p=0.01). Females reporting Pap smear abnormalities were significantly younger than those reporting 
no Pap smear abnormalities (42 years compared to 52 years, p=0.01). The median time since 
transplant for those reporting common infections such as influenza and zoster was six years (Table 3).  
Hepatitis B, Bordetella pertussis (whooping cough), Haemophilus influenzae type b (Hib), 
Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus) and Influenza 
A/B are infections for which vaccination is recommended in the first post-transplant year. Overall, 
41.7% of the transplant cohort reported having had at least one of these vaccine preventable 
infections. Most of these were due to influenza. Excluding influenza, this rate decreased to 10.6%.  
Hepatitis B, hepatitis C and tuberculosis were reported in six, four and three patients, respectively. It 
is not known whether these infections represented reactivated disease or de novo infections. 
 
Table 2: Post-transplant infectious diseases 
Infectious disease (N=number of 
responses) 
  
Number reporting the 
disease (%) 
Bacterial 
Pertussis (412) 11 (2.7%) 
Pneumococcal disease (N=415) 21 (5.1%) 
Haemophilus influenzae type B (N=411) 12 (2.9%) 
Meningococcal disease (N=412) 0 (0%) 
Tuberculosis (N=412) 3 (0.7%) 
Viral 
Influenza-like-illness/recurrent colds 
(N=429) 197 (45.9%) 
Varicella zoster Infections:   
– primary (chicken pox) (N=416) 19 (4.6%) 
– herpes zoster/shingles (N=420) 117 (27.9%) 
Hepatitis A (N=414) 1 (0.2%) 
Hepatitis B (N=413) 6 (1.5%) 
Hepatitis C (N=414) 4 (0.9%) 
Measles (N=413) 3 (0.7%) 
Mumps (N=414) 2 (0.5%) 
Rubella (N=413) 2 (0.5%) 
Human papillomavirus-related disease:   
– Pap smear abnormalities (females, 
N=184) 18 (9.8%) 
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Genital warts:   
– Male (N=230) 12 (5.2%) 
– Female (N=182) 3 (1.6%) 
Fungal 
Fungal infections (N=408): 62 (15.2%) 
–  Mucocutaneous  (thrush/candida/skin) 29 (7.1%) 
– Aspergillosis/ Lung/sinus 12 (2.9%) 
– Onychomycosis (nails) 7 (11.3%) 
– Invasive mycosis (prosthetic valve) 1 (1.6%) 
– Not specified 14 (1.9%) 
Unspecified 
Recurrent colds (N=402) 92 (22.9%) 
 
Table 3: Distribution of post-transplant infections by age and years post-transplant 
Infection  
N=number of 
responses 
Number 
reporting 
infection (%) 
Median age 
(range) 
p value 
Median years since transplant 
for those with disease (range) 
Recurrent 
colds (N=402) 
    
0.32 6 (1–14) Yes  92 (22.9%) 52 (19–74) 
No 310 (77.1%) 54 (21–79) 
Influenza-like-
illness (N=419) 
   
0.97 6 (1–14) Yes 161 (38.4%) 54 (19–79) 
No 258 (61.6%) 53 (21–75) 
Influenza/ 
Recurrent 
colds (N=429)     0.42 6 (<2-14) 
Yes 197 (45.9%) 54 (19-79) 
No 232(54.1%) 54 (21-75) 
Pertussis (412)     
0.01 7 (4–11) Yes 11 (2.7%) 65 (43–73) 
No 401 (97.3%) 54 (19–79) 
Pneumococcal 
disease 
(N=415) 
    
0.01 8 (1–13) 
Yes 21 (5.1%) 62 (30–73) 
No 394 (94.9%) 53 (19–79) 
Haemophilus 
ib (N=411) 
    
0.87 3 (<2–8) Yes 12 (2.9%) 52 (29–68) 
No 399 (97.9%) 54 (19–79) 
Tuberculosis 
(N=412) 
    
0.09 7 (4–10) Yes 3 (0.7%) 70 (51–71) 
No 409 (99.3%) 54 (19–79) 
Hepatitis A 
(N=414) 
    
N/A 9 Yes  1 (0.2%) 34 
No 413 (99.8%) 54 (19–79) 
Hepatitis B 
(N=413) 
    
0.28 5 (<2, 11) Yes  6 (1.5%) 60 (47–66) 
No 407 (98.5%) 54 (19–79) 
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Hepatitis C 
(N=414) 
    
0.31 6 (<2–14) Yes  4 (0.9%) 60 (52–62) 
No 410 (99.1%) 54 (19–79) 
Varicella zoster 
infections 
    
0.72 5 (<2, 11) 
Primary 
(chicken pox) 
(N=416) 
   
Yes  19 (4.6%) 56 (27–69) 
No 397 (95.4%) 54 (19–79) 
Zoster/shingles 
(N=420) 
    
0.09 6 (<2–14) Yes  117 (27.9%) 56 (21–74) 
No 303 (72.1%) 53 (19–79) 
Measles 
(N=413) 
    
0.46 2 (3–11) Yes 3 (0.7%) 61 (40–70) 
No 410 (99.3%) 54 (19–79) 
Mumps 
(N=414) 
    
0.09 3, 11 Yes 12 (0.5%) 61 (40–70) 
No 412 (99.5%) 54 (19–79) 
Rubella 
(N=413) 
    
0.09 3, 11 Yes 2 (0.5%) 61 (40–70) 
No 411 (99.5%) 54 (19–79) 
Pap smear 
abnormalities 
(females, 
N=184) 
    
0.01 8 (<2–14) 
Yes  18 (9.8%) 42 (22–65) 
No 150 (80.6%) 52 (19–75) 
N/A 16 (8.6%)   
Genital warts     
0.74 7 (3–13) 
– Male (N=230)      
Yes 12 (5.2%) 55 (29–70) 
No 218 (94.8%) 55 (21–79) 
– Female 
(N=182) 
    
0.31 9 (3–11) Yes 3 (1.6%) 50 (30–58) 
No 179 (98.4%) 52 (19–75) 
Meningococcal 
disease 
(N=412) 
0 (0%)      
Fungal 
infection 
(N=408) 
    
0.83 5 (<2–14) 
Yes 62 (15.2%) 55 (21–73) 
No 346 (84.8%) 54 (19–79) 
Vaccination uptake  
Pre-transplant vaccination uptake and setting  
Forty-seven per cent of patients reported having received an annual influenza vaccination pre-
transplant. Of these, 50% were older than 51 years of age at transplant. A much smaller proportion 
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(15%) reported having ever had pneumococcal vaccination, and of these the median age at transplant 
was 53 years. Human papillomavirus vaccine (HPV) had been administered to a total of four females, 
three of whom were aged 17 to 25 years at transplantation, and one aged 58 years.  
Pre-transplant vaccination was most often administered by a GP (40.4%), followed by hospital (5.4%) 
or a community clinic (0.5%).  
Post-transplant vaccination: uptake and setting  
The uptake of inactivated vaccines in HSCT recipients was reported as follows (Figure 2): influenza 
82%, dTpa 72%, polio 67%, hepatitis B 65%, pneumococcal vaccine 55%, Haemophilus influenzae 56% 
and Neisseria meningitidis 49%. Overall, 136 (30.8%) of HSCT recipients had received all inactivated 
vaccines recommended on the post-transplant schedule.  
 
Figure 2: Uptake of recommended inactivated vaccinations post HSCT 
The uptake of live-attenuated vaccinations was reported as follows: MMR 55% and varicella 26.4%. 
The proportion of those on immunosuppression at the time of survey reported lower uptake; 38.7% 
for MMR and 14.8% for varicella. For HSCT recipients that reported ever having had a diagnosis of 
cGVHD, the rates of live attenuated vaccination was 49.5% for MMR and 20.9% for varicella. Sixteen 
(27.6%) and 11 (19%) of the 58 HSCT recipients who were less than 2 years post-transplant reported 
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receiving MMR and varicella vaccination respectively. This compares to 210 (54.8%) and 95 (24.8%) of 
the 383 HSCT recipients who were more than 2 years post-transplant.  
Patients with lower income showed a trend towards having not completed the recommended post 
HSCT vaccination schedule (adjusted OR 3.32, 95% CI 0.83, 13.4; p=0.09). Non-completion of the 
recommended schedule of inactivated vaccines showed no significant association with education 
(adjusted OR 0.5, 95% CI.13, 1.91 p=0.31) or cGVHD (adjusted OR2.33; 95% CI 0.62, 8.75) on 
multivariable analysis (Table 4). 
Table 4: Comparison of patients who have received no vaccines and those who have 
received all inactivated vaccines (excepting HPV) recommended post-transplant  
Factors No 
vaccines 
(N=31) 
All 
vaccines** 
(N=136) 
OR 
(95% 
CI) 
p value 
Adjusted OR (95% 
CI) 
(N=number of responses) (p value) 
Age (years) Median (IQR) 
57 
(48,63) 53 (45,62) 
  
0.45 
1.00 (0.94, 1.06) 
  0.93 
GENDER      
2.60 
(1.05, 
6.85) 
0.03 
  
Male (N=88)  22 (71%) 66 (48.5%) 2.74 (0.81, 9.35) 
Female (N-79) 9 (29%) 70 (51.5%) 0.11 
Income strata           
Income Low (N=58)  14/26 (53.8%) 
44/134 
(32.8%) 2.38 
(0.92, 
6.14) 
0.04 
3.32 (0.83, 13.4) 
Middle/High (N=102) 12/26 (46.1%) 
90/134 
(67.2%) 0.09 
RESIDENCE           
City/metro (N=117) 24/31 (77.4%) 
93/134 
(69.4%) 1.51 
(0.57, 
4.48) 
0.51 
1.27 (0.36, 4.52) 
Regional/remote (N=48) 7/31 
(22.6%) 
41/134 
(30.6%) 0.71 
MARITAL STATUS           
Married/defacto (N=136)  25/31 (80.6%) 
111/133 
(83.5%) 0.82 
(0.28, 
2.75) 
0.79 
2.87 (0.45, 18.4) 
Other (N=28) 6/31 (19.4%) 
22/133 
(16.5%) 0.26 
EDUCATION           
Higher (N=64)  9/22 (40.9%) 55 (52.8%) 0.62 
(0.21, 
1.72) 
0.35 
0.50 (0.13, 1.91) 
Other (N=62) 13/22 (59.1%) 49 (47.1%) 0.31 
cGVHD           
Yes (N=111)  21 (67.7%) 90 (66.7%) 1 2.33 (0.62, 8.75) 
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No (N=55) 10 (32.3%) 45 (33.3%) 
1.05 
(0.43, 
2.71) 
0.21 
Early  post-transplant (< 2 
yrs) 
          
Yes (N=31)  11/31 (35.5%) 
20/136 
(14.7%) 3.19 
(1.18, 
8.24) 
0.007 
12.2 (3.02, 49.0) 
No (N=136) 20/31 (64.5%) 
116/136 
(85.3%) <0.001 
** pertussis, tetanus, diphtheria, haemophilus, pneumococcus, meningococcus, hep B, influenza 
Post-transplant vaccinations were administered by GPs alone for 308 respondents (69.8%), in the 
hospital setting alone for 48 (10.9%), in community clinics alone for two (0.5%), in other settings (not 
specified) for two (0.5%). A combination of settings for vaccination (GP + other, hospital + other) was 
used by 32 respondents (7.2%).  
Vaccination records  
Two hundred and ninety-nine of the 417, (71.1%) reported having been given a post-HSCT vaccination 
schedule, 75 (18.0%) had never received a schedule and 43 (10.3%) were uncertain if they had 
received one. When asked if their GP had received a copy of the post-transplant vaccination schedule, 
216 (52.1%) of 414 respondents said yes, 183 (24.9%) said no and 95 (23%) were uncertain. When 
asked if they had a personal record (book) of any vaccinations they had received, 175 (41.8%) of the 
410 respondents said yes, 230 (54.9%) said no and 14 (3.3%) were uncertain. 
Discussion 
Protecting HSCT survivors against VPD with improved vaccine uptake is an important aspect of post-
transplant care.  In this study, the largest ever of Australian long-term allogeneic HSCT survivors, we 
found a high incidence of self-reported VPDs (42%) together with low complete revaccination rates 
(31%) for recommended inactivated vaccines. While our revaccination rates are poor, they are 
consistent with international literature and with Australian single centre studies; complete 
revaccination rates of HSCT survivors range from 20-33%19,35-37. Live attenuated vaccinations were 
analysed separately in this study as the recommendation for their use is limited by levels of post-
transplant immunosuppression, and incomplete immune reconstitution in the post-transplant period 
which is expected to take at least 24 months. So, while 55% and 26.4% of all respondents reported 
receiving MMR and varicella respectively, it is worthy of note that 27.6% of patients who were less 
than 2 years post-transplant reported receiving MMR, and 19% receiving the varicella vaccine. 
Although rates of live attenuated vaccine use was lower in those with a history of cGVHD or those 
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currently on immunosuppression, the cross sectional nature of this study was unable to determine if 
these vaccines were given when cGVHD or immunosuppression were contemporaneous. 
Despite 82% of our survivors reporting receiving an annual influenza vaccination (and influenza 
vaccines providing up to 80% efficacy38),a high rate (46%) of influenza-like -illness or recurrent upper 
respiratory tract infections was reported. There may be a number of possible explanations for this 
finding including reporting bias, misattribution, the inconsistent uptake of annual seasonal influenza 
vaccination or the variable efficacy of the vaccine, such as that which occurs with seasonal mismatch 
with circulating strains. In previous studies laboratory confirmed influenza has been reported to occur 
in 1.3% - 3.5% of HSCT recipients39-41, which likely underrepresents the true burden of disease.  
Influenza in the post HSCT setting can result in an increased risk of bacterial pneumonia, 
hospitalisation, mechanical ventilation and mortality38,40-42. It is important therefore that risk 
mitigation strategies are implemented including improving the uptake of pre and post- influenza 
vaccination rates in HSCT recipients (only 47% of our population reported receiving influenza 
vaccination pre-HSCT), annual vaccination of household contacts, and administration of annual 
influenza vaccination to health care workers caring for HSCT recipients38.   
Pneumococcal disease occurs more commonly post HSCT compared to the general population35,39.  In 
this study 5.1% of respondents reported the disease. This is double that of a 2014 Australian study 
that reported invasive pneumococcal disease (IPD) in 2.3%39 of HSCT recipients. Our high rates may 
be explained by reporting bias; we did not ask specifically if the survivor had IPD or non-invasive 
pneumococcal disease and a number of other factors. Only 15% reported receiving the vaccine pre-
HSCT as recommended, only 55% of survivors reported receiving the vaccine post-HSCT, and those 
who experienced the disease were almost 10 years older than those who did not contract the disease 
(62yrs vs 53yrs, p=0.01).  Vaccine underutilisation, immunosenescence and (where vaccination did 
occur) vaccine failure may be responsible – a combination of increasing age of survivors43 and poor 
maintenance of specific immunity to pneumococcal disease among long-term HSCT survivors44.  
Similarly, in the case of pertussis, the vaccine was administered to 72% of post-HSCT survivors, 2.9% 
reported the disease and those that did so were >10years older than those that reported not having 
the disease (65yrs vs 54yrs, p=0.01)).   
Notably, in the general Australian population, the uptake of immunisations is relatively high such that 
the vaccination rate for 5 years olds is 94%45.  Clearly, however, there must be barriers to vaccination 
uptake in older persons.  Polysaccharide pneumococcal vaccine (PPV) is subsidised on the 
Pharmaceutical Benefits Schedule (PBS) for transplant recipients of any age, and all Australians 65 
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years and over are eligible to receive PPV free of charge on the National Immunisation Program (NIP). 
The protein conjugate pneumococcal vaccine (PCV), recommended as a three-dose schedule post-
transplant receives no government subsidy. Influenza vaccines are free on the NIP, for those medically 
at risk and for all Australians 65 years and over. Despite these funding provisions only 51% of 
Australian adults over 65 years are immunised against these diseases (AIHW 2009, Australia’s health 
2018). 
On multivariate analysis cGVHD was not associated with vaccination status of our survivors.  This 
implies that there are potential barriers to vaccination uptake in the first two years post-HSCT which 
is unrelated to the presence or severity of cGVHD. This is important and requires attention since the 
AIH guidelines recommend that HSCT survivors are fully revaccinated by 12 months post-HSCT 
(excluding live vaccines), when the risk for some VPDs is highest.  
Importantly, lower income showed a non-significant trend towards not completing the revaccination 
schedule.  As the majority of our survivors received their vaccinations via their GP (40.4% pre-HSCT 
and 69.8% post-HSCT), the effect of cost of revaccination to adherence to recommended post-HSCT 
must be considered.  In Australia, HSCT recipients are not eligible to receive childhood vaccinations 
free of charge on the NIP.  The revaccination schedule requires multiple visits to medical practitioners 
at 6, 8, 12 and 24 months post-HSCT.  Given the cost associated with the purchase of the vaccines, 
additional consultation costs will add to the out-of-pocket expenses borne by the patient. The lack of 
financial subsidy for the majority of vaccinations recommended on the post transplant vaccination 
schedule may therefore be a potentially important barrier to vaccination uptake (It is estimated that 
the cost for all vaccines post HSCT is >$1,000, depending on what pharmacies chose to charge for 
individual vaccines and their dispensing fees). 
As mentioned, the vast majority of HSCT recipients (69.8%) receive their vaccinations via their GP.  
Given that this is regularly devolved to local medical officers (LMOs/GPs) 20,46 it is important that HSCT 
survivors and their GPs are aware of the revaccination schedule.  In our study 71.1% of survivors had 
been given a vaccination schedule, and 52% reported that their GP had been provided with the 
schedule.  The low revaccination completion rates highlights the need for better education and 
communication between tertiary and primary health services, and between public and private 
practices.   
Our survey also asked survivors if they had received a vaccination record.  Only 41.8% had been given 
written proof of any vaccines they had received post-HSCT.  Fortunately, the Australian Government 
expanded its previous Childhood Immunisation Record (ACIR) to become the Australian Immunisation 
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Register (AIR) in September 2016.  This is a national register that records vaccines given to people of 
all ages in Australia and theoretically may overcome the lack of vaccine records for HSCT survivors, 
GPs and BMT centres. This was not available at the time of survey completion.  Other strategies used 
to increase vaccination adherence and education include vaccination cards and reminder telephone 
calls36, and dedicated post-HSCT vaccination clinics.47    
This was a multi-centre study and the sample size and high response rate (76%) make it likely that 
these results represent an accurate account of the impact of HSCT on NSW survivor’s post-transplant 
infection rates and vaccine uptake.  Nevertheless, there are a number of limitations to our study that 
may limit the general applicability of these results to HSCT survivors in other countries and other 
settings.  Some of the limitations include participation bias, self-reporting and not capturing data on 
non-responders.  Furthermore, we did not verify self-reported infections with patient medical 
records/pathology reports (this is particularly relevant when considering the high rate of influenza 
reported and also that we do not know if survivors had IPD or non-invasive pneumococcal disease and 
therefore cannot be sure of the effectiveness of vaccination in this setting), and nor did we have access 
to vaccination records.  Additionally, we did not ask why survivors had not completed the 
revaccination schedule.  This would be very important data to consider in addressing rates of vaccine 
uptake (cost, knowledge, health status, physician decision etc all need to be considered). Also, since 
only those individuals who could read and write English were eligible to participate, we do fail to 
capture some data from individuals who may derive from diverse ethnic backgrounds.  This is an 
important consideration since culturally and linguistically diverse (CALD) cancer populations often 
have worse engagement with health services and outcomes than those of their white/Caucasian 
counterparts48, and may be at a disadvantage socioeconomically prior to HSCT. Lastly, cross-sectional 
studies restrict inferences about casual or temporal relationships.  
Optimising vaccination adherence post HSCT represents a highly attractive strategy to improve the 
outcome and the quality of life of long-term survivors49.  The results of this study necessitate 
immediate and critical improvements in vaccination practices post-HSCT.  Survivors, carers, BMT 
specialists and GPs require continuing education, as well as infrastructure, funding and support to 
ensure survivors are vaccinated according to best practices guidelines.  Areas for investigation include 
prospective measurement of the response to vaccines late after HSCT to identify the benefits and 
limitations of vaccination, particularly for those with GVHD or on prolonged immunosuppressive 
treatment (IST).  Decreasing the rates of VPD has the potential to decrease long term morbidity, 
mortality, hospitalisations, cost to patients and the health system and minimise antimicrobial drug 
resistance – a worthy post-HSCT pursuit.  
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12.5. Synopsis 
This paper presents the most comprehensive account of the prevalence of self-reported infectious 
diseases and vaccination uptake in an Australian cohort of allogeneic BMT recipients.   It provides 
detailed data on VPD incidence, and AIH vaccination schedule adherence according to established 
sociodemographic and transplant variables. The results indicate that VPD incidence is high and that 
few survivors complete the recommended schedule of post-BMT vaccination.   Importantly no single 
factor including cGVHD, education or income predicts vaccination adherence, suggesting that more 
fundamental factors (e.g. education, communication, service organisation) may explain rates of 
adherence.  
The low rates of post-BMT vaccination reported here are consistent with international literature and 
with Australian single centre studies (ranging between 20-33%(1-3).   This finding is deeply 
problematic as infection is one of the major causes of post-BMT mortality, with over 40% of survivors 
in this study reporting a VPD.    
The results of this study also suggest that ignorance and inadequate communication between health 
providers and patients may explain part of the low rates of vaccination adherence, with few GPs 
receiving advice regarding post-BMT vaccination or details of the post-BMT vaccination schedule. This 
suggest that much more needs to be done to improve communication with and education of BMT 
survivors, BMT healthcare professionals, GPs who care for long-term BMT survivors and policy makers 
involved in supporting and funding community vaccination programs in Australia.  
While there is a clear rationale for vaccination of BMT survivors to reduce rates of post-BMT infection, 
it is noteworthy that there is limited data about the efficacy of vaccination post-BMT(4).  This is a 
major lacunae as without these data it may be difficult to convince clinicians, health services and policy 
maker to change their practice and/or be willing to fund potentially important, and life-saving 
vaccines.   
The results of this study have important implications for BMT patients, BMT units, local 
haematologists, GPs, APNs, and others who are involved in the care of BMT survivors.   These results 
are also relevant to Australian and state government policymakers and to those responsible for 
development and translation of the National Immunisation Program (NIP)(5). 
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Chapter 13: Epidemiology of complementary and alternative medicine therapy 
use in allogeneic hematopoietic stem cell transplant survivorship patients in 
Australia 
13.1. Chapter overview 
This chapter reports on the use of CAM therapies in long-term survivors of BMT.  It consists of a 
published manuscript entitled, ‘Epidemiology of complementary and alternative medicine therapy use 
in allogeneic hematopoietic stem cell transplant survivorship patients in Australia’.  The manuscript 
reports on the frequency and type of CAM therapy use and its association with demographic, 
socioeconomic, transplant factors, medical complications, cGVHD and QoL. Specifically, we asked 
about survivors use of dietary modification, vitamin therapy, mind-body therapy, herbal 
supplementation, manipulative and body-based therapies, Chinese medicine, reiki and homeopathy. 
Our results demonstrate that over half of the BMT survivors in this cohort used at least one form of 
CAM therapy post-BMT and that approximately 30% used more than two forms of CAM. Vitamin 
therapies, manipulative body-based therapies (massage, acupuncture, chiropractic and osteopathy) 
and mind-body therapies (meditation, hypnosis/breathing and spiritual healing) were the CAM 
modalities most often used by our respondents. While we did not specifically inquire as to the reasons 
why survivors used CAMS post-BMT, the literature suggests that this may, in part, be because BMT 
survivors have physical, psychological and/or spiritual needs that orthodox medicine has been unable 
to address.  There may of course be other reasons why survivors choose to use CAMs – they may be 
consistent with patients ‘world view’, they represent the only way that patients can express their 
agency, and they may provide genuine benefit.  But CAM use is also expensive and may be associated 
with risks, due to either CAM itself or because of interactions with allopathic medicines.  Additional 
risks include CAM use leading patients to delay initiation of conventional therapy or to refuse 
conventional therapy.  The problem here is that we have little empirical data regarding the risks and 
benefits of CAM in group of patients.  
Irrespective of the evidence surrounding CAM, the high prevalence of its use revealed in this study 
suggests that CAM should be the subject of further research and that CAM use should be specifically 
addressed in the education and counselling pre-BMT and in long-term follow up. Clinicians involved in 
the long-term care of BMT survivors must be aware that many survivors may seek complementary, 
and less frequently, alternative therapies, and must therefore be willing to discuss the established and 
potential harms and benefits of CAM use to ensure that survivors are informed about their choices.  
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1Introduction
Worldwide, 90,000 [1] allogeneic HSCTs were performed 
between 2001 and 2011, with 4369 [2] of these procedures 
occurring in Australia. With improvements in donor selec-
tion, conditioning therapies, and supportive care, 35–80% 
of HSCT recipients can now be expected to become long- 
term survivors and be cured of their underlying disease 
[3]. While HSCT provides a clear benefit for many patients 
with malignant and nonmalignant disease, it is also asso-
ciated with significant morbidity and mortality [4].
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Abstract
In addition to prescribed conventional medicines, many allogeneic hematopoietic 
stem cell transplant (HSCT) survivors also use complementary and alternative 
medical therapies (CAM), however, the frequency and types of CAMs used by 
allogeneic HSCT survivors remain unclear. Study participants were adults who 
had undergone an allogeneic HSCT between 1st January 2000 and 31st December 
2012. Participants completed a 402- item questionnaire regarding the use of 
CAM, medical complications, specialist referrals, medications and therapies, 
infections, vaccinations, cancer screening, lifestyle, and occupational issues and 
relationship status following stem cell transplantation. A total of 1475 allogeneic 
HSCT were performed in the study period. Of the 669 recipients known to be 
alive at study sampling, 583 were contactable and were sent study packs. Of 
432 participants who returned the completed survey (66% of total eligible, 76% 
of those contacted), 239 (54.1%) HSCT survivors used at least one form of 
CAM. These included dietary modification (13.6%), vitamin therapy (30%), 
spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipula-
tive and body- based therapies (26%), Chinese medicine (3.5%), reiki (3%), and 
homeopathy (3%). These results definitively demonstrate that a large proportion 
of HSCT survivors are using one or more form of CAM therapy. Given the 
potential benefits demonstrated by small studies of specific CAM therapies in 
this patient group, as well as clearly documented therapies with no benefit or 
even toxicity, this result shows there is a large unmet need for additional studies 
to ascertain efficacy and safety of CAM therapies in this growing population.
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In recent years, there has been growing literature on 
the long- term (or late) psychosocial and medical com-
plications experienced by HSCT survivors. The impact of 
these is profound with HSCT survivors experiencing a 
30% lower life expectancy than a matched population 
cohort [4]. While many survivors rate their quality of 
life highly at 2 years posttransplant, many HSCT recipients 
experience considerable difficulty coping with the short- , 
medium- , and long- term physical and psychological seque-
lae of HSCT and with the uncertainties of their prognosis. 
Given the extent and impact of late complications of 
HSCT, ongoing long- term follow- up and multidisciplinary 
care of HSCT recipients is essential [5].
In addition to prescribed conventional medicines, many 
HSCT survivors also use complementary and alternative 
medical therapies (CAM). However, the prevalence and 
extent of the usage of CAMs in this patient group remains 
unclear. A review published in 1998 found the prevalence 
of CAM use among cancer patients ranges from 7% to 
64% of patients sampled in 26 studies conducted world-
wide [6]. This is consistent with CAM use in the general 
population, estimated at 40% in Australia, Canada, Europe, 
New Zealand, and the United States [7].
Studies in the United States have reported that the 
most common complementary practices and products used 
by individuals with cancer are vitamin/mineral supple-
ments, prayer for self, intercessory prayer, chiropractic/
osteopathic manipulation, and herbal therapies [8]. To 
date, no studies have reported CAM usage by HSCT 
patients.
Despite the lack of literature on the epidemiology of 
CAM use in HSCT patients, there have been a number 
of small trials, including randomized controlled studies 
showing a potential benefit for some CAM therapies such 
as mind and body interventions, although the majority 
of CAM treatments show inconclusive mixed results [9]. 
The authors of a recent literature review of these known 
studies of CAMs in HSCT proposed that a current barrier 
to the use and research in CAM therapy is the recogni-
tion and acceptance of CAM use in this population and 
that epidemiologic estimates were required [9]. The aim 
of this study was to describe the frequency and types of 
CAM used by HSCT survivors, with the intention of 
enhancing recognition of CAM use.
Methods
Patients and procedures
Study participants were eligible if they were >18 years of 
age and had undergone an allogeneic HSCT between 1st 
January 2000 and 31st December 2012 in New South 
Wales (NSW) (NSW is Australia’s most populous state 
– with a population of ~7.5 million [10]), and could 
read and write English. Potential participants were identi-
fied from the transplant databases of all allogeneic trans-
plant centers in NSW, with names and phone numbers 
provided to the research team. Consenting participants 
were given the option to self- complete the questionnaire 
or to complete it via a phone interview with one of the 
researchers. A second round of telephone calls was made 
to consenting participants who had not returned the survey 
within a month. The study protocol was approved by 
the Northern Sydney Coast Human Research Ethics 
Committee (NSLHD Reference: 1207–217M).
Instruments
The Sydney Post HSCT Study survey (SPBS) was developed 
by the research team. Item construction was informed by 
a review of the literature and discussions with patients 
attending HSCT long- term follow- up clinics. It consisted 
of 402 questions, including questions relating to the use 
of CAMs, specifically: Nutrition and Dietary approaches, 
Herbal supplements, Vitamin therapies, Mind–Body thera-
pies (e.g., Meditation), Manipulative and Body therapies 
(e.g., Acupuncture), Traditional medicine (e.g., Traditional 
Chinese Medicine), Energy medicine (e.g., Reiki), and 
Homeopathy. Other relevant domains included demographic 
data, medical complications, specialist referrals, tests and 
assessments, medications and therapies, infections, vaccina-
tions, cancer screening, close personal contacts, lifestyle, 
occupation, and relationship status following stem cell 
transplantation. The questionnaire used tick box response, 
short answer questions, and 5- step Likert scales measuring 
attitudes and other factors, and takes approximately 1 h 
to complete. The questionnaire was piloted in clinic and 
phone interviews to assess face and content validity and 
to check for comprehension of the survey questions.
An additional one page HSCT clinical data form (The 
Sydney Post HSCT Clinical Data Form) was used to col-
lect information from the transplant database including 
date of transplant, date of diagnosis, stage at transplant, 
transplant conditioning, Graft- versus- Host Disease (GvHD) 
prophylaxis, stem cell source, and donor type.
Measures
Participants were classified as CAM users if they used at 
least one therapy in any of the CAM categories. CAM 
use was correlated with demographics, medical complica-
tions, posttransplant medical therapies, treatments and 
clinical variables, relationship status, and social determi-
nants including income and occupational status. The 
relationship of CAM use was further explored against a 
range of survey instruments that measured quality of life 
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(Functional Assessment of Cancer Therapy – Bone Marrow 
Transplant (FACT- BMT Version 4), anxiety, stress, and 
depression (The DASS 21), chronic GVHD (The Chronic 
GVHD Activity Assessment – Patient Self Report (Form 
B) and The Lee Chronic GVHD Symptom Scale), and 
an assessment of life change in response to traumatic 
events (The Post Traumatic Growth Inventory score).
Statistical considerations
Categorical responses were summarized using frequencies 
and percentages. Parametric continuous variables were 
summarized using means and standard deviations, and 
nonparametric variables using medians and interquartile 
ranges. The Pearson’s X 2 test or Fishers Exact tests were 
used for comparative analysis of dichotomous categorical 
variables. Two sample comparisons of means and medians 
were determined using the independent t test and Wilcoxon 
Rank Sum tests, respectively; greater than two sample 
comparisons of means and medians were determined using 
one- way analysis of Variance (ANOVA) and Kruskal–Wallis 
tests, respectively. A two- tailed P < 0.05 was used as the 
level of statistical significance.
Results
Study subjects
A total of 1475 Allogeneic HSCT were performed in the 
study period. Of the 669 recipients known to be alive at 
study sampling, 583 were contactable and were sent study 
packs. A total of 432 (66% of total eligible, 76% of those 
contacted) returned the completed survey. Three percent 
declined participation.
Transplantation details
Median survival time post- HSCT was 5 years (range: 1 year 
4 months–22 years). The main indication for transplanta-
tion was acute leukemia (AML/ALL) in 226 (52.3%). 
Remission status was reported in 406 HSCT, of which 
271 (66.8%) were CR1 or CR2. Donor type was reported 
in 432 transplant procedures of which the majority were 
siblings (57.1%) and matched unrelated donors (35.8%). 
Peripheral blood stem cells were used in 381 (88.1%) of 
transplants. Myeloablative conditioning regimens were used 
in 216 (50.0%) and of these 103 (47.7%) employed total 
body irradiation (TBI). T- cell depleting therapy was 
reported in 122 (28.2%). Antithymocyte globulin (ATG) 
accounted for 92.6% of T- depleting modalities, with 
Alemtuzumab accounting for 3.3%.
Usage of complementary and alternative 
medicine therapies
A total of 239 (54.2%) of HSCT survivors used at least 
one form of CAM, including dietary modification (13.4%), 
vitamin therapy (including minerals and oils) (29.3%), 
spiritual and mind–body therapy (17.2%), herbal supple-
ments (13.2%), manipulative and body- based therapies 
(25.4%), Chinese medicine (3.4%), reiki (3%), and home-
opathy (3%) (Table 1). One hundred and seventeen (27.2%) 
patients used more than one form of CAM, ranging up 
to seven forms of CAM (Table 2).
Characteristics of CAM users are shown in Table 3. 
There was no age difference between CAM users and 
nonusers. Women (P = 0.019), people living in a major 
city (P = 0.017), those with a university education 
(P = 0.001), and those with bone disease (P = 0.029) 
were significantly more likely to use at least one CAM. 
When comparing pretransplant diagnosis, type of condi-
tioning or time from transplant, cGvHD, diabetes, car-
diovascular risk, thyroid problems, anxiety, and depression, 
no difference in CAM use was seen.
Additionally, patients taking antibacterial, antiviral, or 
antifungal treatment were significantly less likely to use 
CAMs (P = 0.041), whereas patients taking other prescrip-
tion drugs, including immunosuppressant, cardiovascular, 
hormone replacement, or psychotropic medications, were 
no more or less likely to use CAMs. Patients who rou-
tinely saw a Psychologist (P = 0.024) or Physiotherapist 
(P = 0.010) were more likely to use CAMs, as were those 
who did regular exercise (P = 0.049). There was no 
Table 1. Total complementary and alternative medical therapies (CAM) 
usage.
Overall CAM users 54.2% (239)
Dietary modification 13.6% (59)
Vitamin therapy (ex Calcium/Vit D) 27.3% (109)
Mind–body therapy (inc spiritual) 17.2% (74)
Herbal supplementation 13.5% (58)
Manipulative and body- based therapies 26.0% (112)
Chinese medicine 3.5% (15)
Reiki 3.0% (13)
Homeopathy 3.0% (13)
Table 2. Total complementary and alternative medical therapies (CAM) burden.
Number of CAMs Nil At least 1 1 2 3 4 5 6 7
Patients 43.8% (193) 54.2% (239) 26.0% (116) 14.5% (62) 6.6% (27) 4.3% (17) 0.9% (4) 0.9% (4) 0.7% (3)
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Table 3. Characteristics of CAM users.
Variables CAM users (%) Nonusers (%) P value OR (CI)
Demographic
Gender 0.019 0.63 (0.42–0.92)
Male (n = 244) 123/239 (51.5) 121/193 (62.7)
Female (n = 188) 116/239 (48.5) 72/193 (37.3)
Age (years) 0.73 1.06 (0.73–1.56)
<54 (n = 221) 124/239 (51.9) 97/193 (50.3)
≥54 (n = 211) 115/239 (48.1) 96/193 (49.7)
Postcode 0.017 1.68 (1.0–2.5)
City – metro (n = 305) 180/234 (76.9) 125/188 (66.5)
Regional or remote (n = 117) 54/234 (23.1) 63/188 (33.5)
Socioeconomic
Education
Some high school (n = 53), completed high school 
(n = 78), Trade/diploma (n = 44), Some university 
(n = 24), completed university (n = 126)
0.018 –
University education (n = 150) 98/179 (54.7) 52/146 (35.6) 0.001 2.18 (1.36–3.42)
Other (n = 175) 81/179 (45.3) 94/146 (64.4)
Posttransplant income 0.43 0.85 (0.57–1.27)
Low income (n = 153) 81/230 (35.2) 72/185 (38.9)
Middle- high income (n = 262) 149/230 (64.8) 113/185 (61.1)
Occupational status
Full/Part time (n = 211) 118/220 (53.6) 93/194 (47.9) 0.24 1.25 (0.85–1.85)
Unemployed, Retired or Casual ( n = 203) 102/220 (46.4) 101/194 (52.1)
Transplant factors
Pretransplant cancer diagnosis 0.78 1.05 (0.71–1.55)
Acute leukemia (n = 219) 122/228 (53.5) 97/186 (52.2)
Other (n = 195) 106/228 (46.5) 89/186 (47.8)
Years since transplant N = 239 N = 193 0.053 –
<2 years (n = 57) 27 (11.3) 30 (15.5)
2 < 6 years (n = 199) 105 (43.9) 94 (48.7)
6 < 10 years (n = 115) 64 (26.8) 51 (26.4)
≥10 years (n = 61) 43 (18) 18 (9.3)
Conditioning 0.213 –
Myeloablative (n = 216) 239 193
Reduced intensity (n = 225) 122 (51) 88 (45.6)
Missing (n = 2) 115 (48.1) 105 (54.5)
Clinical factors
cGvHD N = 233 N = 192 0.39 1.23 (0.82–1.87)
Yes (n = 294) 166 (71.2) 128 (66.7)
No (n = 131) 67 (28.8) 64 (33.3)
Diabetes N = 209 N = 180 0.75 0.91 (0.51– 1.6)
Yes (n = 56) 29 (13.9) 27 (15)
No (n = 333) 180 (86.1) 153 (85)
Thyroid N = 205 N = 176 0.40 1.50 (0.57–3.9)
Yes (n = 19) 12 (5.9) 7 (4.0)
No (n = 362) 193 (94.1) 169 (96.0)
CV Risk N = 219 N = 186 0.49 1.14 (0.77–1.70)
Yes (n = 175) 98 (44.7) 77 (41.4)
No (n = 230) 121 (55.3) 109 (58.6)
Self- reported anxiety or depression N = 215 N = 185 0.142 1.38 (0.89–2.15)
Yes (n = 1160 69 (32.1) 47 (25.4)
No (n = 284) 146 (67.9) 138 (74.6)
Bone disease N = 214 N = 178 0.029 1.62 (1.04–2.52)
Yes (n = 121) 76 (35.5) 45 (25.3)
No (n = 271) 138 (64.5) 133 (74.7)
(Continues)
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Variables CAM users (%) Nonusers (%) P value OR (CI)
Skin/Mouth cancers N = 215 N = 183 0.59 1.13 (0.71–1.85)
Yes (n = 94) 53 (24.7) 41 (22.4)
No (n = 304) 162 (75.3) 142 (77.6)
Other medication use
Med group 1 (penicillin, antiviral drug, bactrim, antifungal 
drug)
N = 239 N = 193 0.041 0.66 (0.45–0.98)
Yes (n = 176) 87 (36.4) 89 (46.1)
No (n = 256) 152 (63.6) 104 (53.9)
Med group 2 (immune drug, prednisolone) N = 239 N = 193 0.31 0.81 (0.54–1.21)
Yes (150) 78 (32.6) 72 (37.3)
No (282) 161 (67.4) 121 (62.7)
Med group 3 (any blood pressure drug) N = 239 N = 193 0. 16 0.73 (0.47–1.13)
Yes (107) 53 (22.2) 186 (77.8)
No (325) 54 (28) 139 (72)
Med group 4 (antidepressant, any sleeping tablet, antianxiety 
drug)
N = 239 N = 193 0.50 1.17 (0.73–1.88)
Yes (89) 52 (21.8) 187 (78.2)
No (343) 37 (19.2) 156 (80.8)
Calcium N = 239 N = 193 0.27 1.23 (0.84–1.50)
Yes (205) 119 (49.8) 86 (44.6)
No (227) 120 (50.2) 107 (55.4)
Vitamin D N = 239 N = 193 0.43 1.16 (0.79 –1.7)
Yes (244) 139 (58.2) 105 (54.4)
No (188) 10 (41.8) 88 (45.6)
Bone strengthening drug N = 239 N = 193 0.41 1.25 (0.73–2.14)
Yes (65) 39 (16.3) 26 (13.5)
No (367) 200 (83.7) 167 (86.5)
Med Group 5 (hormonal replacement) N = 239 N = 193 0.116 1.55 (0.89–2.73)
Yes (62) 40 (16.7) 22 (11.4)
No (370) 199 (83.3) 171 (88.6)
Psychosocial
Psychiatrist N = 220 N = 181 0.99 0.99 (0.47–2.08)
Yes (n = 31) 17 (7.7) 14 (7.7)
No (n = 370) 203 (92.3) 167 (92.3)
Psychologist N = 221 N = 185 0.024 1.82 (1.07–3.09)
Yes (n = 74) 49 (22.2) 25 (13.5)
No (n = 332) 172 (77.8) 160 (86.5)
Social worker N = 221 N = 183 0.21 1.4 (0.79–2.67)
Yes (n = 51) 32 (14.5) 19 (10.4)
No (n = 353) 189 (85.5) 164 (89.6)
Dietician N = 222 N = 185 1.00 1.0 (0.63–1.57)
Yes (n = 99) 54 (24.3) 45 (24.3)
No (n = 308) 168 (75.7) 140 (75.7)
Physiotherapist N = 220 N = 183 0.010 1.8 (1.1–3.0)
Yes (n = 97) 64 (29.1) 33 (18)
No (n = 306) 156 (70.9) 150 (82)
Exercise physiologist N = 218 N = 182 0.067 2.0 (0.93–4.3)
Yes (n = 33) 23 (10.6) 10 (5.5)
No (n = 367) 195 (89.4) 172 (94.5)
Lifestyle
BMI group N = 239 N = 193 0.519 –
Normal (193) 112 (46.9) 81 (42)
Obesity (66) 36 (15.1) 30 (15.5)
Overweight (125) 66 (27.6) 59 (30.6)
Underweight (13) 9 (3.8) 4 (2.1)
Missing (35) 
Median (IQR)
Median 24.48  
 (22.1–28.03)
Median 25.1  
 (22.5–28.3)
Table 3. Characteristics of CAM users. (Continued)
(Continues)
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significant relationship with FACT- BMT and patients’ use 
of CAMs.
Dietary modification
Fifty- Nine (13.6%) HSCT survivors modified their diet 
in some way, including caloric supplementation (3; 0.7%), 
low calorie diet (6; 1.4%), gluten- free diet (6; 1.4%), 
lactose- free diet (3; 0.7%), probiotic usage (4; 0.9%), low 
carbohydrate diet (2; 0.5%), vegetarian or pescetarian diet 
(8; 1.8%), low cholesterol diet (4; 0.9%), and use of 
organic food (14; 3.2%). Women were more likely to 
make modifications to their diet post- HSCT than men, 
with 32 (17%) of women and 27 (11%) of men (Male: 
OR: 0.59 [0.34–1.03]). Nine HSCT survivors consulted a 
dietician (2%).
Diagnosis, comorbidities (diabetes mellitus, cardiovascular 
disease), bone disease, and posttransplant cancer diagnosis 
were not significantly associated with dietary modification. 
Those using dietary modification were significantly more 
likely to be further out from their transplant date (median 
6.6 years compared to 5.0 years [P = 0.04]) and reported 
significantly higher FACT- BMT scores (Median 109, IQR 
99–121), indicative of better quality of life.
Herbal therapy
Herbal therapies were uncommonly used by HSCT survi-
vors, with the most common therapies including Ginseng 
(5; 1.1%) and Garlic (3; 0.7%). Women were more likely 
to use herbal therapies (Male: P = 0.056, OR: 0.58 
[0.33–1.01]) as were patients living in an urban area (Rural: 
P = 0.051, odds 2.0 [0.98–4.14]). Although not significant, 
patients using herbal supplements had higher odds of hav-
ing a pretransplant diagnosis of AML/ALL (OR: 1.42 
[0.798–2.55]), cardiovascular risk factors (OR: 1.32 [0.73–
2.39], bone disease (OR: 1.7 [0.95–3.31]), and of seeing a 
psychiatrist (OR: 1.35 [0.49–3.70]). Those using herbal 
supplements had lower odds of being diabetic (OR: 0.83 
[0.33–2.0]) or seeing a social worker (OR: 0.72 [0.21–1.92]) 
or a dietician (OR: 0.45 [0.19–1.04]). Patients were sig-
nificantly less likely to take herbal supplements the more 
prescription medications they took (P = 0.004). There was 
no significant relationship between FACT- BMT and patient’s 
use of herbs.
Vitamin therapy (including minerals and oils)
Self- medication of vitamins (excluding Vitamin D and 
Calcium) was taken by 129 (29.3%) patients, including 
vitamin B (24; 5.4%), vitamin C (33; 7.5%), vitamin E 
(2; 0.5%), fish oil (28; 6.3%), magnesium (15; 3.4%), 
zinc (8; 1.8%), CoQ10 (3; 0.7%), and multivitamins (38; 
8.6%). Calcium was taken by 211 (47.2%) patients and 
vitamin D by 250 (56.7%) patients (Table 4). Patients 
were more likely to take vitamin therapies if they had 
a university degree (OR: 1.36 [0.84–2.19], however, no 
other correlations were identified. Of the 239 patients 
taking vitamin supplements, the total number of supple-
ments (supplement burden) varied, with most patients 
taking one (61; 51%) or two (32; 27%) supplements 
(Table 5).
Variables CAM users (%) Nonusers (%) P value OR (CI)
Doing exercise N = 236 N = 191 0.076 1.45 (0.96–2.19)
Yes (n = 296) 172 (72.9) 124 (64.9)
No (n = 131) 64 (27.1) 67 (35.1)
>3times/Week (199) 124 (73.4) 75 (62.3) 0.049 0.60 (0.36–1.00)
<3 times /Week(90) 45 (26.6) 45 (37.5)
FACT- BMT total score 108.3 (89.7–120) 104.6 (90–119) NS –
Total lee 17.2 (8.5–31.1) 20.85 (10.3–29.9) NS –
Uncertainty score 13.5 (9–17) 14 (10–17) NS –
Factor total 58 (40–68) 50 (30–66) 0.001 –
FACT- BMT, functional assessment of cancer therapy – bone marrow transplant, CAM, complementary and alternative medical therapies. Lee cGVHD 
scale, a valid measure of cGVHD manifestations.
Table 3. Characteristics of CAM users. (Continued)
Table 4. Vitamin supplementation.
Total Vitamin 
Modification
(ex Vit D/ Calcium) Vitamin B Vitamin C Vitamin E Fish oil Magnesium Zinc CoQ10 Multivitamin Calcium Vitamin D
24.7% (109) 5.4% (24) 7.5% (33) 0.5% (2) 6.3% (28) 3.4% (15) 1.8% (8) 0.7% (3) 8.6% (38) 47.8% (211) 56.7% (250)
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Mind–body therapies (including spiritual 
healing)
Mind–body therapies were used by 74 (17.1%) patients, 
including meditation (45; 10.2%), hypnosis/breathing 
exercise (7; 1.6%), spiritual healing (9; 2.0%), yoga (8; 
1.8%), and tai chi (5; 1.1%). Women were more likely 
to use mind–body therapies (22%) versus men (13%). 
Patients with university degrees were significantly more 
likely to use a spiritual and/or mental therapy (P = 0.008 
OR: 2.20 [0.21–3.99]). Likewise, those who saw a 
Psychologist (P = 0.009, OR: 2.19 [1.21–3.99]), Psychiatrist 
(P = 0.015, OR: 2.62 [1.17–5.86]), Physiotherapist 
(P = 0.049, OR: 1.77[0.99–3.14]), Exercise physiologist 
(P = 0.022, OR: 2.48 [1.11–5.51]), or those who exercised 
more than three times per week (P = 0.042, OR: 0.48 
[0.244–0.97]).
Manipulative and body- based therapies
Manipulative and body- based therapies were used by 112 
(26%) patients, including acupuncture (28; 6.3%), chiro-
practic (28; 6.3%), massage (64; 14%), osteopathy (9; 2%), 
physiotherapy (8; 1.8%), and reflexology (6; 1.4%). There 
was a marginal difference in genders seen with 58 (31.2%) 
women and 54 (22%) men using physical therapies. Those 
patients with university degrees were significantly more 
likely to use a manipulative and body- based therapy 
(P = 0.001, OR: 2.24 [1.37–3.67]), whereas those with 
cGVHD also had a greater odds of use (OR: 1.38 [084 
–2.26]).
Traditional Chinese/ayurvedic medicine, 
reiki, and homeopathy
Traditional Chinese/ayurvedic medicine was used by 15 
(3.5%) patients, of which 10 (5.4%) were women and 
5 (2.1%) were men. The patients were significantly less 
likely to take herbal traditional Chinese/ayuredic medicine 
the more prescription medications they took (P = 0.023). 
Reiki (or “energy medicine”) was used by 13 (3%) 
patients, of which 10 (5.4%) were women and 3 (1.2%) 
were men. Homeopathy was used by 13 (3.1%) patients, 
of which 8 (4.4%) were women and 5 (2.1%) were 
men.
Discussion
In this survey of 583 allogeneic Australian HSCT survivors, 
over half (54.2%) used at least one CAM. The most com-
mon CAM therapies used were vitamin therapies (27.3%) 
and manipulative body- based therapies (26.0%), with 
survivors also using mind–body therapies (17.2%), dietary 
modification (13.6%), and herbal supplementation 
(13.5%). This usage is consistent with internationally 
reported CAM usage in cancer patients [6, 11]. The types 
of CAM therapies used by HSCT survivors in our study 
are similar to those used by cancer patients, with vitamins, 
manipulative body- based therapies, and herbal supplemen-
tation used more often than other CAMs.
Few participants (3.1%) reported using homeopathy 
compared to other studies in cancer patients, which report 
usage up to 10% [12]. This may reflect low rates of 
homeopathy usage in Australia compared to the United 
States, and/or the results of recent efforts by the Australian 
NHMRC (National Health and Medical Research Council) 
which released an advisory noting the absence of evidence 
for homeopathy and calling for restrictions on education 
and health insurance subsidies of homeopathy [13]. At 
the same time it is of some concern that only half of 
responders reported taking calcium (47.8%) and vitamin 
D supplements (56.7%), given that these have shown to 
be beneficial in this high- risk patient group [14].
As has been documented in other studies of CAM use, 
both in the general population and in cancer patients [6, 
11, 12], we found a higher proportion of CAM usage by 
women (across all CAM subgroups), those with a uni-
versity education and people living in a major city (which 
may be due to a lack of access to CAM in remote regions 
and smaller towns). We did not see any correlation between 
CAM usage and cGVHD or patient age. Although a cohort 
study using a questionnaire risks selection bias, with such 
a large response rate (76%) of our patient cohort of all 
contactable HSCT survivors over a 13- year period, we 
believe selection bias is minimal and this is an accurate 
proportion of CAM usage.
Given the number of HSCT survivors taking CAM 
therapies, it is important to be aware of the potential 
harms CAM therapies may have, including interactions 
with conventional allogeneic therapies, particularly immu-
nosuppressants and antifungals, as well as risks of 
Table 5. Vitamin supplementation burden.
Number of vitamin 
supplements per patient 
excl calcium +Vit D 1 2 3 4 5 6 7
51% (61) 27% (32) 13% (16) 5% (6) 3% (4) 0 0.8% (1)
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manipulative therapies in patients with underlying bone 
disease and potential harm of overuse of vitamins [15–17]. 
Other direct toxicity with CAM usage including diarrhea 
and vomiting are also a particular concern in transplant 
recipients as they may exacerbate concurrent gastrointestinal 
disease including cGVHD [16]. It is also possible that by 
increasing polypharmacy and the pill burden experienced 
by allogeneic HSCT survivors (a group already taking a 
large number of supportive care medications), CAM thera-
pies may also increase the likelihood of nonadherence [18]. 
Alternatively, several randomized controlled studies, par-
ticularly mind and body interventions were found to have 
potential benefits in this patient group [9]. For example, 
Takatsuka et al. demonstrated a beneficial effect of fish 
oil on the incidence of graft- versus- host disease (GVHD) 
in patients after HSCT [19] and two studies have found 
a significant positive correlation between massage therapy 
and a decline in anxiety and depression level in patients 
after HSCT [20, 21]. Although our subgroup analysis did 
not replicate these results, with no significant differences 
in CGVHD or FACT- BMT scores, the design of the study 
was inadequate for this purpose; rather it has demonstrated 
that a large proportion of HSCT recipients are using these 
CAMs up to 10 years posttransplant.
It is crucial that CAM usage is routinely assessed as 
part of HSCT long- term follow- up (LTFU). While the 
decision to use a CAM always remains the right of the 
patient, it is essential that this decision to do so is informed. 
These results definitively demonstrate a large proportion 
of HSCT survivors are using one or more form of CAM 
therapy. Given the potential benefits demonstrated by small 
studies of specific CAM therapies in this patient group, 
as well as clearly documented therapies with no benefit 
or even toxicity, this result shows there is a large unmet 
need for additional studies to ascertain efficacy and safety 
of CAM therapies in this growing population.
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13.5. Synopsis 
This manuscript provides the largest and most comprehensive account of CAM use post allogeneic 
BMT in Australia.  The results indicate that CAMs are commonly used by Australian BMT survivors, 
particularly by women, those who live in metropolitan areas, those with a university degree, those 
with bone disease and those who routinely see a psychologist or physiotherapist.  Interestingly, we 
did not find any correlation between physical (co-morbidities (excluding bone disease) and cGVHD) 
and/or psychological (FACT-BMT scores) distress and CAM use, suggesting either that survivors were 
not using these CAM therapies to relive physical or psychological symptoms, or that CAM therapies 
were effective in doing so. This raises questions as to the adequacy of BMT care in meeting the 
psychological, physical and/or spiritual needs of BMT survivors.  
The insights provided by the study are critically important both because data relating to CAM therapy 
use in Australian BMT recipients has previously not been available, and because assessment of CAM 
use is not routinely a part of post-BMT assessment or BMT care. This is, of course, because assessment 
of CAM therapy use is not recommended by international or national screening and preventive care 
guidelines for BMT LTFU(1, 2). Given its wide-spread use in both the general population and in cancer 
survivors(3) and the lack of data with regard to its safety and efficacy, this study suggests that CAM 
therapy use can no longer be ignored by researchers, clinicians and policy makers.  The results of 
recent research which suggest that CAM use by patients with cancer may be associated with lower 
rates of treatment adherence and higher risk of death provide a further incentive to closely examine 
the use of CAMs in BMT recipients(4). 
BMT recipients must have a full understanding of the impact that BMT will have on their lives and 
must be empowered through education to take steps to improve their post-transplant outcomes.  The 
importance of adhering to therapeutic recommendations made by the transplant team, informing 
clinicians about their use of over-the-counter (OTC) products and CAM therapies, and avoiding CAM 
therapies that may compromise their health, must be emphasised to BMT recipients both pre and 
post-BMT. This requires not only a willingness on the part of BMT clinicians to discuss CAM use, but 
also an awareness of why BMT patients use CAM and what risks and benefits may be associated with 
their use. This should be the subject of ongoing research.  
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Chapter 14: Haematopoietic stem cell transplantation survivorship and 
quality of life: is it a small world after all? 
14.1. Chapter overview 
This chapter reports on the lived experience of BMT survivorship.  It consists of a published manuscript 
entitled, ‘Haematopoietic stem cell transplantation survivorship and QoL: is it a small world after all?’.  
The manuscript reports on the qualitative analysis of responses to a single question put to BMT 
survivors, ‘What would you say are the three things that have had the most impact on your quality of 
life since your transplant (or that cause you the most distress)?’  The purpose of this open-ended 
question was to elicit qualitative data not currently captured by standard psychometric measures of 
QoL post-BMT by allowing BMT survivors to describe in their own words and without direction or 
constraint, how BMT had impacted upon their lives.   
The results of this study demonstrate that BMT has a significant and pervasive impact on the lives of 
long-term survivors of BMT and on their perceptions of their QoL.  In broad terms survivors described 
a ‘shrinking life world’ post-BMT with five common themes identified from participant responses; the 
‘failing body’ and diminishing physical effectiveness, the ‘changed mind’, the ‘loss of social 
connectedness’, the ‘loss of functional self’ and the sense that a BMT patient was a ‘patient for life’.  
These findings have profound implications for many aspects of BMT including the policies and 
processes and content of consent to BMT, and the education, counselling and support of BMT 
recipients and their families’ pre and post-BMT.  The findings are of methodological significance as 
they also suggest that a single open-ended question may encourage BMT patients to talk about their 
fears and about the things that are impacting most on their QoL.  This is important, not simply because 
it may be used to study the QoL of BMT survivors, but also because it suggests the clinical utility of a 
single question in each routine post-BMT clinic appointment, and therefore has clinical utility in 
routine post-BMT care.  
14.2. Publication details 
Brice L, Gilroy N, Dyer G, Kabir M, Greenwood M, Larsen S, Moore J, Hertzberg M, Kwan J, Brown L, 
Hogg M, Brice L, Huang G, Ward C. & Kerridge, I. “Haematopoietic stem cell transplantation 
survivorship and QoL: is it a small world after all?” Support Care Cancer. 2017;25(2):421-7. 
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Abstract
Purpose The aim of this qualitative study was to gain a rich
understanding of the impact that haematopoietic stem cell
transplantation (HSCT) has on long-term survivor’s quality
of life (QoL).
Method Participants included 441 survivors who had under-
gone HSCT for a malignant or non-malignant disease. Data
were obtained by a questionnaire positing a single open-ended
question asking respondents to list the three issues of greatest
importance to their QoL in survivorship. Responses were
analysed and organised into QoL themes and subthemes.
Results Major themes identified included the following: the
failing body and diminished physical effectiveness, the
changed mind, the loss of social connectedness, the loss of
the functional self and the patient for life. Each of these themes
manifests different ways in which HSCTsurvivor’s world and
opportunities had diminished compared to the unhindered and
expansive life that they enjoyed prior to the onset of disease
and subsequent HSCT.
Conclusions HSCT has a profound and pervasive impact on
the life of survivors—reducing their horizons and shrinking
various parts of their worlds. While HSCT survivors can de-
scribe the ways in which their life has changed, many of their
fears, anxieties, regrets and concerns are existential in nature
and are ill-defined—making it exceeding unlikely that they
would be adequately captured by standard psychometric mea-
sures of QoL post HSCT.
Keywords Quality of life . Bone marrow transplantation .
Haematopoietic stem cell transplantation . Cancer
Haematopoietic stem cell transplantation (HSCT) is a de-
manding therapeutic intervention used in the treatment of a
range of life-threatening malignant and non-malignant dis-
eases, with high treatment-related mortality. For those who
survive, their lives are often complicated by a wide range of
debilitating physical sequelae, with over 90 % of HSCT sur-
vivors experiencing at least one serious late adverse effect of
treatment [1]. The coexistence of multiple late sequelae, par-
ticularly chronic graft-versus-host disease (cGVHD), is wide-
ly recognised as having a profound impact upon HSCT survi-
vor’s quality of life (QoL). Therefore, obtaining QoL infor-
mation is a crucial part of the assessment of treatment success,
as improved overall survival is no longer the only factor rele-
vant to the evaluation of a successful medical outcome.
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Recent reviews of QoL post HSCT have concluded that
many aspects of the individual’s physical, functional, so-
cial and psychological QoL improve despite high symp-
tom burden [2–5]. Typical concerns of HSCT survivors
include compromised fertility and sexual functioning, fa-
tigue, cognitive declines and physical and emotional dis-
tress [2–4, 6, 7]. Fear of recurrence, the challenge of
managing uncertainty and frustration at loss of control
are also commonly cited psychological sequelae of post-
HSCT survivorship [8, 9]. Inevitably, each of these chal-
lenges can compromise the survivor’s social roles and
identity and may have significant implications for their
social interactions and relationships [10–13].
Previous research has highlighted the deleterious im-
pact that late-onset and persistent adverse effects of
HSCT may have on survivor’s daily functioning and the
intense frustration that survivors may feel as a conse-
quence of these limitations and the intractable unpredict-
ability of recovery [14]. Despite the challenges that HSCT
survivorship brings, many survivors, however, are still
able to reflect on the positive, transformative nature of
HSCT and experience a renewed appreciation for life, a
renegotiation of priorities, an enhanced spirituality, liber-
ation from hospitals and the possibility of returning to
study/work [15, 16]. While the experience of illness, sur-
vival and limitation may encourage many patients to re-
flect on their own lives and on the human condition, it
remains the case that many survivors, particularly those
dealing with the effects of chronic GVHD, struggle with
the limitations on their lives and functioning as a conse-
quence of the adverse sequelae of HSCT [17, 18]. Indeed,
a review of the literature reveals how patients report being
surprised by the severity and duration of distressing side
effects particularly as it impacts on their ability to return
to activities of daily living such as driving and returning
to education or employment [14, 19].
While the concept of a ‘shrinking life world’ has been used
to describe the patient’s experience in a range of chronic ill-
nesses, including the way in which illness may disrupt or
diminish employment, restrict or limit social interactions and
erode an individual’s self-concept [20], this concept has yet to
be explored in the context of HSCT survivorship. In part, this
may be a consequence of what is known about long-term
survival post HSCT, as the vast majority of studies reporting
on the QoL of HSCT survivors are quantitative studies, and
often retrospective registry reviews, and rely upon a limited
range of measures to assess QoL. While such studies provide
important and useful information about QoL, at the same time,
they often fail to fully capture the ways in which survivor’s
lives have changed, including the existential and often ill-
defined regrets, concerns, fears and anxieties that they experi-
ence. Although a number of important qualitative studies have
provided some insights into the everyday challenges of
survivorship [6, 14, 21, 22], there is also no doubt that more
qualitative exploration of HSCTsurvivorship needs to be done
in order to guide the development of models of care to im-
prove symptom management, identify survivors at increased
risk of poor QoL, provide opportunities for early intervention
and help both health professionals and survivors with medical
decision-making. This study describes the qualitative insights
gained by asking a population of long-term survivors of
HSCT a single open-ended question about the quality of their
life post HSCT.
Methods
The study sample was selected from allogeneic haematopoietic
stem cell transplantation databases of the four major adult met-
ropolitan hospitals in New SouthWales, Australia, that perform
HSCT. Participants were eligible if they were ≥18 years of age
and had undergone an allogeneic BMT between 1 January 2000
and 31 December 2012 and could read and write English.
Consenting participants were given the option to self-
complete the questionnaire or to complete a telephone interview
with one of the researchers. A second round of telephone calls
was made to consenting participants who had not returned the
survey within a month. A total of 1475 allogeneic HSCTwere
performed in the study period. Of the 669 recipients known to
be alive at study sampling, 583 were contactable and were sent
study packs and 441 returned the completed survey. No respon-
dent opted for a telephone interview. Three percent declined
participation. Demographic characteristics of the study respon-
dents are depicted in Table 1. The study was approved by the
Northern Sydney Local Health District Human Research Ethics
Committee (NSLHD Reference: 1207-217M).
In order to capture the diversity of responses and to avoid a
positive or negative bias, data was obtained by positing a
single open-ended question asking respondents to list the three
issues of greatest importance to their QoL post HSCT.
Responses to the QoL question were copied verbatim, main-
taining confidentiality, into a word document. The analytical
framework used for initial coding was guided by the model of
QoL conceived by Ferrell et al. [23]. We further refined the
thematic scheme through multiple readings and line-by-line
coding. Initially 232 codes were identified. The codes were
then grouped together with codes of similar meaning. The
consolidated codes were further condensed to five common
themes: the failing body and diminishing physical effective-
ness, the changed mind, the loss of social connectedness, the
loss of the functional self and the patient for life. The first and
last authors performed the analysis, but final agreement on the
themes was only reached after three other authors had inde-
pendently read and provided commentary on both the codes
and the characteristics of each category. Qualitative analysis
was performed on NVivo software.
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Results
While some survivors experienced relatively good QoL post
HSCT, many struggled with pervasive and unrelenting side
effects. The overwhelming theme evident in the responses of
those struggling with QoL was that their world and opportu-
nities had become profoundly diminished compared to the life
they enjoyed prior to disease and HSCT. (A selection of
participant quotes exemplifying the themes are detailed in
Table 2.)
The failing body and diminishing physical effectiveness
The majority of respondents reported that the toxicity and
immunosuppression associated with HSCT resulted in a pleth-
ora of long-term impairments of survivor’s physical, emotion-
al and psychosocial function. A considerable number of sur-
vivors reflected on the impact of cGVHD. Reference to
GVHD was frequently linked to comments highlighting the
unrelenting implications for the individual’s physical, social
and psychological functioning. A large number of survivors
reflected on the physical burden of transplant which was often
associated with reduced emotional and social functioning in-
cluding, inter alia, fatigue, employment, depression and de-
clines in socialisation. Some respondents reflected that their
social world had shrunk as a consequence of their physical
restrictions and incapacity to regain fitness. Many reflected
that the complications of transplant transformed their personal
world and their intimate relationships, particularly their sexual
identity, sexual functioning and fertility. A large number of
women reported early onset of menopause, decreased sexual
enjoyment, reduced fertility, vaginal dryness, irritation, pain
and bleeding, while some men reported erectile dysfunction,
lowered libido and decreased sexual enjoyment. Infertility and
reports of sexual dysfunction were often linked to the survi-
vor’s lowmood, poor self-esteem and relationship difficulties.
The impact of HSCT on fertility, sexuality, identity and phys-
ical function led some respondents to reflect on the difficulty
they faced in trying to secure future relationships. Despite
many respondents reflecting on the persistence of significant
medical complications and the functional limitations that com-
promised their QoL, the vast majority of respondents reported
feeling a deep appreciation for life post HSCT.
The changed mind
Many survivors noted a range of mood changes post trans-
plant including anger, frustration, anxiety and depression.
Some survivors linked mood disturbances to social isolation.
Several HSCTsurvivors also described cognitive changes fol-
lowing HSCT, including memory deficits, decreased concen-
tration and attention, mental fatigue and reduced reaction
times. Some survivors linked these cognitive impairments to
Table 1 Patient demographics and clinical characteristics
Characteristics No. of patients (%)
Age group
19–29 30 (6.8)
30–39 49 (11.1)
40–49 83 (18.7)
50–59 130 (29.5)
60–69 127 (28.7)
>70 22 (5.0)
Median; range 54; 19–79
Gender
Male 250 (56.7)
Female 191 (43.3)
Culture, ethnicity
Australian/European 323 (73.2)
Indigenous Australian 2 (0.5)
Asian 30 (6.8)
Middle Eastern 7 (1.6)
Other 10 (2.3)
Unknown 69 (15.6)
Years since transplant
<2 58 (13.1)
2 to >6 204 (46.3)
6 to <10 117 (26.5)
≥10 62 (14.1)
Median; range 5; 1–14
Underlying diagnosis
AML/ALL 226 (51.2)
CML/MDS/myelofibrosis 60 (13.6)
Other 137 (31.1)
Unknown 18 (4.1)
Remission status
CR1/CR2 271 (61.4)
>CR2 22 (5.0)
Other 46 (10.4)
Chronic phase 18 (4.1)
Accelerated phase and blast crisis 3 (0.7)
Refractory 22 (5.0)
Partial remission 23 (5.2)
Unknown 36 (8.2)
Donor type
Sibling 250 (56.7)
Haploidentical 10 (2.3)
Matched unrelated 158 (35.8)
Mismatched unrelated 21 (4.8)
Unknown 2 (0.4)
Stem cell source
Bone marrow 48 (10.9)
PBSCT 381 (86.4)
Cord 12 (2.7)
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problems with employment and relationships. One of the most
dominant emotions expressed by many respondents was
fear—the fear of disease recurrence, the fear of chronic
GVHD and the fear of secondary malignancies occurring post
HSCT. According to several subjects, this created enormous
distress. For some subjects, this deep and pervasive fear made
them reluctant to take risks or plan for the future, which further
perpetuated shrinking opportunities in their life.
The loss of social connectedness
Perhaps unsurprisingly, family and friends featured promi-
nently in respondents’ descriptions of their QoL post HSCT,
Table 2 A selection of participant responses to QoL question:What are
the three things that have had the most impact on your quality of life since
your transplant?
1. The failing body and diminishing physical effectiveness
BGVHD had the biggest impact on my QoL. In particular it attacked my
tear glands and saliva glands – both no longer work. I have dry eyes
andmuch discomfort regularly in my eyes. I can no longer drive, watch
TVor read or go on the Internet because focusingmy eyes hurts andmy
eyes are very sensitive to all forms of light. Earlier this year, my eyes
really affected my mental health and it made me depressed.^
BI just don’t have the same amount of energy. I feel as if I only have 60%
of my energy since my SCT. This frustrates me…. It took me a long
time to listen to my body and rest when I am tired, It does frustrate me
as prior to the SCT I was always on the go. We don’t plan things too
often. I see how I feel when I wake up and if I have the energy, we go
out for the day. I feel like my lack of energy rules my life.^
BPrior to my transplant I was fit and healthy and now find I am unable to
regain the fitness which means I can only do fitness activities including
work, sport and leisure for short periods before tiring and requiring a
rest. This lack of fitness makes it difficult to find suitable employment
for my trade.^
BMy hormone levels are all over the place. My libido is very low. I’ve
tried different things to help but nothing is helping and it is becoming a
problem in my marriage. I am 28 and going through menopause. It is
really hard and depressing. I wish I knew this before treatment.^
BFinding a woman who will like me for who I am and not judge me for
what I have been through…^
BI enjoy everyday. Some days I need to lie down for a few hours due to
fatigue and body aches. But, I am so happy and live my life to the
fullest. I have accepted that I will need ongoing health checks and I am
very grateful for the opportunity to undergo the transplant.^
2. The changed mind
BAnxiety & depression – I don’t sleep, am always fearful, nervous and
on-guard. I don’t cope with little things. It’s a big change to my
personality. I withdraw from social situations.^
BFeels like my memory is foggy. Sometimes unable to find the word or
form a sentence properly. Unable to remember as well as I did prior to
transplant. I feel I wouldn’t be able to cope with a high pressure role. I
find multi-tasking difficult and get stressed easier and am unable to
juggle tasks and live like I used to.^
BFear of recurrence, further side effects and additional problems with
health. This fear has restricted my social life and how I react with my
family.^
BI feel that my disease has set me back in my life so much for me and my
family. We have lost 5 years of our lives and it has crippled our future
plans and our dreams as a family. Everyone seems to be moving
forward except for us. So much time lost….^
BIt took quite a long time to rediscover my old self. Who I am?What am I
supposed to do, act and feel? I felt like a non-entity and this was my
main concern. Five years after BMT and I am only now coming to
terms with my old/new self.^
3. The loss of social connectedness
BThe most important factor in my successful recovery was the love,
support and encouragement of my wife, son and close friends. I cannot
imagine how anyone would survive a BMT and the complications that
follow it on their own.^
BFeeling that I am a major drain on my wife’s time and lifestyle, even
though she does it all willingly and doesn’t feel that way.^
BChanges in family relationships – There is a distance between me and
my wife and each of my 3 children…. I feel I have a disconnect.^
Table 2 (continued)
BI am reliant on others. Losing my independence. Not knowing if I may
have a dizzy turn means I am restricted as to what I do or try. Having been
totally independent and self reliant prior to AML it is difficult to take a
complete 180 turn around.^
4. The loss of the functional self
BI’ve tried to work lasted one day put me back 3 months aggravated the
GVHD.Working or not working is probably number 1 on the list. I won’t
go back to the position I held before the illness, or work again unless my
mind gets better… It is killing me mentally and physically.^
BI have reduced my workload in a limited way. I was formally the
managing partner of my law firm – Now I have reduced responsibilities
and I sometimes feel I have lost some respect. I also feel my firm has
suffered from my new role and I could have done it better.^
BNot being able to work. Less household income. Difficult to pay bills
and medical expenses. Plus isolation, no longer having access to work,
friendships and support. Loneliness and isolation.^
BI have lost everything, my home, all my savings because it has been a
very long treatment in and out of hospital for about 1 year for blood
transfusions and had spleen removed, lots of costs for hospital parking
and other things.^
5. The patient for life—the unrelenting nature of follow-up
BTravel to the transplant unit sometimes monthly, fortnightly and at the
moment twice weekly. I cannot work andmy wife has had to stop work to
become my full time carer. The large regime of medication I take to try
and control GVHD and the side effects of medications are numerous and
debilitating. I am always fatigued and cannot get motivated. I get over one
thing and something else appears. There seems to be no end.^
BI feel I need to be near my medical team and this restricts the distance I
can travel from home. I am very wary as to where I go in case the
communication with the team is not there, so I live in my safety zone.^
BRunning to doctors all the time, going to the hospital all the time, doctors
in the country hospitals have no idea what’s wrong, or what to do, even
when told by the transplant team. They just don’t care up here in the bush.
One of the doctors was told by my team how to treat GVHD, but did
nothing for 14 days.^
BMy local GP has caused me unnecessary anxiety due to his inability to
cope with my situation. I feel he is lost and a bit afraid in dealing with me
to the extent I have lost confidence in him. An example is my vaccination
requirements where I had to fight to get the required vaccinations even
though they were listed for him.^
BI have a great relationship with my local doctor where I can have a
conversation rather than just a consultation – this enables me to make
health decisions that are supported an acknowledged.^
SCT stem cell transplant, BMT blood and marrow transplant (these terms
are synonymous with HSCT and can used interchangeably), AML acute
myeloid leukaemia
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with many emphasising the importance of both the physical
and emotional support they received from significant others
throughout both treatment and survivorship. At the same time,
however, many subjects described the terrible impact that
HSCT had had on their loved ones and the guilt that they felt
about the way HSCT had changed not only their own lives but
also the lives of those close to them. Some respondents also
noted the degree to which they were dependent—physically,
emotionally, socially and financially—upon others and the
way that this made them feel.
The loss of the functional self
Many respondents reported an association between undergo-
ing transplant and the loss of some of the certainties that most
people take for granted—like health, stable relationships,
sustained employment and financial security. For some, the
loss of employment and the loss of capacity to work were
linked to their sense of self-worth. Indeed for many subjects,
work, while previously a central part of their lives, had be-
come stressful and exhausting. Many survivors reported miss-
ing numerous workdays due to ill health, and some reported a
loss of career momentum including the necessity to change
their job or downsize to part-time job. Numerous subjects also
reported that they were unable to return to work at all, with
many describing how these changes caused them further dis-
tress including anxiety, depression and impairments in social
functioning. A few survivors also reflected on the financial
burden of HSCT including the loss of income. References to
the financial burden of transplant were often linked to com-
ments regarding the patient’s sense of self-worth and financial
security.
The patient for life—the unrelenting nature of follow-up
Many survivors described the burdensome requirement of
life-long follow-up to prevent, identify and treat the myriad
of late effects that complicate transplant survival. Some re-
ported on the redirection of their attention from broader life
issues to an intense focus on health and well-being. Some
reflected on the restrictions in their life perpetuated by the
unrelenting nature of follow-up including loss of productive
function, social isolation and a diminished self-concept.
Importantly, while many reflected on the fact that long-term
follow-up (LTFU) was onerous, some respondents recognised
how necessary it was and described how much they relied
upon access to multidisciplinary long-term care and the exper-
tise available through their transplant centre. Some survivors
stated their desire to live within a safe distance from their
transplant centre. This specification was often linked to the
individual’s anxiety about the uncertainties and dangers posed
by the future.
A few survivors felt that the special expertise, knowledge
and care provided by their haematologist and HSCT team
were simply not available elsewhere. In many cases, this sense
was heightened by adverse experiences that HSCT survivors
had experienced before transplant and subsequent to it. This
was particularly true for patients living in rural, regional or
remote areas. Concerns regarding lack of expertise and knowl-
edge were not, however, specific to those living in rural areas,
with a few survivors expressing concerns regarding the lack of
knowledge of their general practitioners. Importantly, howev-
er, even though some expressed concerns about their local
doctor, others were very grateful for their relationship with
them.
Conclusions
As survival following HSCT has improved, attention has in-
creasingly turned to the impact of HSCTupon recipients’QoL
and their experience of survivorship. Although a number of
quantitative studies suggest that those who survive at least 1–
2 years following HSCT have an acceptable QoL [2–5], it is
clear that long-term survivors of HSCT face ongoing chal-
lenges and experience limitations in many domains of their
life. By asking survivors one simple question—to describe the
three complications of HSCT that have had the most impact
upon their QoL—we were rewarded with a rich picture of the
challenges of survivorship. What was clear from the accounts
provided by HSCT survivors in this study was that QoL was
most impacted by the physical burden of the failing body, the
cognitive and mood changes, the diminished social connect-
edness, the loss of functionality and the burden of being a
patient for life. These QoL challenges were shown to shrink
various aspects of the HSCTsurvivor’s world—restricting not
only their capacities and function but also their identity and
relationships. While existing literature has described the
changes in self-concept and the loss of identity associatedwith
reductions in HSCT survivor’s ability to perform everyday
functions of living, this is the first study to conceptualise these
losses in terms of a shrinking life world [24, 25].
Many respondents to our study reported feeling a sense of
dislocation and isolation in the years following their trans-
plant—a sense heightened and perpetuated by their real or
perceived fear of infection and GVHD. The functional impair-
ments suffered as a result of overwhelming fatigue were also
ubiquitous. Prior research has identified that GVHD and fa-
tigue often compromise survivor’s QoL for many years post
transplant and are a frequent cause of mood disturbance [3, 4,
24]. For some survivors, this physical and psychological de-
bility was so severe that they felt they had lost their sense of
identity, independence and self-worth and were unable to ful-
fil the social, familial and professional roles that marked out
‘who they were’ before their HSCT. For others, fears about
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their capacity to cope intensified their degree of dependence—
binding them to their transplant centre and to the healthcare
professionals that they trusted and preventing them from see-
ing a world beyond the geographical and emotional ‘gaze’ of
their medical care. Not surprisingly, many survivors were dis-
tressed by their loss of function, particularly as it compro-
mised those things that provide certainty and stability, like
sustained employment and financial security. This is an im-
portant finding and is consistent with other recent studies that
have highlighted the ongoing challenges associated with job
insecurity, discrimination, career derailment and delayed
goals, financial loss and instability and constraints on job mo-
bility [19].
According to the literature, family and friends play an
important function in providing social support. However,
patients also worry that they may become a burden to
others. One study concluded that some survivors felt their
inability to contribute to the family and their lack of pro-
ductivity made them feel useless [11]. These findings were
consisted with the results of this study which highlighted
both the importance of family to survivors and the guilt
they experienced as a result of their physical, emotional,
social and financial dependence. While prior to HSCT
many haematologists and allied health professionals en-
courage survivors to consider the possibility that they
may become ‘a patient for life’, in reality, it is difficult,
if not impossible, to convey what this actually means,
what impact transplantation may have on every aspect of
a survivor’s life, how unrelenting follow-up may feel and
how difficult it may be for survivors to adapt to their post-
HSCT challenges. Previous studies have concluded that
while many survivors report adequate QoL, many do not
believe they have returned to normal [25]. However, this
is not to say that survivors of HSCT (particularly those
that modify their expectations and accept that their lives
are different post HSCT than they were beforehand) do
not adapt, do not resume normal activities, do not cope
with the uncertainty implicit in survival post HSCT or do
not accommodate the need to cease or downsize their em-
ployment or modify their relationships and social roles
[23]. Rather, it is to acknowledge that some survivors of
HSCT will be more profoundly impacted upon than others
by their failing body, impaired cognition, emotional dis-
tress and social isolation [3, 4].
Previous research has highlighted the important role that
pre- and post-transplant education may play in improving the
QoL of HSCT survivors and in enabling them to learn strate-
gies to assist them cope with the changes in their lives [14]. As
a result, it is now generally recognised that transplant centres
should endeavour to incorporate education, counselling and
support into every stage of the transplant recipient’s journey
[14]. But information in any form is very different to personal
experience. It is one thing for a patient who is shortly to
undergo a HSCT to be told by the transplant team that they
have a 60 % chance of developing chronic GVHD but a very
different thing to experience it. And it is one thing to record
the frequency or numerical grade or extent of HSCT compli-
cations but another thing again to describe in one’s own words
what it is to experience them. While it is important to collec-
tive quantitative measures of QoL, it is also crucial to recog-
nise the limitations of this form of data and supplement it with
qualitative data that may reveal the full extent and meaning of
the challenges to HSCT survivors’ QoL.
The results of this study are important not simply because
they contribute to the growing qualitative literature on post-
HSCT survivorship but because it suggests that a single ques-
tion may provide important insights into the experience of sur-
vival post HSCT. And this is important, because, unlike hour-
long in-depth interviews, time could be found in the routine
follow-up of HSCT survivors to ask them a question about
how they are coping and what is of most concern to them.
This study has some very clear limitations that caution against
over-generalising the results to all HSCT survivors. Our analy-
sis was based upon written responses to a single question about
QoL, and we did not use other qualitative methods, such as in-
depth interviews or ethnographic methods that would have un-
doubtedly provide a more nuanced account of the experience of
survival post HSCT. But while other qualitative methodologies
may have provided more detailed accounts of the experience of
survivorship, the use of a single question prompt in this study to
elicit qualitative descriptions of post-HSCT survivorship sug-
gests other benefits. Firstly, our results suggest that asking a
single, very specific question of HSCT survivors about their
QoL may enrich and triangulate the quantitative description of
survivorship provided by other psychometric measures of QoL
commonly used in post-HSCT follow-up. And secondly, our
results provide the possibility of translation, as unlike complex
surveys or in-depth, unstructured interviews, regularly asking a
patient to describe the main things that are having an adverse
impact upon their QoL may be easily done, have clinical utility
and have limited resource costs.
It is clear from the accounts provided by the respondents to
this survey that while HSCT provides enormous benefits, it
also is enormously challenging and may have a range of com-
plex impacts upon the QoL of HSCT recipients and upon their
experience of survivorship. While many will cope, and adapt,
and continue to cherish the life they have, the vast majority
will face challenges along the way. While better education of
HSCT recipients may help the work that survivors need to do
post HSCT, it is unlikely that it will ever be able to completely
prepare HSCT recipients for what lies ahead. In these circum-
stances, what may be most important is for HSCT services to
acknowledge and understand the pervasive impact of HSCT
and offer reassurance that no matter what occurs, whether
expected or unanticipated, they will always be available to
provide care and support.
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14.5. Synopsis 
This manuscript provides the largest qualitative account of the impact of BMT survival on long-term 
QoL.  The results indicate that while survivors QoL scores improve post-BMT(1) and may be similar to 
quantitative evaluations of the QoL of the general population, when asked to describe the impact of 
BMT on QoL in their own words, many survivors describe continued and pervasive physical, 
psychological, social, financial and existential impacts of BMT.  Further, while many survivors reported 
feeling enormously appreciative that they were alive, their experience of survivorship was punctuated 
by regrets, concerns, fears, anxieties and shrinking opportunities, a result of, inter alia, cGVHD, 
infection risk, under/unemployment, and the loss of family and social roles and identity.   
While there are many studies that report quantitative data on the QoL of BMT survivors, there is by 
comparison relatively little qualitative data.  In this regard the results of this study make a significant 
contribution to what is known about the experience of long-term survivorship. While it is tempting to 
feel that survivors of BMT have succeeded simply by virtue of ‘surviving in the face of death’ – data 
like those described here provide a richer and more complex account of what it is like to live post-BMT 
and what life is like when constrained by the late effects of BMT. These insights make BMT much more 
than a medical intervention – reminding us that BMT is personal, intimate, relational and social and 
profoundly changes survivors’ world and world view.  The incredible richness of the data here – elicited 
by asking respondents just one question – also reminds us how the care of BMT patients many be 
enlightened if clinicians are willing to ask their patients open questions about the impact of treatment 
on their QoL, and how this may paint a much richer picture than any form of psychometric survey.  
Indeed if post-BMT care is changed in this small way – by making space for hermeneutic enquiry – 
post-BMT care may be transformed and the education, counselling and support provided to this 
vulnerable and high-risk group can be made more targeted and more personal.  
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Chapter 15: Nutritional issues and body weight in long-term survivors of 
allogeneic blood and marrow transplant (BMT) in NSW Australia 
15.1. Chapter overview 
This chapter reports on issues relating to nutrition, body weight and body image in long-term survivors 
of BMT, and their impact on QoL.  It consists of a published manuscript entitled, ‘Nutritional issues 
and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW 
Australia’.  The manuscript reports on demographics, socioeconomics, transplant factors and co-
morbidities associated with gastrointestinal symptoms (GI), body weight and body image and the 
correlation of these with BMT survivors’ QoL.  Specifically, survivors were asked about nausea, 
vomiting, constipation/diarrhoea, taste and smell alterations, poor appetite, mouth ulcers and dry 
mouth post-BMT, to report their current height and weight (to allow calculation and categorisation of 
BMI), and to reveal whether they were happy with their current weight.   
The results of this study demonstrate that survivors of BMT continue to experience GI and oral and 
nutritional symptoms long after transplant, and that some symptoms do not diminish even years after 
BMT.  The results also demonstrate that QoL is significantly negatively impacted by GI symptoms, that 
many (almost half) of long-term BMT survivors are overweight or obese, and that most report 
returning to (healthy and unhealthy) pre-BMT eating habits.  These findings highlight the importance 
of dietary education, nutrition review, and weight assessment long-term post-BMT, and suggest that 
an integrated, multi-disciplinary approach may be needed to reduce the prevalence of obesity, 
metabolic syndrome and CVD post-BMT. 
15.2. Publication details 
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Brown L, Tan J, Huang G, Kwan J, Larsen S, Ward C and Kerridge I. “Nutritional issues and body weight 
in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia”. Support 
Care Cancer. 2017;25(1):137-44. 
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Abstract
Purpose The aims of this study were to describe the long-term
nutrition, body weight and body image issues facing survivors
of Allogeneic Blood and Marrow Transplant (BMT) and their
impact on quality of life. It also describes survivors’ percep-
tion of enteral feeding during BMT.
Methods Four hundred and forty-one survivors who had un-
dergone a BMT in NSW, Australia between 2000 and 2012
(n = 441/583) completed the Sydney Post BMT Study Survey
(SPBS).
Results Forty-five percent of survivors less than 2-year post-
transplant reported a dry mouth, 36 % reported mouth ulcers
and 19 % had diarrhoea. This was consistent across all survi-
vor groups, regardless of time since transplant. Patients with
one or more gastrointestinal (GI) symptoms had significantly
lower quality of life scores. There was a significant difference
in quality of life scores when comparing those with no GI
symptoms to those with one or more symptoms
(P = <0.0001). Quality of life was significantly higher in those
who once again enjoyed mealtimes (P < 0.0001). Males were
more likely to be satisfied with their body weight compared to
females (P = 0.009). The median body mass index (BMI) for
all patients reporting body weight satisfaction was significant-
ly lower (BMI 23.5) than those reporting dissatisfaction (BMI
27.5) (P = <0.0001). Survivors who had a normal BMI had
significantly higher rates of body weight satisfaction com-
pared to underweight, overweight and obese survivors
(P = <0.0001). Those survivors who were overweight or
obese were significantly more likely to be diabetic
(P = 0.008).
Conclusion This study revealed an important relationship be-
tween gastrointestinal symptoms, body weight and body im-
age and survivor’s quality of life. It provides further support
for the importance of nutrition therapy post-BMT.
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Introduction
Survivorship from allogeneic Blood and Marrow Transplant
(BMT) continues to improve through advances in histocom-
patibility testing, conditioning regimes, supportive care and
the management of Graft-versus-Host Disease (GVHD) [1].
Although BMT provides children and adults with a range of
malignant and non-malignant disease with their best chance of
survival, it is still associated with significant rates of morbidity
and mortality [2–4]. There is increasing recognition that the
survivors of BMT experience a wide range of complications
including cardiovascular disease [5], metabolic syndrome [6],
endocrine dysfunction [7], renal impairment [8], liver dys-
function [7], chronic Graft-versus-Host Disease (cGVHD)
[9] and compromised functional status [7].
Routine nutritional assessment and management is an es-
sential component of supportive care for patients undergoing
BMT [10]. Malnutrition prior to BMT has been linked to an
increased length of stay and trend towards higher mortality
[11]. Early adverse side effects such as oral and gastrointesti-
nal complications can induce nutrition-related symptoms
which in turn reduce a patient’s ability to tolerate adequate
oral intake leading to weight loss and a decline in nutritional
status. For these reasons, it is generally accepted that oral,
enteral or parenteral nutritional support during BMT is essen-
tial to prevent further deterioration in nutritional status [12].
Impaired nutritional status is associated with reduced quality
of life, lower activity levels, an increase in treatment related
symptoms, reduced tumour response to treatment and reduced
survival [13].
Although nutrition support is an established part of sup-
portive care prior to and during BMT [14], little is known
about the long-term nutritional issues facing survivors.
Urbain et al. [15] described the nutritional status and body
composition in the first 100-day post-BMT, but there is limit-
ed published data describing nutrition status beyond this. Few
studies have also investigated the link between nutritional,
body weight and body image issues on survivors’ quality of
life.
The primary aim of this study was to describe the nutrition-
al, body weight and body image issues facing survivors of
allogeneic BMT and the impact these have on quality of life.
Nutritional issues of interest included salient gastrointestinal
symptoms, changes in dietary habits post-BMT, use of nutri-
tional supplements/natural therapies and rates of overweight
and obesity. The secondary aim was to describe BMT survi-
vors’ perception of enteral feeding during BMT.
Methods
Study population
All adult survivors (≥17 years) who had undergone an alloge-
neic BMT between 1 January 2000 and 31 December 2012 in
New South Wales, Australia, and who were at least 12-month
post-transplant were eligible to participate in this cohort study.
Patients were excluded if they could not read or write English.
Signed informed consent was obtained from all participants.
This study was approved by the Northern Sydney Coast
Human Research Ethics Committee (NSLHD Reference:
1207-217M).
Study design
Eligible participants were identified from the BMT databases at
each of the allogeneic transplant hospitals in NSW, Australia.
Patients were informed about the study at their clinic visit or via
a telephone call from one of the researchers. Participants were
given the study pack containing an invitation letter, a patient
information sheet and consent form, the questionnaires and a
stamped self-addressed envelope. All participants were given
the option to self-complete the questionnaire or to complete it
via a phone interview with one of the researchers.
Participants completed the Sydney Post BMT Study Survey
(SPBS), the Functional Assessment of Cancer Therapy–Bone
Marrow Transplant (FACT-BMT Version 4) [16], the Chronic
GVHD Activity Assessment–Patient Self Report (Form B)
[17], the Lee Chronic GVHD Symptom Scale [18], DASS21
[19], the Post Traumatic Growth Inventory [20], and the Fear of
Recurrence Scale [21, 22]. These seven survey instruments
were amalgamated into one 20-page document for ease of com-
pletion by participants. Oncewritten consent was received from
participants, researchers completed the Sydney Post BMT
Clinical Data form.
The Sydney Post BMT Study Survey (SPBS) The SPBS
was developed by the research team. Item construction was
informed by a review of the literature and discussions with
patients attending BMT long-term follow-up clinics. It
consisted of 402 questions grouped into 20 sections including
demographics, medical complications, referrals, tests and as-
sessment and time, medications and treatments, oral and den-
tal health, infections, vaccinations, complementary therapy
use, cancer screening, travel history, close personal contacts,
lifestyle, diet/nutrition, occupation, infection risk, occupa-
tion–work status and functioning, fertility and sexual function,
relationships, long-term follow-up care, social, occupational
attitudes, physical and psychological concerns and an open
text qualitative question. The questionnaire was piloted in
clinic and phone interviews to assess face and content validity
and to check for comprehension of the survey questions.
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Functional assessment of cancer therapy—bone marrow
transplant (FACT-BMT version 4) The FACT-BMT is a
validated questionnaire for measuring quality of life in BMT
recipients [16]. It combines two instruments: the FACT-G and
a BMT subscale. The FACT-G (Version 4) is a 27-item self-
report instrument that measures quality of life (QOL) in cancer
patients [23]. It consists of five subscales measuring physical
(seven items), functional (seven items), social (six items) and
emotional wellbeing (six items) and satisfaction with the
doctor/patient relationship. The BMT subscale includes 10
items designed to test QOL in BMT patients. The FACT-
BMT plus the BMT subscale provides an overall quality of
life score. Patients rate themselves over the past 7 days using
5-step Likert scales with responses used to calculate overall
quality of life and subscale wellbeing scores.
The Sydney Post BMT Clinical Data form A one-page
BMT Clinical Data form was developed by the research team
to collect information regarding the date of transplant, date of
diagnosis and stage at transplant, transplant conditioning,
GVHD prophylaxis, stem cell source and donor type of
BMT survivors. It contained 10 questions and was completed
by the research team.
Statistical analysis
Categorical responses were summarised using frequencies
and percentages. Chi squared tests of significance was used
for categorical data. Two sample comparisons of means and
medians were determined by the independent t test and
Wilcoxon Rank Sum tests, respectively. Regression analysis
was used for examining associations between continuous var-
iables such as FACT-BMT and multivariable regression anal-
ysis to control for potential confounders. A two-tailed P value
<0.05 was considered as the level of statistical significance.
Statistical analysis was performed using Stata®_Version 12.1
(Statacorp, Texas). For the purpose of analysis, time periods
were separated into three categories: less than 2 years, 2 to
5 years and greater than 5 years. BMI was categorised as per
theWorld Health Organisation: ≤18.5 underweight, 18.5–24.9
normal weight, 25.0–29.9 overweight, ≥30.0 obese [24].
Results
Study population
Patient demographics
A total of 1475 allogeneic BMT were performed during the
study period (1 January 2000 to the 31 December 2012). Of
those, there were 669 BMT survivors known to be alive at the
time of study sampling (29/04/2014). Of the 669 survivors,
583 (83 %) were contactable and were sent study packs. Four
hundred and forty-one BMTsurvivors returned the completed
survey, 76 % (441/583) of the total number who were sent the
survey. Three percent (17/583) explicitly refused consent.
The median age of the study group was 54 years (range 19–
79). Fifty-seven percent of respondents were male (250/441)
and 43 % (191/441) female, and the most common cultural
group was Australian/European (73 %, 323/441) (Table 1).
Transplant characteristics
The median years post-transplant was 5 years (range 1–14),
and the most common underlying diagnosis was acute mye-
loid leukaemia (AML)/acute lymphoblastic leukaemia (ALL)
(51 %, 226/441). The majority of patients (61 %, 271/441)
were in complete response/remission 1 (CR1) or complete
response/remission 2 (CR2). Fifty-seven percent of patients
(250/441) had undergone a transplant from a sibling donor
and the most common source of stem cell collection was pe-
ripheral blood (86 %, 381/441). Forty-eight percent (214/441)
underwent myeloablative conditioning treatments (Table 1).
Cardiovascular comorbidities post-BMT, including hyper-
tension, high cholesterol and diabetes mellitus were reported
by 29 % (118/409), 24 % (96/402) and 14 % (57/308) of
survivors, respectively. Sixty-nine percent (301/434) of pa-
tients reported whether or not they had a chronic GVHD di-
agnosis since transplant. Of this number, 20 % (61/301) had
involvement of the stomach and/or intestines.
Gastrointestinal symptoms and quality of life post transplant
Gastrointestinal symptoms, including nausea, vomiting, con-
stipation, diarrhoea, taste alterations, smell alterations, poor
appetite, mouth ulcers and dry mouth, are listed in Table 2.
Of note, 48 % (26/58) of survivors less than 2-year post-trans-
plant report an altered taste and a dry mouth, 36 % (21/58)
reported mouth ulcers and 33% (19/58) reported altered smell
(Table 2). The prevalence of mouth ulcers and a dry mouth
was similar across all survivors regardless of time since trans-
plant whereas alterations in smell and taste were less common
in longer term survivors. A poor appetite was particularly
common in early transplant survivors (28 %, 16/58) but was
reportedly less of an issue in the longer term survivors (18 %,
40/224).
The proportion of survivors with diarrhoea was consistent
(~19 %) across all time categories (less than 2 years, 2 to
5 years or greater than 5-year post-transplant). There was a
reduction in those survivors reporting nausea and vomiting
from less than 2 years to greater than 5 years.
FACT-BMTscores, as a measure of quality of life, declined
as the number of gastrointestinal symptoms reported by sur-
vivors escalated (Fig. 1). The association between number of
gastrointestinal symptoms and quality of life (FACT-BMT
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scores) using simple regression analysis showed a significant
negative correlation (regression coefficient −5.8; 95 % CI
−6.7, − 4.9: P < 0.001). This negative correlation maintained
significance even after adjusting for the effects of age, gender
and years from transplant in a multivariable regression model
(regression coefficient −5.8; 95 % CI −6.9, −4.9: P < 0.001).
Eating habits, dietary choices and nutritional supplements
post-transplant
Almost 65 % of survivors (37/57) in the early post-transplant
group reported that their eating habits had returned to normal.
In those survivors who were two or more years post-trans-
plant, 77 % (292/379) reported that their eating habits had
returned to normal. Survivors who were two or more years
post-transplant were significantly more likely to have returned
to their normal eating habits (odds ratio (OR) 1.81 95 % CI
0.94 to 3.39; P = 0.05). Eating habits were significantly more
likely to have returned to pre-transplant levels in survivors
who were two or more years post-BMT compared to those
survivors less than 2-year post-BMT (OR 1.94 95 % CI 1.06
to 3.56; P= 0.01). Quality of life was significantly higher in
those participants who experienced a return to enjoyment of
meals with a P value < 0.0001. (Fig. 2).
One hundred and thirty-one survivors reported changing
their diet since having a BMT (29.6 %). The four most com-
mon changes included avoiding particular food and food
Table 1 Patient demographics and clinical characteristics
Characteristics No. of patients (%)
Demographics
Age group
19–29 30 (6.8 %)
30–39 49 (11.1 %)
40–49 83 (18.7 %)
50–59 130 (29.5 %)
60–69 127 (28.7 %)
>70 22 (5.0 %)
Median; range 54; 19–79
Gender
Male 250 (56.7 %)
Female 191 (43.3 %)
Culture, ethnicity
Australian/European 323 (73.2 %)
Indigenous Australia 2 (0.5 %)
Asian 30 (6.8 %)
Middle Eastern 7 (1.6 %)
Other 10 (2.3 %)
Unknown 69 (15.6 %)
Years since transplant
<2 years 58 (13.2 %)
2 to 5 years 159 (36.0 %)
≥5 years 224 (50.8 %)
Median; range 5; 1–14
Underlying diagnosis and remission status
Underlying diagnosis
AML/ALL 226 (51.2 %)
CML/MDS/myelofibrosis 60 (13.6 %)
Other 137 (31.1 %)
Unknown 18 (4.1 %)
Remission status
CR1/CR2 271 (61.4 %)
>CR2 22 (5.0 %)
Other 46 (10.4 %)
Chronic phase 18 (4.1 %)
Accelerated phase and blast crisis 3 (0.7 %)
Refractory 22 (5.0 %)
Partial remission 23 (5.2 %)
Unknown 36 (8.2 %)
Transplant characteristics
Number of transplants by year
2000–2006 136 (30.8 %)
2006–2012 305 (69.2 %)
Donor type
Sibling 250 (56.7 %)
Haploidentical 10 (2.3 %)
Matched unrelated 158 (35.8 %)
Mismatched unrelated 21 (4.8 %)
Unknown 2 (0.4 %)
Table 1 (continued)
Characteristics No. of patients (%)
Stem cell source
Bone marrow 48 (10.9 %)
PBSCT 381 (86.4 %)
Cord 12 (2.7 %)
Conditioning
Myeloablative 214 (48.5 %)
With TBI (n, % of myeloablative regimens) 101 (47.2 %)
Non-myeloablative 225 (51.0 %)
With TBI (n, % of myeloablative regimens) 26 (11.5 %)
Not known 2 (0.5 %)
Cardiovascular comorbidities and chronic Graft-versus-Host Disease
(cGvHD)
Hypertension 118/409 (28.8 %)
Hypercholesterolaemia 96/402 (23.9 %)
Diabetes mellitus 57/398 (14.3 %)
Chronic GvHD 301/434 (69.3 %)
n = 441
AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia,
CML chronic myeloid leukaemia, MDS myelodysplastic syndrome,
CR1 clinical remission 1, CR2 clinical remission 2, PBSCT peripheral
blood stem cell transplant, TBI total body irradiation
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groups (37 %, n = 48/131), focus on healthy eating (35 %, 46/
131), reducing meat consumption (16 %, 21/131) and choos-
ing organic foods (11 %, 14/131).
Twelve percent (52/441) of survivors were taking oral nu-
tritional supplements at the time of the survey. The use of
nutritional supplementation in the early post-transplant period
(less than 2 years) was significantly higher than those in the
late (greater than 2 years) post-transplant group (OR 2.58
95 % CI 1.17 to 5.40; P = 0.006).
In contrast to the use of nutritional supplements, the pro-
portion of survivors consuming ‘natural’ therapies such as
nutrition and dietary therapies, herbal supplements, vitamin
therapies and manipulative therapies increased over time
post-transplant (Table 3).
Body weight and body mass index (BMI)
Self-reported height and weight for BMI revealed that 3 %
(13/405) of patients were underweight, 49 % (197/405) were
of normal weight, 32 % (128/405) were overweight and 16 %
(67/405) were obese. Figure 3 shows the distribution of
weight ranges by years post-transplant. The proportion of
survivors who were overweight was the highest in the early
post-transplant group. The proportion of survivors who were
obese was the greatest in survivors more than 5-year post-
transplant.
Those survivors who were overweight or obese were sig-
nificantly more likely to be diabetic compared to those who
were underweight or with normal BMI (OR 2.25, 95 % CI
1.18 to 4.41; P = 0.008).
Perceptions of body weight and body image
In terms of survivor perception of their own BMI, the highest
agreement between actual and perceived BMI was seen with
those survivors who thought they were overweight (84 %,
122/146) and the lowest agreement was with those patients
who felt they were underweight (20 %, 10/51). When com-
paring body perception between male and females, females
had a body perception that was more likely to align to the
Fig. 1 FACT-BMT scores compared with number of gastrointestinal
symptoms Fig. 2 FACT-BMT scores compared with survivors enjoyment of eating
Table 2 Prevalence of gastronitestinal symptoms after transplantation
Symptom <2 years (% < 2 year
post-transplant with
symptom) n = 58
2–5 years (% 2–5 year
post-transplant) with
symptom n = 159
>5 (% > 5 years
post-transplant
with symptom) n = 224
Total
Nausea 8 (13.8 %) 21 (13.2 %) 21(9.4 %) 50
Vomiting 3 (5.2 %) 10 (6.3 %) 6 (2.7 %) 19
Constipation 10 (17.2 %) 15 (9.4 %) 41 (18.3 %) 66
Diarrhoea 11 (19.0 %) 29 (18.2 %) 43 (19.2 %) 83
Taste alterations 26 (44.8 %) 53 (33.3 %) 55 (24.5 %) 134
Smell alternations 19 (32.8 %) 34 (21.4 %) 35 (15.6 %) 88
Poor appetite 16 (27.6 %) 29 (18.2 %) 40 (17.9 %) 85
Mouth ulcers 21 (36.2 %) 46 (28.9 %) 77 (34.4 %) 145
Dry mouth 26 (44.8 %) 65 (40.9 %) 93 (41.1 %) 184
Median number symptoms (range) 2 (0–9) 1 (0–9) 1 (0–7) 1 (0–9)
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BMI reference ranges than male survivors (77 % 135/176
females; 59 % 133/228 males; OR 2.35 95 % CI 1.49 to
3.74, P = 0.0001).
Overall, 56 % (244/435) of patients were satisfied with
their current body weight. Males were more likely to be sat-
isfied with their body weight compared to females (OR 1.7
95% CI 1.11 to 2.50; P = 0.009). The median BMI for all
patients reporting body weight satisfaction was significantly
lower (BMI 23.5) than those reporting dissatisfaction (BMI
27.5) (P = <0.0001). Those that had a normal BMI had sig-
nificantly higher rates of bodyweight satisfaction compared to
underweight, overweight and obese survivors (OR 3.76 95 %
CI 2.43 to 5.83; P = <0.0001).
Body mass index was compared to the FACT-BMT total
scores. This revealed no significant difference in the total
FACT-BMT score across each BMI category (P = 0.11), or
when stratified by years post-transplant (<2 years P = 0.12, 2–
5 years P = 0.95, >5 years P = 0.28). Survivors who were
underweight, however, had consistently lower FACT-BMT
scores compared to those who were normal, overweight or
obese. This was seen across all time periods post-transplant.
Use of dietetic services post-transplantation
Overall, 23 % (99/416) of survivors had been referred to a
dietitian after transplantation. Referral to a dietitian was more
likely in the early (less than 2 years) survivor group (30.4 %
17/56), though this was not significant (P = 0.21). Those sur-
vivors with a diagnosis of diabetes (OR 3.28 95 % CI 1.73 to
6.17; P = <0.0001), high blood pressure (OR 1.97, 95 % CI
1.16 to 3.17; P = 0.007), gut chronic GVHD (OR 1.92, 95 %
CI 1.00 to 3.80; P = 0.03) or high cholesterol (OR 1.90, CI
95% 1.09–3.29; P = 0.01) were significantly more likely to be
referred to a dietitian.
Enteral feeding
One hundred and twenty-eight patients (30 %, 128/432) re-
ported that they were enterally fed during their BMT. One
hundred and nine of these survivors (87 %) reported that en-
teral feeding was beneficial to their care and 75 % (92/122)
said they would recommend it to others. There was no signif-
icant difference in reported rates of cGVHD (P = 0.57) or in
gastrointestinal GVHD (P = 0.63) in those who had or had not
received enteral feeding.
Discussion
This study provides the first comprehensive experience of
long-term survivors of allogeneic BMT. It demonstrates
clearly that gastrointestinal symptoms such as altered taste
and smell, dry mouth, mouth ulcers, anorexia and diar-
rhoea are not limited to the early post-BMT period but
remain problematic for long-term survivors, many of
whom are still experiencing the unpleasant complications
of their treatment years after transplant. These findings are
consistent with those of Lenssen et al. [25] who document-
ed nutritional issues affecting survivors during the first
12 months after transplant. As this study yielded a high
response rate, 76 % of total eligible survivors, it is likely
that the results presented here provide an accurate picture
of nutritional issues facing survivors of allogeneic BMT.
However, the results may not be transferrable to other eth-
nic groups as 73 % of survivors were from an Australian/
European ethnic background. Additionally, the fact that the
Table 3 Use of natural therapies
Natural therapies <2-year post-transplant 2–5-year post-transplant >5-years post-transplant Total
Nutrition/dietary approaches 5/54 (9.3 %) 17/157 (10.8 %) 37/222 (16.7 %) 59/433 (13.6 %)
Herbal supplements 4/56 (7.1 %) 17/153 (11.1 %) 37/218 (17.0 %) 58/427 (13.6 %)
Vitamin therapies 14/55 (25.5 %) 41/155 (26.4 %) 73/214 (34.1 %) 128/424 (30.2 %)
Mind-body therapies 11/55 (20.0 %) 27/156 (17.3 %) 36/216 (16.7 %) 74/427 (17.3 %)
Manipulative therapies 12/56(21.4 %) 39/156 (25 %) 61/217 (28.1 %) 112/429 (26.1 %)
Traditional whole medicine systems 2/54 (3.7 %) 4/156 (2.6 %) 9/215 (4.2 %) 15/425 (3.5 %)
Energy medicine 1/55 (1.8 %) 5/156 (3.2 %) 7/216 (3.2 %) 13/427 (3.0 %)
Homoeopathy 2/55 (3.6 %) 3/155 (1.9 %) 8/214 (3.7 %) 13/424 (3.1 %)
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study relied upon self-reporting and did not capture data on
non-responders also limits the findings. It should also be
noted that as only two of the respondents had a recurrence
of the malignancy for which they were transplanted, the
findings only apply to survivors who remain disease free
following BMT. Also, as respondents were not asked about
nutritional status, gastrointestinal symptoms, body image
and exercise pre-BMT, correlation between pre-and post-
BMT beliefs and behaviours were not able to be made .
More than 20 % of survivors who were five or more
years post-BMT reported taste alterations, mouth ulcers
and dry mouth. These symptoms had a significant adverse
impact upon quality of life with survivors reporting lower
quality of life as the number of gastrointestinal symptoms
increased. Reasons for food avoidance particularly mouth
sensitivity caused by spicy/hard/rough or hot foods caused
many BMT survivors to alter their diet following trans-
plant. There was also a notable association between return
of appetite and enjoyment of eating to pre-transplant levels
and FACT-BMT scores indicating that nutrition impacts
quality of life in BMT survivors.
In the study population, the rates of overweight and obesity
were found to be lower than in the general Australian popula-
tion (48.2 % verse 63 %) [26]. Although BMI scores did not
correlate to QOL outcomes, the fact that almost half of the
long-term survivors of BMT are overweight and obese re-
mains a significant concern as this adds to the comorbidities
experienced by survivors including metabolic syndrome, ac-
celerated vascular disease, diabetes mellitus and musculoskel-
etal disorders [2]. Further research is needed to establish
whether assisting survivors to maintain or achieve a normal
body weight, to eat healthily and exercise regularly militates
against the burden of disease experienced by the long-term
survivors of allogeneic BMT.
While this study was not designed to assess the impact of
nutritional support on BMT outcomes, including GVHD and
infection (11, 27, 28) this study provides useful data on patient
perspectives on enteral feeding. Interestingly, a large majority
of patients surveyed thought enteral feeding was beneficial to
their care, and they would recommend it to other transplant
patients.
It is generally accepted that a comprehensive nutritional
assessment should be performed prior to BMT and that
nutrition monitoring during transplant plays an important
role in preventing nutrition decline [27]. This study pro-
vides further support for the roles of nutrition therapy
(within a comprehensive multidisciplinary survivorship
clinic setting) post-BMT, particularly for survivors with
diabetes, obesity, hypercholesterolemia, hypertension and
gastrointestinal symptoms. Future studies are required to
investigate the effectiveness of nutrition therapy in manag-
ing nutritional issues facing survivors of BMT and how
this impacts quality of life.
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15.5. Synopsis 
This manuscript provides the only published account of nutrition, body weight and body image and its 
association with QoL in allogeneic BMT survivors.  The results indicate GI symptoms post-BMT are 
common, with some (dry mouth, mouth ulcers and diarrhoea) continuing more than five years post-
BMT.  Importantly, the results also highlight the negative impact that GI symptoms and poor 
nutritional status have on the QoL of long-term survivors.   
While rates of overweight and obesity in our BMT survivors were less than that of the Australian 
general population (overweight 32% vs 35.3%, obesity 16% vs 27.5%) these rates are still deeply 
problematic, both for BMT survivors as they are significantly associated with metabolic syndrome and 
DM – and for society more generally given the enormous health and financial impact of DM (with 
direct costs and government subsidies directed to the impact of DM totalling more than A$14.6 billion 
in 2010(1)).  
Interestingly, while GI symptoms negatively impacted upon BMT survivors’ QoL, BMI did not.  This 
provides a cogent reminder that simply recording a patients’ weight and height does not reveal what 
it means to them and that discriminatory judgement based on assessment of BMI or morphology are 
unjustifiable and unhelpful.  In this regard it was also noteworthy that only 23% of survivors has been 
referred to a dietitian post-transplant which, given the prevalence and duration of GI symptoms, high 
rates of overweight and obesity, predisposition to DM and associated cardiovascular complications, 
and the negative impact of symptoms on QoL, would seem inconsistent with high quality long-term 
care.  These results, and those of other studies of the endocrine and cardiovascular late-effects of BMT 
(detailed in Chapter 2), suggest that there is an urgent need to improve nutritional and dietary services 
post-BMT and to include dietary assessment in the routine care of BMT recipients.   
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Chapter 16: Discussion and Conclusion 
16.1. Chapter overview 
This chapter summarises how the research reported in this thesis meets the aims of the study.  As 
each of the papers reported here are already discussed in Chapters 5-15, this chapter integrates the 
main findings of this thesis and their implications for improving the experience of survival following 
allogeneic BMT in NSW, outlines the strengths and limitations of this study, and makes 
recommendations for future research, clinical practice, and education. 
16.2. Study background 
While impressive progress has been made in clinical BMT over the past fifty years, with more and 
more patients offered BMT for conditions previously thought untreatable or incurable, and more and 
more patients gaining years of the disease-free survival(1-3), the long term and late effects of BMT 
remain a major cause of morbidity and mortality. And despite publication of international and local 
guidelines for BMT LTFU (The ACI, BMT Network published clinical guidelines for BMT LTFU in 2016(4)), 
and efforts by international, national and local agencies to emphasis life-long follow-up of BMT 
survivors(4-6), the establishment of  sustainable LTFU services and effective MOCs for post-BMT care 
have proven enormously difficult.  A number of factors have mitigated against the development and 
integration of BMT LTFU services including the increasing numbers of BMTs being performed, the 
increasing numbers of survivors requiring LTFU, the capacity (human, infrastructure, cost) and 
preference of BMT centres/clinicians, the complexity and fragmentation of the health care system, 
the complexity of complications following BMT, and the lack of empirical data regarding the 
experience of BMT survivorship.   
This research sought to provide a comprehensive description of the experience of survival following 
allogeneic BMT in NSW, Australia.  In order to obtain as much meaningful data as possible from the 
largest feasible sample size, the study consisted of a large cross-sectional analysis using seven survey 
instruments (six validated and one purposed designed for the study) which asked a total of 518 
questions.  It was a state-wide multicentre study of a contemporary cohort of adult BMT survivors 
with data collection occurring at one point in time.     
Specifically, the study aimed: 
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1. to describe the incidence and range of late complications of BMT and their association with
the health and functional status of survivors in NSW;
2. to address limitations in BMT survivorship literature – particularly with regard to the financial,
occupational and psychosocial impact of BMT;
3. to identify gaps in service provision provided to this vulnerable and high-risk patient group;
4. to provide better information to patients contemplating BMT, and to their families and
guardians, regarding the possible long-term sequelae of BMT; and
5. to support clinical and health policy decision-making around BMT through the provision of
more comprehensive data regarding the late sequelae of BMT in an Australian setting.
16.3. Main findings 
The findings of this research make clear the large burden of morbidity following BMT and the 
deficiencies in support that long-term survivors of allogeneic BMT in NSW currently receive.  The 
results of this study provide a comprehensive account of the long-term physical and psychosocial 
impact of BMT in Australia, contribute significant insights into the experience of post-BMT 
survivorship, and address major deficiencies in the existing literature surrounding LTFU post-BMT.  The 
results provide the case for building and strengthening LTFU services and for changing the way that 
we design and deliver health services for those undergoing BMT and for those that survive it.   
This research revealed that the most common problems reported by long-term survivors of BMT were 
cGVHD affecting the skin, eye, vagina and/or mouth (69.3%), sexual dysfunction (66% of females and 
51% of males), VPD (41.5%), tooth decay (36.8%), iron overload (32.5%), alterations in taste (30.9%), 
osteoporosis/osteopenia (29.1%), cataracts (28.9%), HTN (29%), high cholesterol (24.0%), secondary 
malignancy (24.5%), depression (23.3%), anxiety (20.6%), altered smell (20.7%) poor appetite (20.2%), 
diarrhoea (19.4%), and DM (14.3%). 
The study also revealed that despite their increased risks of chronic diseases and infection, survivors 
continue to engage in high risk health behaviours, including smoking, drinking (>14 standard 
drinks/week), and not being ‘sun smart’, in 7.5%, 7.7% and 22.9% of cases respectively. Thirty two 
percent reported being overweight, 16% were obese and only 45.1% reporting doing regular exercise 
(at least 3 time/week). Many recipients also did not receive appropriate post-BMT vaccinations with 
7.2% reporting being completely unvaccinated, 57.9% receiving only some of the recommended 
vaccines and only 31.8% receiving the full vaccination schedule.  Furthermore, despite the risks of 
secondary malignancies, adherence with cancer screening following BMT was low with 32.4% of 
survivors following screening guidelines for bowel cancer, 63.4% of eligible female survivors having a 
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PAP smear and 53.5% a mammogram, and only 52.3% attending for regular skin cancer ‘checks’.  
Importantly, the most commonly cited reason for not complying with cancer screening was lack of 
advice to do so by the treating team. 
This work also revealed that compliance with recommended assessment for non-malignant or chronic 
conditions of BMT was also suboptimal.  While approximately three-quarters of the survey 
respondents had had BMD scans and lung function tests (LFT) post-BMT, cardiac function assessment 
(gated heart pool scan (GHPS) or echocardiography (ECG)) was less commonly reported (49.3%), and 
thyroid assessment (palpation, ultrasound or scan) even less so (23.8%). Almost 10% of patients 
reported having no formal screening assessments post-BMT.  Together, these data provide a rich 
picture of the incidence and range of late-stage complications in BMT survivors in NSW.   
In contrast to the vast majority of extant literature on BMT survivorship, this study provides important 
data about the changes in social, occupational and financial status that many BMT survivors 
experience.   Full time employment post-BMT decreased from 64% to 32.5%, and those in the lowest 
income strata increased from 21% to 36%. Ill-health as the cause for not working increased almost 
four-fold pre to post-transplant.  Over 15% of survivors also reported a change in relationship status 
post-transplant. CAM therapy was used by 54.1% of respondents and survivors often required care 
from many specialist medical practitioners (median three), with the most common being 
dermatologists (60.3%), ophthalmologists (43.6%) and respiratory physicians (28.2%).  
When survivors were asked about their preference for LTFU three quarters reported a preference for 
LTFU with their transplant physician and in a location that either included, or was linked with, the 
transplant centre (such as a satellite clinic or telemedicine facility).  
16.4. Strengths and limitations  
The research that provided the data for the papers reported in this thesis had a number of major 
strengths.  The study presented was a comprehensive, multi-centre, state-wide survey of a 
contemporary cohort of long-term BMT survivors, with a large sample size (n=441) and high response 
rate (76%).  It also used a range of validated instruments to assess the experience of survival and 
enable comparisons with other cohorts of BMT survivors.  This makes it highly likely that these results 
provide an accurate account not only of the experience of survival following allogeneic BMT in NSW, 
but also of the experience of BMT survivors across Australia.  This is turn, lends support for the use of 
the results to inform the education and counselling of BMT recipients and their families, health care 
professionals, and policy makers in Australia. 
211 
 
Nevertheless, there are a number of limitations to this study that may limit the applicability of these 
results to BMT survivors in other countries and other settings.  Some of the limitations include 
participation bias, inclusion of self-reported data, and failure to capture data on non-responders or 
those who had died (thereby missing data on BMT recipients who may have experienced ‘earlier’ or 
more severe complications of BMT).  We also did not correlate self-reported medical and psychosocial 
issues with medical records, employment records, or financial statements, or assess pre-BMT health 
risk behaviour or cancer and health screening adherence.  Furthermore, we did not explicitly 
consistently ask why survivors had not completed all screening and preventative recommendations, 
adhered with re-vaccination schedules, complied with health promotion messages, or followed 
recommendations for screening for chronic conditions, and psychosocial issues.  This limits any 
conclusions that can be made about low rates of screening/health promotion adherence, and about 
the differential impact of different influences on adherence including the cost of care, knowledge 
about disease precautions and health promotion, health status of survivors and adequacy of existing 
services and communication from health care professionals.  Importantly, while we explored 
survivors’ preference for post-BMT care we did not specifically explore survivors’ views regarding 
nurse-led clinics for BMT survivors. This is a significant omission as evidence has shown that nurse-led 
clinics may provide important resources for BMT survivors - improving health outcomes, reducing 
waiting times for patients and decreasing rates of hospital admission(7, 8).  Australia’s geographical 
size, predominantly urban population, climate, and health care system (which includes universal 
publicly funded and private health care) make the findings most relevant to Australian survivors and 
inevitably may limit conclusions that can be drawn about LFTU care in other settings.   
Additionally, since only those individuals who could read and write English were eligible to participate, 
we may have failed to capture data from individuals from diverse ethnic backgrounds.  This is an 
important consideration because Australia is a highly diverse nation (49% of Australian’s population 
were born overseas or have a parent who was born overseas, and more than 300 languages are 
reported to be spoken in Australia homes(9)), because haploidentical transplantation (which is 
increasingly being undertaken(10)) is often done where patients lack a suitable matched  related or 
unrelated donor – many of whom often come from minority populations, and because patients from 
culturally and linguistically diverse (CALD) populations often have worse engagement with health 
services and outcomes than those of their white/Caucasian counterparts, and may be at a 
disadvantage socioeconomically prior to BMT(11).  
Finally, because this was a cross-sectional study, this research has the methodological limitations of 
all such studies.  Firstly, inferences about casual or temporal relationships are restricted; it is not 
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possible to definitively comment on which complications arose from the BMT procedure, from 
complications of cGVHD, or from complications resulting from cGVHD treatment. (It is possible 
however, to use these data to develop hypotheses to test causal relationships).  And secondly, as this 
research is historically defined, it reflects the experience of survival following BMT at a particular point 
in time.  Thus, while these results provide a rigorous account of the issues facing BMT survivors 
currently, as BMT practices change, prevention and treatments of infection and cGVHD improve, and 
effective LTFU MOC are implemented and assessed, the long-term and late effects of BMT and the 
experience of survival following BMT may profoundly change.   
16.5. Discussion  
The burden of post-BMT morbidity and the experience of BMT survival described in this study is 
broadly consistent with the international literature. Cardiac and circulatory disease, endocrine 
dysfunction, genital disease and sexual dysfunction, lung and respiratory disease, renal impairment, 
liver dysfunction, skeletal disorders, oral and dental disease, immunodeficiency and infection, 
secondary cancers, ocular disease, neurocognitive impairments, anxiety and depression, and changes 
to QoL, social and functional status all commonly occur post BMT(12-34).  More than half of the 
respondents in this study reported one or more chronic medical co-morbidities post-BMT, with cGVHD 
in particular being associated with  many long-term complications and profoundly impacting upon the 
QoL of BMT survivors(35, 36). All of this is congruent with other studies of BMT survivors from across 
the globe(37, 38). 
What is significant about this study is that the data reported here provides the first comprehensive 
picture of allogeneic BMT survivorship in a contemporary Australian cohort.  Prior to this research 
being published long-term health related data on Australian adult allogenic BMT survivors were 
scarce.   The CAST (Cancer After Stem Cell Transplantation) study had been undertaken but not yet 
published (manuscripts were published in 2015 and 2016 and included population data on cancer 
occurrence post BMT for both adult and paediatric autologous and allogeneic survivors(39-41)).  A 
single centre retrospective study of ninety-nine allogenic BMT survivors had also been published (in 
2014)(42).  While this reported a high incidence of cGVHD and high burden of chronic illness post BMT, 
it did not analyse the outcomes by socio-demographic or transplant factors.  A small survey of 
Australian haematologists (n=20, response rate 18%) and BMT recipients (n=34, response rate 28%) 
on post-BMT vaccination practices(43) demonstrated wide variation in vaccination practices across 
Australia but lacked rigour or power.  In sum, prior to this study there was much that remained 
unknown about Australian BMT survivors.   
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The data reported in this thesis provides a rich and comprehensive account of the incidence and range 
of late complications experienced by Australian BMT survivors, and the impact these have on 
survivors’ health and functional status. Consequently, clinicians can now provide BMT recipients and 
BMT survivors, and those who care for them, with a more informed description of the range of possible 
long term and late complications that Australian survivors may experience.  In addition, following this 
study, we now have empirical data on the potential financial, occupational and psychosocial impact 
of BMT which clearly shows that financial insecurity and occupational vulnerability is a very real issue 
for long-term BMT survivors.  This is important information because it can be used by not only 
clinicians, but also by a range of government agencies including the Department of Health, 
Department of Jobs and Small Business, Department of Human Services (Centrelink), MSAC, PBAC, as 
well as workers unions and not-for-profit and charitable patient and carer support services such as the 
Cancer Council, Arrow Foundation and the Leukaemia Foundation, to prepare potential BMT 
recipients and BMT survivors and their families for financial, occupational and social life changes post 
BMT.   
Importantly, this study also suggests that currently available ‘standard’ psychometric measures of 
post-BMT QoL, such as FACT-BMT, may not necessarily provide a meaningful or sufficient account of 
the QoL, the health, personal and social challenges that survivors of BMT may experience.  While post-
BMT QoL scores reported by BMT survivors are often ‘good’ to ‘excellent’, and return to pre-BMT 
levels with time(44, 45),  the qualitative data provided by BMT survivors in this study suggest that the 
physical burden of the ‘failing body’, the cognitive and mood changes, the diminished social 
connectedness, the  loss of functionality and the burden of being a ‘patient for life’  profoundly ‘shrink’ 
the life world of BMT survivors and impact upon their QoL.   None of this, of course, is currently 
captured by the FACT-BMT or other validated QoL questionnaires.  And lastly, this study makes clear 
that (at least at the time of data collection) LTFU of BMT survivors was not routinely implemented 
across NSW, with a high burden of unmet need and profound deficiencies in the care provided to BMT 
survivors, and in the screening they received.  
Indeed, this research reveals that despite the adult cancer survivorship movement being more than 
twenty years old, and the BMT LTFU movement being more than 12 years old(6, 46), the care provided 
to long-term survivors of allogeneic BMT in NSW is clearly suboptimal.  LTFU is not consistent with 
either international LTFU recommendations or NSW specific LTFU guidelines(4, 5), and varies 
enormously between patients and centres.  This is particularly evident in the assessment and 
management of sexual dysfunction post-BMT, in the utilisation of fertility sparing procedures offered 
to BMT recipients of child bearing age pre-BMT, and in the failure to ensure adherence with post-BMT 
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testing, cancer screening and oral and dental health checks.  The fact that survivors continue to engage 
in high risk health behaviour, do not complete revaccination schedules post-BMT, suffer high rates of 
VPD, do not undergo all recommended screening tests and assessments, and do not receive expert or 
nutritional advice post-BMT, and frequently use CAM therapies suggests that LTFU care is lacking and 
that much more can be done to improve the experience of BMT survivorship. 
In this regard it is noteworthy that deficiencies in LTFU in this study were often attributed to a lack of 
knowledge and awareness on behalf of health care professionals and a lack of education and 
counselling provided to BMT recipients, survivors and their families. While these explanations are 
undoubtably true, and are consistent with the international literature, they are not the only barriers 
or challenges to LTFU care.  Health care providers and patients themselves, and the health care system 
itself, all contribute to the barriers, challenges and frustrations faced by those wanting to improve 
LTFU care(47-50).  
Cancer/BMT, haematology and other health care providers may contribute to suboptimal LTFU 
because they lack resources for LTFU care, lack interest in LTFU, lack time for LTFU or for developing 
LTFU programs, lack awareness of the clinical and psychosocial needs of survivors, lack awareness of 
screening and preventive care guidelines, lack evidence-based tools to facilitate care, are provided 
insufficient reimbursement for providing care for survivors, and are unwilling to ‘let go’ of their 
patients.  Poor communication between specialist health care providers, the patient and their carers, 
and GPs may also compromise LTFU and lead to a lack of clarity regarding responsibility for LTFU(48-
50).  In this regards, it is noteworthy that GPs specifically report inadequate training in survivorship 
and LTFU, and that Cancer/BMT specialists report uncertainty regarding general preventive care and 
the responsibility to oversee it(51, 52). 
Patients themselves may also lack awareness of the long-term and late effects of BMT and the 
magnitude of risk of complications, lack awareness of screening and preventive care guidelines, lack 
trust in health care professionals other than their cancer/BMT specialist, have competing priorities 
(eg. employment/schooling status) that erode their willingness to adhere with recommendations for 
LTFU, and socio-demographic barriers (eg. socioeconomic status, residential location distance from 
BMT centre) and experience economic hardship, particularly related to insurance coverage and out-
of-pocket costs, that reduce the possibility of optimal follow-up(51, 53). 
Healthcare system barriers to the provision of optimal LTFU include inadequate funding of LTFU 
services, insufficient financial and professional incentives for health professionals to participate in 
LTFU care, a lack of resources and specialists with an interest in LTFU, insufficient ‘political’ will to 
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overcome ‘cultural’, professional and structural obstacles to the introduction of new MOCs for LTFU, 
and insufficient prospective randomized trials to guide the care of survivors or identify the optimal 
organisation of health care services post-BMT(47, 48, 54). 
16.6. Implications 
Given the increasing numbers of BMTs being performed and the increasing numbers of people 
surviving long-term post-BMT (Chapter 1), the high incidence of complex late morbidity leading or 
contributing to early death (Chapter 2), and the burden of LTFU testing, care and education required 
(Chapter 3), and the existing deficiencies in care of long-term survivors of BMT, there is an urgent need 
to implement new and effective MOC for BMT LTFU.  
Models of care for BMT LTFU  
As discussed in Chapter 3, there are many ways in which LTFU care can be delivered.  Commonly 
identified service models include: 
• LTFU care provided during routine follow-up in the BMT Clinic: 
BMT specialist/BMT advanced practice nurse continues to see the survivor in the BMT clinic. 
 
• LTFU care undertaken as a ‘stand-alone’ assessment/clinic visit either within the BMT clinic or 
in a dedicated BMT LTFU clinic:   
The survivor is transitioned to a dedicated LTFU clinic/team. This is distinct from the early 
post-BMT clinic, is often held in an alternate space or on a different day, (but may be run 
alongside the early post-BMT clinic), and may be staffed by a multidisiplinary team.  
 
• Collaborative LTFU care shared between the BMT centre and other providers (eg. sub-
specialists, local haematologists, GPs): 
The survivor is seen infrequently in the BMT centre (often for purposes of LTFU review and 
data collection) with the majority of follow-up tests and assessments and health care 
delivered by the survivors local haematologist/GP and community health care providers. 
 
• LTFU care with local haematologist/GP: 
The survivor is transitioned or discharged from the BMT service to the care of their local 
haematologist or GP with a care plan and recommendations for follow up.  
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Although it is neither possible nor necessary to dictate the type of LTFU MOC/clinic that individual 
BMT centres adopt (due to variability in infrastructure, capacity, patient numbers and ‘case-mix’), 
there are some elements of LTFU that must be included within any MOC.  These include screening for, 
and treatment of, late effects of BMT; surveillance for disease recurrence and second cancers; 
education to prevent late effects of BMT; psychosocial support; health promotion; data collection to 
enable reporting to national and international transplant registries and to facilitate continuous quality 
improvement, audit and research; and co-ordination of care for survivors both within BMT centres 
and as survivors transition between services.   
In this regard it is noteworthy that following publication of data from this study, and increasing 
recognition of the need for comprehensive BMT LTFU care, that there have been substantial 
improvements in the delivery of post-BMT services in NSW.  An informal survey of BMT LTFU service 
provision in mid-2018 found that all allogeneic BMT units in NSW now provide some form of BMT 
LTFU services and almost all have employed APNs to provide and co-ordinate BMT LTFU (Table 16.1).  
While this has undoubtably improved the long-term care provided to survivors of BMT in NSW, all 
services report facing the same barriers and challenges described above.  Furthermore, while 
establishment of LTFU services represent great progress, much more needs to be done to improve 
long-term outcomes following BMT.   
16.7. Recommendations for research and practice  
This thesis has highlighted a number of areas where BMT LTFU can be improved and identified areas 
for future research. 
Improve data collection 
Prior to this study there were no comprehensive LTFU data on Australian BMT survivors, with the 
ABMTRR collecting limited data date last seen, cGVHD, second malignancies and death.  While this 
data provides some information on survival, it is not overly helpful when trying to identify, plan for, 
benchmark or improve long-term BMT survivor medical and psychosocial outcomes.  In 2018, 
recognition of the limitations of the existing dataset led to a pilot project conducted by the ABMTRR 
and the ACI, in which comprehensive, state-wide, real-time data was collected on long-term survivors 
(ASTRO BMT LTFU Module).  Despite some problems with implementation, this provided important 
data on local adherence with clinical guidelines for BMT LTFU and reduced the number of patients 
who were lost to follow-up in the BMT centres in which it was trialled (personal communication).   
Since this time however, no further progress has been made in implementing this BMT LTFU module 
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state- or nation-wide, and APNs that co-ordinate the LTFU services at each centre have returned to 
collecting data on their own ‘databases’.  
Implementation of a standardised platform for collecting data on LTFU should be a priority as 
collection of data will enable audit of contemporaneous long-term outcomes, and facilitate 
retrospective and prospective post-BMT research, and enable health economists to calculate the cost 
of long-term care and the potential benefits of LTFU.   
Conduct more research  
As BMT practices change these may impact upon long-term sequalae of BMT and the experience of 
BMT survivors.  These impacts however, will only be visible if data on LTFU is routinely collected as 
part of care.  
But, as this study makes clear, more research is also needed to inform the understanding of BMT 
survivorship.  This should include research on CALD BMT survivors and research to ascertain exactly 
why the care of BMT LTFU survivors is suboptimal.  
Randomised clinical trials of interventions to prevent and treat long-term and late effects should also 
be a priority as many of the recommendations for LTFU care are currently based on expert consensus 
opinion.  
Importantly, research is also needed on the MOC best able to improve long-term and late effects of 
BMT.  For while the IOM and other BMT societies recommend that BMT LTFU care include a MDT 
approach that utilises the expertise of BMT clinicians, referring physicians, GPs and other relevant 
health care providers and advise provision of treatment summaries and survivorship care plans to 
survivors and their carers(55-57), there is limited data to support these recommendations or to assess 
their impact.  This is an important area for ongoing study as there is little doubt that in the coming 
years clinicians and health services will increasingly use emerging technologies to deliver BMT LTFU, 
including telemedicine, patient owned health records, online support and education 
resources/portals. 
Perform an economic evaluation 
Allogeneic BMT is enormously expensive(58).  Improving LTFU and reducing the long-term and late 
effects of BMT may therefore produce economic benefit to justify their ongoing support.  Once robust, 
validated, comprehensive data has been collected on survivors, economic evaluation of the true cost 
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of long-term post-BMT care can be performed (including all health outcomes and psychosocial impacts 
such as absenteeism, lost work days, hospital admissions).  This can evaluate the cost (including the 
disability and years of life lost) of providing inadequate and fragmented care to BMT survivors, and 
the cost-saving that follows practice improvement(59).  
This in turn may support applications for funding for LTFU care, and to applications to the MSAC and 
the PBAC to fund care and treatments for long-term BMT survivors.  
Increase the capacity for nurse-led BMT LTFU services  
Nurse-led services offer a holistic and cost-effective solution to some of the barriers mentioned. 
Evidence has shown nurse-led clinics provide vital access to health advice and treatment and result in 
improved health outcomes(7, 8).  In the context of care provision for children and adults with cancer, 
nurses have been able to address unmet survivorship needs, and provided leadership in defining, 
implementing, and evaluating MOCs to advance survivorship research and clinical practice(60).  With 
a plateauing BMT physician workforce(61-63), and increasing health care costs, nurses are arguably 
best placed to deliver care focussed on health promotion, education, chronic disease management 
and psychosocial concerns.  
Placing APNs at the centre of BMT LTFU is likely therefore to optimise post-BMT care, improve 
compliance with BMT LTFU guidelines, standardise reporting of post-BMT outcomes, allow the 
development of evidence-based clinical improvement activities, enable audit and research of post 
BMT care, improve cost-efficiency and sustainability of BMT LTFU across NSW through the 
identification and use of shared resources and services, assist in the transition of survivors from the 
transplant program to local haematologists/oncologist/GPs and support advocacy for increased 
resourcing for BMT LTFU services in NSW(57). 
Develop and disseminate LTFU clinical guidelines and education materials  
This study demonstrated that health care professional, BMT survivors and their carers all had deficient 
knowledge about the need for LTFU care. The development and dissemination of high quality, 
evidence-based survivor and carer education and guidance regarding the prevention and 
management of the late effects of allogeneic BMT is therefore greatly needed.  
BMT recipients and their carers should be provided with information on the importance of LTFU and 
long-term complications both as part of the pre-BMT consent process and at discharge post-BMT. And 
clinicians should be constantly reminded the importance of life-long follow-up at regular intervals.  
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Health professional undergraduate, post-graduate and professional and other CPD earning 
curriculums should also include LTFU and survivorship information on cancer and BMT(64). These 
courses should be readily available for all healthcare professionals who care for BMT recipients, 
including nurses, allied health professionals, subspecialists, GPs and local haematologists.  
Increase the capacity of BMT centres to provide and assist with LTFU care  
By 2030 it is predicted that there will be over half a million BMT survivors in the US alone(65). In 
recognition of this fact, FACT-JACIE guidelines require that BMT centres have infrastructure, policies, 
and standard operating procedures (SOPs) in place for the provision of appropriate LTFU treatment 
and care planning(66).  There are a number of ways in which BMT centre can increase their capacity 
to provide better LTFU.  This includes implementation of and support for nurse-led clinics; 
establishment of a register of subspecialists, allied health professionals and community services who 
are willing to treat survivors of BMT; increased funding on LTFU and support care delivery and 
communication between all providers and the survivor; and the use of standardised, validated, 
evidence-based tools for LTFU assessment, including use of qualitative questions inviting accounts of 
the ‘lived experience’ of BMT survivorship.   
16.8. Conclusion 
This study successfully achieved all of its aims, elucidating the incidence and range of late 
complications of BMT and their association with the health and functional status of survivors; 
addressing limitations in the literature regarding the financial, occupational and psychosocial impact 
of BMT; exposing gaps in service provision provided to this vulnerable and high-risk patient group; and 
providing comprehensive data regarding the long-term and late sequelae of Australian survivors of 
BMT .  This means, really for the first time, that we have comprehensive and rigorous data to improve 
the design and deliver of post-BMT care, and the experience of BMT survivorship.   
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Table 16.1: BMT LTFU Models of Care employed across NSW at study completion (2018) 
Centre 
# 
Allos/ 
year 
2017 
BMT LTFU 
FTE 
Clinic Type 
Delivery mode 
(Led by) 
Located within Provider involvement 
1st BMT 
LTFU visit 
(mo) 
Frequency of 
LTFU 
WH 60 
0.6 CNS2 
Specialised LTFU Clinic – Multi-
disciplinary 
Specialised LTFU 
care 
 
(BMT LTFU CNC) 
BMT LTFU Clinic 
BMT LTFU CNC2 
BMT physicians 
Dermatology 
Gynaecology 
Endocrinology 
Concurrent Respiratory medicine clinic 
runs in private rooms 
1-year post Annually 
Late Effects Clinic – Multi 
disciplinary 
Routine post-BMT 
care 
 
(BMT LTFU CNC) 
BMT LTFU Clinic 
 
 
BMT CNC2 
BMT Physicians 
Runs concurrently with LTFU Clinic on 1st 
& 3rd Thursday/month 
Patient 
status 
depen- 
dent 
 
0.3 CNC 
Post-BMT Clinic – Satellite 
Clinic (Newcastle) 
Routine post-BMT 
care 
(Newcastle BMT-Co-
ordinator) 
Westmead pt 
specific Post-
BMT Clinic 
BMT-Coordinator 
BMT Physician from Westmead (rotating 
physicians on a monthly basis) 
3mo post Annually 
SVH 42 
0.6 VMO 
Specialised LTFU Clinic – BMT 
only 
Specialised LTFU 
Clinic 
 
(VMO 
BMT-Co-ordinator 
arranges blood tests, 
FACT-BMT 
questionnaire, other 
investigations) 
LTFU Clinic 
(operates 
Tuesdays, 
Wednesday & 
Thursdays) 
 
Referral required 
from BMT 
Physician to 
VMO 
VMO 
In-house referrals to: 
Respiratory clinic 
Endocrinology 
Ophthalmology 
Private provider referrals 
Gynaecology 
Not defined  
 Post-BMT Clinic 
Routine post-BMT 
care 
 
(BMT Physician) 
Haematology 
Clinic 
BMT Physician 
Referrals made within and outside SVH as 
required/per physician discretion 
Physician 
discretion 
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RNSH 33 
0.8 NP (0.2 
Myeloma 
care) 
BMT LTFU Clinic 
Collaborative 
and specialised LTFU 
care 
 
(BMT NP) 
 
Post BMT clinic 
(fortnightly) 
BMT Physician 
BMT NP 
BMT Psychologist 
In-house referrals 
Dermatology 
Ophthalmology 
Endocrinology 
Respiratory medicine 
In-house private referrals (but agreeing 
to bulk bill BMT patients): 
Gynaecology 
Cardiology 
Referrals outside of RNSH: 
Dentist 
6mo post 
6mo, 12mo 
then 
Annually 
RPA 21 
0.5 CNC (0.5 
lymphoma) 
Specialised LTFU – BMT only 
 
Collaborative and 
Stand-alone LTFU 
assessments/ 
Review – 
piggybacked on to 
routine post-BMT 
care 
 
(BMT LTFU CNC) 
 
Haematology 
Clinic 
BMT LTFU CNC 
BMT physician 
In-house referrals: 
Gynaecology 
Ophthalmology 
Endocrinology 
Neurology 
Dermatology 
Referred outside RPA: 
Vaccinations, skin checks/cancer 
screening - GP 
Dentist 
Andrology (Concord Hospital) 
 
3mo post 
3mo, 12mo, 
then 
Annually 
LH 6 0.6 CNS2 Post-BMT Clinic 
Routine Post-BMT 
care 
 
(BMT CNS) 
Post-BMT Clinic 
BMT Physician 
BMT CNS2 
BMT CNS organises blood tests etc and 
refers on to specialist inhouse) 
Physician 
discretion 
 
CNS, Clinical Nurse Specialist; CNC, Clinical Nurse Consultant; NP, Nurse Practitioner; VMO, Visiting Medical Officer. 
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[Insert institutional letterhead] 
[insert name of local institution/s where research is being conducted] 
19 December 2018 
[insert name & address] 
Dear………………….. 
The Experience of Bone Marrow Transplant (BMT) in Sydney, 
Australia 
Thank you for agreeing to participate in the Experience of Bone Marrow Transplant 
(BMT) in Sydney study and for your time in completing these forms.  Your feedback 
regarding your own experience will provide an invaluable insight that will assist us 
caring for patients undergoing BMT in the future.  
Please read the Patient Information Sheet attached and if you are still happy to 
participate please sign the consent form and complete the survey.  When you have 
finished please return the consent form and survey to us in the stamped self- 
addressed envelope at your earliest convenience.  The Patient Information Sheet is 
for you to keep. 
Yours sincerely, 
[insert BMT director details] 
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Appendix C: Sydney post-BMT study invitation letter, Patient information sheet (PIS), Informed consent 
form (ICF)
Westmead Hospital, Royal North Shore Hospital, St Vincent’s Hospital & Royal Prince 
Alfred Hospital 
PARTICIPANT INFORMATION SHEET
The Experience of survival following BMT in Sydney, Australia 
1. Invitation
You are invited to participate in a research study because you have previously 
had a bone marrow transplant at one of the BMT hospitals in Sydney (Westmead 
Hospital, Royal North Shore Hospital, St Vincents Hospital and ROayl Prince 
Alfred Hospital). You have been identified as a potential candidate for this study 
by your treating haematologist. This research will help us to understand the effect 
that transplant had had on you and the challenges or problems that you have 
faced since your transplant.  This information will assist us in designing and 
delivering the services that people who are undergoing BMT will need in the 
future.  This project will also help people like you to make difficult decisions about 
whether or not to undergo a bone marrow transplant.  
The study is being conducted by clinicians and researchers from all the allogeneic 
transplant centres in NSW including: 
• A/Prof Ian Kerridge, Staff Specialist & BMT Physician, Royal North Shore Hospital.
• Dr Matthew Greenwood, Staff Specialist & Director Stem Cell Transplant Program, Royal
North Shore Hospital.
• Dr Mark Hertzberg, Director of Blood and Marrow Transplant Services, Westmead
Hospital.
• Dr John Moore, Senior Staff Specialist, St Vincent’s Hospital & BMT Network NSW.
• Dr Stephen Larson, Director of BMT Services, Royal Prince Alfred Hospital.
• Dr Nicole Gilroy, Senior Staff Specialist, St Vincent’s Hospital, Royal North Shore Hospital
& Blood and Marrow Transplant Network NSW.
• Dr Lisa Brice, Clinical Psychologist, Royal North Shore Hospital.
• Ms Gemma Dyer, Clinical Nurse Consultant - BMT Long Term Follow Up Project, Blood &
Marrow Transplant Network.
Before you decide whether or not you wish to participate in this study, it is 
important for you to understand why the research is being done and what it will 
involve. Please take the time to read the following information carefully and 
discuss it with others if you wish. If you don’t wish to take part, you don’t have to.
You are not required to participate in this study in order to receive care and 
services.  
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2. ‘What is the purpose of this study?’
The purpose of this research is to: 
• examine the physical and psychosocial impact of BMT and the quality of life of
allogeneic bone marrow transplant patients;
• to identify gaps in services provided to survivors of bone marrow  transplant;
• to provide better information to patients about the possible late effects of BMT
and to healthcare professionals.
3. ‘Why have I been invited to participate in this study?’
You are eligible to participate in this study because you have undergone a allogeneic 
bone marrow transplant as part of your treatment for a malignant or non-malignant 
disease at the BMT unit of Westmead Hospital, Royal North Shore Hospital, St 
Vincent’s Hospital or Royal Prince Alfred Hospital 
. 
4. ‘What if I don’t want to take part in this study, or if I want to withdraw
later?’
Participation in this study is voluntary. It is completely up to you whether or not 
you participate. If you decide not to participate, it will not affect the treatment  you 
receive now or in the future. Whatever your decision, it will not affect your 
relationship with the staff caring for you. 
If you wish to withdraw from the study once it has started, you can do so at any 
time without having to give a reason. 
5. ‘What does this study involve?’
Procedures 
If you agree to participate in this study, you will be asked to fill out 4 
questionnaires. These questionnaires cover a number of areas which will assess 
medical complications of BMT, quality of life, medications, oral and dental health, 
infections, vaccinations, complementary therapies, cancer screening, travel, 
health behaviours, diet/nutrition, fertility and sexual function, relationships and 
long term follow up care.  The 4 questionnaires will take approximately 30 minutes 
to complete.  
Once you have completed the survey you will be asked to return it to is in a self-
addressed postage-paid envelope.  You can contact the investigators to ask any 
questions you might have about any aspect of this study.   
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The consent to access your personal medical records is also required. The 
records will be used to collect information about your transplant, including details 
about your diagnosis.   
Reimbursement 
You will not be paid for your participation in this research. 
6. ‘Are there risks to me in taking part in this study?’
This research poses no physical risks.  Very rarely, people may find questions 
about their diagnosis or transplant, or their life since transplant upsetting.  If this 
occurs we suggest that you discuss your thoughts or feelings with your partner, 
family or friends or raise them with your transplant team. 
7. ‘Will I benefit from the study?’
This study aims to further medical knowledge about issues that affect survivors of 
bone marrow transplant and the results will be used to inform the design and 
delivery of healthcare services to BMT patients in NSW.  The results of this study 
may not, however, be of direct benefit to you. 
8. ‘How will my confidentiality be protected?’
Surveys will use an identification number and will not ask for your name, therefore 
none of your normal treatment team will know whether or not you participating in 
this study.  Any identifiable information that is collected about  you in connection 
with this study will remain confidential and will be locked in an office or stored on a 
password protected database. Only the researchers named above will have 
access to your details and results that will be held securely in the Haematology 
Department of the Royal North Shore Hospital. 
9. ‘What happens with the results?’
Following completion of this study we plan to publish the results in academic 
medical publications and present them at scientific meetings.  In all publications 
and presentations, study information will be provided in such way that you cannot 
be identified. Results of the study will be provided to you, if you wish. 
10. ‘What should I do if I want to discuss this study further before I
decide?’
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When you have read this information, the researchers, Gemma Dyer or Lisa Brice, 
will discuss it with you and any queries you may have. If you would like to know 
more at any stage, please do not hesitate to contact Gemma on 0459 805 603. 
11. ‘Who should I contact if I have concerns about the conduct of this
study?’
This study has been approved by Northern Sydney Coast Human Research 
Ethics Committee. Any person with concerns or complaints about the conduct of this 
study should contact the Research Officer who is nominated to receive complaints 
from research participants. You should contact them on 02 9926 4590 and quote 
[HREC  project number]. 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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Westmead Hospital, Royal North Shore Hospital, St Vincent’s Hospital & Royal Prince 
Alfred Hospital 
CONSENT FORM 
The Experience of survival following BMT in Sydney, Australia 
1. I,.................................................................................................................
of................................................................................................................  
agree to participate as a subject in the study described in the participant 
information statement attached to this form. 
2. I acknowledge that I have read the participant information statement, which
explains why I have been selected, the aims of the study and the nature and the
possible risks of the investigation, and the statement has been explained to me
to my satisfaction.
3. Before signing this consent form, I have been given the opportunity of asking any
questions relating to any possible physical and mental harm I might suffer as a
result of my participation and I have received satisfactory answers.
4. I understand that I can withdraw from the study at any time without prejudice to
my relationship to Westmead Hospital, Royal North Shore Hospital, St Vincent’s
Hospital or Royal Prince Alfred Hospital.
5. I agree that research data gathered from the results of the study may be
published, provided that I cannot be identified.
6. I understand that if I have any questions relating to my participation in this
research, I may contact Gemma Dyer on telephone 0459 805 603, who will be
happy to answer them.
7. I acknowledge receipt of a copy of this Consent Form and the Participant
Information Statement.
Complaints may be directed to [insert local details] 
Signature of subject   Please PRINT name   Date 
_______________________________________________________________ 
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Signature of investigator  Please PRINT name  Date 
_______________________________________________________________ 
[Institutional letterhead] 
Westmead Hospital, Royal North Shore Hospital, St Vincent’s Hospital and Royal Prince 
Alfred Hospital 
The Experience of survival following BMT in Sydney, Australia 
REVOCATION OF CONSENT 
I hereby wish to WITHDRAW my consent to participate in the study described above 
and understand that such withdrawal WILL NOT jeopardise any treatment or my 
relationship with Royal North Shore Hospital or St Vincent’s Hospital.  
Signature Date 
Please PRINT Name 
The section for Revocation of Consent should be forwarded to Gemma Dyer, Royal 
North Shore Hospital, Haematology Department, Level 4, Pacific Highway, St Leonards, 
NSW 2065+ 
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TheSydneyPost-BMTstudy
A collaborative study conducted by the BMT Network of NSW including 
the bone marrow transplant units at Westmead Hospital, 
St Vincents Hospital, Royal North Shore Hospital and 
Royal Prince Alfred Hospital.
This study is supported by the Agency for Clinical Innovation (ACI).
Cross the boxes like this: 
INSTRUCTIONS
Print clearly in the boxes like this: 
Correct mistakes like this: 
In general, would you say your health is:
(Mark one only)
When you go to a General Practitioner:
(Mark one on each line)
What is your postcode?
(PRINT clearly in the boxes)
Excellent
Very good
Good
Fair
Poor
Do you go to the same place?
You would mark this one if you
think your health is good.
If you make a mistake, simply scribble it out 
and mark the correct answer with a circle.
Always
Most of
the time Sometimes
Rarely or
never
Use a black or blue biro Do not fold or bend this survey
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Appendix D: Sydney post-BMT study survey instrument
- 2 - 
1. Date of birth:
TheSydneyPost-BMTstudy
We are interested in finding out about your experiences of life after having a Bone Marrow Transplant (BMT).  
We would like to know about the complications of BMT that have affected you most and also what lifestyle 
choices you have made.  Your answers will remain strictly confidential.
DEMOGRAPHICS : Please tell us a little bit about you;
MEDICAL COMPLICATIONS : We know that BMT patients can experience many complications after treatment.  
We are particularly interested in finding out if any medical problems, including Graft vs Host Disease (GvHD) and 
other chronic conditions, have affected your health.
Male Female
3. Postcode:
5. Gender:
Yes No7. Have you ever been diagnosed with chronic Graft versus Host Disease (GvHD)?
If yes, please indicate which parts of your body have been affected by GVHD below (mark all that apply).
Since your BMT have you ever been diagnosed with any of the following? 
Some high school Trade qualifications/diploma
Some university
Completed 
university
6. Education:
2. Transplant date:
4. Ethnicity:
Survey No.:
/ // /
Skin8.
An underactive thyroid
An overactive thyroid
Osteopaenia/Osteoporosis
Avascular Necrosis (dead bone in your joints)
Any spinal/hip fracture
Cataracts
Diabetes
High blood pressure
High cholesterol
Iron overload (too much iron in your body)
Depression
Anxiety
Mouth Cancer
Recurrent colds
Skin Cancer
Any other Cancer?
If yes, please specify:
Any other medical problems that we haven’t 
mentioned?
NO YES
NO YES
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
39.
40.
41.
Eyes9. Lungs10. Mouth11.
Liver12. Stomach or intestines13. Nails14. Vagina15.
Penis16. Muscles/joints17. Other organ18. Not sure19.
If YES, what type was it?
42.   If YES, please specify:
BCC35. SCC36.
Melanoma37. Don’t know38.
Completed high school
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REFERRALS, TESTS & ASSESSMENTS & TIME : We are interested in finding out if you have undergone any 
tests for long term medical complications as well as who has been involved in your care following BMT.
Have you had any of the following tests or assessments since your BMT?
We are interested in finding out how much time (days) you are required to spend attending hospital/medical 
appointments/tests/assessments related to your BMT or complications from your BMT?  
Heart scan (Gated Heart Pool Scan, Cardiac Echo or Heart Ultrasound)
Lung Function Tests
Bone Mineral Density Scan
Thyroid examination (had your thyroid felt by a doctor or had a Thyroid Ultrasound/Scan)
NO YES
43.
44.
45.
46.
Hospital accommodation
Other subsidised accommodation (eg funded by the Leukaemia Foundation)
You stay with friends or family
You pay for private accommodation (eg Hotel/motel)
NO YES
74.
75.
76.
77.
Since your BMT have you been referred to any of the following specialists or services?
Ophthalmologist (Eye Specialist)
Dermatologist (Skin Specialist)
Cardiologist (Heart  Specialist)
Respiratory Doctor (Lung Specialist)
Endocrinologist/Diabetes Doctor
Neurologist (Brain and Nervous System Specialist)
Gastroenterologist (Bowel Specialist)
Hepatologist (Liver Specialist)
Infectious Diseases Specialist
Gynaecologist
Fertility Specialist
Nephrologist (Kidney Specialist)
Urologist (Bladder Specialist)
Rehabilitation Specialist 
ENT Doctor (Ears, Nose, Throat Specialist)
Orthopaedic Doctor (Bone Specialist)
Psychologist
Psychiatrist
Social Worker
Occupational Therapist
Dietician
Physiotherapist
Exercise Physiologist
Any other specialist or service not mentioned
 
71.  If yes, please specify:
NO YES
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
More than once a week Once per week Once per month
Once every 6 months Yearly Less than yearly
Once every 3 months
Yes No
72. On average, how often do you attend a hospital or medical practice/facility: (please mark one option)
73. Are you ever required to stay overnight close to the hospital/medical 
practice when you attend appointments/tests?
If yes, where do you stay:
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MEDICATIONS & TREATMENTS : BMT patients may need to take medications for many years after 
transplant. We would like to know about the medications that you are currently taking.
ORAL & DENTAL HEALTH : BMT patients sometimes develop dental problems after their transplant.  
We would like to know about your dental health.
Please indicated which medications you are currently taking: (Please mark all that apply)
BMT patients also may need medical treatments for many years after transplant.  
We would like to know about the treatments you are currently receiving. 
Please indicate which treatments which you are currently receiving: (please tick all that apply)
Do you take all the medication that you are prescribed and at the doses prescribed?
If not, why not (mark as many as apply)?
95.
Penicillin78.
Cost96. Side effects97. You don’t feel they are necessary98.
Venesection (blood removed)100. Immunoglobulin infusion (eg Intragam)101.
PUVA (Ultraviolet Light Therapy)102. ECP (Extracorporeal Photopheresis)103.
Cyclosporine/Tacrolimus/Mycophenolate (Immune drug)79.
Any cholesterol lowering drug80. Acyclovir/Valaciclovir (Antiviral drug)81.
82. Any bone strengthening drug (eg Zometa)83.Prednisolone
88. A drug to reduce iron (eg Exjade)89.
Antidepressant90.
Vitamin D
91.
Any sleeping tablet/sedative92.
Anti-anxiety drug
93. Hormone replacement/Oral contraceptive pill
94. Other, please specify:  (include over-the-counter medications)
84. Bactrim/Septrin 85.
Any blood pressure drug86.
Calcium
87. Fluconazole/ Posaconazole/Itraconazole  
(Antifungal drug)
99. Other, please specify:
104. Other, please specify:
Yes No
Do you regularly go to the dentist?
106.  If yes, date last attended:
105. Yes No
108.  Time 109.  Cost
111.  It has not been advised by your treatment team
112.  Other, please specify:
110.  You don’t feel it’s necessary
107.  How often do you attend? 
         (times per year)
If no, why not (tick as many as apply):
/ /
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Since your transplant, have you been diagnosed with the following?
Have you been diagnosed with any of the following since your transplant?
NO YES
113.
114.
115.
116.
117.
118.
Annual flu shot (Influenza)
Pneumococcus
Human Papillomavirus Vaccine (HPV) vaccine, otherwise known as 
cervical cancer vaccine (Gardasil or Cervarix) 
NO YES
137.
138.
139.
Mouth ulcers
Dry mouth
Gum disease (Gingivitis)
Tooth abscess
Decaying teeth/Cavities
Any other dental problem not mentioned:
 119. If yes, please specify:
NO YES
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
Hepatitis A
Hepatitis B                              
Hepatitis C                              
Haemophilus Influenza type B 
Pneumococcal disease
Meningococcus
Varicella / Chicken pox
Zoster (Herpes Zoster) / Shingles
Influenza “flu”
Measles
Mumps
Rubella
Pertussis “whooping cough”
Tuberculosis
Pap smear abnormality/HPV infection (females)
Genital warts
Fungal infection
 
If yes, please specify:
INFECTIONS : Infections are a major concern for BMT patients.  We would like to know about your infection 
history.
VACCINATIONS : Vaccinations are an effective way of preventing some infections.  We would like to know 
about your vaccination status after your diagnosis and after your BMT.
After your diagnosis, but before your transplant, did you receive the following vaccinations?
If yes, where did you receive this vaccine or these vaccines?
N/A
N/A
140.  GP 141.  Hospital 143.  Other142.  Community clinic
Was this location:
144.  Urban 145.  Rural 146.  Remote
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COMPLEMENTARY THERAPIES : Complementary therapy use has increased over the years.  We would like 
to know if this is something you have tried since having your BMT.
Have you tried, or do you use any of the following complementary therapies?
Nutrition and dietary approaches (eg macrobiotic diet)167. Yes No
After your transplant, did you receive the following vaccinations?  NO YESUNSURE
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
Diphtheria, Tetanus, Pertussis 
Polio vaccine
Haemophilus Influenza type B
Hepatitis B
Pneumococcus 
Influenza (flu shot)
Meningococcus
Measles, Mumps, Rubella (MMR)
Varicella (Shingles)
HPV  
Unsure No Yes
Unsure No Yes
N/A No Yes
164.
165.
166.
Did you receive a vaccination schedule?
Did your GP receive a vaccination schedule?
Do you have a personal record (book) of any 
vaccinations you received?
If yes, where did you receive this vaccine or these vaccines?
157.  GP 158.  Hospital 160.  Other159.  Community clinic
Was this location: 162.  Rural 163.  Remote161.  Urban
168. If yes, please specify:
Herbal supplements (eg Ginseng)169. Yes No
170. If yes, please specify:
Vitamin therapies171. Yes No
172. If yes, please specify:
Mind-body therapies (eg Meditation, hypnosis, spiritual healing)173. Yes No
174. If yes, please specify:
Energy Medicine (eg Reiki)179. Yes No
Homeopathy181. Yes No
Any other type not mentioned182. Yes No
180. If yes, please specify:
183. If yes, please specify:
Manipulative and body based therapies (eg Acupuncture, Chiropractic, 
massage, reflexology)
175.
Yes No
176. If yes, please specify:
Traditional whole medicine systems (eg Traditional Chinese Medicine, 
Indian (Ayurvedic Medicine)
177.
Yes No
178. If yes, please specify:
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Since your transplant, please indicate if you have ever had the following:
No Yes184. Skin check 185. If yes, date last attended:
If not, why not? (Mark as many as apply) 186. How often do you attend (times per year?)
CANCER SCREENING : We would like to know if you have had any cancer screening tests or checks since your 
BMT.
TRAVEL HISTORY : Most people enjoy travel, but travelling overseas can pose some health risks depending 
on the countries visited.  We would like to know about any international travel you have undertaken since your 
BMT and whether there were any risks to your health while you were away.
/ /
187.  Time
188.  Cost 190.  It has not been advised by your treatment team
189.  You don’t feel it’s necessary
FOR WOMEN
FOR MEN
No Yes198. Pap smear 199. If yes, date last attended:
If not, why not? (Mark as many as apply) 200. How often do you have this done? (each year, every 2 years, etc)
/ /
201.  Time
204.  Cost203.  It has not been advised by your treatment team
205.  I don’t need it because I have had the HPV Vaccination
202.  You don’t feel it’s necessary
208. How often do you have this done? 
        (each year, every 2 years, etc)
209. How old were you when you had 
        your first mammogram?
No Yes
191. Bowel cancer check (eg stool/bowel motion check, colonoscopy &/or haemoccult blood test)
192. If yes, date last attended:
If not, why not? (Mark as many as apply) 193. How often do you have this done? (each year, every 2 years, etc)
/ /
194.  Time
195.  Cost 197.  It has not been advised by your treatment team
196.  You don’t feel it’s necessary
210.  Time
211.  Cost
Other
213.  It has not been advised by your treatment team
212.  You don’t feel 
         it’s necessary
No Yes
214. Prostate check (eg blood test for PSA level or prostate check by a doctor (Digital Rectal Exam)
215. If yes, date last attended:
If not, why not? (Mark as many as apply) 216. How often do you attend? (times per year)
/ /
217.  Time
218.  Cost 220.  It has not been advised by your treatment team
219.  You don’t feel it’s necessary Other
No Yes206. Mammogram (Breast Screen)
207. If yes, date last attended:If not, why not? (Mark as many as apply) / /
Yes No221. Have you travelled overseas since your transplant?
222. If yes, where have you travelled (including region) and what years did you travel overseas (please list all).
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Have you avoided travel because of (please tick all that apply): NO YES
223.
224.
225.
226.
227.
228.
Not interested in travel
Physical limitations  
The risk of exposure to new infections
Costs of travel
Costs of travel insurance
Did you take out travel insurance before you travelled? 
No Yes
No
No Yes
Yes
257.
259.
260.
261.
262.
Do you live with any children?
Have they been fully vaccinated?
Who else do you live with?  What is your relationship to them?
Do the people you live with have the Influenza Vaccine (flu shot) every year?
Do you care for young children (in your occupation or as a personal carer eg. grandparent)?
258. If yes, what are their ages?
If no, was this because (please tick all that apply): NO YES
NO YES
229.
230.
231.
232.
233.
Unable to afford Insurance premium  
No policy covering you for preexisting or existing conditions
You did not consider it necessary to take out  travel insurance
Other
If yes, please specify:
Who did you seek information from about what vaccinations you needed before you travelled (tick as many 
as apply)?
GP234. Transplant doctor235. Travel clinic236. Other237.
Did you have any of the following problems while you were away? (Please tick all that apply)
Diarrhoea241. Vomiting242. Respiratory infection243.
What kind of activities did you participate in whilst away? (Please tick all that apply)
Swimming244. Caving/kayaking 245. Outdoor adventure type exercise etc246.
No outdoor activities247.
Did not seek information238.
Where did you eat while away? (Please tick all that apply) 
Restaurants248. 249. 250.
Prepared your own251. All of the above252.
Yes No239. Did you require any additional vaccines or medicines to prevent infection?
240. If yes, please specify:
Street food Friends/Family
What kind of water did you drink? (Please tick all that apply) 253. Bottled 254. Tap
255. River 256. Lake
CLOSE PERSONAL CONTACTS : People who have had a transplant are at risk of infections – including from 
their family.  School-aged children, in particular, often get infections and can pass them on easily.  
We are interested in finding out who you live with and what their vaccination status is.
No Yes
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No Yes263. Do you smoke? 264. If yes, how many cigarettes per day?
LIFESTYLE : Lifestyle habits can have an impact on a person’s health.  We are interested in finding out about 
your lifestyle choices.  
DIET / NUTRITION : We are interested in finding out about your eating habits and any ongoing symptoms 
which may be affecting you.
No Yes265. Do you drink alcohol? 266. If yes, how many standard drinks 
        per week (on average)?
No Yes267. Do you exercise or play sport? 268. If yes, how many times 
        per week?
269. How many minutes per 
        session?
No Yes270. Is your ability to exercise compromised in anyway by your BMT or by 
complications of your transplant?
No Yes
272. Do you always/routinely use sun protection (eg sunscreen, hat, sunglasses, avoid 
being in the sun between 11am-3pm, wear shirts with long sleeves and a collar)?
276. Are you happy with your current weight?
271. If yes, how?
Underweight Overweight Neither
Yes No
273. What is your height (cm)?
275. Do you feel like you are:
274. What is your weight (kg)?
NO YES
Do you have any of following symptoms?
Nausea
Vomiting
Constipation
Diarrhoea
Taste alterations
Smell alterations
Poor appetite
Are your eating habits back to normal since your BMT?
Do you find eating as enjoyable as before your transplant?
Have you made any significant changes to your eating habits since your BMT transplant? 
(eg: organic, vegetarian, avoiding specific foods, as a result of a new diagnosis of 
diabetes etc)
If yes, please describe changes you have made to your diet?
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
NO YES
NO YES
Do you take any nutritional supplements? (eg: Sustagen, Ensure, Fortisip, Twocal, 
Protein powder etc)
Did you have enteral nutrition (tube feeding) during your transplant?
If yes,
288.
289.
Do you think that tube feeding was a beneficial part of your care?
Would you recommend it to others?
290.
291.
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OCCUPATION – INFECTION RISK : Some occupations are associated with an increased risk of infection or 
injury.  We would like to know if you are involved in certain occupations.
OCCUPATION – WORK STATUS & FUNCTIONING : We are interested in finding out if there has been a 
change to your occupation or work status since your transplant.
Do you fall within any of the following occupational groupings:
If you are involved in farming, what type of farming:
NO YES
292.
293.
294.
295.
296.
297.
298.
299.
300.
NO YES
301.
302.
Gardener or landscaper
Plumber
Building or construction worker
Armed Forces/Police/ emergency services/ worker at correctional facility 
Laboratory worker
Child care worker
Teacher 
Health Care Worker 
Agricultural worker/farmer 
Livestock/ animal husbandry or poultry
Crops
303.  What was your pre-transplant work status?
Worked Full-time Worked Part-time Homemaker Casual
Unemployed Unable to work because of poor health Retired
304.  What is your post-transplant work status?
305.  If you are retired was your retirement related to your health post-transplant?                                
307.  What was the nature of your pre-transplant work?                             
309.  What was your pre-transplant household annual income?                         
Worked Full-time Worked Part-time Homemaker Casual
<$20,000 $20,000 - $39,999 $40,000 - $59,999 $60,000 - $79,000   
$80,000 - $99,999 $100,000 - $200,000 >$200,000
310.  What is your post-transplant household annual income?                         
<$20,000 $20,000 - $39,999 $40,000 - $59,999 $60,000 - $79,000   
$80,000 - $99,999 >$200,000
Unemployed Unable to work because of poor health Retired
Yes No
306.  If you are not retired and also not working is this due to your health post-transplant?                    Yes No
Physical: please specify Non-physical: please specify
308.  What is the nature of your post-transplant work?                             
Physical: please specify Non-physical: please specify
$100,000 - $200,000
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No Yes311. Have you attended a job interview since your transplant?
No Yes
320. Physical limitations
322. Cognitive limitations
321. Psychological/emotional limitations
319. Has your occupation/field of work changed since transplant?
No Yes312. Did you disclose that you had had a BMT in your job interview?
No Yes314. Have you had any occupational counselling regarding your legal rights?
If yes, where was this provided?
If yes, why? You were unable to do previous work because of (please tick all that apply):
If yes, was this discrimination related to:
Being employed Not being employed313. Did you feel that being a BMT recipient was a factor in your:
NO YES
At work
Your healthcare provider/BMT service
Centrelink
Other (eg.Leukaemia Foundation, Cancer Council)
315.
316.
317.
318.
NO YES
Bank sperm
Bank embryos after a cycle of IVF  
Have ovarian tissue or eggs frozen  
If not, why not? (Please tick one option)
338.
339.
340.
341.
Other, please specify:342.
NO YES
You were concerned about the risks to you in your workplace
You were made redundant
Your employer had concerns about their liability or about the risks to you
Your employer felt that you were unable to do your job.
Unsatisfactory redeployment/change in your work responsibilities
Reallocation of hours/shifts
Exhausted sick leave to attend appointments
323.
324.
325.
326.
327.
328.
329.
No Yes
This was not offered to you
You had completed your family
You declined It was not an option for you because you were too 
sick or had other health problems
330. Have you ever experienced job discrimination as a result of your health after transplant?
NO YES
Job transfer
Denial of promotion
Difficulty finding employment
Limitation on work responsibilities
Workplace harassment
Forced redundancy
Other, please specify:
331.
332.
333.
334.
335.
336.
337.
Before your BMT, did you:
FERTILITY AND SEXUAL FUNCTION : Most BMT patients experience problems with fertility and many report 
having sexual difficulties or problems with intimacy after transplantation.  We would like to know about any 
concerns you may have had.
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If you have had a baby since your transplant, did you use:
NO YES
343.
344.
Have you tried to have a baby since your transplant?
If yes, were you successful?
349.
350.
Have you resumed sexual activity since your BMT?
If yes, have you had any difficulties with sexual function since your BMT?
Not sexually active No Yes
No Yes
NO YES
345.
346.
347.
348.
IVF
Donor sperm
Donor eggs  
You did not require medical assistance (Your baby was conceived ‘naturally’)
FOR MEN
If yes, what type of sexual problems have you had? NO YES
Decreased enjoyment of sex
Difficulty getting or sustaining an erection
Pain with intercourse
Decreased sexual desire
Difficulties with your partner regarding the issue of sex
Other, please specify:
351.
352.
353.
354.
355.
356.
357.
358.
Have you resumed sexual activity since your BMT?
If yes, have you had any difficulties with sexual function since your BMT?
Not sexually active No Yes
No Yes
FOR WOMEN
If yes, what type of sexual problems have you had?
Apart from sexual problems, have you had any of the following genital problems since your BMT? 
(Tick as many as apply):
If yes,
years
NO YES
Decreased enjoyment of sex
Pain with intercourse
Decreased sexual desire
Difficulties with arousal
Difficulties with your partner regarding the issue of sex
Other, please specify:
359.
360.
361.
362.
363.
364.
NO YES
Vaginal dryness
Narrowing of the vagina
Vaginal irritation or soreness not related to sex
Vaginal bleeding
Recurrent vaginal infections
Recurrent thrush
Bladder infections/cystitis
Lower back pain
Other, please specify:
Were you still menstruating at the time of your BMT?
365.
366.
367.
368.
369.
370.
371.
372.
373.
374.
NO YES
Did your periods ever cease following BMT
If your periods stopped following BMT – did they later recommence?
If yes, were they regular?
If yes, how long after BMT did they recommence?
375.
376.
377.
378. months
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No Yes380. Since your transplant has there been a change in your relationship status?
Single Married De facto Divorced Separated
379. What is your relationship status now?
Single Married De facto Divorced Separated
381. If yes, how?  Prior to your transplant were you:
NO YES
GP
Local Haematologist
Transplant Doctor/Transplant Centre
382.
383.
384.
QUITE
A BIT
VERY
MUCH
A
LITTLE
BIT
SOME-
WHAT
NOT
AT
ALL
My income is a lot less now than it was prior to having a BMT
Since my transplant I have trouble remembering where I put 
things, like my keys or my wallet 
Since my transplant, I have trouble paying attention when people 
are talking to me
My disease and treatment had a major financial impact on me and 
my family
Since my transplant I have  to use written lists so I don’t forget 
things
Since my transplant I have trouble forming thoughts 
I have had to downsize my career since my transplant
Since my transplant I have  trouble remembering new information, 
like phone numbers
Since my transplant it’s hard for me to find the words to say what 
I mean in conversations with others
Since my transplant my thinking is slower
Since my transplant I have had trouble concentrating
My medical expenses are overwhelming
390.
391.
392.
393.
394.
395.
396.
397.
398.
399.
400.
401.
NO YES
At your GP
With your local Haematologist
At the Transplant Centre (hospital) where your transplant was done
At a local ‘Satellite Clinic’ run by your transplant centre and staffed by transplant staff 
from the hospital where your transplant was done?
At your local hospital/clinic using telemedicine (a virtual consultant with the team from your 
transplant centre)
385.
386.
387.
388.
389.
LONG TERM FOLLOW UP CARE : We are interested in your views on how you would like your BMT long term 
follow up care delivered.
SOCIAL, OCCUPATIONAL ATTITUDES, PHYSICAL & PSYCHOLOGICAL CONCERNS : The table below 
includes a list of statements that other people with your illness have said are important. Please mark one number 
per line to indicate your response to each question.
If given the choice, who would you prefer was primarily responsible for your 
BMT long term follow up care?
If given the choice, where would you prefer to have your BMT long term follow up care?
RELATIONSHIPS : BMT can have a significant impact on your life and the life of those around you.  
We are interested in any changes to your relationship after your BMT.
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DIS-
AGREE
STRONGLY
DIS-
AGREEAGREE
NOT
CERTAIN
STRONGLY
AGREE
Because cancer is unpredictable, I feel I cannot 
plan for the future.
I will probably have a relapse in the next 5 years.
My fear of having my cancer coming back gets in the 
way of my enjoying life.
I am afraid of my cancer coming back.
I am certain that I have been cured of cancer
402.
403.
404.
405.
406.
543210
My priorities about what is important in life
An appreciation for the value of my own life
I developed new interests
A feeling of self-reliance
A better understanding of spiritual matters
Knowing that I can count on people in times of trouble
I established a new path for my life
A sense of closeness with others
A willingness to express my emotions
Knowing I can handle difficulties
I’m able to do better things with my life
Being able to accept the way things work out
Appreciating each day
New opportunities are available which wouldn’t have been otherwise
Having compassion for others
Putting effort into my relationships
I’m more likely to try to change things which need changing
I have a stronger religious faith
I discovered that I am stronger than I thought I was
I learned a great deal about how wonderful people are
I accept needing others
407.
408.
409.
410.
411.
412.
413.
414.
415.
416.
417.
418.
419.
420.
421.
422.
423.
424.
425.
426.
427.
POSSIBLE AREAS OF GROWTH AND CHANGE : Please mark one box per line to indicate for each of the 
statements below the degree to which this change occurred in your life as a result of having a bone marrow 
transplant.  Please using the following scale:
0
1
2
3
4
5
=
=
=
=
=
=
I did not experience this change as a result of my crisis
I experienced this change to a very small degree
a small degree
a moderate degree
a great degree
a very great degree as a result of my crisis
Listed below are a number of statements concerning cancer patients’ beliefs about having had cancer. 
In thinking about the past week, please indicate how much you agree or disagree with each statement: 
Strongly Agree, Agree, Not Certain, Disagree, or Strongly Disagree. 
[Please circle the number of your answer.]
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Please read each statement and mark the box 0, 1, 2 or 3 which indicates how much the statement applied to 
you over the past week.  There are no right or wrong answers.  Do not spend too much time on any statements.
The rating scale is as follows:
0
1
2
3
=
=
=
=
Did not apply to me at all
Applied to me to some degree, or some of the time
Applied to me to a considerable degree, or a good part of time
Applied to me very much, or most of the time
3210
I found it hard to wind down
I was aware of dryness of my mouth
I couldn't seem to experience any positive feeling at all
I experienced breathing difficulty (eg, excessively rapid breathing, breathlessness 
in the absence of physical exertion)
I found it difficult to work up the initiative to do things
I tended to over-react to situations
I experienced trembling (eg, in the hands)
I felt that I was using a lot of nervous energy
I was worried about situations in which I might panic and make a fool of myself
I felt that I had nothing to look forward to
I found myself getting agitated
I found it difficult to relax
I felt down-hearted and blue
I was intolerant of anything that kept me from getting on with what I was doing
I felt I was close to panic
I was unable to become enthusiastic about anything
I felt I wasn't worth much as a person
I felt that I was rather touchy
I was aware of the action of my heart in the absence of physical exertion 
(eg, sense of heart rate increase, heart missing a beat)
I felt scared without any good reason
I felt that life was meaningless
428.
429.
430.
431.
432.
433.
434.
435.
436.
437.
438.
439.
440.
441.
442.
443.
444.
445.
446.
447.
448.
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449.  We are interested in hearing about what matters to you.  What would you say are the 3 things that have 
had the most impact on your quality of life since your transplant (or that cause you the most distress)?
i.
ii.
iii.
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Below is a list of statements that other people with your illness have said are important. 
Please mark one box per line to indicate your response as it applies to the past 7 days. 
Please mark one box per line to indicate your response as it applies to the past 7 days. 
Very
much
Quite a
bit
Some-
what
A
little bitNot at all
I have a lack of energy
I have nausea
Because of my physical condition, I have trouble 
meeting the needs of my family
I have pain
I am bothered by side effects of treatment
I feel ill
I am forced to spend time in bed
GP1
GP2
GP3
GP4
GP5
GP6
GP7
Very
much
Quite a
bit
Some-
what
A
little bitNot at all
I am satisfied with my sex lifeGS7
PHYSICAL WELL-BEING
Very
much
Quite a
bit
Some-
what
A
little bitNot at all
I feel sad
I am satisfied with how I am coping with my illness
I am losing hope in the fight against my illness
I feel nervous
I worry about dying
I worry that my condition will get worse
GE1
GE2
GE3
GE4
GE5
GE6
EMOTIONAL WELL-BEING
I feel close to my friends
I get emotional support from my family
I get support from my friends
My family has accepted my illness
I am satisfied with family communication about my 
illness
I feel close to my partner (or the person who is my
main support)
GS1
GS2
GS3
GS4
GS5
GS6
Regardless of your current level of sexual activity, please answer the following question. 
If you prefer not to answer it, mark this box:          
and go to the next question.
 
Q1
SOCIAL/FAMILY WELL-BEING
FACT-BMT(Version 4)
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Very
much
Quite a
bit
Some-
what
A
little bitNot at all
I am able to work (include work at home)
My work (include work at home) is fulfilling
I am able to enjoy life
I have accepted my illness
I am sleeping well
I am enjoying the things I usually do for fun
I am content with the quality of my life right now
GF1
GF2
GF3
GF4
GF5
GF6
GF7
FUNCTIONAL WELL-BEING
Very
much
Quite a
bit
Some-
what
A
little bitNot at all
I am concerned about keeping my job (include work 
at home)
I feel distant from other people
I worry that the transplant will not work
The effects of treatment are worse than I had imagined
I have a good appetite
I like the appearance of my body
I am able to get around by myself
I get tired easily
I am interested in sex
I have concerns about my ability to have children
I have confidence in my nurse(s)
I regret having the bone marrow transplant
I can remember things
I am able to concentrate
I have frequent colds/infections
My eyesight is blurry
I am bothered by a change in the way food tastes
I have tremors
I have been short of breath
I am bothered by skin problems (e.g. rash, itching)
I have trouble with my bowels
My illness is a personal hardship for my close family
members
The cost of my treatment is a burdern on me or
my family
BMT1
BMT2
BMT3
BMT4
C6
C7
BMT5
BMT6
BL4
BMT7
BMT8
BMT9
BMT10
Br1
BMT11
BMT12
BMT13
BMT14
B1
BMT15
BMT16
BMT17
BMT18
ADDITIONAL CONCERNS
Please mark one box per line to indicate your response as it applies to the past 7 days. 
CHRONIC GRAFT VERSUS HOST DISEASE
If you have ever been diagnosed with chronic GvHD, please complete all the 
questions that follow. 
If you have never been diagnosed with chronic GvHD, then you have no more 
questions to answer.
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ChronicGVHDActivityAssessment – Patient Self Report Form B
Please rate how severe the following symptoms have been in the last seven days. Please mark the box below 
from ‘0’ (symptom has not been present) to ‘10’ (the symptom was as bad as you can imagine it could be) for
each item.
SYMPTOMS
What is your main complaint 
with regard to your eyes?
Do you have any burning, pain or discomfort in the area of your 
vagina, vulva or labia?
OR 
Do you have any discomfort or pain with sexual intercourse?
1. Overall, do you think that your chronic graft host disease is mild,
    moderate or severe?
2. Please mark the box indicating how severe your chronic graft versus host disease symptoms are,
where ‘0’ is cGVHD symptoms that are not at all severe and ‘10’ is the most severe chronic GVHD symptoms
possible.
3. Compared to a month ago, overall would you say that your cGVHD symptoms are:
Please rate how severe is this eye symptom, 
between ‘0’ (not at all severe) and ‘10’ 
(most severe)
EYES
VULVOVAGINAL SYMPTOMS (FEMALES ONLY)
PATIENT GLOBAL RATINGS
100 1 2 3 4 5 6 7 8 9
Not
present
As bad as
you can imagine
100 1 2 3 4 5 6 7 8 9
100 1 2 3 4 5 6 7 8 9
Your skin itching AT ITS WORST?
Your mouth dryness AT ITS WORST?
Your mouth pain AT ITS WORST?
Your mouth sensitivity AT ITS WORST?
FORM B
Yes
No
Not applicable
None
Mild
Severe
Moderate
+3
+2
+1
0
–1
–2
–3
Very much better
Moderately better
A little better
About the same
A little worse
Moderately worse
Very much worse
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By marking one box per line, please indicate how much you have been bothered by the following problems 
in the past month.
Extremely
Quite a
bitModeratelySlightlyNot at all
Abnormal skin colour
Rashes
Thickened skin
Sores on skin
Itchy skin
1
2
3
4
5
SKIN
Dry eyes
Need to use eye drops frequently
Difficulty seeing clearly
Need to avoid certain foods due to mouth pain
Ulcers in mouth
Receiving nutrition from an intravenous line or feeding tube
6
7
8
9
10
11
EYES AND MOUTH
Frequent cough
Coloured sputum
Shortness of breath with exercise
Shortness of breath at rest
Need to use oxygen
12
13
14
15
16
BREATHING
Difficulty swallowing solid foods
Difficulty swallowing liquids
Vomiting
Weight loss
17
18
19
20
EATING AND DIGESTION
Joint and muscle aches
Limited joint movement
Muscle cramps
Weak muscles
21
22
23
24
MUSCLES AND JOINTS
Loss of energy
Need to sleep/take more naps
Fevers
25
26
27
ENERGY
Depression
Anxiety
Difficulty sleeping
28
29
30
MENTAL AND EMOTIONAL
LeeChronicGVHDSymptom scale
This is the end of the survey.   Thank you for your time.
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Clinical data form
Date of BMT:
Diagnosis:
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 2345678910111213141516171819202122232425262728293031323334353637383940414243444546
Survey No.:
/ /
Date of diagnosis: / /
Sibling donor
Haploidentical donor
Matched Unrelated Donor
Mis-matched Unrelated Donor
Stage of disease
at BMT:
Stem Cell Source: Bone Marrow Peripheral Blood Cord Blood
Transplant conditioning:
Myeloablative: Reduced Intensity:
Donor type:
Prognostic Group: Low risk Intermediate risk High risk
SydneyPost-BMT
AML
ALL
CML
CLL
SAA
NHL
HL
MM
MDS/ Myeloproliferative disorder
Other
CR1
CR2
>CR2
Refractory
Chronic Phase
Accelerated Phase
Blast crisis
PR
Other
Bu/Cy
Cy/TBI
Bu/Flu
Cy/ATGAM
Cy/Flu/ATGAM
Bu/Flu/Thymoglobuline/TBI
Etop/TBI
Flu/Cy 
Flu/Cy/TBI
Flu/Mel
FLAMSA 
Flu/BCNU/Mel/ATG
Flu/TBI
Other
GvHD Prophylaxis:
T-Cell Depletion?
CSA+ MTX
CSA+Pred+MTX
CSA+Pred+MMF
Pred+MTX
Yes
No
ATGAM/ATG (Fresenius)/Thymoglobulin
Alemtuzumab (Campath) Other
Tacro+MTX
Cy+Tacro+MMF
MTX+MMF
Other
If YES:
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Appendix E: Sydney post-BMT study clinical data form
Clinical data form
Date of BMT:
Diagnosis:
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 2345678910111213141516171819202122232425262728293031323334353637383940414243444546
Survey No.:
/ /
Date of diagnosis: / /
Sibling donor
Haploidentical donor
Matched Unrelated Donor
Mis-matched Unrelated Donor
Stage of disease
at BMT:
Stem Cell Source: Bone Marrow Peripheral Blood Cord Blood
Transplant conditioning:
Myeloablative: Reduced Intensity:
Donor type:
Prognostic Group: Low risk Intermediate risk High risk
SydneyPost-BMT
AML
ALL
CML
CLL
SAA
NHL
HL
MM
MDS/ Myeloproliferative disorder
Other
CR1
CR2
>CR2
Refractory
Chronic Phase
Accelerated Phase
Blast crisis
PR
Other
Bu/Cy
Cy/TBI
Bu/Flu
Cy/ATGAM
Cy/Flu/ATGAM
Bu/Flu/Thymoglobuline/TBI
Etop/TBI
Flu/Cy 
Flu/Cy/TBI
Flu/Mel
FLAMSA
Flu/BCNU/Mel/ATG
Flu/TBI
Other
GvHD Prophylaxis:
T-Cell Depletion?
CSA+ MTX
CSA+Pred+MTX
CSA+Pred+MMF
Pred+MTX
Yes
No
ATGAM/ATG (Fresenius)/Thymoglobulin
Alemtuzumab (Campath) Other
Tacro+MTX
Cy+Tacro+MMF
MTX+MMF
Other
If YES:
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